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A B S T R A C T
Background
Rotavirus results in more diarrhoea-related deaths in children less than five years of age than any other single agent in countries
with high childhood mortality. It is also a common cause of diarrhoea-related hospital admissions in countries with low childhood
mortality. Currently licensed rotavirus vaccines include a monovalent rotavirus vaccine (RV1; Rotarix, GlaxoSmithKline Biologicals)
and a pentavalent rotavirus vaccine (RV5; RotaTeq, Merck & Co., Inc.). Lanzhou lamb rotavirus vaccine (LLR; Lanzhou Institute of
Biomedical Products) is used in China only.
Objectives
To evaluate rotavirus vaccines approved for use (RV1, RV5, and LLR) for preventing rotavirus diarrhoea.
Search methods
We searched MEDLINE (via PubMed) (1966 to May 2012), the Cochrane Infectious Diseases Group Specialized Register (10 May
2012), CENTRAL (published in The Cochrane Library 2012, Issue 5), EMBASE (1974 to 10 May 2012), LILACS (1982 to 10 May
2012), and BIOSIS (1926 to 10 May 2012). We also searched the ICTRP (10 May 2012), www.ClinicalTrials.gov (28 May 2012) and
checked reference lists of identified studies.
Selection criteria
We selected randomized controlled trials (RCTs) in children comparing rotavirus vaccines approved for usewith placebo, no intervention,
or another vaccine.
Data collection and analysis
Two authors independently assessed trial eligibility, extracted data, and assessed risk of bias. We combined dichotomous data using the
risk ratio (RR) and 95% confidence intervals (CI). We stratified the analysis by child mortality, and used GRADE to evaluate evidence
quality.
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Main results
Forty-one trials met the inclusion criteria and enrolled a total of 186,263 participants. Twenty-nine trials (101,671 participants) assessed
RV1, and 12 trials (84,592 participants) evaluated RV5. We did not find any trials assessing LLR.
RV1
Children aged less than one year: In countries with low-mortality rates, RV1 prevents 86% of severe rotavirus diarrhoea cases (RR 0.14,
95% CI 0.07 to 0.26; 40,631 participants, six trials; high-quality evidence), and, based on one large multicentre trial in Latin America
and Finland, probably prevents 40% of severe all-cause diarrhoea episodes (rate ratio 0.60, 95% CI 0.50 to 0.72; 17,867 participants,
one trial; moderate-quality evidence). In countries with high-mortality rates, RV1 probably prevents 63% of severe rotavirus diarrhoea
cases (RR 0.37, 95% CI 0.18 to 0.75; 5414 participants, two trials; moderate-quality evidence), and, based on one trial in Malawi and
South Africa, 34% of severe all-cause diarrhoea cases (RR 0.66, 95% CI 0.44 to 0.98; 4939 participants, one trial; moderate-quality
evidence).
Children aged up to two years: In countries with low-mortality rates, RV1 prevents 85% of severe rotavirus diarrhoea cases (RR 0.15,
95% CI 0.12 to 0.20; 32,854 participants, eight trials; high-quality evidence), and probably 37% of severe all-cause diarrhoea episodes
(rate ratio 0.63, 95% CI 0.56 to 0.71; 39,091 participants, two trials; moderate-quality evidence). In countries with high-mortality
rates, based on one trial in Malawi and South Africa, RV1 probably prevents 42% of severe rotavirus diarrhoea cases (RR 0.58, 95%
CI 0.42 to 0.79; 2764 participants, one trial; moderate-quality evidence), and 18% of severe all-cause diarrhoea cases (RR 0.82, 95%
CI 0.71 to 0.95; 2764 participants, one trial; moderate-quality evidence).
RV5
Children aged less than one year: In countries with low-mortality rates, RV5 probably prevents 87% of severe rotavirus diarrhoea cases
(RR 0.13, 95% CI 0.04 to 0.45; 2344 participants, three trials; moderate-quality evidence), and, based on one trial in Finland, may
prevent 72% of severe all-cause diarrhoea cases (RR 0.28, 95% CI 0.16 to 0.48; 1029 participants, one trial; low-quality evidence). In
countries with high-mortality rates, RV5 prevents 57% of severe rotavirus diarrhoea (RR 0.43, 95% CI 0.29 to 0.62; 5916 participants,
two trials; high-quality evidence), but there was insufficient data to assess the effect on severe all-cause diarrhoea.
Children aged up to two years: Four studies provided data for severe rotavirus and all-cause diarrhoea in countries with low-mortality
rates. Three trials reported on severe rotavirus diarrhoea cases and found that RV5 probably prevents 82% (RR 0.18, 95% CI 0.07
to 0.50; 3190 participants, three trials; moderate-quality evidence), and another trial in Finland reported on severe all-cause diarrhoea
cases and found that RV5 may prevent 96% (RR 0.04, 95% CI 0.00 to 0.70; 1029 participants, one trial; low-quality evidence). In
high-mortality countries, RV5 prevents 41% of severe rotavirus diarrhoea cases (RR 0.59, 95% CI 0.43 to 0.82; 5885 participants,
two trials; high-quality evidence), and 15% of severe all-cause diarrhoea cases (RR 0.85, 95% CI 0.75 to 0.98; 5977 participants, two
trials; high-quality evidence).
There was no evidence of a vaccine effect on mortality (181,009 participants, 34 trials; low-quality evidence), although the trials were
not powered to detect an effect on this end point.
Serious adverse events were reported in 4565 out of 99,438 children vaccinated with RV1 and in 1884 out of 78,226 children vaccinated
with RV5. Fifty-eight cases of intussusception were reported in 97,246 children after RV1 vaccination, and 34 cases in 81,459 children
after RV5 vaccination. No significant difference was found between children receiving RV1 or RV5 and placebo in the number of
serious adverse events, and intussusception in particular.
Authors’ conclusions
RV1 and RV5 prevent episodes of rotavirus diarrhoea. The vaccine efficacy is lower in high-mortality countries; however, due to
the higher burden of disease, the absolute benefit is higher in these settings. No increased risk of serious adverse events including
intussusception was detected, but post-introduction surveillance studies are required to detect rare events associated with vaccination.
P L A I N L A N G U A G E S U M M A R Y
Vaccines for preventing rotavirus diarrhoea: vaccines in use
Rotavirus infection is a common cause of diarrhoea in infants and young children, and can cause mild illness, hospitalization, and
death. Rotavirus infections results in approximately half a million deaths per year in children aged under five years, mainly in low- and
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middle-income countries. Since 2009, the World Health Organization (WHO) has recommended that a rotavirus vaccine be included
in all national immunization programmes.
This review evaluates a monovalent rotavirus vaccine (RV1; Rotarix, GlaxoSmithKline Biologicals) and a pentavalent rotavirus vaccine
(RV5; RotaTeq, Merck & Co., Inc.). These vaccines have been evaluated in several large trials and are approved for use in many
countries. No trials of the Lanzhou lamb rotavirus vaccine (LLR; Lanzhou Institute of Biomedical Products) were found; this vaccine
is used in China only. The review includes 41 trials with 186,263 participants; all trials compared a rotavirus vaccine with placebo.
The vaccines tested were RV1 (29 trials with 101,671 participants) and RV5 (12 trials with 84,592 participants). The trials took place
in a number of worldwide locations.
In the first two years of life, RV1 prevented more than 80% of severe cases of rotavirus diarrhoea in low-mortality countries, and at
least 40% of severe rotavirus diarrhoea in high-mortality countries. Severe cases of diarrhoea from all causes (such as any viral infection,
bacterial infections, toxins, or allergies) were reduced after vaccination with RV1 by 35 to 40% in low-mortality countries, and 15 to
30% in high-mortality countries.
In the first two years of life, RV5 reduced severe cases of rotavirus diarrhoea by more than 80% in low-mortality countries, and by 40
to 57% in high-mortality countries. Severe cases of diarrhoea from all causes were reduced by 73% to 96% in low-mortality countries,
and 15% in high-mortality countries, after vaccination with RV5. Diarrhoea is more common in high-mortality countries, so even
modest relative effects prevent more episodes in this population. The vaccines when tested against placebo gave similar numbers of
adverse events such as reactions to the vaccine, and other events that required discontinuation of the vaccination schedule.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Patient or population: children
Setting: low-mortality countries (WHO strata A & B)
Intervention: RV1
Comparison: placebo
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Placebo RV1
Severe rotavirus diar-
rhoea
Follow-up: up to 1 year
12 per 1000 2 per 1000
(1 to 3)
RR 0.14
(0.07 to 0.26)
40,631
(6 studies)
⊕⊕⊕⊕
high1
One study (RV1
Vesikari 2007a-EU) re-
ported higher efficacy
compared to the pooled
data. When this study
was excluded from the
analysis, no heterogene-
ity was observed on the
pooled data
Severe rotavirus diar-
rhoea
Follow-up: up to 2 years
22 per 1000 3 per 1000
(3 to 4)
RR 0.15
(0.12 to 0.2)
32,854
(8 studies)
⊕⊕⊕⊕
high
Severe episodes of all-
cause diarrhoea
Follow-up: up to 1 year
34 per 1000 20 per 1000
(17 to 24)
Rate Ratio 0.60
(0.5 to 0.72)
17,867
(1 study)
⊕⊕⊕©
moderate2
One additional European
study reported on cases
of childrenwith severe all-
cause diarrhoea (RR 0.
48, 95% CI 0.37 to 0.61;
3874 participants, one
study); this data could not
be pooled with the study
reporting on number of
episodes
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Severe episodes of all-
cause diarrhoea
Follow-up: up to 2 years
39 per 1000 24 per 1000
(22 to 28)
Rate Ratio 0.63
(0.56 to 0.71)
39,091
(2 studies)
⊕⊕⊕©
moderate3
Two additional studies re-
ported on cases of chil-
drenwith severe all-cause
diarrhoea (RR 0.49, 95%
CI 0.40 to 0.60; 6269
participants, two studies)
; this data could not be
pooled with the studies
reporting on number of
episodes
All-cause death
Follow-up: 2 months to 2
years
12 per 10,000 15 per 10,000
(10 to 21)
RR 1.27
(0.89 to 1.81)
93,321
(18 studies)
⊕⊕©©
low4
All serious adverse
events
Follow-up: 2 months to 2
years
41 per 1000 37 per 1000
(34 to 39)
RR 0.9
(0.84 to 0.95)
91,957
(20 studies)
⊕⊕⊕©
moderate5
Serious adverse events:
intussusception
Follow-up: 2 months to 2
years
66 per 100,000 57 per 100,000
(34 to 96)
RR 0.87
(0.52 to 1.46)
91,832
(11 studies)
⊕⊕©©
low6
*The basis for the assumed risk is the control group risk across studies. The corresponding risk (and its 95% CI) is based on the assumed risk in the comparison group and the relative
effect of the intervention (and its 95% CI).
CI: confidence interval; RR: risk ratio
GRADE Working Group grades of evidence
High-quality: further research is very unlikely to change our confidence in the estimate of effect.
Moderate-quality: further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low-quality: further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low-quality: we are very uncertain about the estimate.
1 Heterogeneity (I2 = 66%) was observed in the pooled data, but given the strength of the evidence outcome was not downgraded.
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2 Downgraded by 1 for risk of selective reporting bias. Only two of the six studies reporting on severe rotavirus diarrhoea provided data
for this outcome.
3 Downgraded by 1 for risk of selective reporting bias. Only four of the eight studies reporting on severe rotavirus diarrhoea provided
data for this outcome.
4 Downgraded by 2 for imprecision. These trials were not powered to detect an effect on mortality.
5 Downgraded by 1 for risk of bias. Fourteen of the 20 included studies did not sufficiently report method of allocation concealment,
blinding or incomplete outcome data. One study was not double blinded and one study was at high risk of incomplete outcome data
bias.
6 Downgraded by 2 for imprecision. There was a 1:10,000 increased risk of intussusception with a previous rotavirus vaccine (<http://
www.who.int/vaccines-documents/DocsPDF04/wwwSOWV_E.pdf>), therefore, these trials were not powered to detect an association
between RV1 and intussusception.
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B A C K G R O U N D
The global impact of rotavirus infection
Rotavirus is the leading known cause of severe gastroenteritis in
infants and young children worldwide (Vesikari 1997; Parashar
2006a; WHO 2007). It causes more than one-third of all di-
arrhoea-related hospital admissions (Parashar 2006a; Linhares
2008; Tate 2011) and an estimated 450,000 deaths per year, with
most deaths occurring in developing countries (Parashar 2006a;
Linhares 2008; Tate 2011). More deaths occur in resource-lim-
ited countries due to poor access to oral rehydration solution and
medical facilities, and due to underlying conditions, such as mal-
nutrition. However, in more industrialized countries, hospital ad-
missions due to rotavirus gastroenteritis escalate with increasing
income despite improved sanitation and hygiene (Malek 2006;
Parashar 2006a).
Epidemiological and clinical features of rotavirus
infection
Rotavirus is transmitted primarily via the faecal-oral route with
symptoms typically developing one to two days following infec-
tion. Most children become infected with rotavirus at least once
within the first three years of life, and epidemiological studies de-
pict a peak incidence of rotavirus diarrhoea between six and 24
months of age (CDC-ASIP 1999; Linhares 2008). In some coun-
tries, a significant number of hospitalizations associated with ro-
tavirus disease occur in infants aged less than six months (Bresee
2005). Infection may be asymptomatic or result in a severe, life-
threatening illness characterized by vomiting, fever, watery diar-
rhoea, and dehydration (AAP 1998). However, in the day-to-day
clinical setting especially in developing countries, the distinction
between all-cause diarrhoea and rotavirus diarrhoea may not be
made, as tests for rotavirus infection may not be available or may
not be routinely used.
Rotavirus strain diversity
Rotaviruses are double-stranded RNA viruses that evolve by point
mutation, genetic reassortment, and interspecies transmission.
While complete genomic analysis includes all eleven genome seg-
ments, the two proteins that together comprise the outer virus
layer (VP7 and VP4) have been most extensively examined. The
enormous diversity and capacity of human rotaviruses for change
suggest that rotavirus vaccines must demonstrate protective effi-
cacy against all of the major circulating strain types (de Quadros
2004) as well as new strains that will continue to emerge (Gentsch
2005). Out of at least 15 VP7 (G, for glycoprotein) types and 26
VP4 (P, for protease-sensitive) types that have been recognized in
humans to date (see Figure 1 for details), five combinations of G
and P type are prevalent worldwide: these are G1, G3, G4, G9
with P[8] VP4 type, and G2 P[4] strains (Santos 2005; Linhares
2008).
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Figure 1. A simplified diagram of the location of rotavirus structural proteins (source: Graham Cohn,
Wikipedia (public domain image)): Rotaviruses are segmented, double-stranded RNA viruses. The mature,
triple-layered virus particle comprises a core (which contains the viral genome), a middle layer (comprised of
viral protein (VP)6, and an outer layer (comprised of VP7 and VP4) as shown in the figure. VP6 defines
rotavirus group, and most rotaviruses that infect humans are of group A. The two outer capsid proteins
independently induce neutralizing antibodies: VP7, a glycoprotein, defines G-serotype; and the protease-
sensitive VP4 protein defines P-serotype. G-serotype determined by serological methods correlates precisely
with G-genotype obtained through molecular assays, whereas there is an imperfect correlation of P-serotype
and P-genotype; P-genotype is thus included in square brackets.
A brief summary of the development of
rotavirus vaccines
The first reports of clinical trials of rotavirus vaccine candidates,
which were based on animal rotavirus, were published in the early
1980s.
Early vaccine candidates were single-strain animal viruses that
replicate poorly in the human host. However, the efficacy of
such ’monovalent’ vaccines was highly variable, possibly due to
a predominant homotypic (type-specific) response. In an effort
to broaden the protection afforded by rotavirus vaccines, multi-
valent human-animal reassortant vaccines (created in cell culture
through the insertion by reassortment of human rotavirus VP7
or VP4 genes into the backbone of bovine or rhesus monkey ro-
tavirus strains), and attenuated strains of human rotaviruses were
included in second-generation vaccines (Henchal 1996).
The rhesus-human tetravalent reassortant rotavirus vaccine (RRV-
TV, RotaShield, Wyeth-Lederle, USA) was the first vaccine to be
licensed (in 1998), but, due to an association with intussuscep-
tion (described below), the vaccine was withdrawn from use in
1999. This withdrawal caused the rotavirus vaccine experts and
other interested parties to meet and re-evaluate the direction of
research (WHO/UNICEF 2003). The group recommended de-
veloping new rotavirus vaccine candidates with testing in devel-
oped and developing countries undertaken in parallel due to the
differences in the epidemiology of rotavirus and the urgent need to
introduce rotavirus vaccines in the world’s poorest countries. They
also recommended that the World Health Organization (WHO)
encourage research activities on the pathogenesis and epidemiol-
ogy of intussusception.
Vaccines approved for use
This review evaluates three vaccines: a monovalent rotavirus vac-
cine (RV1; Rotarix, GlaxoSmithKline Biologicals) and a pentava-
lent rotavirus vaccine (RV5; RotaTeq, Merck & Co., Inc.), which
have been evaluated in several large trials and are approved for
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use in many countries; and Lanzhou lamb rotavirus vaccine (LLR;
Lanzhou Institute of Biomedical Products), which is approved for
use in China only.
RV1 is an oral, live-attenuated, human rotavirus vaccine derived
from the most common circulating wild-type strain G1P[8]. RV1
is based on a rotavirus of entirely human origin, and is adminis-
tered to infants in two oral doses with an interval of at least four
weeks between doses. The manufacturer states that the “vaccina-
tion course should preferably be given before 16 weeks of age, but
must be completed by the age of 24 weeks” (EMA 2011). RV1
was approved first in Mexico (2004) and has since been approved
in over 116 countries (GSK 2010 (press release)), including the
USA (GSK 2008 (press release)) and European Union (GSK 2006
(press release)); and has been included in national immunization
programmes in over 20 countries including Brazil, El Salvador,
Mexico, Panama, South Africa, and Venezuela (GSK 2007 (press
release); WHO 2011). In 2008, it was included in theWHO’s list
of vaccines for purchase by United Nations (UN) agencies (WHO
2008a).
RV5 is an oral, live, human-bovine, reassortant, multivalent, ro-
tavirus vaccine developed from an original Wistar calf 3 (WC3)
strain of bovine rotavirus. The vaccine contains five live, human-
bovine reassortant rotavirus strains. Four reassortant rotavirus
strains each express one of the common human VP7 (G) types
including G1, G2, G3, and G4, and the fifth reassortant expresses
the common human VP4 (P) type P[8]. The three-dose liquid
vaccine is intended for infants aged between six and 32 weeks with
the first dose given at six to 12 weeks and subsequent doses ad-
ministered at four to 10 week intervals; however, the third dose
should not be given after 32 weeks of age (Merck 2008 (press
release)). RV5 has been approved in 97 countries around the world
(Merck 2011), including the European Union (EMEA 2008) and
USA (FDA 2008). It has been included in national immunization
programmes in over 10 countries including the USA, Nicaragua,
Belgium and most recently Iraq (WHO 2011). As with RV1, it
was included in the WHO’s November 2008 list of vaccines for
purchase by UN agencies (WHO 2008a).
LLR is a live-attenuated, monovalent (G10 P[12]) vaccine derived
from a lamb (WHO 2008b). This oral, three-dose vaccine was
developed by the Lanzhou Institute of Biomedical Products in
China and was licensed in China in 2000 (Fu 2007). There is a
paucity of publicly available data regarding this vaccine.
Vaccines no longer in use
Several vaccines, including the first licensed rotavirus vaccine
(RRV-TV; RotaShield, Wyeth Laboratories) were developed,
tested in trials, and later abandoned or withdrawn from use; these
are covered in a separate Cochrane Review (Soares-Weiser 2004).
The first licensed rotavirus vaccine, RRV-TV, a tetravalent rhesus-
human reassortant vaccine, was withdrawn from use in 1999 fol-
lowing reports of intussusception (bowel obstruction which occurs
when one segment of bowel becomes enfolded within another seg-
ment). Evaluations have since suggested a strong age-related risk
of intussusception, with 80% of intussusception cases occurring
in infants who were more than 90 days old when the first vaccine
dose was administered (Simonsen 2005). Although it is still cur-
rently licensed, this vaccine is no longer in clinical use (Dennehy
2008).
Rationale for rotavirus vaccination and
recommendations
Vaccination is considered to be the intervention with themost po-
tential for reducing the impact of rotavirus disease for several rea-
sons. Although rotavirus infects most infants, predicting the pro-
gression of the disease to severe diarrhoea and dehydration is not
possible. Moreover, improvements in hand hygiene and sanitation
have limited impact on prevention of the disease (Vesikari 2008a).
Also, other measures for the prevention of rotavirus gastroenteri-
tis, such as passive immunization or probiotics, are only partially
effective and are not suitable for large-scale use (Mrukowicz 2008).
Vaccination of infants, before the first rotavirus infection, is there-
fore required to prevent most severe cases of the disease (Vesikari
2008a), with early and sustained protection required during the
first two years of life (Linhares 2008).
Ideally, rotavirus vaccines would be given concomitantly with
other childhood vaccines (eg polio virus vaccine) without affecting
or being affected by them. Also, universal rotavirus vaccination
would include special paediatric populations, such as preterm in-
fants, malnourished children, and immunocompromised children
(including those infected with human immunodeficiency virus
(HIV)), and the vaccines should be safe and effective for these
children.
Recommendations and guidelines for rotavirus
vaccine use
Vaccination with RV1 and RV5 were first recommended in 2006
in Europe and the Americas, where the vaccines efficacy have been
demonstrated. In April 2009, theWHOStrategic Advisory Group
of Experts (SAGE) on Immunization recommended “the inclu-
sion of rotavirus vaccination of infants into all national immuniza-
tion programmes”, with a stronger recommendation for countries
where “diarrhoeal deaths account for ≥10% of mortality among
children aged <5 years” (SAGE 2009). The WHO recommenda-
tion was the culmination of many years of research and develop-
ment, and the prioritisation of the need for a rotavirus vaccine by
the WHO, the Global Alliance for Vaccines and Immunization
(GAVI), the US Centers for Disease Control and Prevention, and
the Rotavirus Vaccine Program at the Program for Appropriate
Technology in Health (PATH) (Vesikari 2008a). SAGE recom-
mended administering the first dose of vaccine RV1 or RV5 to
infants of six to 15 weeks of age, with the last dose administered
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before 32 weeks of age (SAGE 2009). In April 2012, SAGE re-
laxed the age restricted recommendation and advised to vaccinate
“as soon as possible after the age of six weeks” because “the current
age restrictions for the first dose (< 15 weeks) and last dose (< 32
weeks) are preventing vaccination of many vulnerable children”
(SAGE 2012).
Regional rotavirus vaccination guidelines include the European
Society for Paediatric Infectious Diseases/European Society for
PaediatricGastroenterology,Hepatology, andNutritionEvidence-
Based Recommendations for Rotavirus Vaccination in Europe (
Vesikari 2008a; Vesikari 2008b), and the American Academy of
Pediatrics Guidelines for Use of Rotavirus Vaccine (AAP 2009).
Rotavirus biology
The enormous diversity and capacity of human rotaviruses for
change suggest that rotavirus vaccinesmust demonstrate protective
efficacy against all of themajor circulating strain types (deQuadros
2004) as well as new strains that will continue to emerge (Gentsch
2005). Out of at least 15 VP7 (G) types and 26 VP4 (P) types
that have been recognized to date (see Figure 1 for details), five
combinations of G and P type are prevalent worldwide: these are
G1, G3, G4, G9 with P[8] VP4 type, and G2 P[4] strains (Santos
2005; Linhares 2008). Early vaccine candidates were developed
solely from single-strain animal viruses that replicate poorly in the
human host, but the efficacy of such ’monovalent’ vaccines was
highly variable, possibly due to a predominant homotypic (type-
specific) response. In an effort to broaden the protection afforded
by rotavirus vaccines, multivalent human-animal reassortant vac-
cines (created in cell culture through the insertion of human ro-
tavirus VP7 or VP4 genes into the backbone of bovine or rhe-
sus monkey rotavirus strains through the process of reassortment),
and attenuated strains of human rotaviruses were included in sec-
ond-generation vaccines (Henchal 1996). Also, a higher titre and
multiple doses of rotavirus vaccine have been suggested to be more
efficacious (Vesikari 1997; Bresee 1999), and have been evaluated
as part of the vaccine development.
Use with other childhood vaccines and special
populations
Ideally, rotavirus vaccines would be given concomitantly with
other childhood vaccines (eg polio virus vaccine) without affecting
or being affected by them. Also, universal rotavirus vaccination
would include special paediatric populations, such as preterm in-
fants, malnourished children, and immunocompromised children
(including those infected with human immunodeficiency virus
(HIV)), and the vaccines should be safe and effective for these
children.
Performance of oral rotavirus vaccines in
developing countries
Many oral vaccines, including rotavirus vaccines, have demon-
strated lower efficacy and immunogenicity in developing coun-
tries in Africa and Asia compared to more developed countries in
North America, South America, and Europe (Levine 2010). A sys-
tematic review evaluating regional variation of rotavirus vaccine
efficacy showed that there is a correlation between lower vaccine
efficacy against severe rotavirus diarrhoea and high country child
mortality rates (Fischer Walker 2011). Reduced vaccine efficacy
in countries with higher child mortality rates could be due to a
combination of factors, such as co-morbidities including malnu-
trition and HIV infection, higher prevalence of enteric pathogens
that may interfere with vaccine “take”, and maternally-derived ro-
tavirus antibodies transmitted to the infant via breast milk or the
placenta (Cunliffe 2007; Levine 2010).
Outcomes of interest
The safety and efficacy of the licensed vaccines for the prevention
of rotavirus gastroenteritis in infants (healthy and special popula-
tions) have been assessed in several randomized controlled trials
(RCTs) worldwide. The goal of the current review is to system-
atically assess these trials and evaluate vaccine efficacy against ro-
tavirus diarrhoea, all-cause diarrhoea, and diarrhoea-related med-
ical visits and hospitalization. We also examine the occurrence of
deaths, serious adverse events, including intussusception, in order
to provide decision-makers, clinicians, and care-givers with the
relevant information to aid decisions about vaccine use.
Development of Cochrane systematic rotavirus
vaccine reviews
The original systematic review of rotavirus vaccines (Soares-Weiser
2004) examined vaccines in use and other vaccines including those
no longer in use or in development. The 2004 version of the re-
view concluded that more trials were needed before routine vac-
cine use could be recommended. An update in 2009 included
a new search, revised inclusion criteria (only vaccines in use in
children), updated review methods and new authors; the review
was updated again in 2010 with nine new studies (Soares-Weiser
2010). The 2010 version of the review concluded that RV1 and
RV5 are both effective vaccines for the prevention of rotavirus di-
arrhoea. Another update in February 2012 added a further nine
new studies, GRADE summary of findings tables and, again, new
authors joined the team (Soares-Weiser 2012). The current update
includes a new search, major restructuring of analyses, including
re-evaluating primary outcomes in consultation with theWHO to
reflect that vaccine efficacy profiles are different in countries with
different mortality rates. In addition, the authors discovered that
two of the included studies were included twice, but as different
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publications; this was adjusted in this update (the study known
in the previous version of the review as RV1 GSK[045] 2007-AS
is the same as RV1 Zaman 2009-AS, and the study known in the
previous version of the review as RV1 Vesikari 2010-EU is the
same as RV1 Vesikari 2007a-EU).
O B J E C T I V E S
Primary objectives were to evaluate the efficacy of rotavirus vac-
cines approved for use (RV1, RV5, and LLR) for preventing ro-
tavirus diarrhoea, all-cause diarrhoea and death in children up to
one and up to two years old for low- and high-mortality countries,
and to evaluate serious adverse events including intussusception
for the same age and mortality groups. Secondary objectives were
to evaluate the efficacy of rotavirus vaccines on hospital admission,
and reactogenicity and immunogenicity profiles.
M E T H O D S
Criteria for considering studies for this review
Types of studies
RCTs.
Types of participants
Children (age as defined in the trials).
Types of interventions
Intervention
Vaccines approved in any country.
Control
Placebo, no vaccination, or other vaccine.
Types of outcome measures
Primary*
• Rotavirus diarrhoea: severe (as defined in trial report).
• All-cause diarrhoea: severe.
• All-cause death.
• Serious adverse events (that are fatal, life-threatening, or
result in hospitalization); eg Kawasaki disease.
• Intussusception.
Secondary
• Rotavirus diarrhoea: of any severity.
• All-cause diarrhoea (as defined in trial report).
• Rotavirus diarrhoea: requiring hospitalization.
• All-cause diarrhoea: requiring hospitalization.
• Emergency department visit.
• Hospital admission: all-cause.
• Reactogenicity (capacity to produce an adverse reaction,
such as fever, diarrhoea, and vomiting).
• Adverse events that require discontinuation of vaccination
schedule.
Other
• Immunogenicity
◦ Vaccine virus shedding in stool.
◦ Seroconversion: conversion from seronegative to
seropositive for anti-rotavirus IgA antibodies.
• Drop-outs.
* Primary outcomemeasures were selected in consultationwith the
WHO and were all stratified according to high- or low-mortality
rate, based on WHO mortality strata (WHO 1999), and up to
one and up to two years follow-up.
Search methods for identification of studies
We attempted to identify all relevant trials regardless of language
or publication status (published, unpublished, in press, and on-
going).
Dr Vittoria Lutje (Information Specialist, Cochrane Infectious
Diseases Group) or KS-W searched the following databases using
the search terms and strategy described in Appendix 1: Cochrane
Infectious Diseases Group Specialized Register (10 May 2012);
Cochrane Central Register of Controlled Trials (CENTRAL),
published in The Cochrane Library (2012, Issue 5); MEDLINE
(via PubMed; 1966 to May 2012); EMBASE (1974 to 10 May
2012); LILACS (1982 to 10May 2012); and BIOSIS (1926 to 10
May 2012). The International Clinical Trials Registry Platform
(ICTRP) was also searched on 10 May 2012, and HB searched
Clinicaltrials.gov Clinical Study Register (www.clinicaltrials.gov)
on 28 May 2012 using ’rotavirus’ as the search term.
We also checked the reference lists of all studies identified by the
above methods.
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Data collection and analysis
Selection of studies
Using an EndNote database containing the results of all search
strategies, KS-W and HM independently screened the title, ab-
stract, or keywords of each EndNote record identified with the
search strategy, and retrieved the full text for potentially relevant
trials and for records where the relevance was unclear. We created
a form with the eligibility criteria in Microsoft Word 2003, which
was piloted in five studies. KS-W and SN, IB-A, or EG indepen-
dently applied the inclusion criteria to each potentially relevant
trial to determine their eligibility, and we resolved any disagree-
ments through discussion with HM. We tabulated the excluded
studies along with the reason for excluding them in the section:
Characteristics of excluded studies. We ensured that data from
each trial were entered only once in our review.
Data extraction and management
We created a form for data collection in Microsoft Word 2003,
which was piloted in five trials independently by two authors, and
revised after the author team’s discussion.
KS-W, HB, and SN extracted data and KS-W, IB-A, or EG cross-
checked the data. All outcomes were dichotomous outcomes, and
we extracted the total number of participants and number of par-
ticipants that experienced the event. We compared the extracted
data to identify errors. We resolved disagreements by consulting
HM or KS-W. KS-W, EG, and HB entered data into Review
Manager (RevMan).
Assessment of risk of bias in included studies
KS-W and HB, SN, IB-A, or EG independently assessed the risk
of bias of each trial using TheCochrane Collaboration’s risk of bias
tool (Higgins 2008). Based on the guidance of the The Cochrane
Collaboration’s risk of bias tool (Higgins 2008), we created a form
to make judgements on the risk of bias for the rotavirus diarrhoea
outcome measure in six domains: sequence generation; allocation
concealment; blinding (of participants, personnel, and outcome
assessors); incomplete outcome data; selective outcome reporting;
and other sources of bias. We categorized these judgements as ’yes’
(low risk of bias), ’no’ (high risk of bias), or ’unclear’. We resolved
disagreements through discussion and by consulting HM or KS-
W.
For the 2012 published version of this review, we asked for help
from Dr Ana Maria Restrepo at the WHO Initiative for Vac-
cine Research, who contacted the vaccine manufacturers Glaxo-
SmithKline (RV1) and Merck (RV5), who were involved in de-
signing and funding the majority of the included trials. We pro-
vided them with an Excel spreadsheet with specific details of each
trial that would impact on the assessment of risk of bias. We re-
ceived details from Merck (RV5), but so far have not received an
answer from GlaxoSmithKline (RV1).
Measures of treatment effect
We analysed dichotomous data by calculating the risk ratio (RR)
for each trial with the uncertainty in each result being expressed
using 95% confidence intervals (CIs).
Unit of analysis issues
When trials had multiple treatment arms and it was considered
suitable, we grouped the trial arms. We excluded irrelevant trial
arms.
Dealing with missing data
Weundertook a complete-case analysis (the number analysed) and
an intention-to-treat analysis when data were available.
Assessment of heterogeneity
We initially assessed heterogeneity on the results of the trials by
inspecting the graphical presentations and by calculating the Chi
2 test of heterogeneity. However, we were aware of the fact that
the Chi2 test has a poor ability to detect statistically significant
heterogeneity among studies. Therefore, we also quantified the
impact of heterogeneity in the meta-analysis using a measure of
the degree of inconsistency in the studies’ results (Higgins 2003).
This measure (I2 statistic) describes the percentage of total vari-
ation across studies that are due to heterogeneity rather than the
play of chance (Higgins 2003). The I2 values lie between 0% and
100%, and a simplified categorization of heterogeneity could be
low, moderate, and high to I2 values of 25%, 50%, and 75% re-
spectively (Higgins 2003).
Assessment of reporting biases
If ten or more studies were included, we examined a funnel plot
for the primary outcome (severe rotavirus diarrhoea) estimating
the precision of trials (plotting the RR against the standard error
(SE) of the log of RR) to estimate potential asymmetry.
Data synthesis
We stratified all analyses by the type of vaccine. Subsequently,
we grouped all outcomes in the meta-analyses according to the
time point when the outcome was measured and/or the number
of rotavirus seasons as follows: less than two months; up to one
year (one rotavirus season); one to two years (up to two rotavirus
seasons); and more than three years (three rotavirus seasons). If
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data were available for more than one time point, we used the
number of completers for each time point in the trial.
For the current update, we stratified each primary outcome (ro-
tavirus diarrhoea, all-cause diarrhoea, all-cause death, all serious
adverse events, and intussusception) and selected secondary out-
comes (rotavirus diarrhoea and all-cause diarrhoea of any severity,
and all-cause hospitalization) by country mortality rate according
to WHO mortality strata (WHO 1999) as follows:
1. Low-mortality: countries in WHO strata A and B (very
low/low child mortality and low adult mortality);
2. High-mortality: countries in WHO strata D and E (high
child mortality and high/very high adult mortality).
We did not identify any studies that were performed in countries
with WHO stratum C (low child mortality and high adult mor-
tality).
We used a fixed-effect model, unless we demonstrated statistically
significant heterogeneity (P < 0.10) for a specific outcome, in
which case we used the random-effects models.
We included separate analyses for cases of diarrhoea (eg a childwho
has diarrhoea regardless of the number of episodes) and episodes
(ie one child can experience more than one episode) where data
permitted. We combined episodes using the rate ratio and SE,
with the uncertainty in each result being expressed using 95% CI.
Summary of findings tables
We interpreted the findings of this review using the GRADE
approach (Schünemann 2008) and we used GRADE profiler
(GRADE 2004) to import data from Review Manager (RevMan)
to create ’Summary of findings’ tables. These tables provide out-
come-specific information concerning the overall quality of evi-
dence from each included study in the comparison, themagnitude
of effect of the interventions examined, and the sum of available
data on all outcomes we rated as important to patient-care and
decision-making, and is reflected as follows: high-quality (“vaccine
prevents....”); moderate-quality (“vaccine probably prevents...”);
and low-quality (“vaccine may prevent....”).
We selected primary outcomes, all stratified by vaccine and high or
low country mortality, for inclusion in the ’Summary of findings’
tables: severe rotavirus diarrhoea; severe all-cause diarrhoea ; all-
cause death; serious adverse events; and intussusception.
Subgroup analysis and investigation of heterogeneity
We planned to perform subgroup analyses to assess the impact
of the following possible sources of heterogeneity for any of the
included vaccines: vaccine protection against specific rotavirus G
types; and vaccination of special groups (preterm, immunocom-
promised (including HIV), breastfed, and children with malnu-
trition). For all but the last two subgroups, we created categor-
ical variables and performed the subgroup analyses in Compre-
hensive Meta-Analysis (Version 2.2) using the analysis of variance
model (Borenstein 2009). In a previous version of this review
(Soares-Weiser 2010), we also analysed vaccine effect according to
each study’s country income status, use of other childhood vac-
cines, number of doses administered, and source of funding. These
subgroup analyses did not show any differences, and are not pre-
sented in the current version; they can be found in Soares-Weiser
2010.
Sensitivity analysis
We also planned to conduct sensitivity analyses for the primary
outcomes according to allocation concealment (high risk of bias,
low risk of bias, and unclear) for outcomes on which data could
not be pooled because of significant heterogeneity (I2 > 75%).
R E S U L T S
Description of studies
See:Characteristics of included studies; Characteristics of excluded
studies; Characteristics of ongoing studies.
We identified and included 41 independent trials (see
Characteristics of included studies), located 25 ongoing studies
(see Characteristics of ongoing studies), and excluded 60 articles
for the reasons given in the Characteristics of excluded studies sec-
tion.
The 41 trials enrolled about 186,263 participants (approximate
number as some trials provided only the number evaluable), and
each trial compared a rotavirus vaccine with a placebo. The vac-
cines tested were RV1 (29 trials reported in 130 publications or
reports; 101,671 participants) and RV5 (12 trials reported in 47
publications or reports; 84,592 participants). None of the identi-
fied trials used LLR.
The trials were conducted around the world, and the location can
be identified in the study reference: AF, Africa; AS, Asia; EU, Eu-
rope; INT, several international locations; LA, Latin America; NA,
North America; or country three-letter acronym according to ISO
3166-1 Alpha-3 (eg BGD for Bangladesh) from http://www.all-
acronyms.com/special/countries˙acronyms˙and˙abbreviations, if
the study was conducted in a single country.
1. RV1
The 29 RV1 trials were published between 1998 and 2012. Five
of the trials are unpublished and were located on the Glaxo-
SmithKline website via clinicalstudyresults.org. Twenty trials en-
rolled around 500 participants or less, two trials enrolled around
1000 participants, six trials enrolled between 2155 and 10,708
participants, and one large trial enrolled 63,225 participants.Most
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children were aged between one and three months at the time of
the first vaccination.
Outcome measures
Each trial reported on one or more of the outcome measures spec-
ified for this review (see Appendix 2). We included data on partic-
ipants requiring medical visits as this was reported in some trials
and is a similar outcome measure to participants requiring hospi-
talization.
Nineteen trials were safety studies, reporting mainly safety out-
comes (eg serious adverse events and reactogenicity), immuno-
genicity outcomes, or both. Eleven of these trials also reported ef-
ficacy outcomes with a follow-up of up to two months. The other
ten trials reported one or more efficacy outcomes (eg rotavirus
diarrhoea) in addition to safety outcomes; most reported one or
more immunogenicity outcomes. The trials varied in the length of
follow-up, but in general the trials that specified efficacy outcome
measures had longer follow-up times (Appendix 2).
As shown in Appendix 3, rotavirus diarrhoea (of any severity) was
the most common efficacy outcome reported (by 18 trials); 11
trials reported on severe rotavirus diarrhoea, and nine reported
on rotavirus diarrhoea requiring hospitalization. Data on all-cause
diarrhoea were provided by ten trials, severe all-cause diarrhoea by
five trials. Most reported all-cause death and drop-outs, but other
efficacy outcomes were reported by few trials.
For safety outcomes (Appendix 4), all but three trials reported
on reactogenicity, all but two trials reported on serious adverse
events, and all but eight reported on adverse events leading to
discontinuation of the intervention.
Most trials reported on one or more immunogenicity outcomes;
see Appendix 4.
Location
Early trials were conducted in North America and Europe, but
since 2005 trials have also been conducted in Asia (Bangladesh,
India, Japan, Philippines, South Korea, Singapore, Thailand,
Vietnam; 11 trials), Latin America (Argentina, Brazil, Chile,
Colombia, Dominican Republic, Honduras, Mexico, Nicaragua,
Panama, Peru, Venezuela; six trials), and Africa (South Africa,
Malawi; four trials); see Appendix 5.Most trials hadmultiple sites,
often in several countries; RV1 Vesikari 2007a-EU included 98
sites in six European countries.
Country mortality rate
Most trials were conducted in countries with low-mortality
rates, corresponding to WHO mortality strata A and B. Six
trials were conducted in countries with high-mortality rates,
(RV1 Steele 2008-ZAF; RV1 Narang 2009-IND; RV1 Zaman
2009-BGD; RV1 Madhi 2010-AF; RV1 Steele 2010a-ZAF; RV1
Steele 2010b-ZAF) corresponding to WHO mortality strata D
and E; see Appendix 5. For RV1Madhi 2010-AF, when available,
data were split between countries into RV1 Madhi 2010-MWI
and RV1 Madhi 2010-ZAF. Two trials were conducted in several
countries spanning both low- and high-mortality countries: RV1
GSK[033] 2007-LAwas conducted in four study centres in a high-
mortality country (Peru), but also in three study centres in two
low-mortality countries (Colombia and Mexico) and was placed
in the high-mortality group, and RV1 Ruiz-Palac 06-LA/EU was
conductedmainly in low-mortality countries in LatinAmerica and
in Finland, but also in two high-mortality countries (Nicaragua
and Peru) and was placed in the low-mortality group.
Vaccine schedule
The trials varied in the vaccine dose and schedule (see Appendix
6). Most trials gave two doses of the vaccine with virus concen-
tration of more than 106 plaque-forming units (PFU). Older tri-
als, conducted between 1998 and 2005, tended to include slightly
lower PFU or a range of PFU for comparison.
RV1 was given as two doses in all but four trials: one trial con-
ducted inpartnershipwithGlaxoSmithKline andPATHRotavirus
Vaccine Program tested two and three doses of the vaccine (RV1
Madhi 2010-AF); another trial conducted by GlaxoSmithKline in
which the poliovirus vaccine was co-administeredwith RV1, tested
two or three vaccine doses to investigate differences in immune
response (RV1 Steele 2010b-ZAF); a third study tested three vac-
cine doses in HIV-positive infants (RV1 Steele 2010a-ZAF); and
a fourth study tested three vaccine doses in healthy infants (RV1
GSK[021] 2007-PAN).
Some trials compared more than one arm: different PFU virus
concentrations (RV1 Vesikari 2004a-FIN; RV1 Dennehy 2005-
NA; RV1 Phua 2005-SGP; RV1 Salinas 2005-LA; RV1 Ward
2006-USA); different formulations (RV1 GSK[021] 2007-PAN;
RV1 GSK[033] 2007-LA; RV1 GSK[101555] 2008-PHL; RV1
Kerdpanich 2010-THA; RV1 Vesikari 2011-FIN); co-adminis-
tration of other vaccine (RV1 Steele 2008-ZAF; RV1 Zaman
2009-BGD); and different intervals between doses (RV1 Anh
2011-PHL; RV1 Anh 2011-VNM).
Infant vaccination status
All but four trial reports referred to vaccination with other infant
vaccines (see Appendix 6). Most trials co-administered other rou-
tine infant vaccines, such as diphtheria-tetanus-acellular pertussis,
Haemophilus influenzae type b (HiB), inactivated polio vaccine,
and hepatitis B vaccine (HBV). Some trials also co-administered
oral polio vaccine. Other trials imposed a two-week separation
between other infant vaccines and rotavirus vaccine or placebo, or
specified other vaccines as not allowed.
Methods for collecting adverse event data
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Twelve of the 29 trials did not provide details of how adverse event
data were collected. Out of the trials that did report the method
of collecting adverse event data, nine trials used passive methods
(eg diary cards), two used an active method (“active surveillance
system”), and five used both passive and active methods (eg diary
card plus regular telephone calls to parents); see Appendix 7.
Source of funding
Most trialswere supported byGlaxoSmithKlineBiologicals, twoof
which were in partnership with PATHRotavirus Vaccine Program
(RV1 Zaman 2009-BGD; RV1 Madhi 2010-AF), and another
two in partnership with RAPID trials and WHO (RV1 Steele
2008-ZAF; RV1 Steele 2010a-ZAF). Three trials were sponsored
by Avant Immunotherapeutics (formerly Virus Research Institute,
Inc.) (RV1 Bernstein 1998-USA; RV1 Bernstein 1999-USA; RV1
Ward 2006-USA).
2. RV5
We identified 12 trials of RV5 vaccine. The earliest was reported
in 2003 and the most recent in 2010. Three of the trials are un-
published and were accessed via clinicalstudyresults.org or clin-
icaltrials.gov. Overall, 84,592 participants were included in the
trials; the largest trial included 70,301 participants (RV5 Vesikari
2006b-INT) and the smallest included 48 participants (RV5
NCT00953056 2010-CHI). All but one trial enrolled children
aged between one and three months; the children in RV5 Vesikari
2006a-FIN were aged between three and six months. For the 2012
published version of this review, we received new information from
Merck (Merck 2012) for some of the trials on the outcomes se-
rious adverse events, intussusception, and deaths. The new infor-
mation has been incorporated into the analyses and indicated in
the Characteristics of included studies section.
Outcome measures
Four trials were safety studies (Appendix 2) reporting safety out-
comes (eg serious adverse events and reactogenicity) and gener-
ally immunogenicity outcomes as well. The other eight trials re-
ported one or more efficacy and safety outcomes, and seven out
of those eight reported immunogenicity outcomes also (Appendix
2). The trials varied in the length of follow-up (Appendix 2), but
in general the trials that specified efficacy outcome measures had
longer follow-up times (up to three years). As for the RV1 trials,
we included data on participants requiring medical visits as this
was reported in some trials and is a similar outcome measure to
participants requiring hospitalization.
As shown in Appendix 3, rotavirus diarrhoea - severe cases and
cases of any severity - were the most common efficacy outcomes
reported (by eight trials); only one of these reported rotavirus
diarrhoea requiring hospitalization. Three trials provided data on
severe cases of all-cause diarrhoea; two also presented data on cases
with any severity. Nine trials reported all-cause death, and 10 of
the 12 trials reported drop-outs.
For safety outcomes, all trials reported on serious adverse events
and reactogenicity, but four did not provide data on adverse events
leading to discontinuation of the intervention; see Appendix 4.
Ten trials reported on an immunogenicity outcome (Appendix 4).
Location
Half of the trials were conducted in low-mortality countries in
North America and Europe. Six trials, including the smallest and
the largest trials, were conducted in other regions: RV5 Armah
2010-AF was conducted in Ghana, Kenya and Mali; RV5 Kim
2008-KOR was conducted in South Korea; RV5 NCT00718237
2010-JPN was conducted in Japan; RV5 NCT00953056 2010-
CHI was conducted in China; RV5 Vesikari 2006b-INT was con-
ducted in 12 countries in Asia, the Caribbean, Europe, Latin
America, North America; and RV5 Zaman 2010-AS was con-
ducted in Bangladesh and Vietnam. Each trial had multiple sites,
ranging from three (RV5 Vesikari 2006a-FIN) to 356 sites (RV5
Vesikari 2006b-INT); see Appendix 5.
Country mortality rate
Most trials were conducted in countries with low-mortality rates,
corresponding to WHO mortality strata A and B; see Appendix
5. Three trials were conducted in several countries spanning both
low- and high-mortality countries. RV5 Armah 2010-AF was con-
ducted in three high-mortality countries,Ghana,Kenya, andMali,
and when available data were split into RV5 Armah 2010-GHA,
RV5Armah2010-KENandRV5Armah2010-MLI.RV5Vesikari
2006b-INT was conducted mainly in European and Latin Amer-
ican low-mortality countries, but also in Guatemala, a high-mor-
tality country, and was placed in the low-mortality group. RV5
Zaman 2010-AS was conducted in one high-mortality country
(Bangladesh) with 1136 participants, and in one low-mortality
country (Vietnam) with 900 participants, and was placed in the
high-mortality group, except when data could be split into RV5
Zaman 2010-BGD and RV5 Zaman 2010-VNM.
Vaccine schedule
Each trial used three doses of RV5 vaccine, with intervals between
doses of four and 10 weeks (see Appendix 6). All but one trial
had one vaccine and one placebo arm; RV5 Vesikari 2006a-FIN
included three vaccine arms in which there were different RV5
components (G1-4, P1A, G1-4, and P1A).
Infant vaccination status
Most trials did not restrict the use of other childhood vaccines,
see Appendix 6. One trial co-administered hepatitis B, diphthe-
ria-tetanus-acellular pertussis, poliovirus, and H. influenzae type
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b vaccines with RV5 (RV5 Ciarlet 2009-EU). Two trials allowed
the use of other licensed childhood vaccines, including oral polio
vaccine (RV5 Armah 2010-AF; RV5 Zaman 2010-AS). Three tri-
als did not allow the use of other vaccines (RV5 Clark 2003-USA;
RV5Clark 2004-USA; RV5NCT00953056 2010-CHI), and one
trial did not mention their use (RV5 NCT00718237 2010-JPN).
Methods for collecting adverse event data
As shown in Appendix 7, six trials used a combination of passive
methods (eg diary cards for parents) and active methods (directly
contacting parents) to collect adverse event data. The other trials
used passive methods only (diary cards, two trials), active methods
only (“active surveillance”, two trials), or the information was not
provided (two trials).
Source of funding
All trials were funded byMerck&Co., Inc. Two of those trials also
received funding and were run by PATH (GAVI Alliance grant)
(RV5 Armah 2010-AF; RV5 Zaman 2010-AS).
Ongoing studies
We identified 25 ongoing trials, 14 of RV1, one of RV5 and ten
others (RV1 together with RV5; RV3-BB; ORV 116E; Brazilian
Rotavirus vaccine; RotaVac and BRV-TV) (see Characteristics of
ongoing studies). As shown inAppendix 8, the RV1 trials are being
conducted in Africa (four), Asia (six), and Europe (three). The
ongoingRV5 trial is inAfrica, and the studies testing other vaccines
are located in Australia, Brazil, India, New Zealand, South Africa,
and the USA.
Risk of bias in included studies
We prepared a risk of bias assessment for each trial, with a focus on
the rotavirus diarrhoea outcome measure. Of the 41 RCTs anal-
ysed in this review, 25 (61%) reported an adequate generation of
allocation sequence, while the method of assignment was unclear
in the remaining studies. The methods used to conceal allocation
were considered adequate in 19 trials (46%), and unclear in the re-
maining studies. Information about blinding of participants, care
providers, or outcome assessors was provided and we considered
it to be adequate in 25 studies (61%), unclear for 15 studies, and
not double-blind for one study (RV1 Kerdpanich 2010-THA).
Incomplete outcome data was adequately addressed in 28 studies
(68%), unclear in 12 studies, and was not addressed adequately
in one study. Sixteen trials were free from selective reporting bias,
eight were not, and the remaining trials were unclear. Most trials
were sponsored by the industry and it was not possible to assess if
they were free of other biases; two recent trials performed in Africa
were considered free from other biases (RV5 Armah 2010-AF;
RV5 Zaman 2010-AS). An overall pictorial summary of the risk
of bias assessment is shown in Figure 2.
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Figure 2. Methodological quality summary: review authors’ judgements about each methodological quality
item for each included study.
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RV1
For all the GlaxoSmithKline unpublished studies (five of the
29 trials) and seven published trials (RV1 Bernstein 1998-USA;
RV1 Vesikari 2004a-FIN; RV1 Phua 2005-SGP; RV1 Ward
2006-USA; RV1 Narang 2009-IND; RV1 Zaman 2009-BGD;
RV1 Kawamura 2010-JPN), little or no information was available
about each criterion, which meant that we had to assess them as
unclear. Generally, the published trials provided more informa-
tion for assessment. We assessed nine of the remaining 17 trials as
having a low risk of bias for three or more criteria, including al-
location concealment (RV1 Bernstein 1999-USA; RV1 Dennehy
2005-NA; RV1 Ruiz-Palac 06-LA/EU; RV1 Vesikari 2007a-EU;
RV1 Phua 2009-AS; RV1Madhi 2010-AF; RV1 Anh 2011-PHL;
RV1 Anh 2011-VNM; RV1 Rivera 2011-DOM). Three trials
were assessed as high risk of bias; one trial for blinding (RV1
Kerdpanich 2010-THA), and two trials for selective reporting bias
(RV1 Ruiz-Palac 06-LA/EU; RV1 Salinas 2005-LA).
RV5
Based on unpublished information provided by Merck, many of
the trials’ risk of bias could be upgraded for the current update
of this review. Details of the new information is indicated in the
risk of bias tables in the Characteristics of included studies sec-
tion. Ten of the twelve RV5 trials were assessed as having a low
risk of bias for sequence generation, allocation concealment and
blinding, and varying risk of bias for attrition, selective reporting
and other bias.Two of these trials (RV5 Armah 2010-AF; RV5
Zaman 2010-AS) were assessed as having an overall low risk of
bias. The remaining two trials (RV5 Clark 2003-USA; RV5 Clark
2004-USA) both had low risk of bias for blinding of participants
and personnel, but amixed risk of bias for the remaining categories
ranging from high to low. Six of all 12 RV5 trials had a high risk
of bias for one or more criteria, most commonly a high risk of
selective reporting.
Effects of interventions
See: Summary of findings for the main comparison RV1
compared to placebo for preventing rotavirus diarrhoea in low-
mortality countries; Summary of findings 2 RV1 compared
to placebo for preventing rotavirus diarrhoea in high-mortality
countries; Summary of findings 3 RV5 compared to placebo
for preventing rotavirus diarrhoea in low-mortality countries;
Summary of findings 4 RV5 compared to placebo for preventing
rotavirus diarrhoea in high-mortality countries
1. RV1
1.1. Primary outcomes
1.1.1. Rotavirus diarrhoea: severe
Eleven trials provided data regarding the efficacy of RV1 to prevent
severe rotavirus diarrhoea in children; see Analysis 1.1 for up to 1
year follow-up andAnalysis 1.2 for two years follow-up. Trials were
performed in low-mortality countries (RV1 Bernstein 1999-USA;
RV1 Vesikari 2004b-FIN; RV1 Phua 2005-SGP; RV1 Salinas
2005-LA; RV1 Ruiz-Palac 06-LA/EU; RV1 Vesikari 2007a-EU;
RV1 GSK[024] 2008-LA; RV1 Phua 2009-AS; RV1 Kawamura
2010-JPN; ), and high-mortality countries (RV1 Madhi 2010-
MWI; RV1 Madhi 2010-ZAF; RV1 Steele 2010b-ZAF). Data
below are grouped accordingly.
Low-mortality countries (WHO strata A & B)
RV1 reduced severe rotavirus diarrhoea by 86%after both one (RR
0.14, 95% CI 0.07 to 0.26; 40,631 participants, six trials) and
two years (RR 0.15, 95% CI 0.12 to 0.20; 32,854 participants,
eight trials). After three years there was no statistically significant
difference between RV1 and placebo (RR 0.10, 95% CI 0.01 to
1.52; 12,109 participants, two trials (RV1 Phua 2009-AS and
RV1 Vesikari 2007a-EU; data not shown)). Pooled results were
significantly heterogeneous at one year (I2 = 66%, Analysis 1.1)
and three years (I2 = 69%, data not shown) follow-up.
High-mortality countries (WHO stratum E)
RV1 reduced rotavirus diarrhoea by 63% during the first year of
follow-up (RR 0.37, 95% CI 0.18 to 0.75; 5414 participants, two
trials) and by 42% after two years (RR 0.58, 95% CI 0.42 to
0.79; 2764participants, one trial). Pooled resultswere significantly
heterogeneous at one year follow-up (I2 = 70%, Analysis 1.1).
A funnel plot assymmetry was observed for trials reporting results
up to one year (Figure 3).
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Figure 3. Funnel plot of comparison: 1 RV1 versus placebo, outcome: 1.1 Rotavirus diarrhoea: severe (up to
1 year follow-up).
1.1.2. All-cause diarrhoea: severe
Severe all-cause diarrhoea was reported as cases in three trials (RV1
Phua 2005-SGP; RV1 Vesikari 2007a-EU; RV1Madhi 2010-AF)
and as episodes in two trials (RV1 Ruiz-Palac 06-LA/EU; RV1
Phua 2009-AS).We have reported these data separately. Trials were
performed in low-mortality countries (RV1 Phua 2005-SGP; RV1
Ruiz-Palac 06-LA/EU; RV1 Vesikari 2007a-EU; RV1 Phua 2009-
AS), and in high-mortality countries (RV1 Madhi 2010-MWI;
RV1 Madhi 2010-ZAF).
Low-mortality countries (WHO strata A & B)
RV1 reduced the number of severe cases of all-cause diarrhoea by
52% at one year (RR 0.48, 95% CI 0.37 to 0.61; 3874 partici-
pants, one trial; Analysis 1.3), by 51% at two years (RR 0.49, 95%
CI 0.40 to 0.60; 6269 participants, two trials; Analysis 1.4). RV1
reduced the number of severe episodes of all-cause diarrhoea by
40% at one year (rate ratio 0.60, 95% CI 0.50 to 0.72; 17,867
participants, one trial; Analysis 1.5), and by 37% at two years (rate
ratio 0.63, 95% CI 0.56 to 0.71; 39,091 participants, two trials;
Analysis 1.6). One trial reported on severe all-cause diarrhoea after
three years follow-up (RV1 Phua 2009-AS), RV1 reduced severe
cases by 27% (RR0.73, 95%CI 0.61 to 0.88; 10,519 participants;
data not shown).
High-mortality countries (WHO stratum E)
RV1 reduced the number of severe cases of all-cause diarrhoea by
30% at one year follow-up (RR 0.66, 95% CI 0.44 to 0.98; 4939
participants, one trial; Analysis 1.3), and by 17% at two years
follow-up (RR 0.82, 95% CI 0.71 to 0.95; 2764 participants, one
trial; Analysis 1.4). Pooled results were significantly heterogeneous
at one year follow-up (I2 = 82%).
1.1.3. All-cause death
Twenty-five trials reported on all-cause death, either as the number
of deaths (RV1 Bernstein 1999-USA; RV1 Phua 2005-SGP; RV1
Vesikari 2007a-EU; RV1 Phua 2009-AS; RV1 Madhi 2010-AF;
RV1 Steele 2010a-ZAF) or, in most trials, as fatal serious ad-
verse events (RV1 Vesikari 2004b-FIN; RV1 Salinas 2005-LA;
RV1 Ruiz-Palac 06-LA/EU; RV1 GSK[041] 2007-KOR; RV1
GSK[033] 2007-LA; RV1GSK[021] 2007-PAN; RV1GSK[024]
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2008-LA; RV1 GSK[101555] 2008-PHL; RV1 Steele 2008-
ZAF; RV1 Narang 2009-IND; RV1 Zaman 2009-BGD; RV1
Kawamura 2010-JPN; RV1 Kerdpanich 2010-THA; RV1 Steele
2010b-ZAF; RV1 Anh 2011-PHL; RV1 Anh 2011-VNM; RV1
Rivera 2011-DOM; RV1 Vesikari 2011-FIN; RV1 Omenaca
2012-EU). Number of deaths and fatal serious adverse events were
pooled; see Analysis 1.7. Details of causes of death for each trial
are presented in Appendix 9. Most trials were performed in low-
mortality countries, and seven trials in high-mortality countries
(RV1 GSK[033] 2007-LA; RV1 Steele 2008-ZAF; RV1 Narang
2009-IND; RV1 Zaman 2009-BGD; RV1Madhi 2010-AF; RV1
Steele 2010a-ZAF; RV1 Steele 2010b-ZAF).
Low-mortality countries (WHO strata A & B)
There was no statistically significant difference in all-cause death
between the two arms (18 trials, 93,321 participants).
High-mortality countries (WHO strata D & E)
There was no statistically significant difference in all-cause death
between the two arms (7 trials, 7481 participants).
1.1.4. All serious adverse events
The total number of serious adverse events were reported in
27 trials, performed in low-mortality countries (RV1 Bernstein
1998-USA; RV1 Vesikari 2004a-FIN; RV1 Vesikari 2004b-FIN;
RV1 Dennehy 2005-NA; RV1 Phua 2005-SGP; RV1 Salinas
2005-LA; RV1 Ruiz-Palac 06-LA/EU; RV1 GSK[041] 2007-
KOR; RV1 GSK[021] 2007-PAN; RV1 Vesikari 2007a-EU;
RV1 GSK[024] 2008-LA; RV1 GSK[101555] 2008-PHL; RV1
Phua 2009-AS; RV1 Kawamura 2010-JPN; RV1 Kerdpanich
2010-THA; RV1 Rivera 2011-DOM; RV1 Anh 2011-PHL; RV1
Anh 2011-VNM; RV1 Vesikari 2011-FIN; RV1 Omenaca 2012-
EU), and in high-mortality countries (RV1 GSK[033] 2007-LA;
RV1 Steele 2008-ZAF; RV1 Narang 2009-IND; RV1 Zaman
2009-BGD; RV1 Madhi 2010-AF; RV1 Steele 2010a-ZAF; RV1
Steele 2010b-ZAF); see Analysis 1.8.
Low-mortality countries (WHO strata A & B)
Fewer children allocated to RV1 had serious adverse events com-
pared with placebo (RR 0.90, 95% CI 0.84 to 0.95; 91,957 par-
ticipants, 20 trials).
High-mortality countries (WHO strata D & E)
There was no statistically significant difference in the number of
serious adverse events between the two arms (RR 0.89, 95% CI
0.76 to 1.04; 7481 participants, seven trials).
1.1.5. Serious adverse events: intussusception
Twelve trials reported cases of intussusception. Trials were per-
formed in low-mortality countries (RV1 Vesikari 2004b-FIN;
RV1 Dennehy 2005-NA; RV1 Phua 2005-SGP; RV1 Salinas
2005-LA; RV1 Ruiz-Palac 06-LA/EU; RV1 Vesikari 2007a-EU;
RV1 GSK[024] 2008-LA; RV1 Phua 2009-AS; RV1 Kawamura
2010-JPN; RV1Rivera 2011-DOM), and in high-mortality coun-
tries (RV1Madhi 2010-AF; RV1 Steele 2010b-ZAF); see Analysis
1.9.
Low-mortality countries (WHO strata A & B)
Twenty-nine cases of intussusception were reported in a total of
49,355 children in the RV1 arm compared with 28 cases of intus-
susception in 42,477 children of the placebo arm. Pooled results
showed no increased risk for intussusception in children receiving
RV1 when compared to placebo (RR 0.87, 95% CI 0.52 to 1.46;
91,832 participants, 11 trials).
High-mortality countries (WHO stratum E)
One case of intussusception was reported in a total of 3677 chil-
dren in the RV1 arm compared with no cases of intussusception
in 1737 children in the placebo arm. Pooled results showed no
increased risk for intussusception in children receiving RV1 when
compared to placebo (RR 1.49, 95% CI 0.06 to 36.63; 5414 par-
ticipants, two trials).
1.2. Secondary outcomes
1.2.1 Serious adverse events: Kawasaki disease
Three trials reported four cases of Kawasaki disease among 7701
children allocated to RV1 compared to no cases in 5416 children
allocated to placebo (RV1 Phua 2005-SGP; RV1 Salinas 2005-LA;
RV1 Phua 2009-AS). We did not observe a statistically significant
difference between the intervention and placebo group (RR 1.79,
95% CI 0.30 to 10.61; 13,117 participants, three trials; Analysis
1.10).
1.2.2. Serious adverse events requiring hospitalization
Two trials reported serious adverse events requiring hospitalization
(RV1 Ruiz-Palac 06-LA/EU; RV1 Steele 2008-ZAF) and found
fewer events in the RV1 group than the placebo group (RR 0.88,
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95% CI 0.81 to 0.96; 63,675 participants, two trials; Analysis
1.11).
1.2.3 Rotavirus diarrhoea of any severity
Eighteen trials provided data regarding the efficacy of RV1 to pre-
vent rotavirus diarrhoea in children; see Analysis 1.12 for two
months safety trial follow-up, Analysis 1.13 for one year follow-
up and Analysis 1.14 for two years follow-up. Trials were per-
formed in low-mortality countries (RV1 Bernstein 1999-USA;
RV1 Vesikari 2004b-FIN; RV1 Phua 2005-SGP; RV1 Salinas
2005-LA; RV1 GSK[041] 2007-KOR; RV1 Vesikari 2007a-EU;
RV1 GSK[101555] 2008-PHL; RV1 Kerdpanich 2010-THA;
RV1 Anh 2011-PHL; RV1 Anh 2011-VNM; RV1 Rivera 2011-
DOM;RV1Vesikari 2011-FIN; RV1Omenaca 2012-EU), and in
high-mortality countries (RV1 Narang 2009-IND; RV1 Zaman
2009-BGD; RV1 Madhi 2010-MWI; RV1 Madhi 2010-ZAF;
RV1 Steele 2010a-ZAF; RV1 Steele 2010b-ZAF). Data below are
grouped accordingly.
Low-mortality countries (WHO strata A & B)
Safety trials (up to two months follow-up): RV1 was not supe-
rior to placebo in the prevention of rotavirus diarrhoea in the trials
assessing outcomes up to two months after vaccination (RR 1.28,
95% CI 0.66 to 2.50; 2853 participants, eight trials). These trials,
although reporting cases of rotavirus diarrhoea, were not designed
to measure efficacy.
Efficacy trials (one to three years follow-up): RV1 reduced ro-
tavirus diarrhoea by 81% at up to one year (RR 0.19, 95%CI 0.08
to 0.47; 5935 participants, three trials) and 67% at the second
year of follow-up (RR 0.33, 95% CI 0.21 to 0.50; 7293 partici-
pants, five trials). Pooled results, however, were significantly het-
erogeneous at one year (I2 = 86%, Analysis 1.13) and two years (I
2 = 52%, Analysis 1.14) of follow-up. At the third year of follow-
up, there were very few reported cases of rotavirus diarrhoea of
any severity. Based on a single trial (RV1Vesikari 2007a-EU, 1590
participants), there was no difference between RV1 and placebo
groups (data not shown).
High-mortality countries (WHO strata D & E)
Safety trials (up to twomonths follow-up):Three trials foundno
difference in the RV1 group compared to placebo when outcomes
were assessed up to two months after vaccination (RR 1.00, 95%
CI 0.41 to 2.41; 757 participants, two trials).
Efficacy trials (one to two years follow-up): RV1 reduced ro-
tavirus diarrhoea by 55% during the first year of follow-up (RR
0.45, 95% CI 0.28 to 0.73; 5414 participants, three trials), and
by 59% during the second year (RR 0.41, 95% CI 0.28 to 0.62;
1251 participants, one trial). Pooled results were significantly het-
erogeneous at one year follow-up (I2 = 81%, Analysis 1.13).
1.2.4. All-cause diarrhoea: of any severity
This outcome was reported as cases in eight trials from low-mor-
tality countries (RV1 Vesikari 2004b-FIN; RV1 Phua 2005-SGP;
RV1 Salinas 2005-LA; RV1 Kerdpanich 2010-THA; RV1 Anh
2011-PHL; RV1 Anh 2011-VNM; RV1 Vesikari 2011-FIN; RV1
Rivera 2011-DOM), in one trial from a high-mortality country
(RV1 Steele 2010a-ZAF), and as episodes in three of the eight tri-
als from low-mortality countries (RV1 Vesikari 2004b-FIN; RV1
Salinas 2005-LA; RV1 Rivera 2011-DOM). We have reported
these data separately.
Low-mortality countries (WHO strata A & B)
Safety trials (up to two months follow-up): RV1 was not better
than placebo in reducing the number of cases of all-cause diarrhoea
at two months (2348 participants, five trials; Analysis 1.15).
Efficacy trials (one to two years follow-up): RV1 was not better
than placebo in reducing the number of cases of all-cause diar-
rhoea at one year follow-up (2204 participants, two trials, Analysis
1.16), or after two years (2789 participants, two trials; Analysis
1.17).Two trials reported the number of episodes, with no statis-
tically significant benefit with RV1 when compared to placebo at
one year (2204 participants, two trials; Analysis 1.18) or at two
years (736 participants, one trial; Analysis 1.19).
High-mortality countries (WHO stratum E)
Safety trials (up to two months follow-up): RV1 was not better
than placebo in reducing the number of cases of all-cause diarrhoea
at two months (100 participants, one trial; Analysis 1.15).
1.2.5. All-cause hospitalizations
One trial, performed in Singapore (RV1 Phua 2005-SGP) pro-
vided data regarding the efficacy of RV1 to prevent all-cause hos-
pitalizations.
Low-mortality countries (WHO stratum A)
RV1 reduced hospitalizations in the second year of follow-up by
64% (RR 0.36, 95%CI 0.15 to 0.86; 2421 participants, one trial;
Analysis 1.20).
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1.2.6. Rotavirus diarrhoea: requiring hospitalization or
medical attention
Hospitalizations were reduced by 81% after one year (RR 0.19,
95% CI 0.08 to 0.43; 39,260 participants, six trials), 86% at
two years (RR 0.14, 95% CI 0.09 to 0.23; 32,183 participants,
six trials), and 95% at three years (RR 0.05, 95% CI 0.02 to
0.16; 10,519 participants, one trial (RV1 Phua 2009-AS, data not
shown)); pooled results were significantly heterogeneous at one
year of follow-up (I2 = 63%); see Analysis 1.21.
RV1 reduced medical visits by 92% at one year (RR 0.08, 95% CI
0.04 to 0.16; 3874 participants, one trial) and 78% at two years
(RR 0.22, 95% CI 0.16 to 0.31; 7017 participants, three trials);
see Analysis 1.22.
1.2.7. All-cause diarrhoea: requiring hospitalization
There was no significant difference between RV1 and placebo re-
garding cases of hospitalization for all-cause diarrhoea (14,393 par-
ticipants, two trials; Analysis 1.23). At two years follow-up, RV1
reduced cases by 48% (RR0.52, 95%CI 0.27 to 0.99; 14,367 par-
ticipants, two trials; Analysis 1.23). RV1 Phua 2009-AS reported
hospitalizations due to all-cause diarrhoea at three years follow-
up, RV1 reduced hospitaizations by 28% (RR 0.72, 95% CI 0.59
to 0.86; 10,519 participants, data not shown). Pooled results were
significantly heterogeneous at one year (I2 = 83%) and at two years
follow-up (I2 = 77%).
RV1 Ruiz-Palac 06-LA/EU presented data on the number of
episodes (Analysis 1.24); RV1 reduced hospitalizations by 42% at
one year (rate ratio 0.58, 95% CI 0.47 to 0.71; 17,867 partici-
pants, one trial) and 47% at two years (rate ratio 0.53, 95% CI
0.46 to 0.61; 14,286 participants, one trial).
1.2.8. Reactogenicity
The occurrence of fever (Analysis 1.25), diarrhoea (Analysis 1.26),
and vomiting (Analysis 1.27) were evaluated at several time points:
after the first dose, after the second dose, after the third dose, and
at the end of the follow-up period. Most trials contributed data to
these outcomes. There were similar results for RV1 and placebo
for each outcome and time point.
1.2.9. Adverse events that require discontinuation of
vaccination schedule
There was no statistically significant difference between RV1 and
placebo in the number of adverse events leading to discontinua-
tion of the vaccination schedule (RR 1.07, 95% CI 0.86 to 1.34;
90,604 participants, 21 trials; Analysis 1.28).
1.3. Immunogenicity
Data on immunogenicity was not stratified by WHO strata. RV1
was more immunogenic than placebo when measured by vaccine
virus shedding at the end of follow-up (RR 12.07, 95% CI 5.23
to 27.85; 2606 participants, 15 trials; Analysis 1.29), although the
results were significantly heterogeneous (I2 = 77%, Analysis 1.29).
It was also more immunogenic when measured by seroconversion
at all time points (Analysis 1.30); although the pooled data were
significantly heterogeneous after dose one (I2 = 57%) and two (I
2 = 82%).
1.4. Drop-outs before the end of trial
Twenty-two trials reported on the number of participants who
dropped out of the trial before it ended. Overall, there was no
statistically significant difference between the RV1 and placebo
groups (RR 0.91, 95% CI 0.81 to 1.02; 25,005 participants, 22
trials; Analysis 1.31).
1.5. Subgroup analyses
1.5.1. G type
Rotavirus diarrhoea: of any severity
There were significantly fewer episodes of rotavirus diarrhoea of
any severity in the group receivingRV1when compared toplacebo,
regardless of G type; however, the pooled data for G1 andG9 types
were significantly heterogeneous (I2 = 66% and 81% respectively),
see Analysis 1.32.
Rotavirus diarrhoea: severe
There were significantly fewer severe episodes of rotavirus diar-
rhoea in the RV1 groups compared with placebo in all episodes
attributed to the G1 type (RR 0.20, 95% CI 0.11 to 0.37; 36,100
participants, five trials), G2 type (RR 0.40, 95% CI 0.16 to 0.98;
37,117 participants, four trials), and G9 type (RR 0.15, 95% CI
0.07 to 0.33; 19,250 participants, three trials); see Analysis 1.33.
Results were not statistically significant for G3 types (12,940 par-
ticipants, two trials) or for G4 types (2421 participants, one trial).
The pooled data for G3 types were significantly heterogeneous (I
2 = 72%), with the larger of the two included trials (RV1 Phua
2009-AS) reporting a statistically significant difference favouring
RV1, whereas the smaller trial (RV1 Phua 2005-SGP) reported no
statistically significant difference.
1.5.2. Malnourished children
Rotavirus diarrhoea: of any severity
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One trial, RV1 Salinas 2005-LA, provided data separately as the
number of cases of rotavirus diarrhoea of any severity in a sub-
group of malnourished children. RV1was significantly better than
placebo in preventing rotavirus diarrhoea for this subgroup at one
year of follow-up (RR 0.39, 95% CI 0.19 to 0.79; 287 partici-
pants, Analysis 1.34).
1.5.3. Children infected with HIV
Rotavirus diarrhoea: of any severity
One safety trial, RV1 Steele 2010a-ZAF, included only confirmed
HIV-positive, asymptomatic or mildly symptomatic children. At
one month follow-up, no statistically significant difference be-
tween the RV1 and placebo arms for rotavirus diarrhoea was re-
ported (100 participants, one trial; Analysis 1.35).
One efficacy trial, RV1 Madhi 2010-AF, included children who
were infectedwithHIV or children that have been exposed toHIV,
as long as they were not clinically immunosuppressed (eg AIDS)
at the age of vaccination (six weeks). HIV tests were performed in
approximately 46% of children fromMalawi and 23% of children
from South Africa. Specific analysis for this population was not
conducted, but the authors stated that demographic characteristics
and the proportion of children who were infected with HIV were
similar across the study groups.
1.5.4. Premature babies
One trial (RV1 Omenaca 2012-EU) included only prematurely
born infants.
Serious adverse events
RV1 Omenaca 2012-EU included only prematurely born infants.
There was no statistically significant difference between children
that received RV1 and those that received placebo for serious ad-
verse events (1009 participants, Analysis 1.36).
1.5.5. Breast fed or formula fed children
Feeding practices of infants in one trial (RV1 Vesikari 2007a-EU)
were recorded as breast fed for at least one dose or exclusively
formula fed.
Rotavirus diarrhoea: severe
At up to two years follow-up, RV1 compared to placebo reduced
severe rotavirus diarrhoea in breast fed children by 91% (RR 0.09,
95% CI 0.06 to 0.14; 3046 participants, one trial), and by 98%
(RR 0.02, 95% CI 0.00 to 0.14; 828 participants, one trial) in
formula fed children; see Analysis 1.37.
1.6 Sensitivity analysis
1.6.1 Primary outcomes with high heterogeneity according
to allocation concealment
To investigate heterogeneity for primary outcomes with pooled
results where I2 > 75%, we pooled data only from studies with
good allocation concealment. There was no significant change to
RR and 95% CI for these outcomes, and heterogeneity remained
high, see Analysis 1.38.
Summary of findings
Summary of findings of primary outcomes according to country
mortality rate (WHO strata A-E) are presented in Summary of
findings for the main comparison (RV1, low-mortality countries),
and in Summary of findings 2 (RV1, high-mortality countries).
2. RV5
2.1. Primary outcomes
2.1.1. Rotavirus diarrhoea: severe
Six trials provided data regarding the efficacy of RV5 to prevent
severe rotavirus diarrhoea in children; see Analysis 2.1 for one
year follow-up and Analysis 2.2 for two years follow-up. Trials
were performed in low-mortality countries (RV5 Clark 2004-
USA; RV5 Vesikari 2006b-INT; RV5 Block 2007-EU/USA; RV5
NCT00718237 2010-JPN), one trial was split between low-mor-
tality Vietnam in stratum B (RV5 Zaman 2010-VNM) and high-
mortality Bangladesh in stratum D (RV5 Zaman 2010-BGD),
and another between high-mortality Ghana and Mali in stratum
D (RV5 Armah 2010-GHA; RV5 Armah 2010-MLI) and high-
mortality Kenya in stratum E (RV5 Armah 2010-KEN). Data be-
low are grouped accordingly.
Low-mortality countries (WHO strata A & B)
RV5 reduced severe rotavirus diarrhoea by 87% at one year (RR
0.13, 95% CI 0.04 to 0.45; 2344 participants, three trials) and
82% by two years (RR 0.18, 95% CI 0.07 to 0.50; 3190 partici-
pants, three trials).
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High-mortality countries (WHO strata D & E)
RV5 reduced severe rotavirus diarrhoea by 57% at one year (RR
0.43, 95%CI 0.29 to 0.62; 5916 participants, two trials) and 41%
by two years (RR 0.59, 95% CI 0.43 to 0.82; 5885 participants,
two trials). Pooled results were significantly heterogeneous at two
years follow-up (I2 = 43%); see Analysis 2.2.
2.1.2. All-cause diarrhoea: severe
Three trials provided data regarding the efficacy of RV5 to prevent
severe all-cause diarrhoea in children; see Analysis 2.3 for 1 year
follow-up and Analysis 2.4 for two years follow-up. Trials were
performed in a low-mortality country (RV5 Vesikari 2006a-FIN),
and in high-mortality countries (RV5 Armah 2010-GHA; RV5
Armah 2010-KEN; RV5 Armah 2010-MLI; RV5 Zaman 2010-
AS).
Low-mortality countries (WHO stratum A)
A single trial showed a reduction in the number of severe cases of
diarrhoea with RV5 compared to placebo at one year by 72% (RR
0.28, 95%CI 0.16 to 0.48; 1029 participants, one trial). This trial
was conducted in Finland (RV5 Vesikari 2006a-FIN) and reported
this outcome for only 53% of the enrolled patients. At the two
year follow-up, there was a 96% reduction with RV5 compared to
placebo (RR 0.04, 95% CI 0.00 to 0.70; 1029 participants, one
trial). However, this large reduction is unlikely as the reduction
for severe rotavirus diarrhoea was smaller (Analysis 2.2). It was
probably a matter of chance as the sample size for this study was
small and different studies reported on severe rotavirus diarrhoea.
High-mortality countries (WHO strata D & E)
There was no statistically significant difference between RV5 and
placebo for all-cause severe diarrhoea at one year follow-up (4085
participants, three trials). At two years follow-up, RV5 reduced
severe cases by 15% (RR 0.85, 95% CI 0.75 to 0.98; 5977 partic-
ipants, four trials). Pooled results were significantly heterogeneous
at one year follow-up (I2 = 46%); see Analysis 2.3.
2.1.3. All-cause death
Nine trials reported on all-cause death, in most trials as the
number of deaths (RV5 Merck[009] 2005-USA; RV5 Vesikari
2006a-FIN; RV5 Vesikari 2006b-INT; RV5 Armah 2010-AF;
RV5 NCT00953056 2010-CHI; RV5 NCT00718237 2010-
JPN; RV5 Zaman 2010-AS), and in two trials as fatal serious ad-
verse events (RV5 Block 2007-EU/USA; RV5 Ciarlet 2009-EU).
Number of deaths and fatal serious adverse events were pooled; see
Analysis 2.5. Details of causes of death for each trial are presented
in Appendix 9. Most trials were performed in low-mortality coun-
tries, one trial was split between low-mortality Vietnam in stratum
B (RV5 Zaman 2010-VNM) and high-mortality Bangladesh in
stratum D (RV5 Zaman 2010-BGD), and another between high-
mortality Ghana andMali in stratumD (RV5Armah 2010-GHA;
RV5 Armah 2010-MLI) and high-mortality Kenya in stratum E
(RV5 Armah 2010-KEN).
Low-mortality countries (WHO strata A & B)
There was no statistically significant difference in all-cause death
between RV5 and placebo arm (73,603 participants, eight trials;
Analysis 2.5).
High-mortality countries (WHO strata D & E)
There was no statistically significant difference in all-cause death
between the two arms (6604 participants, four trials; Analysis 2.5).
2.1.4. All serious adverse events
Serious adverse events were reported in eight trials, and per-
formed in low-mortality countries (RV5 Vesikari 2006b-INT;
RV5 Block 2007-EU/USA; RV5 Kim 2008-KOR; RV5 Ciarlet
2009-EU; RV5NCT00953056 2010-CHI; RV5NCT00718237
2010-JPN; RV5 Zaman 2010-VNM), and in high-mortality
countries (RV5 Armah 2010-GHA; RV5Armah 2010-KEN; RV5
Armah 2010-MLI; RV5 Zaman 2010-BGD); see Analysis 2.6.
Low-mortality countries (WHO strata A & B)
Pooled results showed no statistically significant difference in the
number of serious adverse events in the RV5 group compared
with the placebo group (RR 0.92, 95% CI 0.84 to 1.01; 71,638
participants, seven trials; Analysis 2.6).
High-mortality countries (WHO strata D & E)
Pooled results showed no statistically significant difference in the
number of serious adverse events in the RV5 group compared
with the placebo group (RR 0.93, 95% CI 0.66 to 1.33; 6588
participants, four trials; Analysis 2.6).
2.1.5. Serious adverse events: intussusception
All twelve trials reported cases of intussusception. Trials were
performed in low-mortality countries (RV5 Clark 2003-USA;
RV5 Clark 2004-USA; RV5 Merck[009] 2005-USA; RV5
Vesikari 2006a-FIN; RV5 Vesikari 2006b-INT; RV5 Block
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2007-EU/USA; RV5 Kim 2008-KOR; RV5 Ciarlet 2009-EU;
RV5 NCT00953056 2010-CHI; RV5 NCT00718237 2010-
JPN; RV5 Zaman 2010-VNM), and in high-mortality countries
(RV5 Armah 2010-GHA; RV5 Armah 2010-KEN; RV5 Armah
2010-MLI; RV5 Zaman 2010-BGD); see Analysis 2.7.
Low-mortality countries (WHO strata A & B)
Fourteen cases of intussusceptionwere reported in a total of 38,321
children in theRV5armcomparedwith 20 cases of intussusception
in 36,553 children in the placebo arm. Pooled results showed no
increased risk of intussusception in children receiving RV5 when
compared to placebo (RR 0.67, 95% CI 0.34 to 1.31; 74,874
participants, 11 trials; Analysis 2.7).
High-mortality countries (WHO strata D & E)
There were no reported cases of intussusception in a total of 3294
children in the RV5 arm and 3294 children in the placebo arm
(two trials).
2.2. Secondary outcomes
2.2.1. Rotavirus diarrhoea: of any severity
Seven trials provided data regarding the efficacy of RV5 to prevent
rotavirus diarrhoea of any severity in children; see Analysis 2.8
for one year follow-up and Analysis 2.9 for two years follow-up.
Trials were performed in low-mortality countries (RV5 Clark
2003-USA; RV5 Clark 2004-USA; RV5 Vesikari 2006b-INT;
RV5 Block 2007-EU/USA; RV5NCT00718237 2010-JPN), and
in high-mortality countries (RV5 Armah 2010-GHA;RV5Armah
2010-KEN; RV5Armah 2010-MLI; RV5 Zaman 2010-AS).Data
below are grouped accordingly.
Low-mortality countries (WHO strata A & B)
RV5 reduced the number of cases of rotavirus diarrhoea by 73% at
one year (RR 0.27, 95% CI 0.22 to 0.33; 7614 participants, four
trials; Analysis 2.8) and 64% during the second year (RR 0.36,
95% CI 0.25 to 0.50; 2280 participants, two trials; Analysis 2.9).
High-mortality countries (WHO strata D & E)
RV5 reduced the number of cases of rotavirus diarrhoea by 48%
at one year (RR 0.52, 95% CI 0.28 to 0.94; 4806 participants,
three trials; Analysis 2.8) and 39% during the second year (RR
0.61, 95% CI 0.45 to 0.83; 6744 participants, four trials; Analysis
2.9). Pooled results were significantly heterogenous at one year (I2
= 67%; see Analysis 2.8) and at two years (I2 = 69%; see Analysis
2.9) years follow-up.
2.2.2. All-cause diarrhoea: of any severity
One trial performed in low-mortality Finland (RV5 Vesikari
2006a-FIN), and one trial in high-mortality Kenya (RV5 Armah
2010-KEN) provided data regarding the efficacy of RV5 to pre-
vent all-cause diarrhoea of any severity; see Analysis 2.10 for one
year and Analysis 2.11 for two years follow-up.
Low-mortality countries (WHO strata A & B)
RV5 reduced the number of cases of all-cause diarrhoea by 59%
at one year follow-up (RR 0.41, 95% CI 0.28 to 0.60; 1030 par-
ticipants, one trial; Analysis 2.10).
High-mortality countries (WHO stratum E)
There was no statistically significant difference between RV5 and
placebo for any severity all-cause diarrhoea at one year (1059 par-
ticipants, one trial; Analysis 2.10) or at two years (1059 partici-
pants, one trial; Analysis 2.10) follow-up.
2.2.3. Rotavirus diarrhoea: requiring hospitalization or
medical attention
RV5 reduced hospitalizations due to rotavirus diarrhoea episodes
by 96% at one year of follow-up (RR 0.04, 95% CI 0.02 to 0.10;
57,134 participants, one trial; Analysis 2.12).
RV5 reduced the number of children requiring medical attention
at one year of follow-up by 93% compared to placebo (RR 0.07,
95% CI 0.04 to 0.12; 57,134 participants, one trial; Analysis
2.13).
Data regarding medical attention and hospitalization rates due to
all-cause diarrhoea were not estimable.
2.2.4. Reactogenicity
The incidences of fever (Analysis 2.14), diarrhoea (Analysis 2.15),
and vomiting (Analysis 2.16) were evaluated after the first dose,
seconddose, and third dose, and at the endof the follow-up period.
There was a 28% increase in the incidence of fever after the first
dose of RV5 vaccine compared to placebo (RR 1.28, 95% CI
1.04 to 1.58; 3090 participants, three trials; Analysis 2.14). No
statistically significant differences were observed between the RV5
and placebo groups for the other reactogenicity outcomes and
timepoints. Significant heterogeneity was observed for the pooled
end of follow-up data on fever (I2 = 52%).
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2.2.5. Adverse events that require discontinuation of
vaccination schedule
Nine trials reported the number of adverse events leading to dis-
continuation of the vaccination schedule, and, overall, there was
no statistically significant difference between RV5 and placebo (
11,437 participants, nine trials; Analysis 2.17).
2.3. Immunogenicity
RV5 is an immunogenic vaccine and immunogenicity was mea-
sured by rotavirus vaccine virus shedding (three trials, Analysis
2.18) and seroconversion (eight trials, Analysis 2.19) after the third
vaccine dose. Data, however, could not be pooled because of sig-
nificant heterogeneity (I2 = 80% and 88%, respectively).
2.4. Drop-outs before the end of trial
Similar numbers of children taking RV5 or placebo dropped
out from trials before they ended (81,573 participants, 10 trials;
Analysis 2.20).
2.5. Subgroup analyses
2.5.1. G type
Rotavirus diarrhoea: of any severity
When the analyses were stratified by the G type (Analysis 2.21),
there were fewer episodes of rotavirus diarrhoea in the RV5 group
compared to the placebo group for the G1 type (RR 0.26, 95%CI
0.21 to 0.33; 7158 participants, three trials) and the G2 type (RR
0.37, 95% CI 0.16 to 0.88; 6043 participants, two trials). The
results were not statistically significant for G3 (7158 participants,
three trials), G4 (6043 participants, two trials), and G9 (5673
participants, one trial).
Rotavirus diarrhoea: severe
Two trials analysed severe cases of rotavirus diarrhoea by G
type (RV5 Vesikari 2006b-INT; RV5 Armah 2010-AF; Analysis
2.22).There were significantly fewer severe episodes of rotavirus
diarrhoea in the RV5 groups for G4 (RR 0.11, 95% CI 0.03 to
0.48; 72,743 participants, two trials). Pooled results were not sig-
nificant, but heterogenous for G1 (I2 = 99%), G2 (I2 = 63%), G3
(I2 = 53%) and for G9 (I2 = 55%).
2.5.2. HIV-infected children
One trial (RV5 Armah 2010-AF) performed HIV tests for 89%
of participants and reported outcomes for HIV-infected children
(38/1158); see Analysis 2.23.
Rotavirus diarrhoea: severe (up to two years follow-up)
1/21 children in the vaccine arm, and 0/17 children in the placebo
arm had severe rotavirus diarrhoea during two years follow-up;
there was no statistically significant difference detected between
the two treatment arms.
All-cause diarrhoea: severe (up to two years follow-up)
5/21 children in the vaccine arm, and 1/17 children in the placebo
arm had severe all-cause diarrhoea during two years follow-up;
there was no statistically significant difference detected between
the two treatment arms.
All-cause death
8/21 children in the vaccine arm, and 4/17 children in the placebo
arm died; there was no statistically significant difference between
the two arms.
Serious adverse events (1-14 days after any dose)
5/21 children in the vaccine arm, and 2/16 children in the placebo
arm had a serious adverse event between one to 14 days after any
dose; there was no statistically significant difference between the
two arms.
2.5.3. Premature babies
Rotavirus diarrhoea: of any severity
In one of the included trials, RV5 Vesikari 2006b-INT, data were
provided separately as the number of cases of rotavirus diarrhoea
in a subgroup of 170 premature babies. RV5 was marginally better
than placebo at one year follow-up (RR0.39, 95%CI 0.15 to 1.06;
Analysis 2.24) in preventing rotavirus diarrhoea for this subgroup
of premature babies.
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2.6 Sensitivity analysis
2.6.1 Primary outcomes with high heterogeneity according
to allocation concealment
There were no primary outcomes with high heterogeneity (I2 >
75%).
Summary of findings
Summary of findings of primary outcomes according to country
mortality rate (WHO strata A-E) are presented in Summary of
findings 3 (RV5, low-mortality countries), and in Summary of
findings 4 (RV5, high-mortality countries).
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Patient or population: children
Settings: high-mortality countries (WHO strata D & E)
Intervention: RV1
Comparison: placebo
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Placebo RV1
Severe rotavirus diar-
rhoea
Follow-up: up to 1 year
50 per 1000 18 per 1000
(9 to 37)
RR 0.37
(0.18 to 0.75)
5414
(2 studies)
⊕⊕⊕©
moderate1
We did not downgrade
for inconsistency as the
heterogeneity observed in
the pooled data (I2 =
70%) was due to within
study heterogeneity (RV1
Madhi 2010-AF results
split per country).
Severe rotavirus diar-
rhoea
Follow-up: up to 2 years
74 per 1000 43 per 1000
(31 to 59)
RR 0.58
(0.42 to 0.79)
2764
(1 study)
⊕⊕⊕©
moderate1
Severe all-cause diar-
rhoea
Follow-up: up to 1 year
137 per 1000 90 per 1000
(60 to 134)
RR 0.66
(0.44 to 0.98)
4939
(1 study)
⊕⊕⊕©
moderate1
We did not downgrade
for inconsistency as the
heterogeneity observed in
the pooled data (I2 =
82%) was due to within
study heterogeneity (RV1
Madhi 2010-AF results
split per country).
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Severe all-cause diar-
rhoea
Follow-up: up to 2 years
233 per 1000 191 per 1000
(166 to 222)
RR 0.82
(0.71 to 0.95)
2764
(1 study)
⊕⊕⊕©
moderate1
All-cause death
Follow-up: 2 months to 2
years
24 per 1000 21 per 1000
(16 to 30)
RR 0.88
(0.64 to 1.22)
7481
(7 studies)
⊕⊕©©
low2
All serious adverse
events
Follow-up: 2 months to 2
years
95 per 1000 84 per 1000
(72 to 99)
RR 0.89
(0.76 to 1.04)
7481
(7 studies)
⊕⊕⊕©
moderate3
Serious adverse events:
intussusception
Follow-up: 2 months to 2
years
0 per 100,000 0 per 100,000
(0 to 0)
RR 1.49
(0.06 to 36.63)
5414
(2 studies)
⊕©©©
very low1,4
*The basis for the assumed risk is the control group risk across studies. The corresponding risk (and its 95% CI) is based on the assumed risk in the comparison group and the relative
effect of the intervention (and its 95% CI).
CI: confidence interval; RR: risk ratio
GRADE Working Group grades of evidence
High-quality: further research is very unlikely to change our confidence in the estimate of effect.
Moderate-quality: further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low-quality: further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low-quality: we are very uncertain about the estimate.
1 Downgraded by 1 for indirectness. Trials were conducted in Malawi and South Africa, generalisation to any high-mortality country is
difficult.
2 Downgraded by 2 for imprecision. These trials were not powered to detect an effect on mortality.
3 Downgraded by 1 for risk of bias. Six of the seven included studies did not adequately report allocation concealment, four did not
adequately report blinding, and two attrition.
4 Downgraded by 2 for imprecision. There was a 1:10,000 increased risk of intussusception with a previous rotavirus vaccine (http:/
/www.who.int/vaccines-documents/DocsPDF04/wwwSOWVE.pdf), therefore, these trials were not powered to detect an association
between RV1 and intussusception.
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Patient or population: children
Settings: low-mortality countries (WHO strata A & B)
Intervention: RV5
Comparison: placebo
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Placebo RV5
Severe rotavirus diar-
rhoea
Follow-up: up to 1 year
18 per 1000 2 per 1000
(1 to 8)
RR 0.13
(0.04 to 0.45)
2344
(3 studies)
⊕⊕⊕©
moderate1
Severe rotavirus diar-
rhoea
Follow-up: up to 2 years
27 per 1000 5 per 1000
(2 to 13)
RR 0.18
(0.07 to 0.5)
3190
(3 studies)
⊕⊕⊕©
moderate1
Severe all-cause diar-
rhoea
Follow-up: up to 1 year
107 per 1000 30 per 1000
(17 to 51)
RR 0.28
(0.16 to 0.48)
1029
(1 study)
⊕⊕©©
low1,2
Although the included
study was conducted in
only one country (Fin-
land), we did not down-
grade for indirectness as
we think it is repre-
sentative of low-mortality
countries
Severe all-cause diar-
rhoea
Follow-up: up to 2 years
15 per 1000 1 per 1000
(0 to 11)
RR 0.04
(0 to 0.7)
1029
(1 study)
⊕⊕©©
low1,2
Although the included
study was conducted in
only one country (Fin-
land), we did not down-
grade for indirectness as
we think it is repre-
sentative of low-mortality
countries3
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All-cause death
Follow-up: 2 months to 2
years
6 per 10,000 7 per 10,000
(4 to 12)
RR 1.18
(0.67 to 2.08)
73,603
(8 studies)
⊕⊕©©
low3
All serious adverse
events
Follow-up: 2 months to 2
years
26 per 1000 24 per 1000
(21 to 26)
RR 0.92
(0.84 to 1.01)
71,638
(7 studies)
⊕⊕⊕⊕
high
Serious adverse events:
intussusception
Follow-up: 2 months to 2
years
55 per 100,000 37 per 100,000
(19 to 72)
RR 0.67
(0.34 to 1.31)
74,874
(11 studies)
⊕⊕©©
low4
*The basis for the assumed risk is the control group risk across studies. The corresponding risk (and its 95% CI) is based on the assumed risk in the comparison group and the relative
effect of the intervention (and its 95% CI).
CI: confidence interval; RR: risk ratio
GRADE Working Group grades of evidence
High-quality: further research is very unlikely to change our confidence in the estimate of effect.
Moderate-quality: further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low-quality: further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low-quality: we are very uncertain about the estimate.
1 Downgraded by 1 for imprecision. The total number of events was very low.
2 Downgraded by 1 for risk of bias. The included study did not sufficiently report incomplete outcome data.
3 Downgraded by 2 for imprecision. These trials were not powered to detect an effect on mortality.
4Downgraded by 2 for imprecision. There was a 1:10,000 increased risk of intussusception with a previous rotavirus vaccine (http:/
/www.who.int/vaccines-documents/DocsPDF04/wwwSOWVE.pdf), therefore, these trials were not powered to detect an association
between RV1 and intussusception.
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Patient or population: children
Settings: high-mortality countries (WHO strata D & E)
Intervention: RV5
Comparison: placebo
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Placebo RV5
Severe rotavirus diar-
rhoea
Follow-up: up to 1 year
30 per 1000 13 per 1000
(9 to 19)
RR 0.43
(0.29 to 0.62)
5916
(2 studies)
⊕⊕⊕⊕
high
Severe rotavirus diar-
rhoea
Follow-up: up to 2 years
63 per 1000 37 per 1000
(27 to 51)
RR 0.59
(0.43 to 0.82)
5885
(2 studies)
⊕⊕⊕⊕
high
Severe all-cause diar-
rhoea
Follow-up: up to 1 year
77 per 1000 62 per 1000
(45 to 85)
RR 0.8
(0.58 to 1.11)
4085
(1 study)
⊕⊕⊕©
moderate1
Severe all-cause diar-
rhoea
Follow-up: up to 2 years
130 per 1000 110 per 1000
(97 to 127)
RR 0.85
(0.75 to 0.98)
5977
(2 studies)
⊕⊕⊕⊕
high
All-cause death
Follow-up: 2 months to 2
years
26 per 1000 24 per 1000
(18 to 32)
RR 0.93
(0.69 to 1.25)
6604
(2 studies)
⊕⊕©©
low2
All serious adverse
events
Follow-up: 2 months to 2
years
19 per 1000 18 per 1000
(12 to 25)
RR 0.93
(0.66 to 1.33)
6588
(2 studies)
⊕⊕⊕©
moderate3
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Serious adverse events:
intussusception
Follow-up: 2 months to 2
years
See comment See comment Not estimable 6588
(2 studies)
⊕⊕©©
low4
No events were reported.
*The basis for the assumed risk is the control group risk across studies. The corresponding risk (and its 95% CI) is based on the assumed risk in the comparison group and the relative
effect of the intervention (and its 95% CI).
CI: confidence interval; RR: risk ratio
GRADE Working Group grades of evidence
High-quality: further research is very unlikely to change our confidence in the estimate of effect.
Moderate-quality: further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low-quality: further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low-quality: we are very uncertain about the estimate.
1 Downgraded by 1 for indirectness. Single trial conducted in three African countries (Mali, Ghana, and Kenya), generalisation to any
high-mortality country is difficult.
2 Downgraded by 2 for imprecision. These trials were not powered to detect an effect on mortality.
3 Downgraded by 1 for imprecision. The 95% CI includes both no effect and appreciable harm.
4 Downgraded by 2 for imprecision. There was a 1:10,000 increased risk of intussusception with a previous rotavirus vaccine (http:/
/www.who.int/vaccines-documents/DocsPDF04/wwwSOWVE.pdf), therefore, these trials were not powered to detect an association
between RV1 and intussusception.
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D I S C U S S I O N
Rotavirus vaccines have been under development since the 1980s,
and four have been approved for use. RRV-TV (Rotashield) has
not been used since 1999. RV1, RV5, and LLR are in use today
and are the focus of this review.
Summary of main results
Forty-one trials were included with 186,263 participants, evaluat-
ing RV1 (29 trials) and RV5 (12 trials); none of the trials assessed
LLR. Our analysis stratified the primary outcomes byWHOmor-
tality strata (high-mortality countries, with high child mortality;
and low-mortality, with low child mortality; WHO 1999).
Trials were not designed or powered to detect an effect on prevent-
ing death or on the occurrence of possible severe adverse effects,
such as intussusception.
1. RV1 in countries with low child mortality
(WHO strata A and B)
Eight trials were conducted in Asia, five in Europe, four in Latin
America, four in North America, and one in Europe and Latin
America.
In infants under one year
RV1 prevents 86% of cases of severe rotavirus diarrhoea: RR 0.14,
95% CI 0.07 to 0.26; 40,631 participants, six trials; moderate-
quality evidence.
RV1 prevents 40% of severe all-cause diarrhoea episodes: Rate
ratio 0.60, 95% CI 0.50 to 0.72; 17,867 participants, one trial;
moderate-quality evidence.
In children up to two years
RV1 prevents 85% of cases of severe rotavirus diarrhoea: RR 0.15,
95%CI0.12 to 0.20; 32,854participants, eight trials; high-quality
evidence.
RV1 prevents 37% of severe all-cause diarrhoea episodes: Rate
ratio 0.63, 95% CI 0.56 to 0.71; 39,091 participants, two trials;
moderate-quality evidence.
For all cause death, an effect of the vaccine has not been shown:
RR 1.27, 95%CI 0.89 to 1.81; 93,321 participants, 18 trials; low-
quality evidence.
For serious adverse events, children receiving RV1 had 10% fewer
events than those receiving placebo: RR 0.90, 95% CI 0.84 to
0.95; 91,957 participants, 20 trials; moderate-quality evidence.
For intussusception, RV1 was not associated with a higher risk:
RR 0.87, 95%CI 0.52 to 1.46; 91,832 participants, 11 trials; low-
quality evidence.
See Summary of findings for the main comparison.
2. RV1 in countries with high child mortality
(WHO strata D and E)
One trial was conducted in Bangladesh, one in India, one in Peru,
three in South Africa, and one in South Africa and Malawi.
In infants under one year
RV1 prevents 63% of cases of severe rotavirus diarrhoea: RR 0.37,
95% CI 0.18 to 0.75; 5414 participants, two trials; moderate-
quality evidence.
RV1 prevents 34% of severe all-cause diarrhoea episodes: RR 0.66,
95% CI 0.44 to 0.98; 4939 participants, one trial; moderate-
quality evidence.
In children up to two years
RV1 prevents 42% of cases of severe rotavirus diarrhoea: RR 0.58,
95% CI 0.42 to 0.79; 2764 participants, one trial; moderate-
quality evidence.
RV1 prevents 18% of severe all-cause diarrhoea episodes: RR 0.82,
95% CI 0.71 to 0.95; 2764 participants, one trial; moderate-
quality evidence.
For all-cause death, an effect of the vaccine has not been shown:
RR 0.88, 95% CI 0.64 to 1.22; 7481 participants, seven trials;
low-quality evidence.
For serious adverse events, an effect of the vaccine has not been
shown: RR 0.89, 95% CI 0.76 to 1.04; 7481 participants, seven
trials; moderate-quality evidence.
For intussception, RV1 was not associated with a higher risk: RR
1.49, 95% CI 0.06 to 36.63; 5414 participants, two trials; very
low-quality evidence.
See Summary of findings 2.
3. RV5 in countries with low child mortality
(WHO strata A and B)
Four trials were conducted in Asia, two in Europe, three in North
America, one in Europe and the USA, and one in Europe and the
Americas.
In infants under one year
RV5 prevents 87% of cases of severe rotavirus diarrhoea: RR 0.13,
95% CI 0.04 to 0.45; 2344 participants, three trials; moderate-
quality evidence.
RV5 prevents 72% of severe all-cause diarrhoea episodes: RR 0.28,
95% CI 0.16 to 0.48; 1029 participants, one trial; low-quality
evidence.
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In children up to two years
RV5 prevents 82% of cases of severe rotavirus diarrhoea: RR 0.18,
95% CI 0.07 to 0.50; 3190 participants, three trials; moderate-
quality evidence.
RV5 prevents 96% of severe all-cause diarrhoea episodes: RR 0.04,
95% CI 0.00 to 0.70; 1029 participants, one trial; low-quality
evidence.
For all cause death, an effect of the vaccine has not been shown:
RR 1.18, 95% CI 0.67 to 2.08; 73,603 participants, eight trials;
low-quality evidence.
For serious adverse events, an effect of the vaccine has not been
shown: RR 0.92, 95% CI 0.84 to 1.01; 71,638 participants, seven
trials; high-quality evidence.
For intussception, RV5 was not associated with a higher risk: RR
0.67, 95% CI 0.34 to 1.31; 74,874 participants, 11 trials; low-
quality evidence.
See Summary of findings 3.
4. RV5 in countries with high child mortality
(WHO strata D and E)
One trial was conducted in Ghana, Kenya and Mali, and one trial
in Bangladesh and Vietnam.
In infants under one year
RV5 prevents 57% of cases of severe rotavirus diarrhoea: RR 0.43,
95% CI 0.29 to 0.62; 5916 participants, two trials; high-quality
evidence.
Data on all-cause diarrhoea was reported in one trial. This sug-
gested a protective effect, but the results were not statistically sig-
nificant: RR 0.80, 95% CI 0.58 to 1.11; 4085 participants, one
trial; moderate-quality evidence.
In children up to two years
RV5 prevents 41% of cases of severe rotavirus diarrhoea: RR 0.59,
95% CI 0.43 to 0.82; 5885 participants, two trials; high-quality
evidence.
RV5 prevents 15% of severe all-cause diarrhoea episodes: RR 0.85,
95% CI 0.75 to 0.98; 5977 participants, two trials; high-quality
evidence.
For all cause death, an effect of the vaccine has not been shown:
RR 0.93, 95% CI 0.69 to 1.25; 6604 participants, two trials; low-
quality evidence.
For serious adverse events, an effect of the vaccine has not been
shown: RR 0.93, 95% CI 0.66 to 1.33; 6588 participants, two
trials; moderate-quality evidence.
For intussception, RV5 was not associated with a higher risk: no
cases were reported, 6588 participants, two trials; low-quality ev-
idence.
See Summary of findings 4.
Children in trials performed in low-mortality countries received
the vaccines according to the country’s immunization schedule.
For trials of RV1 conducted in high-mortality Malawi, South
Africa, and Bangladesh (RV1 Zaman 2009-BGD; RV1 Madhi
2010-AF; RV1 Steele 2010b-ZAF) children received the first dose
of the vaccine at a later age (10 to 12 weeks) than is recommended
in the EPI schedule (six weeks).
Overall completeness and applicability of
evidence
We carried out this systematic review using RCTs. All the included
trials were placebo controlled, which meant there were no data
directly comparing RV1 with RV5. Furthermore, potential herd
protection afforded by vaccination could not be evaluated. We
did not identify any RCTs for LLR, although case-control studies
have demonstrated a vaccine effectiveness for LLR of 77% (Fu
2010). The trials provided only limited data for special groups
of children, such as preterm infants, malnourished children, and
immunocompromised children.
Country mortality rate
Trials of RV1 and RV5 in high-mortality countries in Africa and
Asia demonstrated a lower vaccine efficacy when compared to tri-
als performed in low-mortality countries. Despite the lower ef-
ficacy in high-mortality countries, because of the higher burden
of rotavirus disease, the absolute number of events prevented by
vaccination is greater (RV1 Madhi 2010-AF). The reasons for a
reduced efficacy in high-mortality countries is not known, but is a
feature shared with other live, oral vaccines; factors could include
higher levels of passively transferredmaternal antibody, concurrent
administration of oral polio vaccine (OPV), breastfeeding, mal-
nutrition, and enteric co-infections (Cunliffe 2007; Patel 2009;
Levine 2010).
Reduced efficacy in high-mortality countries in trials reporting
two years of follow-up could be explained by waning vaccine-in-
duced immunity, or some protection in the placebo group result-
ing from natural rotavirus infection (RV1 Madhi 2010-AF). Ro-
tavirus diarrhoea is particularly associated with severe outcomes
between the ages of three and 35 months of age (Parashar 2006b),
with a peak incidence of all episodes occurring between six and 24
months (CDC-ASIP 1999; Linhares 2008). Protection afforded
by vaccination should therefore extend to at least two years of age.
Schedule and age
Trials performed in high-mortality countries examined the efficacy
of RV1when administered at 10 to 14 weeks of age. It is uncertain
whether the vaccine would perform equally well in high-mortality
settings if given at six to 10 weeks of age, because of potential
interference by maternal antibodies and the first dose of OPV.
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All-cause diarrhoea
The impact of rotavirus vaccination on severe all-cause diarrhoea
from a public health perspective is important as laboratories in
low-income countries may not routinely test for rotavirus infec-
tion, and parents and care-givers are particularly concerned about
severe cases of diarrhoea (Mast 2009). Surprisingly, few trials re-
ported vaccine efficacy against all-cause diarrhoea. In addition, it
should be noted that vaccine efficacy against less severe all-cause
diarrhoea is lower, meaning that vaccination may not have a no-
ticeable impact on milder episodes of diarrhoea occurring in the
community.
Mortality data
The included trials were not individually powered to detect a mor-
tality effect. This review did not detect a difference in the number
of deaths for children receiving any of the vaccines or placebo. Fur-
thermore, many studies were conducted in low-mortality coun-
tries where deaths from diarrhoea are rare. Two recent post-vac-
cine implementation national surveillance studies from Mexico
and Brazil reported that the introduction of RV1 into the national
immunization programme was associated with a decline in the
number of diarrhoea-related deaths (Richardson 2010; do Carmo
2011) in comparison with historical controls.
Safety data
There was no detectable difference in the number of cases of in-
tussusception for children receiving vaccine or placebo. Although
post-introduction safety surveillance in Mexico, Brazil, and Aus-
tralia reported an increased risk of intussusception within a week
of administration of the first or second vaccine dose of RV1 (Patel
2011) and RV5 (Buttery 2011), the association between all live,
oral rotavirus vaccines, and intussusception is debatable. Overall
the risk/benefit analyses in high rotavirus disease burden countries
favours vaccination (Patel 2011).
Quality of the evidence
The trials included in the current review were all placebo-con-
trolled, were conducted in Latin America, North America, Eu-
rope, Asia, and Africa, and the largest included over 60,000 chil-
dren; the need for such trials was identified in the original version
of the review (Soares-Weiser 2004). However, most children were
followed for safety outcomes only. The reporting of trial methods
was poor in many trials and often we could not adequately assess
the risk of bias in the trials. In particular, only 61% of the included
trials reported an adequate generation of allocation sequence and
only 46% described the methods used to conceal allocation. We
have sought to obtain this information from trialists and received
detailed information about the design of studies for most of the
RV5 trials. However, up to the publication of the current update,
we have not yet received information fromGSK on the RV1 trials.
This impacted upon the risk of bias assessments and summary of
findings (see below).
Potential biases in the review process
As can be seen in the summary of findings tables, the quality of
evidence for some of the primary outcomes in this review were
downgraded because the primary studies did not adequately report
details of randomization procedure, allocation concealment, and
procedures to avoid attrition and selection bias. By downgrading
the quality of the evidence, we may have introduced bias.
Agreements and disagreements with other
studies or reviews
We identified three systematic reviews of RCTs that have been con-
ducted since the 2010 update of this Cochrane systematic review:
two evaluated severe episodes of rotavirus diarrhoea and mortal-
ity (Munos 2010; Fischer Walker 2011); and the third attempted
to infer the outstanding challenges of vaccine implementation in
low-income countries (Ustrup 2011). There was little overlap be-
tween the scope of these reviews and the current review.
Relationship to current policies
The data in this review support the WHO’s Strategic Advisory
Groupof Experts (SAGE) on Immunization’s recommendation for
“the inclusion of rotavirus vaccination of infants into all national
immunization programmes” with a stronger recommendation for
countries where “diarrhoeal deaths account for≥10%ofmortality
among children aged <5 years” (SAGE 2009).
A two-dose (6 & 10 week) RV1 schedule recommended byWHO
has not been examined in an efficacy trial.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
• RV1 and RV5 are efficacious vaccines in preventing
rotavirus diarrhoea with comparable safety and efficacy profiles.
The systematic review data support the global WHO rotavirus
vaccine recommendation (SAGE 2009; SAGE 2012).
• The data from the included RCTs exclude a risk of
intussusception with RV1 and RV5 of the magnitude observed
with the first licensed vaccine (RRV-TV, RotaShield). However,
since the data cannot exclude a smaller risk of intussusception or
other rare serious adverse events, routine vaccine introduction
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should be accompanied by safety surveillance (Buttery 2011;
Patel 2011).
• We did not identify any trials of LLR, which is licensed for
use in China.
Implications for research
Placebo controlled efficacy trials of RV1 and RV5 have been un-
dertaken in representative populations of low- and high-mortality
countries and do not require repetition. Further research would
be valuable in the following areas:
• Post-introduction studies to examine vaccine effectiveness
particularly in high-mortality countries.
• A greater understanding of the lower vaccine efficacy
observed in high-mortality countries in Africa and Asia in the
first and second years of life.
• Since the recommended two-dose RV1 schedule at the age
of six and 10 weeks may be less efficacious than the two-dose
schedule examined at 10 and 14 weeks of age in clinical trials in
Africa (eg because of higher levels of maternal antibody and
concurrent administration of the first dose of OPV), vaccine
effectiveness with the 6 and 10 week schedule should be
evaluated following RV1 roll-out in EPI.
• Studies to assess the potential benefit of alternative dosage
schedules of rotavirus vaccine especially in high-mortality
countries (eg neonatal dosing, later dosing, additional dosing).
• Further information on rotavirus vaccine efficacy in special
populations.
• Post-introduction studies in representative countries should
examine vaccine safety with particular respect to intussusception
and analyse the risk/benefit of rotavirus vaccination (Patel 2011).
Given the rareness of the event, data from different countries
may need to be pooled.
A C K N OW L E D G E M E N T S
A number of people contributed to the preparation of the orig-
inal review version and are acknowledged in the original review
(Soares-Weiser 2004). We thank Dr Ana Maria Restrepo (Initia-
tive for Vaccine Research, WHO) for support in acquiring infor-
mation on trials methodology and Merck for providing the rele-
vant information from their trials. We also thank Professor Paul
Fine from the London School of Tropical Medicine for comments
on the previous version of this review (2012, Issue 2). We thank
Professor Paul Garner and Dr David Sinclair for their assistance
and guidance in the preparation of this update (2012).
This document is an output from a project funded by the UKDe-
partment for International Development (DFID) for the benefit
of developing countries. The views expressed are not necessarily
those of DFID.
R E F E R E N C E S
References to studies included in this review
RV1 Anh 2011-PHL {published data only}
∗ Anh DD, Carlos CC, Thiem DV, Hutagalung
Y, Gatchalian S, Bock HL, et al.Immunogenicity,
reactogenicity and safety of the human rotavirus vaccine
RIX4414 (Rotarix) oral suspension (liquid formulation)
when co-administered with expanded program on
immunization (EPI) vaccines in Vietnam and the
Philippines in 2006-2007. Vaccine 2011;29(11):2029–36.
GlaxoSmithKline[109216-063]. A phase II, randomized,
double-blind, placebo-controlled study to evaluate the
immunogenicity, reactogenicity and safety of two doses of
GlaxoSmithKline (GSK) Biologicals’ oral live attenuated
human rotavirus (HRV) liquid vaccine, when given to
healthy infants, in Philippines. ctr.gsk.co.uk/Summary/
Vaccine˙Rotavirus/II˙109216.pdf 2008.
NCT00432380. Immunogenicity and safety of two doses
of GlaxoSmithKline (GSK) Biologicals’ oral live attenuated
human rotavirus (HRV) liquid vaccine (GSK 357941A) in
healthy infants. clinicaltrials.gov/show/NCT00432380
(accessed 6 July 2011).
RV1 Anh 2011-VNM {published data only}
∗ Anh DD, Carlos CC, Thiem DV, Hutagalung
Y, Gatchalian S, Bock HL, et al.Immunogenicity,
reactogenicity and safety of the human rotavirus vaccine
RIX4414 (Rotarix) oral suspension (liquid formulation)
when co-administered with expanded program on
immunization (EPI) vaccines in Vietnam and the
Philippines in 2006-2007. Vaccine 2011;29(11):2029–36.
Anh DD, Thiem VD, Hutagalung Y, Bock HL, Suryakiran
P, Delem A, et al.Immunogenicity, Reactogenicity and
Safety of the Oral Live Attenuated Human Rotavirus
VaccineRIX4414(RotarixTM) Oral Suspension (Liquid
Formulation) in Vietnamese Infants. 13th International
Congress on Infectious Diseases Abstracts, Poster
Presentations 2008.
GlaxoSmithKline[105722-051]. A phase II, randomized,
double-blind, placebo-controlled study to evaluate the
immunogenicity, reactogenicity and safety of two doses of
37Vaccines for preventing rotavirus diarrhoea: vaccines in use (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
GlaxoSmithKline (GSK) Biologicals’ oral live attenuated
human rotavirus (HRV) liquid vaccine, when given to
healthy infants, in Vietnam. ctr.gsk.co.uk/Summary/
Vaccine˙Rotavirus/II˙105722.pdf 2008.
NCT00345956. A placebo-controlled study to evaluate
the immunogenicity, reactogenicity and safety of two doses
of GSK Bio oral live attenuated human rotavirus (HRV)
liquid vaccine, when given to healthy infants, in Vietnam.
clinicaltrials.gov/show/NCT00345956 (accessed 6 July
2011).
RV1 Bernstein 1998-USA {published data only}
Bernstein DI, Smith VE, Sherwood JR, Schiff GM, Sander
DS, DeFeudis D, et al.Safety and immunogenicity of live,
attenuated human rotavirus vaccine 89-12. Vaccine 1998;
16(4):381–7.
RV1 Bernstein 1999-USA {published data only}
Bernstein DI, Sack DA, Reisinger K, Rothstein E, Ward
RL. Second-year follow-up evaluation of live, attenuated
human rotavirus vaccine 89-12 in healthy infants. Journal
of Infectious Diseases 2002;186(10):1487–9.
∗ Bernstein DI, Sack DA, Rothstein E, Reisinger K, Smith
VE, O’Sullivan D, et al.Efficacy of live, attenuated, human
rotavirus vaccine 89-12 in infants: a randomised placebo-
controlled trial. Lancet 1999;354(9175):287–90.
RV1 Dennehy 2005-NA {published data only}
Dennehy PH. A short report on the highlights of world-wide
development of RIX4414: a North American experience
comparative evaluation of safety and immunogenicity of
two dosages of an oral live attenuated human rotavirus
vaccine (RIX4414) in infants in the United States and
Canada. Vaccine 2006;24(18):3780–1.
∗ Dennehy PH, Brady RC, Halperin SA, Ward RL, Alvey
JC, Fischer FH Jr, et al.Comparative evaluation of safety and
immunogenicity of two dosages of an oral live attenuated
human rotavirus vaccine. Pediatric Infectious Disease Journal
2005;24(6):481–8.
GlaxoSmithKline[444563-005]. A phase II, double-
blind, randomized, placebo-controlled study of two doses
of GlaxoSmithKline Biologicals’ live attenuated human
rotavirus (HRV) vaccine at different virus concentrations
(10 5.2 and 10 6.4 ffu) in healthy infants (approximately
2 months of age at first dose) following a 0, 2 month
schedule and previously uninfected with human rotavirus.
ctr.gsk.co.uk/Summary/Vaccine˙Rotavirus/studylist.asp
2005.
RV1 GSK[021] 2007-PAN {published data only}
GlaxoSmithKline[444563-021]. A phase II, double-blind,
randomized, placebo-controlled clinical study to assess
the immunogenicity and reactogenicity of three doses of
a modified vaccine formulation versus GlaxoSmithKline
(GSK) Biologicals’ live attenuated human rotavirus
(HRV) vaccine when orally administered to healthy infants
at 2, 4 and 6 months of age. ctr.gsk.co.uk/Summary/
Vaccine˙Rotavirus/II˙444563˙021.pdf 2007.
RV1 GSK[024] 2008-LA {published data only}
∗ GlaxoSmithKline[444563-024]. A phase III, double-
blind, randomized, placebo-controlled, multi-country and
multi-center study to assess the efficacy, immunogenicity and
safety of two doses of GSK Biologicals’ oral live attenuated
human rotavirus (HRV) vaccine given concomitantly
with routine EPI vaccinations including OPV in healthy
infants. ctr.gsk.co.uk/Summary/Vaccine˙Rotavirus/
III˙444563˙024.pdf 2008.
Gonzalez Ayala S, Rivera L, Rivera-Medina DM, Lopez
P, Valencia A, De León T, et al.Co-administration with
rotavirus vaccine rix4414 (Rotarix™) does not interfere
with the immunogenicity of oral polio vaccine (OPV).
[Poster]. World Society for Pediatric Infectious Diseases
(WSPID), Bangkok, Thailand 15 to 18 November 2007. [:
Not available for review]
RV1 GSK[033] 2007-LA {published data only}
∗ GlaxoSmithKline[444563-033]. A phase III, randomized,
double-blind and placebo-controlled study to assess the
clinical consistency of three production lots of GSK
Biologicals’ HRV vaccine in terms of immunogenicity
and safety when given to healthy infants at 2 and 4
months of age. ctr.gsk.co.uk/Summary/Vaccine˙Rotavirus/
III˙444563˙033˙(rota033).pdf 2007.
Lopez P, Herrera JFG, Cervantes Y, et al.Three consecutive
production lots of the human monovalent RIX4414 G1P(8)
rotavirus vaccine, Rotarix™ induce a consistent immune
response in Latin American infants. [Poster]. 4th World
Congress of The World Society for Pediatric Infectious
Diseases, Warsaw, Poland 1 to 4 September 2005. [: Not
available for review]
RV1 GSK[041] 2007-KOR {published data only}
GlaxoSmithKline[103478-041]. A phase IIIb, double-
blind, randomized, placebo-controlled, multicentre study
to assess the immunogenicity, safety and reactogenicity of
2 doses of GlaxoSmithKline (GSK) Biologicals’ oral live
attenuated human rotavirus (HRV) vaccine in healthy
infants (6-12 weeks of age at first dose) previously
uninfected with human rotavirus. ctr.gsk.co.uk/Summary/
Vaccine˙Rotavirus/III˙103478.pdf 2007.
RV1 GSK[101555] 2008-PHL {published data only}
GlaxoSmithKline[101555]. A phase II, double-blind,
randomized, placebo-controlled study to compare the
immunogenicity, reactogenicity and safety of 2 different
formulations of GlaxoSmithKline (GSK) Biologicals’
live attenuated human rotavirus (HRV) vaccine given
as a two-dose primary vaccination in healthy infants
previously uninfected with HRV. ctr.gsk.co.uk/Summary/
Vaccine˙Rotavirus/II˙101555.pdf 2008.
RV1 Kawamura 2010-JPN {published data only}
Kawamura N, Tokoeda Y, Mori S, Ohshima M, Okahata H,
Ueda D, et al.Efficacy of human rotavirus vaccine RIX4414
in Japanese infants from 2 weeks post dose 2 up to data
lock point. 28th meeting of European Society fr Paediatric
Infectious Diseases (ESPID). Nice, France, 4–8 May 2010.
Kawamura N, Tokoeda Y, Oshima M, Okahata H, Tsutsumi
H, Van Doorn LJ, et al.Efficacy, safety and immunogenicity
38Vaccines for preventing rotavirus diarrhoea: vaccines in use (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
of RIX4414 in Japanese infants during the first two years of
life. Vaccine 2011;29(37):6335–41.
∗ NCT00480324. Efficacy, safety, reactogenicity and
immunogenicity study of the lyophilised formulation
of Rotarix vaccine in healthy Japanese infants.
clinicaltrials.gov/show/NCT00480324 (accessed 20
February 2011).
RV1 Kerdpanich 2010-THA {published data only}
GlaxoSmithKline[103477-039]. A phase IIIb, partially
blind, randomized, placebo-controlled study to asses the
effect on immunogenicity of administration of vaccine
without buffering agent and to assess heat stability in
terms of immunogenicity, reactogenicity and safety of
GlaxoSmithKline Biologicals’ oral live attenuated human
rotavirus (HRV) vaccine following a 0, 2 month schedule, in
healthy infants previously uninfected with human rotavirus.
ctr.gsk.co.uk/Summary/Vaccine˙Rotavirus/III˙103477˙
(rota039).pdf 2007.
Kerdpanich A, Chokephaibulkit K, Watanaveeradej V,
Vanprapar N, Hutagalung Y, Han HH, et al.Exposure to
elevated temperature of 37°C for 7 days does not affect
immunogenicity and reactogenicity of RIX4414. [Poster].
dsRNA Virus Meeting, Cape Town, South Africa. 21 to 26
October 2006. [: Not available for review]
Kerdpanich A, Chokephaibulkit K, Watanaveeradej
V, Vanprapar N, Simasathien S, Phavichitr N, et
al.Immunogenicity of a human rotavirus vaccine (RIX4414)
after storage at 37 degrees C for seven days. Human Vaccine
2011;7(1):74–80.
∗ Kerdpanich A, Chokephaibulkit K, Watanaveeradej
V, Vanprapar N, Simasathien S, Phavichitr N, et
al.Immunogenicity of a live-attenuated human rotavirus
RIX4414 vaccine with or without buffering agent. Human
Vaccines 2010;6(3):254–62.
NCT00169455. Assess the effect on immunogenicity of
administration of vaccine without buffering agent & assess
heat stability in terms of immunogenicity, reactogenicity
& safety of GSK Biologicals’ oral live attenuated human
rotavirus (HRV) vaccine following a 0,2 m schedule, in
healthy infants previously uninfected with human rotavirus.
clinicaltrials.gov/show/NCT00169455 (accessed 12 August
2008).
RV1 Madhi 2010-AF {published data only}
Cunliffe NA, Witte D, Ngwira BM, Todd S, Bostock
NJ, Turner AM, et al.Efficacy of human rotavirus vaccine
against severe gastroenteritis in Malawian children in the
first two years of life: A randomized, double-blind, placebo
controlled trial. Vaccine 2012;30(Suppl 1):A36–43.
∗ Madhi SA, Cunliffe NA, Steele D, Witte D, Kirsten
M, Louw C, et al.Effect of human rotavirus vaccine on
severe diarrhea in African infants. New England Journal of
Medicine 2010;362(4):289–98.
Madhi SA, Kirsten M, Louw C, Bos P, Aspinall S,
Bouckenooghe A, et al.Efficacy and immunogenicity of
two or three dose rotavirus-vaccine regimen in South
African children over two consecutive rotavirus seasons: A
randomized, double-blind, placebo-controlled trial. Vaccine
2012;30(Suppl 1):A44–51.
NCT00241644. Multi-center study to assess the efficacy,
safety and immunogenicity of 2 or 3 doses of GSK
Biologicals’ oral live attenuated human rotavirus (HRV)
vaccine given concomitantly with routine EPI vaccinations
in healthy infants. clinicaltrials.gov/show/NCT00241644
(accessed 12 August 2008).
NCT00598468. Multi-center study to assess efficacy, safety
& immunogenicity of 2 or 3 doses of GSK Biologicals’
oral live attenuated human rotavirus (HRV) vaccine given
concomitantly with routine EPI vaccinations in healthy
infants. clinicaltrials.gov/show/NCT00598468 (accessed
20 February 2011).
RV1 Madhi 2010-MWI {published data only}
∗ Cunliffe NA, Witte D, Ngwira BM, Todd S, Bostock
NJ, Turner AM, et al.Efficacy of human rotavirus vaccine
against severe gastroenteritis in Malawian children in the
first two years of life: A randomized, double-blind, placebo
controlled trial. Vaccine 2012;30(Suppl 1):A36–43.
Madhi SA, Cunliffe NA, Steele D, Witte D, Kirsten M,
Louw C, et al.Effect of human rotavirus vaccine on severe
diarrhea in African infants. New England Journal of Medicine
2010;362(4):289–98.
NCT00241644. Multi-center study to assess the efficacy,
safety and immunogenicity of 2 or 3 doses of GSK
Biologicals’ oral live attenuated human rotavirus (HRV)
vaccine given concomitantly with routine EPI vaccinations
in healthy infants. clinicaltrials.gov/show/NCT00241644
(accessed 12 August 2008).
NCT00598468. Multi-center study to assess efficacy, safety
& immunogenicity of 2 or 3 doses of GSK Biologicals’
oral live attenuated human rotavirus (HRV) vaccine given
concomitantly with routine EPI vaccinations in healthy
infants. clinicaltrials.gov/show/NCT00598468 (accessed
20 February 2011).
RV1 Madhi 2010-ZAF {published data only}
Madhi SA, Cunliffe NA, Steele D, Witte D, Kirsten M,
Louw C, et al.Effect of human rotavirus vaccine on severe
diarrhea in African infants. New England Journal of Medicine
2010;362(4):289–98.
∗ Madhi SA, Kirsten M, Louw C, Bos P, Aspinall S,
Bouckenooghe A, et al.Efficacy and immunogenicity of
two or three dose rotavirus-vaccine regimen in South
African children over two consecutive rotavirus seasons: A
randomized, double-blind, placebo-controlled trial. Vaccine
2012;30(Suppl 1):A44–51.
NCT00241644. Multi-center study to assess the efficacy,
safety and immunogenicity of 2 or 3 doses of GSK
Biologicals’ oral live attenuated human rotavirus (HRV)
vaccine given concomitantly with routine EPI vaccinations
in healthy infants. clinicaltrials.gov/show/NCT00241644
(accessed 12 August 2008).
NCT00598468. Multi-center study to assess efficacy, safety
& immunogenicity of 2 or 3 doses of GSK Biologicals’
oral live attenuated human rotavirus (HRV) vaccine given
concomitantly with routine EPI vaccinations in healthy
39Vaccines for preventing rotavirus diarrhoea: vaccines in use (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
infants. clinicaltrials.gov/show/NCT00598468 (accessed
20 February 2011).
RV1 Narang 2009-IND {published data only}
GlaxoSmithKline[103792-044]. A phase IIIb, randomised,
multicentre double-blind, placebo-controlled study of the
immunogenicity and safety of two doses of GlaxoSmithKline
(GSK) Biologicals’ oral live attenuated human rotavirus
(HRV) vaccine (RIX4414) as primary dosing in healthy
infants in India of approximately 8 weeks of age at the
first dose. ctr.gsk.co.uk/Summary/Vaccine˙Rotavirus/
III˙103792.pdf 2007.
∗ Narang A, Bose A, Pandit AN, Dutta P, Kang G,
Bhattacharya SK, et al.Immunogenicity, reactogenicity and
safety of human rotavirus vaccine (RIX4414) in Indian
infants. Human Vaccines 2009;5(6):414–9.
RV1 Omenaca 2012-EU {published data only}
NCT00420745. Phase IIIb, double blind, randomised,
placebo-controlled, multi-country/centre, study to assess
safety, reactogenicity & immunogenicity of 2 doses of
GSK Biologicals’ oral live attenuated human rotavirus
(HRV) vaccine in pre-term infants. clinicaltrials.gov/show/
NCT00420745 (accessed 20 February 2011).
∗ Omenaca F, Sarlangue J, Szenborn L, Nogueira M,
Suryakiran PV, Smolenov IV, et al.Safety, Reactogenicity
and Immunogenicity of the Human Rotavirus Vaccine in
Preterm European Infants: A Randomized Phase IIIb Study.
Pediatric Infectious Disease Journal 2012;31(5):487–93.
RV1 Phua 2005-SGP {published data only}
De Vos B, Vesikari T, Linhares AC, Salinas B, Perez-
Schael I, Ruiz-Palacios GM, et al.A rotavirus vaccine for
prophylaxis of infants against rotavirus gastroenteritis.
Pediatric Infectious Disease Journal 2004;23(10 Suppl):
179–82. [: No data for review]
De Vos B, et al.RIX4414 vaccine efficacy against rotavirus
gastroenteritis due to G2P[4] strain. Proceedings of the
46th Interscience Conference on Antimicrobial Agents and
Chemotherapy (ICAAC), San Francisco, USA 27 to 30
September 2006. [: Not available for review]
Emmanuel B, et al.Immunogenicity of an acellular pertussis
combination vaccine co-administered with a novel rotavirus
vaccine in Singaporean infants. ACPID 2004 - Asian
Congress on Pediatric Infectious Diseases, Kota Kinabula,
Malaysia 2004. [: Not available for review]
Emmanuel S, Phua KB, Goh P, Quak SH, Datta SK,
Han HH, et al.Immunogenicity of an acellular pertussis
combination vaccine co-administered with a novel rotavirus
vaccine in Singaporean infants. 23rd Annual Meeting
ESPID, Valencia, Spain 18 May 2005. [: Not available for
review]
GlaxoSmithKline[444563-007]. A phase IIb, double-
blind, randomized, placebo-controlled study to assess the
efficacy, immunogenicity, reactogenicity and safety of two
doses of GlaxoSmithKline (GSK) Biologicals’ oral live
attenuated human rotavirus (HRV) vaccine at different
viral concentrations (104.7, 105.2 and 106.1 foci forming
units (ffu)) in healthy infants previously uninfected with
human rotavirus and approximately three months of age,
when administered concurrently with DTPa-IPV/Hib and
HBV vaccines. ctr.gsk.co.uk/Summary/Vaccine˙Rotavirus/
II˙444563˙007˙(rota007).pdf 2008.
Phua KB, Emmanuel SC, Goh P, Quak SH, Lee BW, Han
HH, et al.A rotavirus vaccine for prophylaxis of infant
rotavirus gastroenteritis: The Asian experience. Annals of
the Academy of Medicine, Singapore 2006;35(1):38–44.
Phua KB, Quak SH, Emmanuel S, Goh PS, Han HH,
Hardt K, et al.A short report on highlights of worldwide
development of RIX4414: a Singaporean experience.
Vaccine 2006;24(18):3782–3.
∗ Phua KB, Quak SH, Lee BW, Emmanuel SC, Goh P,
Han HH, et al.Evaluation of RIX4414, a live, attenuated
rotavirus vaccine, in a randomized, double-blind, placebo-
controlled phase 2 trial involving 2464 Singaporean infants.
Journal of Infectious Diseases 2005;192(Suppl 1):6–16.
Phua KB, Quak SH, Lim FS, Goh P, Teoh YL, Datta
SK, et al.Immunogenicity, reactogenicity and safety of a
diphtheria-tetanus-acellular pertussis-inactivated polio and
Haemophilus influenzae type b combination vaccine in a
placebo-controlled rotavirus vaccine study. Annals of the
Academy of Medicine, Singapore 2008;37(7):546–53.
Phua KB, et al.Highlights of world-wide development: A
Singapore experience. VED 2004, Montego Bay, Jamaica
2004. [: Not available for review]
Phua KB, et al.Immunogenicity and reactogenicity of two
doses of an oral human rotavirus (HRV) vaccine at different
concentrations in healthy infants from Singapore. 11th
Asia Pacific Congress of Pediatrics and the 3rd Asia Pacific
Congress of Pediatric Nursing, Bangkok, Thailand 2003. [:
Not available for review]
Phua KB, et al.Intussusception in children: a seven-year
experience in Singapore. 24th ICP, Cancun, Mexico 15 to
20 August 2004. [: Not available for review]
Vesikari T. RIX4414: A new attenuated human rotavirus
vaccine. 23rd Annual Meeting of ESPID, Valencia, Spain 8
to 20 May 2005. [: Not available for review]
Vesikari T, et al.High efficacy of two doses of Rotarix™
(RIX4414) against rotavirus disease in Europe, Latin-
America and Asia. ACPID, Cebu, Philippines 7 to 10
March 2006. [: Not available for review]
RV1 Phua 2009-AS {published data only}
NCT00197210. A phase III, double-blind, randomized,
placebo-controlled, multi-country and multi-center study to
assess the efficacy and safety of two doses of GSK Biologicals’
oral live attenuated human rotavirus (HRV) vaccine in
healthy infants. clinicaltrials.gov/show/NCT00197210
(accessed 12 August 2008).
NCT00329745. A phase III, double-blind, randomized,
placebo-controlled, multi-country and multi-center study to
assess the efficacy and safety of two doses of GSK Biologicals’
oral live attenuated human rotavirus (HRV) vaccine in
healthy infants. clinicaltrials.gov/show/NCT00329745
(accessed 20 February 2011).
∗ Phua KB, Lim FS, Lau YL, Nelson EA, Huang LM, Quak
SH, et al.Safety and efficacy of human rotavirus vaccine
during the first 2 years of life in Asian infants: randomised,
40Vaccines for preventing rotavirus diarrhoea: vaccines in use (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
double-blind, controlled study. Vaccine 2009;27(43):
5936–41.
Phua KB, Lim FS, Lau YL, Nelson EAS, Huang LM, Quak
SH, et al.Rotavirus vaccine RIX4414 efficacy sustained
during the third year of life: A randomized clinical trial in
an Asian population. Vaccine 2012. [In Press].
RV1 Rivera 2011-DOM {published data only}
NCT00396630. A Phase IIIb, randomized, double-
blind, placebo-controlled study to explore the existence
of horizontal transmission of the RIX4414 vaccine strain
between twins within a family. clinicaltrials.gov/show/
NCT00396630 (accessed 20 February 2011).
∗ Rivera L, Peña LM, Stainier I, Gillard P, Cheuvart
B, Smolenov I, et al.Horizontal transmission of a human
rotavirus vaccine strain--a randomized, placebo-controlled
study in twins. Vaccine 2011;29(51):9508–13.
RV1 Ruiz-Palac 06-LA/EU {published data only}
Costa Clemens SA, et al.Operational organization of a large
scale phase III clinical trial of rotavirus vaccine in multiple
sites and countries in Latin America. ICP, Cancun, Mexico
15 to 20 August 2004. [: Not available for review]
De Vos B, et al.Rotarix™: an effective way to prevent
rotavirus diarrhoea and vomiting. Proc. 9th Congress of
the Asian Pan Pacific Society of Paediatric Gastroenterology,
Hepatology and Nutrition & 27th Annual Congress of the
Malaysian Paediatric Association, Kuala Lumpur 16 to 19
June 2005. [: Not available for review]
GlaxoSmithKline[444563-023-pt1]. A phase III, double-
blind, randomized, placebo-controlled, multi-country
and multi-center study to assess the efficacy, safety
and immunogenicity of two doses of GSK Biologicals’
oral live attenuated human rotavirus (HRV) vaccine
in healthy infants. (Efficacy data from Visit 1 to
Visit 4). ctr.gsk.co.uk/Summary/Vaccine˙Rotavirus/
III˙444563˙023˙Final˙efficacy˙V1˙V4.pdf 2007.
GlaxoSmithKline[444563-023-pt2]. A phase III, double-
blind, randomized, placebo-controlled, multi-country
and multi-center study to assess the efficacy, safety
and immunogenicity of two doses of GSK Biologicals’
oral live attenuated human rotavirus (HRV) vaccine
in healthy infants. (2nd year efficacy from Visit 4 to
Visit 6). ctr.gsk.co.uk/Summary/Vaccine˙Rotavirus/
III˙444563˙023˙2nd˙efficacy˙V4˙V6.pdf 2007.
GlaxoSmithKline[444563-023-pt3]. A phase III, double-
blind, randomized, placebo-controlled, multi-country
and multi-center study to assess the efficacy, safety
and immunogenicity of two doses of GSK Biologicals’
oral live attenuated human rotavirus (HRV) vaccine in
healthy infants. (Safety for the period between Visit 1
and Visit 3). ctr.gsk.co.uk/Summary/Vaccine˙Rotavirus/
III˙444563˙023˙Safety˙data.pdf 2007.
Linhares AC, Velazquez FR, Perez-Schael I, Saez-Llorens X,
Abate H, Espinoza F, et al.Efficacy and safety of an oral
live attenuated human rotavirus vaccine against rotavirus
gastroenteritis during the first 2 years of life in Latin
American infants: a randomised, double-blind, placebo-
controlled phase III study. Lancet 2008;371(9619):1181–9.
Lopez P, et al.Early protection against severe rotavirus
gastroenteritis - RIX4414 experience in Latin America.
Proceedings of the 24th Annual Meeting of European
Society for Paediatric Infectious Diseases (ESPID), Basel,
Switzerland. 3 to 5 May 2006. [: Not available for review]
Macias M, et al.The rotavirus vaccine RIX4414 (Rotarix)
is not associated with intussusception in one year old
infants. Proceedings of the 45th Interscience Conference
on Antimicrobial Agents and Chemotherapy (ICAAC),
Washington DC, USA. 16 to 19 December 2005. [: Not
available for review]
NCT00139347. A multi-country & multi-center study to
assess the efficacy, immunogenicity & safety of two doses
of GSK Biologicals’ oral live attenuated HRV vaccine given
concomitantly with routine EPI vaccinations including
OPV in healthy infants. clinicaltrials.gov/ct2/show/
NCT00139347 (accessed 8 September 2008). [: Trial
registration document (no data for review)]
NCT00140673. Placebo-controlled, multi-country
& multi-center study to assess the efficacy, safety &
immunogenicity of 2 doses of GSK Biologicals’ oral live
attenuated human rotavirus (HRV) vaccine in healthy
infants. clinicaltrials.gov/ct2/show/NCT00140673
(accessed 8 September 2008). [: Trial registration document
(no data for review)]
Perez-Schael I, et al.Two doses of the human attenuated
rotavirus vaccine RIX4414 (Rotarix) show heterotypic
protection in Latin America and Europe. Proceedings of the
45th Interscience Conference on Antimicrobial Agents and
Chemotherapy (ICAAC), Washington DC, USA. 16 to 19
December 2005. [: Not available for review]
Pike M. New rotavirus vaccine is effective and appears to
have no increased risk of intussusception. Clinical Research
Abstracts For Pediatricians 2006;149(1):143.
Ruiz-Palacios G, et al.Two doses of the human-attenuated
monovalent G1P[8] rotavirus vaccine, Rotarix show high
efficacy in Mexican children against severe rotavirus
gastroenteritis and severe overall gastroenteritis. Proceedings
of the 45th Interscience Conference on Antimicrobial
Agents and Chemotherapy (ICAAC), Washington DC,
USA. 16 to 19 December 2005. [: Not available for review]
∗ Ruiz-Palacios GM, Perez-Schael I, Velazquez FR, Abate
H, Breuer T, Clemens SC, et al.Safety and efficacy of an
attenuated vaccine against severe rotavirus gastroenteritis.
New England Journal of Medicine 2006;354(1):11–22.
Tregnaghi MW, Abate HJ, Valencia A, Lopez P, Da Silveira
TR, Rivera L, et al.Human Rotavirus Vaccine Is Highly
Efficacious When Coadministered With Routine Expanded
Program of Immunization Vaccines Including Oral
Poliovirus Vaccine in Latin America. Pediatric Infectious
Disease Journal 2011: Jun;30(6):e103–e8.
Velázquez FR, Abat H, Clemens S-A Costa, Espinoza
F, Gillard P, Linhares AC, et al.The human monovalent
G1P[8] rotavirus vaccine, Rotarix is highly efficacious and
provides crossprotection against G1 and non-G1 serotypes.
23rd Annual meeting of European Society for Paediatric
41Vaccines for preventing rotavirus diarrhoea: vaccines in use (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Infectious Diseases (ESPID), Valencia, Spain. 18 to 20 May
2005.
Velázquez RF, et al.RIX4414, the human G1P[8] rotavirus
vaccine is highly efficacious during the second year of
life. Proceedings of the 46th Interscience Conference on
Antimicrobial Agents and Chemotherapy (ICAAC), San
Francisco, USA. 27 to 30 September 2006. [: Not available
for review]
Vesikari T, et al.Overcoming the safety hurdle: the rotavirus
vaccine RIX4414 is not associated with intussusception.
23rd Annual Meeting of European Society for Paediatric
Infectious Diseases (ESPID), Valencia, Spain. 18 to 20 May
2005. [: Not available for review]
RV1 Salinas 2005-LA {published data only}
Araujo EC, Clemens SAC, Oliveira CS, Justino MCA,
Rubio P, Gabbay YB, et al.Safety, immunogenicity, and
protective efficacy of two doses of RIX4414 live attenuated
human rotavirus vaccine in healthy Brazilian infants
[Segurança, imunogenicidade e eficácia protetora de duas
dosesda vacina RIX4414 contendo rotavírus atenuado de
origem humana]. Jornal de Pediatria 2007;83(3):217–24.
De Vos B, Hardt K, Linhares AC, et al.Efficacy of two doses
of a human monovalent rotavirus vaccine, Rotarix™ in
preventing gastro-enteritis due to G1 and Non-G1 rotavirus
in Brazil, Mexico and Venezuela [Presentation]. Proceedings
of the 8th International Symposium on Double-Stranded
RNA Viruses, Lucca, Italy. 13 to 18 September 2003. [:
Not available for review]
De Vos B, Vesikari T, Linhares AC, Salinas B, Perez-Schael I,
Ruiz-Palacios GM, et al.A rotavirus vaccine for prophylaxis
of infants against rotavirus gastroenteritis. Pediatric
Infectious Disease Journal 2004;23(10 Suppl):179–82.
GlaxoSmithKline[444563-006-Annex]. A phase IIb,
double-blind, randomized, placebo-controlled study to
assess the efficacy, immunogenicity, reactogenicity and safety
of two doses of GlaxoSmithKline (GSK) Biologicals’ live
attenuated human rotavirus (HRV) vaccine at different virus
concentrations (104.7, 105.2 and 105.8 foci forming units
[ffu]) in healthy infants (approximately 2 months of age at
first dose) following a 0, 2 month schedule and previously
uninfected with HRV, when administered concurrently with
DTPw-HBV and Hib vaccines. [This summary presents
results for the second and combined efficacy periods and
results from the 3-Dose subset. Results from the first
efficacy period are presented in 444563/006 (Rota-006)
summary.]. ctr.gsk.co.uk/Summary/Vaccine˙Rotavirus/
II˙444563˙006˙(rota006Annex).pdf 2007.
GlaxoSmithKline[444563-006]. A phase IIb, double-blind,
randomized, placebo-controlled study to assess the efficacy,
immunogenicity, reactogenicity and safety of two doses of
GlaxoSmithKline (GSK) Biologicals’ live attenuated human
rotavirus (HRV) vaccine at different virus concentrations
(104.7, 105.2 and 105.8 foci forming units [ffu]) in
healthy infants (approximately 2 months of age at first
dose) following a 0, 2 month schedule and previously
uninfected with HRV, when administered concurrently with
DTPw-HBV and Hib vaccines. ctr.gsk.co.uk/Summary/
Vaccine˙Rotavirus/II˙444563˙006˙(rota006).pdf 2007.
Linhares A, Perez-Schael I, Ruiz-Palacios M, et
al.Immunogenicity and reactogenicity of an oral human
rotavirus (HRV) vaccine in Latin American infants [Poster].
3rd World Congress of Pediatric Infectious Diseases,
Santiago, Chile. 19 to 23 November 2002. [: Not available
for review]
Linhares AC, Ruiz-Palacios GM, Guerrero ML, Salinas
B, Perez-Schael I, Clemens SA, et al.A short report on
highlights of world-wide development of RIX4414: a Latin
American experience. Vaccine 2006;24(18):3784–5.
Linhares AC, Verstraeten T, Wolleswinkel-van den Bosch J,
Clemens R, Breuer T. Rotavirus serotype G9 is associated
with more-severe disease in Latin America. Clinical
Infectious Diseases 2006;43(3):312–4. [: Not available for
review]
NCT00385320. To assess the efficacy, immuno &
safety of 2 doses of GSK HRV vaccine at different virus
concentrations in healthy infants aged 2 months &
previously uninfected with HRV, concurrently given with
DTPw-HBV, Hib. clinicaltrials.gov/show/NCT00385320
(accessed 16 March 2011).
Perez-Schael I, Salinas B, Linhares A, Guerrero M, Ruiz-
Palacios G, Clemens S, et al.Protective efficacy of an oral
human rotavirus (HRV) vaccine in Latin American infants
[Poster]. 42nd Interscience Conference on Antimicrobial
Agents and Chemotherapy. 2002:18, LB-23. [: Not
available for review]
Perez-Schael I, Salinas B, Tomat M, Linhares AC, Guerrero
ML, Ruiz-Palacios GM, et al.Efficacy of the human
rotavirus vaccine RIX4414 in malnourished children.
Journal of Infectious Diseases 2007;196(4):537–40.
Ruiz-Palacios G, Guerrero L, Cervantes Y, et al.Impact
of maternal antibodies on the immune response to an
oral human rotavirus (HRV) vaccine in Mexican infants
[Presentation]. 3rd World Congress of Pediatric Infectious
Diseases. 19 to 23 November 2002. [: Not available for
review]
Ruiz-Palacios G, Guerrero L, Linhares AC, et al.Efficacy
of an oral human rotavirus (HRV) vaccine in preventing
diarrhoea due to G1 and non-G1 rotavirus [Presentation].
3rd World Congress of Pediatric Infectious Diseases,
Santiago, Chile. 19 to 23 November 2002. [: Not available
for review]
Ruiz-Palacios G, Guerrero ML, Linhares AC, et al.Two-
year efficacy of GlaxoSmithKline Biologicals’ live attenuated
rotavirus vaccine in Latin American children [Poster].
Proceedings of the 24th International Congress of Pediatrics,
Cancun, Mexico. 15 to 20 August 2004. [: Not available
for review]
Ruiz-Palacios GM, Guerrero ML, Bautista-Marquez A,
Ortega-Gallegos H, Tuz-Dzib F, Reyes-Gonzalez L, et
al.Dose response and efficacy of a live, attenuated human
rotavirus vaccine in Mexican infants. Pediatrics 2007;120
(2):e253–61. [: Not available for review]
∗ Salinas B, Perez Schael I, Linhares AC, Ruiz Palacios
GM, Guerrero ML, Yarzabal JP, et al.Evaluation of safety,
42Vaccines for preventing rotavirus diarrhoea: vaccines in use (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
immunogenicity and efficacy of an attenuated rotavirus
vaccine, RIX4414: A randomized, placebo-controlled trial
in Latin American infants. Pediatric Infectious Disease
Journal 2005;24(9):807–16.
Salinas B, Perez-Schael I, Ruiz-Palacios G, et al.Early
protection by GlaxoSmithKline Biologicals’ live attenuated
rotavirus vaccine in Latin American children. [Poster].
Proceedings of the 24th International Congress of Pediatrics,
Cancun, Mexico. 15 to 20 August 2004. [: Not available
for review]
Salinas B, Tomat MA, Yarzabal JP, et al.Efficacy of the
rotavirus vaccine (RIX4414) among infants in Carabobo
State, Venezuela. [Poster]. Asocación Venezolana para el
Avance de la Cienca (AsoVAC), Venezuela. 2004. [: Not
available for review]
RV1 Steele 2008-ZAF {published data only}
GlaxoSmithKline[444563-014]. A phase II, double-blind
before the 2002 rotavirus season and single blind with respect
to OPV after, randomised, placebo-controlled study of the
safety, reactogenicity and immunogenicity of two doses of
GSK Biologicals’ oral live attenuated human rotavirus
(HRV) vaccine (RIX4414 at 105 ffu) co-administered with
either oral polio vaccine (OPV) or inactivated polio vaccine
(IPV) in healthy infants (approximately 5-10 weeks old)
in South Africa. www.clinicalstudyresults.org/documents/
company-study˙2414˙0.pdf 2007.
NCT00346892. Reactogenicity & immunogenicity study
of two doses of GSK Biologicals’ oral live attenuated
HRV vaccine co-administered with either OPV or IPV in
healthy infants (approximately 5-10 weeks old) in South
Africa. clinicaltrials.gov/show/NCT00346892 (accessed 8
September 2008).
Steele AD, Tumbo J, Armah G, et al.Immunogenicity and
reactogenicity of a new live attenuated oral rotavirus vaccine
(RIX4414) when administered concurrently with poliovirus
vaccines in African infants. 24th International Congress of
Pediatrics Cancun, Mexico 15 to 20 August 2004. [: Not
available for review]
Steele AD, Tumbo JM, Armah GE, Reynders J, Scholtz F,
Bos P, et al.Concomitant administration of a live-attenuated
oral rotavirus vaccine (RIX4414) with poliovirus vaccines
in African infants. 23rd Annual Meeting of the European
Society for Pediatric Infectious Diseases-ESPID, Valencia,
Spain 18 to 20 May 2005. [: Not available for review]
∗ Steele AD, De Vos B, Tumbo J, Reynders J, Scholtz F,
Bos P, et al. Co-administration study in South African
infants of a live-attenuated oral human rotavirus vaccine
(RIX4414) and poliovirus vaccines. Vaccine 2010 ;28(39):
6542–8.
RV1 Steele 2010a-ZAF {published data only}
ISRCTN11877362. A phase II, double-blind, randomised,
placebo-controlled study to assess the safety, reactogenicity
and immunogenicity of three doses of GlaxoSmithKline
(GSK) Biologicals’ oral live attenuated human rotavirus
(HRV) vaccine (RIX4414 at 106.5 CCID50) administered
to human immunodeficiency virus (HIV) infected infants at
6, 10 and 14 weeks of age in South Africa. www.controlled-
trials.com/ISRCTN11877362 (accessed 12 August 2008).
∗ Steele AD, Madhi SA, Louw CE, Bos P, Tumbo
JM, Werner CM, et al. Safety, Reactogenicity, and
Immunogenicity of Human Rotavirus Vaccine RIX4414 in
Human Immunodeficiency Virus-positive Infants in South
Africa. Pediatric Infectious Diseases Journal 2011;30(2):
125–30.
RV1 Steele 2010b-ZAF {published data only}
GlaxoSmithKline[444563-013]. A phase II, double-blind
before the 2002 rotavirus season and single blind with
respect to OPV after, randomised, placebo-controlled
study of the safety, reactogenicity and immunogenicity
of two doses of GSK Biologicals’ oral live attenuated
human rotavirus (HRV) vaccine (RIX4414 at 105
ffu) co-administered with either oral polio vaccine
(OPV) or inactivated polio vaccine (IPV) in healthy
infants (approximately 5-10 weeks old) in South Africa.
ctr.gsk.co.uk/Summary/Vaccine˙Rotavirus/II˙444563˙013˙
(Rota013).pdf 2007.
∗ Steele AD, Reynders J, Scholtz F, Bos P, de Beer MC,
Tumbo J, et al. Comparison of 2 different regimens for
reactogenicity, safety, and immunogenicity of the live
attenuated oral rotavirus vaccine RIX4414 coadministered
with oral polio vaccine in South African infants. Journal of
Infectious Diseases 2010;202(Suppl):S93–100.
RV1 Vesikari 2004a-FIN {published data only}
GlaxoSmithKline[444563-003]. A phase II, double-blind,
randomized, placebo-controlled, dose-escalating, stepwise
study to assess safety, reactogenicity and immunogenicity
of GlaxoSmithKline Biologicals’ live attenuated human
rotavirus (HRV) vaccine in healthy infants previously
uninfected with human rotavirus. ctr.gsk.co.uk/Summary/
Vaccine˙Rotavirus/II˙444563˙003˙(rota003).pdf 2005.
∗ Vesikari T, Karvonen A, Korhonen T, Espo M, Lebacq
E, Forster J, et al.Safety and immunogenicity of RIX4414
live attenuated human rotavirus vaccine in adults, toddlers
and previously uninfected infants. Vaccine 2004;22(21-2):
2836–42.
RV1 Vesikari 2004b-FIN {published data only}
De Vos B, Vesikari T, Linhares AC, Salinas B, Perez-Schael I,
Ruiz-Palacios GM, et al.A rotavirus vaccine for prophylaxis
of infants against rotavirus gastroenteritis. Pediatric
Infectious Disease Journal 2004;23(10 Suppl):179–82.
GlaxoSmithKline[444563-004-Annex]. A phase IIb,
double-blind, randomized, placebo-controlled study to
assess the efficacy, immunogenicity, reactogenicity and safety
of two doses of GSK Biologicals’ oral live attenuated human
rotavirus (HRV) vaccine in healthy infants approximately 2
months of age and previously uninfected with HRV. [This
summary presents results for the second efficacy period
(from the end of the first rotavirus season post-vaccination
until the end of the second rotavirus season) and for the two
consecutive rotavirus seasons.]. ctr.gsk.co.uk/Summary/
Vaccine˙Rotavirus/II˙444563˙004˙(rota004annex).pdf
2005.
GlaxoSmithKline[444563-004]. A phase IIb, double-blind,
randomized, placebo-controlled study to assess the efficacy,
43Vaccines for preventing rotavirus diarrhoea: vaccines in use (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
immunogenicity, reactogenicity and safety of two doses of
GSK Biologicals’ oral live attenuated human rotavirus
(HRV) vaccine in healthy infants approximately 2 months
of age and previously uninfected with HRV. [Results for
the first efficacy period (starting from 2 weeks after Dose 2
until the end of the first RV season following vaccination)].
ctr.gsk.co.uk/Summary/Vaccine˙Rotavirus/II˙444563˙004˙
(rota004)˙Year1.pdf 2005.
Vesikari T, Karvonen A, Espo M, Korhonen T, Delem A,
de Vos B. Efficacy evaluation of an oral human rotavirus
(HRV) vaccine in previously uninfected Finnish infants.
42nd Interscience Conference on Antimicrobial Agents and
Chemotherapy, San Diego, California. 27 to 30 September
2002. [: Not available for review]
∗ Vesikari T, Karvonen A, Puustinen L, Zeng SQ, Szakal
ED, Delem A, et al.Efficacy of RIX4414 live attenuated
human rotavirus vaccine in Finnish infants. Pediatric
Infectious Disease Journal 2004;23(10):937–43.
RV1 Vesikari 2007a-EU {published data only}
GlaxoSmithKline[102247-036-Annex]. A phase IIIb,
double-blind, randomized, placebo-controlled, multi-
country and multi-center study to assess the efficacy, safety
and immunogenicity of two doses of GlaxoSmithKline
(GSK) Biologicals’ oral live attenuated human rotavirus
(HRV) vaccine in healthy infants in co-administration
with specific childhood vaccinations. [This summary
presents results for the second and combined efficacy
periods]. ctr.gsk.co.uk/Summary/Vaccine˙Rotavirus/
III˙Rota˙036˙annex.pdf 2007.
GlaxoSmithKline[102247-036-Yr3]. A phase IIIb, double-
blind, randomized, placebo-controlled, multi-country
and multi-center study to assess the efficacy, safety and
immunogenicity of two doses of GlaxoSmithKline (GSK)
Biologicals’ oral live attenuated human rotavirus (HRV)
vaccine in healthy infants in co-administration with specific
childhood vaccinations. [A phase IIIb open study to assess
the long-term efficacy and safety of GlaxoSmithKline
(GSK) Biologicals’ oral live attenuated human rotavirus
(HRV) vaccine approximately three years after vaccination
in healthy infants aged 6-12 weeks at the time of first
vaccination in the Rota-036 study (eTrack No.102247)
in Finland.]. ctr.gsk.co.uk/Summary/Vaccine˙Rotavirus/
III˙109810.pdf 2008.
GlaxoSmithKline[102247-036]. A phase IIIb, double-
blind, randomized, placebo-controlled, multi-country
and multi-center study to assess the efficacy, safety and
immunogenicity of two doses of GlaxoSmithKline (GSK)
Biologicals’ oral live attenuated human rotavirus (HRV)
vaccine in healthy infants in co-administration with specific
childhood vaccinations. [This summary presents results
from the first efficacy period.] [102247-036]. ctr.gsk.co.uk/
Summary/Vaccine˙Rotavirus/III˙Rota˙036.pdf 2007.
NCT00140686. A multi-country & multi-center study
to assess the efficacy, safety & immunogenicity of 2 doses
of GSK Biologicals’ oral live attenuated human rotavirus
(HRV) vaccine in healthy infants in co-administration with
specific childhood vaccines. clinicaltrials.gov/ct2/show/
record/NCT00140686 (accessed 8 September 2008). [:
Trial registration document]
Schuster V, et al.RotarixTM An oral human Rotavirus
vaccine, is highly immunogenic when co-administered with
a Streptococcus pneumoniae conjugate vaccine (PrevenarTM)
in healthy infants from France and Germany. 24th Annual
Meeting Meeting of the European Society for Paediatric
Infectious Diseases (ESPID), Basel, Swizterland. 15 to 18
June 2006. [: Not available for review]
Tejedor JC, et al.Rotarix, an oral Human Rotavirus vaccine,
is highly immunogenic when co-administered with a
Neisseria meningitides Serogroup C vaccine (MeningitecTM)
in healthy infants from Spain. 24th Annual Meeting
Meeting of the European Society for Paediatric Infectious
Diseases (ESPID), Basel, Switzerland. 15 to 18 June 2006.
[: Not available for review]
Vesikari T, Karvonen A, Ferrante SA, Kuter BJ, Ciarlet M.
Sustained efficacy of the pentavalent rotavirus vaccine, RV5,
up to 3.1 years following the last dose of vaccine. Pediatric
Infectious Disease Journal 2010;29(10):957–63.
∗ Vesikari T, Karvonen A, Prymula R, Schuster V, Tejedor
JC, Cohen R, et al.Efficacy of human rotavirus vaccine
against rotavirus gastroenteritis during the first 2 years of life
in European infants: randomised, double-blind controlled
study. Lancet 2007;370(9601):1757–63.
Vesikari T, Prymula R, Schuster V, Tejedor JC, Cohen R,
Bouckenooghe A, et al.Efficacy and immunogenicity of
live-attenuated human rotavirus vaccine in breast-fed and
formula-fed European infants. Pediatric Infectious Disease
Journal 2012;31(5):509–13.
Vesikari T, et al.Early protection against Rotavirus, Rotarix,
experience in an European setting. Proceedings of the 12th
International Congress for Infectious Diseases, Lisbon,
Portugal. 15 to 18 June 2006. [: Not available for review]
Vesikari T, et al.Human rotavirus vaccine Rotarix is
highly efficacious in Europe. 24th Annual Meeting of
the European Society for Paediatric Infectious Diseases
(ESPID), Basel, Switzerland. 15 to 18 June 2006. [: Not
available for review]
Vesikari T, et al.Rotarix, an oral human Rotavirus vaccine,
is highly immunogenic in healthy infants from 6 European
countries. 24th Annual Meeting of the European Society for
Paediatric Infectious Diseases (ESPID), Basel, Switzerland.
15 to 18 June 2006. [: Not available for review]
Vesikari T, et al.Rotarix, an oral human rotavirus vaccine, is
highly immunogenic when co-administered with diphteria-
tetanus-pertussis (DTPA)-combined vaccines in healthy
infants from Europe. 24th Annual Meeting of the European
Society for Paediatric Infectious Diseases (ESPID), Basel,
Switzerland 15 to 18 June 2006. [: Not available for review]
Vesikari T, Karvonen A, Prymula R, Schuster V, Tejedor
JC, Thollot F, et al. Immunogenicity and safety of the
human rotavirus vaccine Rotarix co-administered with
routine infant vaccines following the vaccination schedules
in Europe. Vaccine 2010;28(32):5272–9.
RV1 Vesikari 2011-FIN {published data only}
GlaxoSmithKline[104480-048]. A phase II, double-blind,
44Vaccines for preventing rotavirus diarrhoea: vaccines in use (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
randomized, placebo controlled study to compare the
immunogenicity, reactogenicity and safety of two different
formulations of GlaxoSmithKline (GSK) Biologicals’
live attenuated human rotavirus (HRV) vaccine given
as a two-dose primary vaccination in healthy infants
previously uninfected with HRV. ctr.gsk.co.uk/Summary/
Vaccine˙Rotavirus/II˙104480.pdf 2007.
NCT00137930. Compare the immunogenicity,
reactogenicity & safety of 2 different formulations of GSK
Biologicals’ live attenuated human rotavirus (HRV) vaccine
given as a two-dose primary vaccination in healthy infants
previously uninfected with HRV. clinicaltrials.gov/ct2/
show/record/NCT00137930 (accessed 6 July 2011).
∗ Vesikari T, Karvonen A, Bouckenooghe A, Suryakiran
PV, Smolenov I, Han HH. Immunogenicity, reactogenicity
and safety of the human rotavirus vaccine RIX4414 oral
suspension (liquid formulation) in Finnish infants. Vaccine
2011;29(11):2079–84.
Vesikari T, et al.Immunogenicity of liquid formulation of
the oral live attenuated human rotavirus vaccine (Rotarix™)
[Poster]. Sociedad Latinoamericana de Infectología
Pediátrica (SLIPE) 8, Costa Rica 11 May 2007. [: Not
available for review]
RV1 Ward 2006-USA {published data only}
Ward RL, Kirkwood CD, Sander DS, Smith VE, Shao M,
Bean JA, et al.Reductions in cross-neutralizing antibody
responses in infants after attenuation of the human rotavirus
vaccine candidate 89-12. Journal of Infectious Diseases 2006;
194(12):1729–36.
RV1 Zaman 2009-BGD {published data only}
GlaxoSmithKline[103992-045]. A phase II, randomised,
double-blind, placebo-controlled study to evaluate the
immunogenicity, reactogenicity and safety of two doses of
GSK Biologicals’ oral live attenuated human rotavirus
(HRV) vaccine (RIX4414 at 106.5 CCID50) when
given concomitantly with OPV versus when given alone
(HRV vaccine dose given 15 days after the OPV dose) in
healthy infants in Bangladesh. ctr.gsk.co.uk/Summary/
Vaccine˙Rotavirus/II˙103992˙045.pdf 2007.
NCT00139334. Evaluate immunogenicity, reactogenicity
& safety of 2 doses of GSK Biologicals’ oral live attenuated
HRV vaccine (RIX4414 at 106.5 CCID50) when given
concomitantly with OPV versus given alone (HRV vaccine
dose given 15 days after the OPV dose) in healthy infants
in Bangladesh. clinicaltrials.gov/show/NCT00139334
(accessed 16 March 2011).
∗ Zaman K, Sack DA, Yunus M, Arifeen SE, Podder G,
Azim T, et al.the Bangladesh Rotavirus Vaccine study
group. Successful co-administration of a human rotavirus
and oral poliovirus vaccines in Bangladeshi infants in a 2-
dose schedule at 12 and 16 weeks of age. Vaccine 2009;27:
1333–9.
RV5 Armah 2010-AF {published data only}
Armah GE, Breiman RF, Tapia MD, Dallas MJ, Neuzil
KM, Binka FN, et al.Immunogenicity of the pentavalent
rotavirus vaccine in African infants. Vaccine 2012;30(Suppl
1):A86–93.
∗ Armah GE, Sow SO, Breiman RF, Dallas MJ, Tapia
MD, Feikin DR, et al. Efficacy of pentavalent rotavirus
vaccine against severe rotavirus gastroenteritis in infants in
developing countries in sub-Saharan Africa: a randomised,
double-blind, placebo-controlled trial. Lancet 2010;376
(9741):606–14.
Breiman RF, Zaman K, Armah G, Sow SO, Anh DD,
Victor JC, et al.Analyses of health outcomes from the 5 sites
participating in the Africa and Asia clinical efficacy trials of
the oral pentavalent rotavirus vaccine. Vaccine 2012;30
(Suppl 1):A24–9.
NCT00362648. Efficacy, safety, and immunogenicity
of RotaTeqT M among infants in Asia and Africa.
clinicaltrials.gov/ct2/show/record/NCT00362648 (accessed
8 August 2008).
Tapia MD, Armah G, Breiman RF, Dallas MJ, Lewis
KD, Sow SO, et al.Secondary efficacy endpoints of the
pentavalent rotavirus vaccine against gastroenteritis in sub-
Saharan Africa. Vaccine 2012;30(Suppl 1):A79–85.
RV5 Armah 2010-GHA {published data only}
Armah GE, Sow SO, Breiman RF, Dallas MJ, Tapia
MD, Feikin DR, et al. Efficacy of pentavalent rotavirus
vaccine against severe rotavirus gastroenteritis in infants in
developing countries in sub-Saharan Africa: a randomised,
double-blind, placebo-controlled trial. Lancet 2010;376
(9741):606–14.
∗ Tapia MD, Armah G, Breiman RF, Dallas MJ, Lewis
KD, Sow SO, et al.Secondary efficacy endpoints of the
pentavalent rotavirus vaccine against gastroenteritis in sub-
Saharan Africa. Vaccine 2012;30(Suppl 1):A79–85.
RV5 Armah 2010-KEN {published data only}
Armah GE, Sow SO, Breiman RF, Dallas MJ, Tapia
MD, Feikin DR, et al. Efficacy of pentavalent rotavirus
vaccine against severe rotavirus gastroenteritis in infants in
developing countries in sub-Saharan Africa: a randomised,
double-blind, placebo-controlled trial. Lancet 2010;376
(9741):606–14.
∗ Feikin DR, Laserson KF, Ojwando J, Nyambane G,
Ssempijja V, Audi A, et al.Efficacy of pentavalent rotavirus
vaccine in a high HIV prevalence population in Kenya.
Vaccine 2012;30(Suppl 1):A52–60.
Laserson KF, Nyakundi D, Feikin DR, Nyambane G, Cook
E, Oyieko J, et al.Safety of the pentavalent rotavirus vaccine
(PRV), RotaTeq((R)), in Kenya, including among HIV-
infected and HIV-exposed infants. Vaccine 2012;30(Suppl
1):A61–70.
Tapia MD, Armah G, Breiman RF, Dallas MJ, Lewis
KD, Sow SO, et al.Secondary efficacy endpoints of the
pentavalent rotavirus vaccine against gastroenteritis in sub-
Saharan Africa. Vaccine 2012;30(Suppl 1):A79–85.
RV5 Armah 2010-MLI {published data only}
Armah GE, Sow SO, Breiman RF, Dallas MJ, Tapia
MD, Feikin DR, et al. Efficacy of pentavalent rotavirus
vaccine against severe rotavirus gastroenteritis in infants in
developing countries in sub-Saharan Africa: a randomised,
45Vaccines for preventing rotavirus diarrhoea: vaccines in use (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
double-blind, placebo-controlled trial. Lancet 2010;376
(9741):606–14.
∗ Sow SO, Tapia M, Haidara FC, Ciarlet M, Diallo F, Kodio
M, et al.Efficacy of the oral pentavalent rotavirus vaccine in
Mali. Vaccine 2012;30(Suppl 1):A71–8.
Tapia MD, Armah G, Breiman RF, Dallas MJ, Lewis
KD, Sow SO, et al.Secondary efficacy endpoints of the
pentavalent rotavirus vaccine against gastroenteritis in sub-
Saharan Africa. Vaccine 2012;30(Suppl 1):A79–85.
RV5 Block 2007-EU/USA {published data only}
∗ Block SL, Vesikari T, Goveia MG, Rivers SB, Adeyi BA,
Dallas MJ, et al.Efficacy, immunogenicity, and safety of
a pentavalent human-bovine (WC3) reassortant rotavirus
vaccine at the end of shelf life. Pediatrics 2007;119(1):11–8.
Merck[PN-007]. Study of the efficacy, safety, and
immunogenicity of RotaTeq™ at expiry potency
NCT00092443 (PN 007). www.clinicalstudyresults.org/
drugdetails/?indication˙id=523&sort=c.company˙name&
page=1&drug˙id=900 2008.
NCT00092443. Study of the efficacy, safety, and
immunogenicity of V260 at expiry. clinicaltrials.gov/ct2/
show/NCT00092443 (accessed 8 September 2008). [: Trial
registration document]
RV5 Ciarlet 2009-EU {published and unpublished data}
∗ Ciarlet M, He S, Lai S, Petrecz M, Yuan G, Liu GF,
et al.Concomitant use of the 3-dose oral pentavalent
rotavirus vaccine with a 3-dose primary vaccination course
of a diphtheria-tetanus-acellular pertussis-hepatitis B-
inactivated polio-Haemophilus influenzae type b vaccine:
immunogenicity and reactogenicity. Pediatric Infectious
Disease Journal 2009;28(3):177–81.
Merck[PN-010]. Safety and immunogenicity of
concomitant use of RotaTeq™ and INFANRIX™ hexa
in healthy infants NCT00258154 (PN 010) [Merck &
Co., Inc. Study Synopsis]. www.clinicalstudyresults.org/
drugdetails/?indication˙id=1101&sort=c.company˙name&
page=1&drug˙id=2823 2008.
NCT00258154. Safety and immunogenicity of
concomitant use of V260 and INFANRIX(Tm) hexa in
healthy infants. clinicaltrials.gov/show/NCT00258154
(accessed 12 September 2008). [: Trial registration
document (no data for review)]
RV5 Clark 2003-USA {published and unpublished data}
Clark HF, Burke CJ, Volkin DB, Offit P, Ward RL, Bresee
JS, et al.Safety, immunogenicity and efficacy in healthy
infants of G1 and G2 human reassortant rotavirus vaccine
in a new stabilizer/buffer liquid formulation. Pediatric
Infectious Disease Journal 2003;22(10):914–20.
RV5 Clark 2004-USA {published and unpublished data}
Clark H, White C, Offit P, Stinson D, Eiden J, Weaver
S, et al.Preliminary evaluation of safety and efficacy of
quadrivalent human-bovine reassortant rotavirus vaccine
[abstract]. Pediatric Research 1995;37:172A. [: No data for
review]
∗ Clark HF, Bernstein DI, Dennehy PH, Offit P, Pichichero
M, Treanor J, et al.Safety, efficacy, and immunogenicity
of a live, quadrivalent human-bovine reassortant rotavirus
vaccine in healthy infants. Journal of Pediatrics 2004;144
(2):184–90.
Clark HF, Offit PA, Ellis RW, Eiden JJ, Krah D, Shaw AR,
et al.The development of multivalent bovine rotavirus
(strain WC3) reassortant vaccine for infants. Journal of
Infectious Diseases 1996;174(Suppl 1):73–80. [: No data for
review]
Ward RL, Bernstein DI, Smith VE, Sander DS, Shaw A,
Eiden JJ, et al.Rotavirus immunoglobulin a responses
stimulated by each of 3 doses of a quadrivalent human/
bovine reassortant rotavirus vaccine. Journal of Infectious
Diseases 2004;189(12):2290–3.
RV5 Kim 2008-KOR {published and unpublished data}
∗ Kim DS, Lee TJ, Kang JH, Kim JH, Lee JH, Ma SH,
et al.Immunogenicity and safety of a pentavalent human-
bovine (WC3) reassortant rotavirus vaccine in healthy
infants in Korea. Pediatric Infectious Disease Journal 2008;
27(2):177–8.
Merck[PN-013]. Immunogenicity and safety of RotaTeq®
in healthy infants in Korea - NCT00166517 (PN 013).
www.clinicalstudyresults.org/drugdetails/?indication˙id=
523&sort=c.company˙name&page=1&drug˙id=2148
2008.
NCT00166517. Immunogenicity and safety of V260
in healthy infants in Korea. clinicaltrials.gov/show/
NCT00166517 (accessed 12 September 2008). [: Trial
registration document (no data for review)]
RV5 Merck[009] 2005-USA {published and unpublished data}
∗ Merck[PN-009]. Protocol 009 - Comparison of the
immunogenicity and safety of three consistency lots
of RotaTeq™ in healthy infants (NCT00092456).
www.clinicalstudyresults.org/drugdetails/?indication˙id=
523&sort=c.company˙name&page=1&drug˙id=1357
2005.
NCT00092456. Comparison of the immunogenicity and
safety of three consistency lots of V260 in healthy infants.
clinicaltrials.gov/ct2/show/record/NCT00092456 (accessed
12 September 2009). [: Trial registration document (no
data for review)]
RV5 NCT00718237 2010-JPN {published and unpublished data}
NCT00718237. A Phase III randomized, placebo-
controlled clinical trial to study the efficacy and safety of
V260 in healthy infants in Japan. clinicaltrials.gov/ct2/show/
record/NCT00718237 (accessed 20 February 2011).
RV5 NCT00953056 2010-CHI {published and unpublished data}
NCT00953056. A Study of V260 in Healthy Chinese
Adults, Children and Infants. http://clinicaltrials.gov/ct2/
show/study/NCT00953056 (accessed 6 July 2011).
RV5 Vesikari 2006a-FIN {published and unpublished data}
Vesikari T, Clark HF, Offit P, Schodel F, Dallas M, Heaton
P, et al.The effect of dose and composition of a pentavalent
rotavirus reassortant vaccine [RotaTeq (R)] in safety,
efficacy, and immunogenicity in healthy infants. Pediatric
Research 2003;53(4 Suppl):307A.
∗ Vesikari T, Clark HF, Offit PA, Dallas MJ, DiStefano DJ,
Goveia MG, et al.Effects of the potency and composition of
46Vaccines for preventing rotavirus diarrhoea: vaccines in use (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
the multivalent human-bovine (WC3) reassortant rotavirus
vaccine on efficacy, safety and immunogenicity in healthy
infants. Vaccine 2006;24(22):4821–9.
RV5 Vesikari 2006b-INT {published and unpublished data}
Chang CC, Chang MH, Lin TY, Lee HC, Hsieh WS, Lee
PI. Experience of pentavalent human-bovine reassortant
rotavirus vaccine among healthy infants in Taiwan. Journal
of the Formosan Medical Association 2009;108(4):280–5.
Dennehy PH, Goveia MG, Dallas MJ, Heaton PM. The
integrated phase III safety profile of the pentavalent human-
bovine (WC3) reassortant rotavirus vaccine. International
Journal of Infectious Diseases 2007;11(Suppl 2):36–42. [:
No data available for review]
Goveia MG, Rodriguez ZM, Dallas MJ, Itzler RF, Boslego
JW, Heaton PM, et al.Safety and efficacy of the pentavalent
human-bovine (WC3) reassortant rotavirus vaccine in
healthy premature infants. Pediatric Infectious Disease
Journal 2007;26(12):1099–104. [: No data available for
review]
Goveia MG, Suprun L, Itzler RF, McFetridge R, Dallas MJ,
Kuter BJ. Efficacy and safety of pentavalent human-bovine
reassortant rotavirus vaccine when administered with greater
than 10 weeks between doses. Pediatric Infectious Disease
Journal 2010;29(3):263–5.
Grant LR, Watt JP, Weatherholtz RC, Moulton LH, Reid R,
Santosham M, et al.Efficacy of a pentavalent human-bovine
reassortant rotavirus vaccine against rotavirus gastroenteritis
among American Indian children. Pediatric Infectious
Disease Journal 2012;31(2):184–8.
Itzler R, Koch G, Matson DO, Gothefors L, Van Damme P,
Dinubile MJ, et al.Robustness of the healthcare utilization
results from the Rotavirus Efficacy and Safety Trial
(REST) evaluating the human-bovine (WC3) reassortant
pentavalent rotavirus vaccine (RV5). BMC Pediatrics 2010;
10:42.
Merck[PN-006]. Safety and efficacy of pentavalent (G1,
G2, G3, G4, and P1) human-bovine reassortant rotavirus
vaccine in healthy infants NCT00090233 (PN 006).
www.clinicalstudyresults.org/drugdetails/?indication˙id=
523&sort=c.company˙name&page=1&drug˙id=1144
2008. [: No data available for review]
NCT00090233. Safety and efficacy of pentavalent (G1,
G2, G3, G4, and P1) human-bovine reassortant rotavirus
vaccine in healthy infants. clinicaltrials.gov/ct2/show/
record/NCT00090233 (accessed 12 September 2009). [:
Trial registration document]
Rodriguez ZM, Goveia MG, Stek JE, Dallas MJ, Boslego
JW, DiNubile MJ, et al.Concomitant use of an oral live
pentavalent human-bovine reassortant rotavirus vaccine
with licensed parenteral pediatric vaccines in the United
States. Pediatric Infectious Disease Journal 2007;26(3):
221–7.
Vesikari T, Itzler R, Karvonen A, Korhonen T, Van Damme
P, Behre U, et al.RotaTeq, a pentavalent rotavirus vaccine:
efficacy and safety among infants in Europe. Vaccine 2009;
28(2):345–51.
Vesikari T, Itzler R, Matson DO, Santosham M, Christie
CD, Coia M, et al.Efficacy of a pentavalent rotavirus vaccine
in reducing rotavirus-associated health care utilization
across three regions (11 countries). International Journal of
Infectious Diseases 2007;11(Suppl 2):29–35.
Vesikari T, Karvonen A, Ferrante SA, Ciarlet M. Efficacy of
the pentavalent rotavirus vaccine, RotaTeq(R), in Finnish
infants up to 3 years of age: the Finnish Extension Study.
European Journal of Pediatrics 2010;169(11):1379–86.
∗ Vesikari T, Matson DO, Dennehy P, Van Damme P,
Santosham M, Rodriguez Z, et al.Safety and efficacy of a
pentavalent human-bovine (WC3) reassortant rotavirus
vaccine. New England Journal of Medicine 2006;354(1):
23–33.
Vesikari T, Karvonen A, Ferrante SA, Kuter BJ, Ciarlet
M. Sustained efficacy of the pentavalent rotavirus vaccine,
RV5, up to 3.1 years following the last dose of vaccine.
Pediatric Infectious Disease Journal 2010;29(10):957–63.
RV5 Zaman 2010-AS {published data only}
Breiman RF, Zaman K, Armah G, Sow SO, Anh DD,
Victor JC, et al.Analyses of health outcomes from the 5 sites
participating in the Africa and Asia clinical efficacy trials of
the oral pentavalent rotavirus vaccine. Vaccine 2012;30
(Suppl 1):A24–9.
NCT00362648. Efficacy, safety, and immunogenicity
of RotaTeqTM among infants in Asia and Africa.
clinicaltrials.gov/ct2/show/record/NCT00362648 (accessed
8 August 2008).
Shin S, Anh DD, Zaman K, Yunus M, Mai le TP, Thiem
VD, et al.Immunogenicity of the pentavalent rotavirus
vaccine among infants in two developing countries in
Asia, Bangladesh and Vietnam. Vaccine 2012;30(Suppl 1):
A106–13.
∗ Zaman K, Dang DA, Victor JC, Shin S, Yunus
M, Dallas MJ, et al. Efficacy of pentavalent rotavirus
vaccine against severe rotavirus gastroenteritis in infants in
developing countries in Asia: a randomised, double-blind,
placebo-controlled trial. Lancet 2010;376(9741):615–23.
RV5 Zaman 2010-BGD {published data only}
Feller AJ, Zaman K, Lewis KD, Hossain I, Yunus M,
Sack DA. Malnutrition levels among vaccinated and
unvaccinated children between 2 and 3 years of age
following enrollment in a randomized clinical trial with the
pentavalent rotavirus vaccine (PRV) in Bangladesh. Vaccine
2012;30(Suppl 1):A101–5.
Zaman K, Yunus M, Arifeen SE, Azim T, Faruque AS,
Huq E, et al.Methodology and lessons-learned from the
efficacy clinical trial of the pentavalent rotavirus vaccine in
Bangladesh. Vaccine 2012;30(Suppl 1):A94–A100.
∗ Zaman K, Dang DA, Victor JC, Shin S, Yunus
M, Dallas MJ, et al. Efficacy of pentavalent rotavirus
vaccine against severe rotavirus gastroenteritis in infants in
developing countries in Asia: a randomised, double-blind,
placebo-controlled trial. Lancet 2010;376(9741):615–23.
RV5 Zaman 2010-VNM {published data only}
∗ Zaman K, Dang DA, Victor JC, Shin S, Yunus
M, Dallas MJ, et al. Efficacy of pentavalent rotavirus
vaccine against severe rotavirus gastroenteritis in infants in
47Vaccines for preventing rotavirus diarrhoea: vaccines in use (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
developing countries in Asia: a randomised, double-blind,
placebo-controlled trial. Lancet 2010;376(9741):615–23.
References to studies excluded from this review
OTHER Bucher 2012 {published data only}
Bucher A, Rivara G, Briceno D, Huicho L. [Use of a rapid
rotavirus test in prescription of antibiotics in acute diarrhea
in pediatrics: an observational, randomized, controlled
study]. Revista de Gastroenterologia del Peru 2012;32(1):
11–5.
OTHER Chatterjee 2012 {published data only}
Chatterjee A, O’Keefe C, Varman M, Klein NP, Luber
S, Tomovici A, et al.Comparative immunogenicity and
safety of different multivalent component pertussis vaccine
formulations and a 5-component acellular pertussis vaccine
in infants and toddlers: a randomized, controlled, open-
label, multicenter study. Vaccine 2012; Vol. 30, issue 23:
3360–68.
OTHER Davidson 2007 {published data only}
Davidson G, Elliott EJ, Kirkwood C, Pearce R. Preventing
rotavirus gastroenteritis: do you have the facts?. Journal of
the Paediatrics and Child Health 2007;43(7-8):564–7.
OTHER de Palma 2010 {published data only}
∗ de Palma O, Cruz L, Ramos H, de Baires A, Villatoro
N, Pastor D, et al. Effectiveness of rotavirus vaccination
against childhood diarrhoea in El Salvador: case-control
study. BMJ 2010;340:c2825.
OTHER Diness 2010 {published data only}
Diness BR, Christoffersen D, Pedersen UB, Rodrigues
A, Fischer TK, Andersen A, et al.The effect of high-dose
vitamin A supplementation given with bacille Calmette-
Guerin vaccine at birth on infant rotavirus infection and
diarrhea: a randomized prospective study from Guinea-
Bissau. Journal of Infectious Disease 2010;202(Suppl):
S243–51.
OTHER Dutta 2011 {published data only}
Dutta P, Mitra U, Dutta S, Rajendran K, Saha TK,
Chatterjee MK. Randomised controlled clinical trial of
Lactobacillus sporogenes (Bacillus coagulans), used as
probiotic in clinical practice, on acute watery diarrhoea in
children. Tropical Medicine and International Health 2011;
16(5):555–61.
OTHER Freedman 2007 {published data only}
Freedman SB. Acute infectious pediatric gastroenteritis:
beyond oral rehydration therapy. Expert Opinion on
Pharmacotherapy 2007;8(11):1651–65.
OTHER Gagneur 2011 {published data only}
Gagneur A, Nowak E, Lemaitre T, Segura JF, Delaperriere
N, Abalea L, et al.Impact of rotavirus vaccination on
hospitalizations for rotavirus diarrhea: The IVANHOE
study. Vaccine 2011;29:3753–9.
OTHER Glass 2004 {published data only}
Glass RI, Bresee JS, Parashar UD, Jiang B, Gentsch J. The
future of rotavirus vaccines: a major setback leads to new
opportunities. Lancet 2004;363(9420):1547–50.
OTHER Kapikian 1989 {published data only}
Kapikian AZ, Flores J, Midthun K, Hoshino Y, Green
KY, Gorziglia M, et al.Strategies for the development
of a rotavirus vaccine against infantile diarrhea with an
update on clinical trials of rotavirus vaccines. Advances in
Experimental Medicine and Biology 1989;257:67–89.
OTHER Kempe 2007 {published data only}
Kempe A, Daley MF, Parashar UD, Crane LA, Beaty BL,
Stokley S, et al.Will pediatricians adopt the new rotavirus
vaccine?. Pediatrics 2007;119(1):1–10.
OTHERMuhsen 2010 {published data only}
Muhsen K, Shulman L, Kasem E, Rubinstein U, Shachter
J, Kremer A, et al.Effectiveness of rotavirus vaccines
for prevention of rotavirus gastroenteritis-associated
hospitalizations in Israel: a case-control study. Human
Vaccines 2010;6(6):450–4.
OTHER NCT01195844 {published data only}
NCT01195844. Rotavirus Gastroenteritis in Children Less
Than 5 Years-old. Surveillance Performed in Hospitals
From Four Brazilian Regions. http://clinicaltrials.gov/show/
NCT01195844 (accessed 4 July 2011).
OTHER NCT01236066 {published data only}
NCT01236066. A Study on the Impact of Rotavirus
Vaccination on Hospitalisations for Rotavirus
Gastroenteritis in Children Aged <5 Years in Australia.
http://clinicaltrials.gov/show/NCT01236066 (accessed 4 July
2011).
OTHER NCT01375907 {published data only}
NCT01375907. A Phase 1 study to evaluate safety and
reactogenicity of a Vietnamese rotavirus vaccine (Rotavin-
M1 at 10e6.3FFU/Dose) among healthy adults in Vietnam.
http://clinicaltrials.gov/show/NCT01375907 (accessed 4 July
2011).
OTHER Prymula 2009 {published data only}
Prymula R, Siegrist CA, Chlibek R, Zemlickova H, Vackova
M, Smetana J, et al.Effect of prophylactic paracetamol
administration at time of vaccination on febrile reactions
and antibody responses in children: two open-label,
randomised controlled trials. Lancet 2009;374(9698):
1339–50.
OTHER Rivera 2011 {published data only}
Rivera L, Pena LM, Stainier I, Gillard P, Cheuvart B,
Smolenov I, et al.Horizontal transmission of a human
rotavirus vaccine strain--a randomized, placebo-controlled
study in twins. Vaccine 2011;29(51):9508–13.
OTHER Tate 2012 {published data only}
Tate JE, Burton AH, Boschi-Pinto C, Steele AD, Duque
J, Parashar UD. 2008 estimate of worldwide rotavirus-
associated mortality in children younger than 5 years
before the introduction of universal rotavirus vaccination
programmes: A systematic review and meta-analysis. Lancet
Infectious Diseases 2012;12(2):136–41.
OTHER Thyagarajan 2011 {published data only}
Thyagarajan V, Glass R, Rodgers K, Quinlan S, Holick CN,
Rosillon D, et al.Validity of current procedural terminology
48Vaccines for preventing rotavirus diarrhoea: vaccines in use (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
codes for rotavirus vaccination in two commercially-
insured us populations. Pharmacoepidemiology and Drug
Safety 2011;Conference: 27th International Conference
on Pharmacoepidemiology and Therapeutic Risk
Management Chicago, IL United States. Conference
Start: 20110814 Conference End: 20110817.
Conference Publication: (var.pagings). 20:S242.
RV1 Anonymous 2004 {published data only}
Anonymous. Rotavirus vaccine--AVANT
immunotherapeutics/GlaxoSmithKline: 89-12, RIX4414.
Drugs in R & D 2004;5(2):113–5.
RV1 Araujo 2007 {published data only}
Araujo EC, Clemens SA, Oliveira CS, Justino MC, Rubio
P, Gabbay YB, et al.Safety, immunogenicity, and protective
efficacy of two doses of RIX4414 live attenuated human
rotavirus vaccine in healthy infants. Jornal de Pediatria
2007;83(3):217–24.
RV1 Cervantes 2006 {published data only}
Cervantes-Apolinar MY, Cassart JP, Bouckenooghe A.
Introduction of human rotavirus vaccine in Latin America.
Archives of Medical Research 2006;37(4):568-9; author reply
570.
RV1 Cheuvart 2009 {published data only}
Cheuvart B, Friedland LR, Abu-Elyazeed R, Han HH,
Guerra Y, Verstraeten T. The human rotavirus vaccine
RIX4414 in infants: A review of safety and tolerability.
Pediatric Infectious Disease Journal 2009;28(3):225–32.
RV1 Correia 2010 {published data only}
∗ Correia JB, Patel MM, Nakagomi O, Montenegro
FM, Germano EM, Correia NB, et al. Effectiveness
of monovalent rotavirus vaccine (Rotarix) against severe
diarrhea caused by serotypically unrelated G2P[4] strains in
Brazil. Journal of Infectious Diseases 2010;201(3):363–9.
RV1 CTRI/2012/02/002454 {published data only}
CTRI/2012/02/002454. Comparison of immunogenicity
of a 3 dose and a 5 dose schedule of oral rotavirus vaccine in
south Indian infants. http://www.ctri.nic.in/Clinicaltrials/
pmaindet2.php?trialid=4262 (accessed 28 May 2012).
RV1 Dennehy 2008 {published data only}
Dennehy PH, Bertrand HR, Silas PE, Damaso S, Friedland
LR, Abu-Elyazeed R. Coadministration of RIX4414 oral
human rotavirus vaccine does not impact the immune
response to antigens contained in routine infant vaccines in
the United States. Pediatrics 2008;122(5):e1062–6.
NCT00334607. Assess the immunogenicity of 3 doses of
Pediarix®, Prevnar® & ActHIB® given to healthy infants
when administered with GSK Biologicals’ 2 dose oral live
attenuated human rotavirus vaccine given during the same
vaccination visit or separately. clinicaltrials.gov/show/
NCT00334607 (accessed March 20011).
RV1 De Vos 2006 {published data only}
De Vos B, Delem A, Hardt K, Bock HL, Meurice F, Innis B.
A short report on clinical evaluation of RIX4414: highlights
of world-wide development. Vaccine 2006;24(18):3777–8.
RV1 De Vos 2009 {published data only}
De Vos B, Han HH, Bouckenooghe A, Debrus S, Gillard
P, Ward R, et al.Live attenuated human rotavirus vaccine,
RIX4414, provides clinical protection in infants against
rotavirus strains with and without shared G and P
genotypes: integrated analysis of randomized controlled
trials. Pediatric Infectious Disease Journal 2009;28(4):261–6.
RV1 GSK[107077-057] 2008 {published data only}
GlaxoSmithKline[107077-057]. A phase III, open,
randomized study to assess the immunogenicity,
reactogenicity and safety of two different formulations of
GlaxoSmithKline (GSK) Biologicals’ live attenuated human
rotavirus (HRV) vaccine, given as a two-dose primary
vaccination, in healthy infants previously uninfected
with HRV. ctr.gsk.co.uk/Summary/Vaccine˙Rotavirus/
III˙107077.pdf 2008.
RV1 GSK[107876-061] 2008 {published data only}
GlaxoSmithKline[107876-061]. A phase III, randomised
study to evaluate the clinical consistency in terms of
immunogenicity and reactogenicity of three production
lots of the liquid formulation of GlaxoSmithKline (GSK)
Biologicals’ oral live attenuated human rotavirus (HRV)
vaccine and to evaluate the liquid formulation as compared
to the lyophilised formulation of the HRV vaccine in
terms of immunogenicity, reactogenicity and safety when
administered as a two-dose primary vaccination in healthy
infants previously uninfected with human rotavirus.
ctr.gsk.co.uk/Summary/Vaccine˙Rotavirus/III˙107876.pdf
2008.
RV1 GSK[444563-020] 2007 {published data only}
GlaxoSmithKline[444563-020]. A phase II, double-
blind randomised, placebo controlled clinical dose-range
study to assess the immunogenicity and reactogenicity of
an investigational vaccination regimen, and to assess the
immunogenicity of OPV orally co-administered to healthy
infants at 2, 4 and 6 months of age. ctr.gsk.co.uk/Summary/
Vaccine˙Rotavirus/II˙444563˙020.pdf 2007.
RV1 NCT00353366 {published data only}
NCT00353366. A study to evaluate the safety &
reactogenicity of GSK Bio’s live attenuated oral HRV
vaccine, Rotarix when administered according to prescribing
information, in Filipino subjects aged between 6 weeks
& 14 weeks at first vaccination. clinicaltrials.gov/show/
NCT00353366 (accessed 8 September 2008).
RV1 NCT00382772 2008 {published data only}
NCT00382772. Study to evaluate clinical consistency of
the liquid formulation of GSK Biologicals’ HRV vaccine
and to evaluate liquid formulation compared to lyophilised
formulation of the HRV vaccine administered as a two-dose
primary vaccination. clinicaltrials.gov/ct2/show/record/
NCT00382772.
RV1 NCT00653198 {published data only}
NCT00653198. Hospital-based, case-control study to
assess the vaccine effectiveness of Rotarix™ against rotavirus
severe gastroenteritis (RV SGE) among hospitalised children
born after 1 March 2006 and at least 12 weeks of age, in
49Vaccines for preventing rotavirus diarrhoea: vaccines in use (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Panama. clinicaltrials.gov/show/NCT00653198 (accessed 8
September 2008).
RV1 NCT00655187 {published data only}
NCT00655187. Hospital-based, case-control study to
assess the vaccine effectiveness of Rotarix™ against rotavirus
severe gastroenteritis (RV SGE) among hospitalised children
< 5 years of age in KKHospital, Singapore. clinicaltrials.gov/
show/NCT00655187 (accessed 8 September 2008).
RV1 NCT01162590 {published data only}
NCT01162590. Reactogenicity and Safety of a Single
Dose of GlaxoSmithKline (GSK) Biologicals’ Human
Rotavirus (HRV) Vaccine (444563) in Healthy Adults.
http://clinicaltrials.gov/show/NCT01162590 (accessed 4 July
2011).
RV1 NCT01177826 {published data only}
NCT01177826. Case-control Study to Evaluate the Vaccine
Effectiveness of GlaxoSmithKline (GSK) Biologicals’
Live Attenuated Human Rotavirus (HRV) Vaccine
(Rotarix™) Against Community-acquired Rotavirus
Severe Gastroenteritis (RV SGE) Among Hospitalised
Children Born After 1 October 2006, in Belgium. http:
//clinicaltrials.gov/show/NCT01177826 (accessed 4 July
2011).
RV1 NCT01273077 {published data only}
NCT01273077. Evaluation of Universal Rotavirus
Vaccination Program. http://clinicaltrials.gov/show/
NCT01273077 (accessed 4 July 2011).
RV1 NCT01339221 {published data only}
NCT01339221. Epidemiological, Observational, Post
Marketing Study of the Genetic Stability of GSK Biologicals’
Rotavirus Vaccine (Rotarix™) in Children <5 Years of Age
Diagnosed With Severe Gastroenteritis, in Belgium. http:
//clinicaltrials.gov/show/NCT01339221 (accessed 4 July
2011).
RV1 PLOSKER 2011 {published data only}
Plosker GL. Rotavirus vaccine RIX4414 (Rotarix): A
pharmacoeconomic review of its use in the prevention
of rotavirus gastroenteritis in developed countries.
Pharmacoeconomics 2011;29(5):439–54.
RV1 Rojas 2007 {published data only}
Rojas OL, Caicedo L, Guzman C, Rodriguez LS, Castaneda
J, Uribe L, et al.Evaluation of circulating intestinally
committed memory B cells in children vaccinated with
attenuated human rotavirus vaccine. Viral Immunology
2007;20(2):300–11.
RV1 Suryakiran 2011 {published data only}
Suryakiran PV, Vinals C, Vanfraechem K, Han HH, Guerra
Y, Buyse H. The human rotavirus vaccine rix4414 in infants:
An integrated safety summary (ISS). Acta Paediatrica,
International Journal of Paediatrics 2011;Conference:
3rd Excellence in Paediatrics Conference and the
1st PNAE Congress on Paediatric Nursing Istanbul
Turkey. Conference Start: 20111130 Conference End:
20111203. Conference Publication: (var.pagings). 100:
56–7.
RV1 Vesikari 2006 {published data only}
Vesikari T, Karvonen A, Puustinen L, Szakal ED, Zeng SQ,
Delem A, et al.A short report on highlights of world-wide
development of RIX4414: an European experience. Vaccine
2006;24(18):3779.
RV5 [NCT00130832] 2010 {published data only}
Merck NCT00130832. Concomitant Use and Staggered
Use of Vaccine and Oral Poliovirus (OPV) in Healthy
Infants. http://clinicaltrials.gov/ct2/show/results/
NCT00130832 (accessed: 15 March 2011).
RV5 ACTRN12611000559910 {published data only}
ACTRN12611000559910. An observational, cross
sectional, cohort study to assess the impact of rotavirus
vaccine introduction on severe gastroenteritis in
South Australian children. http://www.anzctr.org.au/
ACTRN12611000559910.aspx (accessed 4 July 2011).
RV5 Bernstein 2008 {published data only}
Bernstein D. Efficacy of the pentavalent rotavirus vaccine in
subjects after 1 or 2 doses in the rotavirus efficacy and safety
trial. Pediatrics 2008;121(1):223; author reply 223-4.
RV5 Caple 2006 {published data only}
Caple J. Pentavalent human-bovine reassortant rotavirus
vaccine: a review of its efficacy and safety in preventing
acute rotavirus gastroenteritis in healthy infants. Drugs of
Today 2006;42(5):313–9.
RV5 Ciarlet 2008 {published data only}
Ciarlet M, Sani-Grosso R, Yuan G, Liu GF, Heaton PM,
Gottesdiener KM, et al.Concomitant use of the oral
pentavalent human-bovine reassortant rotavirus vaccine and
oral poliovirus vaccine. Pediatric Infectious Disease Journal
2008;27(10):874–80.
RV5 Clark 2006 {published data only}
Clark HF, Offit PA, Plotkin SA, Heaton PM. The new
pentavalent rotavirus vaccine composed of bovine (strain
WC3) -human rotavirus reassortants. Pediatric Infectious
Disease Journal 2006;25(7):577–83.
RV5 El Khoury 2011 {published data only}
El Khoury AC, Mast TC, Ciarlet M, Markson L, Goveia
MG, Munford V, et al.Projecting the effectiveness of
RotaTeq against rotavirus-related hospitalisations in Brazil.
Memorias do Instituto Oswaldo Cruz 2011;106(5):541–5.
RV5 El Khoury 2011a {published data only}
El Khoury AC, Mast TC, Ciarlet M, Markson LE, Goveia
MG. Projecting the effectiveness of RotaTeq against
rotavirus-related hospitalizations and deaths in six Asian
countries. Human Vaccines 2011;7(5):506–10.
RV5 Goveia 2008 {published data only}
Goveia MG, DiNubile MJ, Dallas MJ, Heaton PM,
Kuter BJ. Efficacy of pentavalent human-bovine (WC3)
reassortant rotavirus vaccine based on breastfeeding
frequency. Pediatric Infectious Disease Journal 2008;27(7):
656–8.
RV5 Goveia 2010 {published data only}
∗ Goveia MG, Suprun L, Itzler RF, McFetridge R, Dallas
MJ, Kuter BJ. Efficacy and safety of pentavalent human-
50Vaccines for preventing rotavirus diarrhoea: vaccines in use (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
bovine reassortant rotavirus vaccine when administered with
greater than 10 weeks between doses. Pediatric Infectious
Disease Journal 2010;29(3):263–5.
RV5 Heyse 2008 {published data only}
Heyse JF, Kuter BJ, Dallas MJ, Heaton P. Evaluating the
safety of a rotavirus vaccine: The REST of the story.
Clinical Trials 2008;5:131–9.
RV5 Keating 2006 {published data only}
Keating GM. Rotavirus vaccine (RotaTeq). Paediatric Drugs
2006;8(3):197-202; discussion 203-4.
RV5 NCT00496054 {published data only}
NCT00496054. Evaluation of safety, tolerability and
immunogenicity of vaccination with Rotateq (V260)
in healthy infants in India. clinicaltrials.gov/show/
NCT00496054 (accessed 4 July 2011).
RV5 Tom-Revzon 2007 {published data only}
Tom-Revzon C. Rotavirus live, oral, pentavalent vaccine.
Clinical Therapeutics 2007;29(12):2724–37.
RV5 Tugcu 2009 {published data only}
Tugcu U, Sahin F, Bozdayi G, Aksakal FN, Alp G, Rota S,
et al.Clinical efficacy of rotavirus vaccine in Turkish infants.
Posters, 12th ESCV, Istanbul, Journal of Clinical Virology
2009;46(Suppl):S15-S61.
RV5 van der Wielen 2008 {published data only}
Van Der Wielen M, Van Damme P. Pentavalent human-
bovine (WC3) reassortant rotavirus vaccine in special
populations: A review of data from the Rotavirus Efficacy
and Safety Trial. European Journal of Clinical Microbiology
& Infectious Diseases 2008;27(7):495–501.
RV5 Vesikari 2011 {published data only}
* Vesikari T, Karvonen A, Borrow R, Kitchin N, Baudin M,
Thomas S, et al.Results from a randomized clinical trial
of coadministration of RotaTeq, a pentavalent rotavirus
vaccine, and NeisVac-C, a meningococcal serogroup C
conjugate vaccine. Clinical Vaccine Immunology 2011 May;
18(5):878–84.
NCT00443846. An open-label, randomised, comparative,
multi-centre study of the immunogenicity and safety of the
concomitant use of a live pentavalent rotavirus vaccine
(RotaTeq®) and a meningococcal Group C conjugate
(MCC) vaccine in healthy infants. clinicaltrials.gov/ct2/
show/record/NCT00443846 (accessed 6 July 2011).
References to ongoing studies
Other ACTRN12610000525088 {published data only}
ACTRN12610000525088. A Phase 1 double-blind,
randomized study to compare the safety, tolerability
and immunogenicity of oral RV3-BB Rotavirus vaccine
and placebo in infants, children and male adults. http://
www.anzctr.org.au/ACTRN12610000525088.aspx (accessed
4 July 2011).
Other ACTRN12611001212943 {published data only}
ACTRN12611001212943. RV3-BB rotavirus vaccine
Phase IIa clinical trial of immunogenicity and safety. http:
//www.anzctr.org.au/ACTRN12611001212943.aspx
(accessed 28 May 2012).
Other CTRI-091-000102 {published data only}
CTRI/2010/091/000102. A Phase III, randomized, double
blind, placebo controlled trial to evaluate the protective
efficacy of three doses of oral rotavirus vaccine (ORV) 116E,
against severe Rotavirus gastroenteritis in infants. http://
www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=1317
(accessed 4 July 2011).
Other CTRI-091-003064 {published data only}
CTRI/2010/091/003064. A randomized, double-blind,
placebo controlled study to assess safety and tolerability
of RotaVac vaccine (live attenuated bovine-human (UK)
reassortant pentavalent rotavirus vaccine). http://ctri.nic.in/
Clinicaltrials/ (accessed 4 July 2011).
Other CTRI2009-091-000821 {published data only}
CTRI-2009-091-000821. A randomized, double-blind,
placebo controlled study to assess the safety and tolerability
of RotaVac vaccine (live attenuated bovine-human (UK)
reassortant pentavalent rotavirus vaccine). www.ctri.in/
Clinicaltrials/ViewTrial.jsp?trialno=1302 (accessed 21
January 2010).
Other NCT00981669 {published data only}
NCT00981669. Evaluation of rotavirus vaccine produced
by Butantan Institute. Phase I - safety, tolerability and
immunogenicity evaluation. clinicaltrials.gov/show/
NCT00981669 (accessed 21 January 2010).
Other NCT01061658 {published data only}
NCT01061658. Phase I/II, randomized, double-blind,
placebo-controlled, dosage selection (10e5.5 or 10e6.25
FFU of each constituent serotype per 0.5 mL) study
to evaluate the safety, tolerability, and immunogenicity
of a 3-dose Series of live attenuated tetravalent (G1-
G4) bovine-human reassortant rotavirus vaccine [BRV-
TV] administered to healthy Indian infants. http://
clinicaltrials.gov/show/NCT01061658 (accessed 4 July
2011).
Other NCT01266850 {published data only}
NCT01266850. Safety and immunogenicity of sequential
rotavirus vaccine schedules With RotaTeq® and Rotarix®.
http://clinicaltrials.gov/show/NCT01266850 (accessed 4 July
2011).
Other NCT01305109 {published data only}
NCT01305109. A Phase III, randomized, double blind,
placebo controlled trial to evaluate the protective efficacy
of three doses of oral rotavirus vaccine (ORV) 116E,
against severe rotavirus gastroenteritis in infants. http:
//clinicaltrials.gov/show/NCT01305109 (accessed 4 July
2011).
Other NCT01571505 {published data only}
NCT01571505. Exploration of the biologic basis for
underperformance of oral polio and rotavirus vaccines
in India (PROVIDE). http://clinicaltrials.gov/show/
NCT01571505 (accessed 28 May 2012).
51Vaccines for preventing rotavirus diarrhoea: vaccines in use (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
RV1 ISRCTN37373664 {published data only}
ISRCTN37373664. A double blind, randomised
placebo controlled study of the safety, reactogenicity and
immunogenicity of two doses of orally administered human
rotavirus vaccine (RIX4414) in healthy infants in South
Africa. www.controlled-trials.com/ISRCTN37373664
(accessed 16 March 2011).
RV1 ISRCTN86632774 {published data only}
ISRCTN86632774. A phase II, double blind
randomised, placebo controlled study to assess the safety
reactogenicity and immunogenicity of three doses of GSK
Biologicals (South Africa). www.controlled-trials.com/
ISRCTN86632774 (accessed 16 March 2011).
RV1 NCT00134732 {published data only}
NCT00134732. Assess the immunogenicity, safety &
reactogenicity of 2 doses of GSK Biologicals’ oral live
attenuated human rotavirus (HRV) vaccine in healthy
infants (6-12 weeks of age at first dose) previously uninfected
with human rotavirus. clinicaltrials.gov/ct2/show/record/
NCT00134732 (accessed 12 August 2008).
RV1 NCT00158756 {published data only}
NCT00158756. Assess immunogenicity & reactogenicity
of 2 formulations of GSK’s DTPw-HBV vaccines vs
concomitant admn of CSL’s DTPw & GSK’s HBV
vaccine, co-admnd with GSK’s rotavirus vaccine, to infants
at 3, 4½ & 6 mths, after birth dose of HBV vaccine.
clinicaltrials.gov/show/NCT00158756 (accessed 16 March
2011).
RV1 NCT00289172 {published data only}
NCT00289172. Amulticenter study of the immunogenicity
& safety of 2 doses of GSK Biologicals’ oral live attenuated
human rotavirus vaccine (RIX4414) as primary dosing of
healthy infants in India aged approximately 8 wks at the
time of the first dose. clinicaltrials.gov/ct2/show/record/
NCT00289172 (accessed 12 August 2008).
RV1 NCT00383903 {published data only}
NCT00383903. A study of the safety, reactogenicity and
immunogenicity of 2 or 3 doses of GSK Biologicals’ oral
live attenuated human rotavirus (HRV) vaccine in healthy
infants (approximately 5-10 weeks old) in South Africa.
clinicaltrials.gov/show/NCT00383903 (accessed 12 August
2008).
RV1 NCT00420316 {published data only}
NCT00420316. To assess long-term efficacy & safety
of subjects approximately 3 years after priming with 2
doses of GlaxoSmithKline (GSK) Biologicals’ oral live
attenuated human rotavirus (HRV) vaccine (Rotarix) in
the primary vaccination study (102247). clinicaltrials.gov/
show/NCT00420316 (accessed 12 August 2008).
RV1 NCT00425737 {published data only}
NCT00425737. A study to assess the efficacy,
immunogenicity and safety of two doses of oral live
attenuated human rotavirus (HRV) vaccine (Rotarix) in
healthy infants. clinicaltrials.gov/show/NCT00425737
(accessed 12 August 2008).
RV1 NCT00429481 {published data only}
NCT00429481. A study to assess the efficacy,
immunogenicity and safety of 2 doses of oral live attenuated
human rotavirus vaccine (Rotarix) at different viral
concentrations in healthy infants. clinicaltrials.gov/ct2/
show/record/NCT00429481 (accessed 12 August 2008).
RV1 NCT01171963 {published data only}
NCT01171963. Efficacy, immunogenicity and safety of
two doses of GlaxoSmithKline (GSK) Biologicals’ oral
live attenuated liquid human rotavirus (HRV) vaccine
(444563), in healthy infants. http://clinicaltrials.gov/show/
NCT01171963 (accessed 4 July 2011).
RV1 NCT01199874 {published data only}
NCT01199874. The immunogenicity of rotavirus vaccine
under different age schedules and the impact of withholding
breast feeding around the time of vaccination on the
immunogenicity of Rotarix vaccine. http://clinicaltrials.gov/
show/NCT01199874 (accessed 4 July 2011).
RV1 NCT01375647 {published data only}
NCT01375647. Exploration of the biologic basis for
underperformance of oral polio and rotavirus vaccines
in Bangladesh PROVIDE. http://clinicaltrials.gov/show/
NCT01375647 (accessed 4 July 2011).
RV1 NCT01575197 {published data only}
NCT01575197. Evaluation of the human rotavirus vaccine
when given at varying schedules in rural Ghana. http:/
/clinicaltrials.gov/show/NCT01575197 (accessed 28 May
2012).
RV1 Tatochenko 2008 {published data only}
Tatochenko VK, Romanenko VV, Kharit SM, Smolenov I,
LeFevre I, De Clercq N, et al.Co-administration of a human
rotavirus vaccine Rix4414 with DTPw-HBv vaccines:
immunogenicity and reactogenicity in healthy infants. 13th
International Congress on Infectious Diseases Abstracts 2008;
Poster Presentations.
RV5 NCT00880698 {published data only}
NCT00880698. Safety and immunogenicity of a live,
attenuated rotavirus (RotaTeqT M ) in HIV-1 infected and
uninfected children born to HIV-1-infected mothers.
clinicaltrials.gov/ct2/show/study/NCT00880698 (accessed
16 March 2011).
Additional references
AAP 1998
American Academy of Pediatrics. Prevention of rotavirus
disease: guidelines for use of rotavirus vaccine. Pediatrics
1998;102(6):1483–91.
AAP 2009
Committee on Infectious Diseases, American Academy
of Pediatrics. Prevention of rotavirus disease: updated
guidelines for use of rotavirus vaccine. Pediatrics 2009;123
(5):1412–20.
Borenstein 2009
Borenstein M, Hedges LV, Higgins JPT, Rothstein HR.
Introduction to meta-analysis. Chichester: John Wiley &
Sons Ltd, 2009.
52Vaccines for preventing rotavirus diarrhoea: vaccines in use (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Bresee 1999
Bresee JS, Glass RI, Ivanoff B, Gentsch JR. Current status
and future priorities for rotavirus vaccine development,
evaluation and implementation in developing countries.
Vaccine 1999;17(18):2207–22.
Bresee 2005
Bresee JS, Hummelman E, Nelson EA, Glass RI. Rotavirus
in Asia: the value of surveillance for informing decisions
about the introduction of new vaccines. Journal of Infectious
Diseases 2005;192(Suppl 1):1–5.
Buttery 2011
Buttery JP, Danchin MH, Lee KJ, Carlin JB, McIntyre PB,
Elliott EJ, et al.Intussusception following rotavirus vaccine
administration: Post-marketing surveillance in the National
Immunization Program in Australia. Vaccine 2011;29(16):
3061–66.
CDC 2010
Advisory Committee on Immunization Practices,
Department of Health and Human Services, Center for
Disease Control and Prevention. Summary Report, October
27-28, 2010. Available from: http://www.cdc.gov/vaccines/
recs/acip/downloads/min-archive/min-oct10.pdf (searched on
March 02, 2012).
CDC-ASIP 1999
Advisory Committee on Immunization Practices. Rotavirus
vaccine for the prevention of rotavirus gastroenteritis among
children. Recommendations of the Advisory Committee on
Immunization Practices (ACIP). MMWR. Recommendations
and reports 1999;48(RR-2):1–20.
Cunliffe 2007
Cunliffe N, Nakagomi O. Introduction of rotavirus vaccines
in developing countries: remaining challenges. Annals of
Tropical Paediatrics 2007;27:157–67.
de Quadros 2004
de Quadros CA, Santos JI. Rotavirus: the search for the
next generation vaccine. Pediatric Infectious Disease Journal
2004;23(10 Suppl):147–8.
Dennehy 2008
Dennehy PH, Brady RC, Halperin SA, Ward RL, Alvey
JC, Fischer FH Jr, et al.North American Human Rotavirus
Vaccine Study Group. Comparative evaluation of safety and
immunogenicity of two dosages of an oral live attenuated
human rotavirus vaccine. Pediatric Infectious Disease Journal
2005;24(6):481–8.
do Carmo 2011
do Carmo GM, Yen C, Cortes J, Siqueira AA, de Oliveira
WK, Cortez-Escalante JJ, et al. Decline in diarrhea
mortality and admissions after routine childhood rotavirus
immunization in Brazil: a time-series analysis. PLoS
Medicine 2011;8(4):e1001024.
EMA 2011
European Medicines Agency. Summary of Product
Characteristics: Rotarix. http://www.ema.europa.eu/docs/
en˙GB/document˙library/EPAR˙-˙Product˙Information/
human/000639/WC500054789.pdf (accessed November
2011).
EMEA 2008
European Medicines Agency. European Public Assessment
Reports for authorised medicinal products for human use:
RotaTeq. www.emea.europa.eu/humandocs/Humans/
EPAR/rotateq/rotateq.htm (accessed 21 November 2008).
FDA 2008
US Food, Drug Administration. Product approval
information [RotaTeq]. www.fda.gov/CbER/products/
rotateq.htm (accessed 21 November 2008).
Fischer Walker 2011
Fischer Walker C, Black R. Rotavirus vaccine and diarrhea
mortality: quantifying regional variation in effect size.
BMC Public Health 2011;11(Suppl 3):S16.
Fu 2007
Fu C, Wang M, Liang J, He T, Wang D, Xu J. Effectiveness
of Lanzhou lamb rotavirus vaccine against rotavirus
gastroenteritis requiring hospitalization: a matched case-
control study. Vaccine 2007;25(52):8756–61.
Fu 2010
Fu C, Tate JE, Jiang B. Effectiveness of Lanzhou lamb
rotavirus vaccine against hospitalized gastroenteritis:
Further analysis and update. Human Vaccines Nov 2010;6
(11):953.
Gentsch 2005
Gentsch JR, Laird AR, Bielfelt B, Griffin DD, Banyai K,
Ramachandran M, et al.Serotype diversity and reassortment
between human and animal rotavirus strains: implications
for rotavirus vaccine programs. Journal of Infectious Diseases
2005;192(Suppl 1):146–59.
GRADE 2004
GRADE Working Group. GRADE Profiler. 3.2. GRADE
Working Group, 2004.
GSK 2006 (press release)
GlaxoSmithKline. Rotarix: first vaccine against
rotavirus available in Europe [Press release: 27 February
2006]. www.gsk.com/media/pressreleases/2006/
2006˙02˙27˙GSK748.htm (accessed 21 November 2008).
GSK 2007 (press release)
GlaxoSmithKline. WHO awards prequalification
status to GSK rotavirus vaccine [Press release: 13
February 2007]. www.gsk.com/media/pressreleases/2007/
2007˙02˙13˙GSK975.htm (accessed 21 November 2008).
GSK 2008 (press release)
GlaxoSmithKline. FDA approves Rotarix [Rotavirus
Vaccine, live, oral], the first vaccine licensed to complete the
rotavirus immunisation series by four months of age [Press
release: 3 April 2008]. www.gsk.com/media/pressreleases/
2008/2008˙pressrelease˙10024.htm (accessed 21 November
2008).
GSK 2010 (press release)
GlaxoSmithKline. Rotarix™ significantly reduced
severe rotavirus gastroenteritis in African babies
during their first year of life [Press release: January
2010]. http://www.gsk.com/media/pressreleases/2010/
2010˙pressrelease˙10011.htm (accessed 7 September 2011).
53Vaccines for preventing rotavirus diarrhoea: vaccines in use (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Henchal 1996
Henchal LS, Midthun K, Goldenthal KL. Selected
regulatory and scientific topics for candidate rotavirus
vaccine development. Journal of Infectious Diseases 1996;
174(Suppl 1):112–7.
Higgins 2003
Higgins JPT, Thompson SG, Deeks JJ, Altman DG.
Measuring inconsistency is preferable to testing for
heterogeneity in meta-analysis. BMJ 2003;327:557–60.
Higgins 2008
Higgins JPT, Altman DG (editors). Chapter 8: Assessing
risk of bias in included studies. In: Higgins JPT, Green
S (editors), Cochrane Handbook of Systematic Reviews
of Intervention. Version 5.0.1 (updated February 2008).
The Cochrane Collaboration, 2008. Available from
www.cochrane-handbook.org.
Lefebvre 2008
Lefebvre C, Manheimer E, Glanville J. Chapter 6:
Searching for studies. In: Higgins JPT, Green S
(editors). Cochrane Handbook for Systematic Reviews of
Interventions Version 5.0.1 [updated September 2008].
The Cochrane Collaboration, 2008. Available from
www.cochrane-handbook.org.
Levine 2010
Levine MM. Immunogenicity and efficacy of oral vaccines
in developing countries: lessons from a live cholera vaccine.
BMC Biology 2010;8:129.
Linhares 2008
Linhares AC, Velázquez FR, Pérez-Schael I, Sáez-Llorens X,
Abate H, Espinoza F, et al.Human Rotavirus Vaccine Study
Group. Efficacy and safety of an oral live attenuated human
rotavirus vaccine against rotavirus gastroenteritis during the
first 2 years of life in Latin American infants: a randomised,
double-blind, placebo-controlled phase III study. Lancet
2008;371(9619):1181–9.
Malek 2006
Malek MA, Curns AT, Holman RC, Fischer TK, Bresee
JS, Glass RI, et al.Diarrhea- and rotavirus-associated
hospitalizations among children less than 5 years of age:
United States, 1997 and 2000. Pediatrics 2006;117(6):
1887–92.
Mast 2009
Mast TC, DeMuro-Mercon C, Kelly CM, Floyd LE, Walter
EB. The impact of rotavirus gastroenteritis on the family.
BMC Pediatrics 2009;9:11.
Merck 2008 (press release)
Merck. WHO list of vaccines for purchase byUNagencies as
of November 2008. www.who.int/immunization˙standards/
vaccine˙quality/pq˙suppliers/en/index.html (accessed 21
November 2008).
Merck 2011
Merck. RotaTeq TM [Rotavirus Vaccine,
Live, Oral, Pentavalent] Registrations
and Indications, February 2011. http://
www.merck.com/corporate-responsibility/docs/access/
ROTATEQ˙REGISTRATION˙STATUS˙FEB˙20119.pdf
(accessed: 7 September 2011).
Merck 2012
Merck, Co. Inc. Quality details for 9 RV5 included trials.
Correspondence, 12 March 2012.
Mrukowicz 2008
Mrukowicz J, Szajewska H, Vesikari T. Options for the
prevention of rotavirus disease other than vaccination.
Journal of Pediatric Gastroenterology and Nutrition 2008;46
(Suppl 2):32–7.
Munos 2010
Munos MK, Walker CL, Black RE. The effect of rotavirus
vaccine on diarrhoea mortality. International Journal of
Epidemiology 2010;39(Suppl 1):i56–62.
Parashar 2006a
Parashar UD, Glass RI. Public health. Progress toward
rotavirus vaccines. Science 2006;312(5775):851–2.
Parashar 2006b
Parashar UD, Alexander JP, Glass RI, Advisory Committee
on Immunization Practices (ACIP), Centers for
Disease Control and Prevention (CDC). Prevention of
rotavirus gastroenteritis among infants and children.
Recommendations of the Advisory Committee on
Immunization Practices (ACIP). MMWR. Recommendations
and Reports 2006;55(RR-12):1–13.
Patel 2009
Patel M, Shane AL, Parashar UD, Jiang B, Gentsch JR,
Glass RI. Oral rotavirus vaccines: how well will they work
where they are needed most?. Journal of Infectious Diseases
2009;200(Suppl 1):39–48.
Patel 2011
Patel MM, Lopez-Collada VR, Bulhoes MM, De Oliveira
LH, Marquez AB, Flannery B, et al.Intussusception Risk
and Health Benefits of Rotavirus Vaccination in Mexico
and Brazil. New England Journal of Medicine 2011;364(24):
2283–92.
Review Manager (RevMan)
Nordic Cochrane Centre, The Cochrane Collaboration.
Review Manager. 5.0. Copenhagen: Nordic Cochrane
Centre, The Cochrane Collaboration, 2008.
Richardson 2010
Richardson V, Hernandez-Pichardo J, Quintanar-Solares
M, Esparza-Aguilar M, Johnson B, Gomez-Altamirano
CM, et al. Effect of rotavirus vaccination on death from
childhood diarrhea in Mexico. New England Journal of
Medicine 2010;362(4):299–305.
Ruuska 1990
Ruuska T, Vesikari T. Rotavirus disease in Finnish children:
use of numerical scores for severity of diarrheal episodes.
Scandinavian Journal of Infectious Diseases 1990;22:259–67.
SAGE 2009
Meeting of the immunization Strategic Advisory Group of
Experts, April 2009--conclusions and recommendations.
2009;84(23):220–36.
54Vaccines for preventing rotavirus diarrhoea: vaccines in use (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
SAGE 2012
Meeting of the immunization Strategic Advisory Group of
Experts, April 2012 - conclusions and recommendations.
Weekly epidemiological record 2012;21(87):201–16.
Santos 2005
Santos N, Hoshino Y. Global distribution of rotavirus
serotypes/genotypes and its implication for the development
and implementation of an effective rotavirus vaccine.
Reviews in Medical Virology 2005;15(1):29–56.
Schünemann 2008
Schünemann HJ, Oxman AD, Vist GE, Higgins JPT, Deeks
JJ, Glasziou P, Guyatt GH. Chapter 12: Interpreting results
and drawing conclusions. Cochrane Handbook for Systematic
Reviews of Interventions. Chichester: John Wiley & Son,
2008:359–83.
Simonsen 2005
Simonsen L, Viboud C, Elixhauser A, Taylor RJ, Kapikian
AZ. More on RotaShield and intussusception: the role of
age at the time of vaccination. Journal of Infectious Diseases
2005;192(Suppl 1):36–43.
Tate 2011
Tate JE, Burton AH, Boschi-Pinto C, Steele AD, Duque
J, Parashar UD, the WHO-coordinated Global Rotavirus
Surveillance Network. 2008 estimate of worldwide
rotavirus-associated mortality in children younger than
5 years before the introduction of universal rotavirus
vaccination programmes: a systematic review and meta-
analysis. Lancet Infectious Diseases 2011;12(2):136–41.
Ustrup 2011
Ustrup M, Madsen LB, Bygbjerg IC, Konradsen F.
Outstanding challenges for rotavirus vaccine introduction in
low-income countries--a systematic review. Danis Medical
Bulletin 2011;58(10):A4323.
Vesikari 1997
Vesikari T. Rotavirus vaccines against diarrhoeal disease.
Lancet 1997;350(9090):1538–41.
Vesikari 2008a
Vesikari T, Van Damme P, Giaquinto C, Gray J, Mrukowicz
J, Dagan R, et al.European Society for Paediatric
Infectious Diseases/European Society for Paediatric
Gastroenterology, Hepatology, and Nutrition evidence-
based recommendations for rotavirus vaccination in Europe:
executive summary. Journal of Pediatric Gastroenterology and
Nutrition 2008;46(5):615–8.
Vesikari 2008b
Vesikari T, Van Damme P, Giaquinto C, Gray J, Mrukowicz
J, Dagan R, et al.European Society for Paediatric
Infectious Diseases/European Society for Paediatric
Gastroenterology, Hepatology, and Nutrition evidence-
based recommendations for rotavirus vaccination in Europe.
Journal of Pediatric Gastroenterology and Nutrition 2008;46
(Suppl 2):38–48.
WHO 1999
World Health Organization. List of Member States by
WHO region and mortality stratum. Available from: http://
www.who.int/whr/2003/en/member˙states˙182-184˙en.pdf
Based on statistics from 1999. (accessed on April 4, 2012).
WHO 2007
World Health Organization. Rotavirus vaccines. Weekly
Epidemiological Record 2007;82(21):285–96.
WHO 2008a
World Health Organization. WHO list of vaccines
for purchase by UN agencies as of November 2008.
www.who.int/immunization˙standards/vaccine˙quality/
pq˙suppliers/en/index.html (accessed 21 November 2008).
WHO 2008b
World Health Organization. Report of the Meeting on Future
Directions for Rotavirus Vaccine Research in Developing
Countries, Geneva, 9-11 February 2000 (whqlibdoc.who.int/
hq/2000/WHO˙V&B˙00.23.pdf). Geneva: World Health
Organization, 2008.
WHO 2011
WHO. WHO vaccine-preventable diseases: monitoring
system 2011 global summary. http://apps.who.int/
immunization˙monitoring/en/globalsummary/
ScheduleResult.cfm (accessed: 7 September 2011).
WHO/UNICEF 2003
World Health Organization. Dept. of Vaccines and
Biologicals. State of the world’s vaccines and immunization.
Geneva: World Health Organization, 2003.
References to other published versions of this review
Soares-Weiser 2004
Soares-Weiser K, Goldberg E, Tamimi G, Pitan OC,
Leibovici L. Rotavirus vaccine for preventing diarrhoea.
Cochrane Database of Systematic Reviews 2004, Issue 1.
[DOI: 10.1002/14651858.CD002848.pub2]
Soares-Weiser 2010
Soares-Weiser K, MacLehose H, Ben-Aharon I, Goldberg
E, Pitan F, Cunliffe N. Vaccines for preventing rotavirus
diarrhoea: vaccines in use. Cochrane Database of
Systematic Reviews 2010, Issue 5. [DOI: 10.1002/
14651858.CD008521]
Soares-Weiser 2012
Soares-Weiser K, MacLehose H, Bergman H, Ben-
Aharon I, Nagpal S, Goldberg E, Pitan F, Cunliffe N.
Vaccines for preventing rotavirus diarrhoea: vaccines in
use. Cochrane Database of Systematic Reviews 2012, Issue 2.
[DOI: 10.1002/14651858.CD008521.pub2]
∗ Indicates the major publication for the study
55Vaccines for preventing rotavirus diarrhoea: vaccines in use (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
RV1 Anh 2011-PHL
Methods RCT
Length of follow-up: 1 month after last dose
Adverse event data collection methods: not reported
Participants Number: 375 enrolled; ATP safety cohort: 345; ATP immunogenicity cohort: 292
Inclusion criteria: healthy infants aged 5-10 weeks at the time of the first study vacci-
nation dose with a birth weight of >2 kg
Exclusion criteria:use of any investigational drug or vaccine other than the study vaccine
or confirmed immunosuppression/immunodeficient conditions or allergy to RIX4414
vaccine/placebo components
Interventions 1. Two doses of RIX4414* plus one dose of placebo according to a PL-V-V schedule
2. Two doses of RIX4414* plus one dose of placebo according to a V-PL-V schedule
3. Three placebo doses
* Human rotavirus [RV1] liquid vaccine, oral suspension (GSK Biologicals, Belgium),
containing at least 106.0 median Cell Culture Infective Dose 50 percent (CCID50) of
live attenuated RIX4414 human rotavirus strain (G1P[8])
Schedule: 3 doses according to a 0, 1, and 2 month schedule
Outcomes Clinical outcome measures (safety and efficacy)
1. Reactogenicity, including fever, diarrhoea and vomiting, 8 days after each dose (col-
lected from GSK report)
2. Adverse events leading to discontinuation
3. Serious adverse events
4. Fatal serious adverse events
5. Drop-outs
6. * Rotavirus diarrhoea, rotavirus antigen isolated from any of the stool samples collected
from children with diarrhoea episodes, up to 1 month after last dose
7. * All-cause diarrhoea, up to 1 month after last dose
Outcomes to measure immunogenicity
8. Anti-rotavirus IgA antibody seroconversion, ≥20 U/mL
* Outcome reported as proportion (P) with 95% CI. Events (n) and totals (N) were
estimated by using the values when two formulas for the standard error (SE) converged
Immunization status Commercially available diphtheria, tetanus, whole-cell pertussis (DTPw), hepatitis B
(HBV) and oral poliovirus (OPV) vaccines were administered concomitantly with the
study vaccine/placebo as part of the routine Expanded Programme of Immunization
(EPI) in the Philippines
Location Philippines (single centre)
WHO mortality stratum B
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RV1 Anh 2011-PHL (Continued)
Notes Study known as RIX GSK[063] 2008-AS in previously published versions of this review
Date: March to September 2007
Source of funding: GlaxoSmithKline Biologicals
Study rationale: “This study will provide data on the immune response and safety of
GSK Biologicals’ HRV [human rotavirus] liquid vaccine when given along with the
routine infant immunizations in Philippines.” “The study also[...]explored the potential
effect of scheduling of the HRV [human rotavirus] vaccine doses with respect to the
existing routine vaccination schedules”
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer generated “Block randomiza-
tion scheme (2:2:1 ratio)with standard SAS
program was used”
Allocation concealment (selection bias) Low risk Central allocation “Based on the block size,
the vaccine doses were distributed to each
of the study centers”
Blinding (performance bias and detection
bias)
All outcomes
Low risk Participants and key personnel were
blinded
“The study was double-blind with respect
to the RIX4414 oral suspension (liquid
formulation), placebo and scheduling of
doses. The parents/guardians of infants, in-
vestigators and study personnel were un-
aware of the study vaccine/ placebo admin-
istered”
“The placebo was identical to the vaccine
in composition”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Attrition balanced across groups with rea-
sons for drop-out/exclusion reported
Selective reporting (reporting bias) Low risk All pre-published outcomes included
Other bias Unclear risk Funded by GlaxoSmithKline Biologicals
RV1 Anh 2011-VNM
Methods RCT
Length of follow-up: 1 month after last dose
Adverse event data collection methods: not reported
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RV1 Anh 2011-VNM (Continued)
Participants Number: 375 enrolled; ATP safety cohort: 352; ATP immunogenicity cohort: 330
Inclusion criteria: healthy infants aged 6 to 10 weeks at the time of the first study
vaccination dose with a birth weight of > 2 kg
Exclusion criteria:use of any investigational drug or vaccine other than the study vaccine
or confirmed immunosuppression/immunodeficient conditions or allergy to RIX4414
vaccine/placebo components
Interventions 1. Two doses of RIX4414* plus one dose of placebo according to a V-V-PL schedule
2. Two doses of RIX4414* plus one dose of placebo according to a V-PL-V schedule
3. Three placebo doses
* Human rotavirus [RV1] liquid vaccine, oral suspension (GSK Biologicals, Belgium),
containing at least 106 median Cell Culture Infective Dose 50 percent (CCID50) of live
attenuated RIX4414 human rotavirus strain (G1P[8])
Schedule: 3 doses according to a 0, 1, and 2 month schedule
Outcomes Clinical outcome measures (Safety and Efficacy)
1. Reactogenicity, including fever, diarrhoea and vomiting, 8 days after each dose (col-
lected from GSK report)
2. Adverse events leading to discontinuation
3. Serious adverse events
4. Fatal serious adverse events
5. Drop-outs
6. * Rotavirus diarrhoea, rotavirus antigen isolated from any of the stool samples collected
from children with diarrhoea episodes, up to 1 month after last dose (outcome not
included in the pre-published protocol)
7. * All-cause diarrhoea, up to 1 month after last dose (outcome not included in the pre-
published protocol)
Outcomes to measure immunogenicity
8. Anti-rotavirus IgA antibody seroconversion, ≥20 U/ML
* Outcome reported as proportion (P) with 95% CI. Events (n) and totals (N) were
estimated by using the values when two formulas for the standard error (SE) converged
Immunization status Commercially available diphtheria, tetanus, whole-cell pertussis (DTPw), hepatitis B
(HBV) and oral poliovirus (OPV) vaccines were administered concomitantly with the
study vaccine/placebo as part of the routine Expanded Programme of Immunization
(EPI) in Vietnam
Location Vietnam (11 satellite centres)
WHO mortality stratum B
Notes Study known as RIX GSK[051] 2008-AS in previously published versions of this review
Date: September 2006 to March 2007
Source of funding: GlaxoSmithKline Biologicals
Study rationale: “To provide specific data on immunogenicity of GSK Biologicals’ hu-
man rotavirus liquid vaccine, when co-administered with the routine Expanded Program
of Immunization (EPI) in Vietnam. The study will also assess reactogenicity and safety
of the human rotavirus liquid vaccine relative to the placebo”
58Vaccines for preventing rotavirus diarrhoea: vaccines in use (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
RV1 Anh 2011-VNM (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer generated “Block randomiza-
tion scheme (2:2:1 ratio)with standard SAS
program was used”
Allocation concealment (selection bias) Low risk Central allocation “Based on the block size,
the vaccine doses were distributed to each
of the study centers”
Blinding (performance bias and detection
bias)
All outcomes
Low risk Participants and key personnel were
blinded.
“The study was double-blind with respect
to the RIX4414 oral suspension (liquid
formulation), placebo and scheduling of
doses. The parents/guardians of infants, in-
vestigators and study personnel were un-
aware of the study vaccine/ placebo admin-
istered”
“The placebo was identical to the vaccine
in composition”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Attrition balanced across groups with rea-
sons for drop-out/exclusion reported
Selective reporting (reporting bias) Unclear risk One outcome (rotavirus diarrhoea) not in-
cluded in the pre-published protocol
Other bias Unclear risk Funded by GlaxoSmithKline Biologicals
RV1 Bernstein 1998-USA
Methods RCT
Length of follow-up: outcomes measured up to 1 month after the second dose
Adverse event data collection methods: participants or their parents filled out a diary
card for 7 days after each dose (passive method)
Participants Number: 42 enrolled; 42 evaluable
Inclusion criteria: all infants aged 6 to 26 weeks recruited from private practice offices
in Cincinnati
Exclusion criteria: not stated
Interventions RV1
1. RIX4414 (RV1): 105 PFU; 21 participants
2. Placebo: 20 participants
Schedule: 2 doses given 6 to 10 weeks apart
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Outcomes Clinical outcome measures
1. Reactogenicity: diarrhoea defined as > 3 stools that were looser than normal in a 24-
h period; fever defined as a temperature > 100.4 °F obtained rectally in infants
2. Serious adverse events
3. Adverse events resulting in discontinuation
Outcomes to measure immunogenicity
4. Vaccine virus shedding: rotavirus shedding after immunization; combined time points
(review includes data from combined time points)
5. Seroconversion: ≥ 4-fold rise in rotavirus IgA antibody (serum and stool) (review
includes data from after dose 1 and dose 2)
Immunization status Rotavirus vaccine was separated from all other infant vaccines by at least 2 weeks
Location Cincinnati, USA
WHO mortality stratum A
Notes Date: August to November 1995
Source of funding: Virus Research Institute, Inc. (now Avant Immunotherapeutics Inc.
)
1 participant in the placebo group did not complete the study because of persistent otitis
media
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not reported
Allocation concealment (selection bias) Unclear risk Not reported
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Not reported
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Not reported
Selective reporting (reporting bias) Unclear risk Not reported
Other bias Unclear risk Trial report does not provide enough details
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Methods RCT
Length of follow-up: outcomes measured at 2 years
Adverse event data collectionmethods: “diary card for 7days after vaccine. Allmoderate
to severe side effects were reported by the investigator to an independent study monitor
on a continuous basis during the study” (passive method); “telephoned parents every 2
weeks after the first immunisation, and then weekly during the expected rotavirus season
(Jan 1-May 31) as a reminder and to collect data on any adverse events” (active method)
Participants Number: 215 randomized; 214 evaluable
Age range: 3 to 6 months
Inclusion criteria: healthy children aged 10 to 16 weeks at the time of the first dose
Exclusion criteria: fever; premature labour; an immunosuppressed or pregnant individ-
ual in the same household; birth at < 36 weeks of gestation; participation in any other
investigational clinical trial; or no telephone in the household
Interventions 89-12 (a precursor of RIX4414 (RV1)
1. 89-12 (a precursor of RIX4414 (RV1)): 105 PFU; 2 doses given 6 to 10 weeks apart;
108 participants
2. Placebo: 105 PFU; 2 doses given 6 to 10 weeks apart; 107 participants
“Infants received an oral dose of 1.0 mL vaccine (105 PFU) or placebo immediately after
2.0 mL of an antacid containing 160 mg aluminium hydroxide and 160 mg magnesium
hydroxide to buffer stomach acid. The infant was not fed for 1 h before or after the
immunisation”
Outcomes Clinical outcome measures
1. All-cause diarrhoea: gastroenteritis defined as vomiting (> 1 h after feeding), diarrhoea
(≥ 3 looser than normal stools in a 24-h period), or both; measured up to 2 years
2. Severe rotavirus diarrhoea: severity assessed using a scoring system with a “20-point
scale identical to that used in previous rotavirus trials. In this system, points are assigned
according to the duration and severity of diarrhoea and vomiting, the severity of fever,
and the presence of dehydration or hospital admissions for each episode of gastroenteritis.
A score greater than 8 was prospectively defined as severe, and a score more than 14 as
very severe”; measured up to 2 years
3. Rotavirus diarrhoea: “An illness was classified as caused by rotavirus if a stool specimen
collected no later than 7 days after resolution of symptoms contained rotavirus antigen.
All episodes of rotavirus gastroenteritis occurring between the second vaccination and
the end of the study were included”; measured up to 7 days
4. Reactogenicity: “Parents filled out a diary card for 7 days after each dose. Signs included
were: daily (evening) rectal temperatures, diarrhoea, vomiting, and the number and
consistency of all stools”; measured up to 7 days
5. All-cause death; measured up to 2 years
6. Emergency department visit; measured up to 2 years
7. Rotavirus diarrhoea requiring hospitalization
Outcomes to measure immunogenicity
8. Vaccine virus shedding (review includes after dose 2 data)
9. Immunogenicity (ELISA): “Serum samples were analysed for IgA and IgG antibody
to rotavirus by an ELISA” and “neutralising antibody to the 89-12 strains by an antigen
reduction assay” (only rotavirus-specific IgA results reported in this review from after
dose 2 time point)
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Immunization status Other vaccines separated from the trial vaccines by at least 2 weeks
Location Cincinnati, Baltimore, and Sellersviller, USA
WHO mortality stratum A
Notes Date: August 1997 to June 1998
Source of funding: Virus Research Institute, Inc. (now Avant Immunotherapeutics Inc.
)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Infants were assigned to receive either 89-
12or placebo according to a computer-gen-
erated randomization schedule (one/one)
in blocks of ten provided by the sponsor
The intention-to-treat analysis included all
participants who received at least one dose
of study vaccine. Before the code was bro-
ken, all cases of rotavirus gastroenteritis and
the severity of each episode were verified”
Allocation concealment (selection bias) Low risk As above
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Double-blind, no details
Incomplete outcome data (attrition bias)
All outcomes
Low risk No impact on intervention effect estimate
“Of the 215 children enrolled, 213 received
both doses of vaccine or placebo, and 214
were followed up for gastrointestinal dis-
ease. One child in the vaccine group did
not receive the vaccine because of persis-
tent fever at the time of the scheduled re-
vaccination, and one child in the placebo
group was found to have a congenital tra-
cheal malformation while in the trial and
was not revaccinated”
Selective reporting (reporting bias) Low risk All expected outcomes included
Other bias Unclear risk Insufficient information
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Methods RCT
Length of follow-up: 10 to 12 months
Adverse event data collection methods: “For the 15 days after each dose of vaccine, the
parent or guardian maintained a daily record that included fever, irritability/fussiness,
diarrhoea, vomiting, loss of appetite and cough/runny nose. In addition, the parent or
guardian was asked to record any gastroenteritis episode occurring in the period from the
first dose until 2 months after the second dose of vaccine.” (passive method); “Subjects
were also monitored for any serious adverse events occurring throughout participation
in the study (10-12 months in total) and for unsolicited adverse events occurring within
43 days after each dose of vaccine or placebo” (active method)
Participants Number: 529 enrolled; 479 evaluable
Age range: 1 to 3 months (beginning)
Inclusion criteria:healthy infants aged 5 to 15weeks at the time of the first dose. Vaccine
administration delayed if acute illness present (fever > 38 °C/gastroenteritis/antibiotics
within 7 days before scheduled vaccination)
Exclusion criteria: premature labour (< 36 weeks); chronic condition; (chronic gas-
trointestinal disease, immunosuppressive diseases); household contact with immunosup-
pressed individuals/pregnant women
Interventions RV1
1. RIX4414 (RV1)
1.1. 105.2; 212 participants
1.2. 106.4; 209 participants
2. Placebo: 108 participants
Schedule: 2 doses given 7 weeks apart
Outcomes Clinical outcome measures (safety and efficacy)
1. Reactogenicity: fever, irritability/fussiness, diarrhoea, vomiting, loss of appetite and
cough/runny nose; measured during 15 days post-vaccination
2. Serious adverse events
3. Adverse events resulting in discontinuation
Outcomes to measure immunogenicity
4. Viral shedding: viral shedding in any stool specimen collected between first dose and
2 months after second vaccine dose (review includes after dose 2 data)
5. Seroconversion: anti-rotavirus IgA ELISA≥ 20 Units/mL in participants negative for
rotavirus antibody before the first dose of vaccine (review includes data from 2 months
after dose 2)
Immunization status Vaccine or placebo given concomitantly with diphtheria-tetanus-acellular pertussis, in-
activated poliovirus, H. influenzae type b, and Streptococcus pneumoniae conjugate vac-
cines for participants in USA or with a diphtheria-tetanus-acellular pertussis/inactivated
poliovirus/H. influenza type b combination vaccine for participants in Canada
“Routine hepatitis B vaccinations were administered according to local practice”
Location 41 centres in USA and Canada
WHO mortality stratum A
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Notes Date: 13 December 2000 to 2 August 2002
Source of funding: GlaxoSmithKline Biologicals
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No details
Allocation concealment (selection bias) Low risk Central allocation; “double blind random-
ized unbalanced allocation scheme (2:2:1
ratio)”
Blinding (performance bias and detection
bias)
All outcomes
Low risk Participants and key personnel; “Study per-
sonnel and families were blinded to group
assignment until study completion”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Missing data balanced across groups;
“Fifty-nine subjects, who were proportion-
ately distributed among vaccine groups, did
not complete the entire 10- to 12-month
study”
Selective reporting (reporting bias) Unclear risk No details
Other bias Unclear risk No details
RV1 GSK[021] 2007-PAN
Methods RCT
Length of follow-up: 1 month after dose 3
Adverse event data collection methods: not reported
Participants Number: 228 enrolled; 203 evaluable
Age range: 1 to 3 months (beginning); 3 to 6 months (end)
Inclusion criteria: healthy infants, born after a normal gestation period of ≥ 36 weeks;
6 to 12 weeks of age at the time of the first dose of the study vaccination course; free
of obvious health problems as established by medical history and clinical examination
before entering into study
Exclusion criteria: any clinically significant history of chronic gastrointestinal disease
including any uncorrected congenital malformation of the gastrointestinal tract or other
serious medical condition as determined by the investigator and previous confirmed
occurrence of rotavirus gastroenteritis
Interventions RV1
1. RIX4414 (RV1): 106.5 PFU*; 177 participants (randomized)
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1.1 Received modified vaccine formulation
1.2 Received a licensed RV1 vaccine
*Dose unclear; in the same study, some use 106.5 PFU and some 105 PFU
2. Placebo: 51 participants (randomized)
2.1 Received a placebo of the modified vaccine formulation
2.2 Received a placebo of the licensed RV1 vaccine
Schedule: 3 doses at 2, 4, and 6 months of age
Outcomes Clinical outcome measures (safety and efficacy)
1. Reactogenicity: for each type of solicited symptom, occurrence of the symptomwithin
the 8-day (days 0 to 7) solicited follow-upperiod after each dose; occurrence of unsolicited
adverse events within 31 days (days 0 to 30) after each dose, according to MedDRA
classification; measured up to 31 days after vaccine/placebo
2. Serious adverse events: occurrence throughout entire study period; measured up to 31
days after vaccine/placebo
3. Drop-outs: measured up to 31 days after vaccine/placebo
4. All-cause death
5. Adverse events resulting in discontinuation
Outcomes to measure immunogenicity
6. Viral shedding: number (%) of participants with rotavirus in at least 1 stool (review
includes data from combined time points)
7. Seroconversion: appearance of anti-rotavirus antibody concentration ≥ 20 U/mL
in participants negative for rotavirus before vaccination (review includes data from 2
months after dose 1 and 2 months after dose 2, and 1 month after dose 3)
Immunization status Use of other vaccines not mentioned
Location 1 centre in Panama
WHO mortality stratum B
Notes Date: 23 August 2002 to 9 May 2003
Source of funding: GlaxoSmithKline Biologicals
Study rationale: “to compare the immunogenicity and safety of a modified vaccine
formulation to the licensed human rotavirus [Rotarix] vaccine”
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No details
Allocation concealment (selection bias) Unclear risk No details; “treatment allocation of 7:7:1:
1”
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk No details; “Double blind with respect to
human rotavirus [Rotarix] vaccine and its
placebo”
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Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Insufficient reporting of attrition/exclu-
sions
Selective reporting (reporting bias) Unclear risk No details
Other bias Unclear risk No details
RV1 GSK[024] 2008-LA
Methods RCT
Length of follow-up: up to 1 year of age
Adverse event data collection methods: not reported
Participants Number: 6568 enrolled; 6349 evaluable
Age range: 1 to 3 months (beginning); 3 to 6 months (end)
Inclusion criteria: males or females between, and including 6 and 12 weeks (42 to 90
days) of age at the time of the first vaccination according to the country recommendations
for the routine vaccination schedules; free of obvious health problems as established by
medical history and clinical examination before entering into the study
Exclusion criteria: history of chronic gastrointestinal disease including any uncorrected
congenital malformation of the gastrointestinal tract or other serious medical condition
as determined by the investigator
Interventions RV1
1. RIX4414 (RV1): 106.5 PFU; 2 doses at 1 or 2months; 4376 participants (randomized)
2. Placebo: 2 doses at 1 or 2 months; 2192 participants (randomized)
Schedule: both groups received RV1 vaccine or placebo vaccine orally; first dose at
month 0 then second dose at month 1 or month 2
2 cohorts: there were two periods of enrolment, each with its own visit schedule:
• Cohort enrolled in 2003 to 2004: visits 1, 2, 3, 4 (for a subset only) and 5
corresponded to month 0 (vaccine dose 1), month 1 to 2 (vaccine dose 2), month 2 to
4, month 3 to 6, and month 10 in the schedule
• Cohort enrolled in 2005: visits 1, 2 (for a subset only), 3, 4 (for a subset only), 5,
6 (for a subset only), and 7 corresponded to month 0 (vaccine dose 1), month 1,
month 2 (vaccine dose 2), month 3, month 4, month 5, and month 10 in the schedule
Outcomes Clinical outcome measures (safety and efficacy)
1. Rotavirus diarrhoea: occurrence of severe rotavirus gastroenteritis (requiring hospital-
izations and/or rehydration therapy in a medical facility) caused by the wild rotavirus
strains during the period starting from 2 weeks after dose 2 until 1 year of age; measured
up to 1 year after vaccine/placebo
2. Serious adverse events: occurrence of throughout the entire study period; measured
up to 1 year after vaccine/placebo
3. Drop-outs: measured up to 1 year after vaccine/placebo
4. All-cause death: fatal serious adverse events; measured up to 1 year after vaccine/
placebo
5. Adverse events resulting in discontinuation
6. All-cause diarrhoea - severe
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Outcomes to measure immunogenicity
7. Seroconversion: serum rotavirus immunoglobulin A (IgA) antibody concentrations
1 to 2 months after second study vaccine dose (at visit 3) in a subset of 300 subjects
enrolled in year 2003-2004 (review includes data from 1 to 2 months after dose 2)
Immunization status All participants received routine infant vaccinations (Hepatitis B vaccine), diphtheria-
tetanus-acellular pertussis, poliovirus, and H. influenzae type b) according to Expanded
Programme of Immunization (EPI) recommendations in each country
First 2 doses of routine EPI vaccinations were co-administered with the RV1 vaccine or
placebo doses; the third routine EPI vaccination was administered 1 to 2 months later
according to the national plan of immunization in each country
Location Multiple sites in 6 countries in Latin America (Argentina, Brazil, Colombia, Dominican
Republic, Honduras, and Panama)
WHO mortality stratum B
Notes Date: 3 December 2003 to 20 March 2007
Source of funding: GlaxoSmithKline Biologicals
Study rationale: “to evaluate the efficacy, immunogenicity and safety of 2 doses of oral
live attenuated human rotavirus [RV1] vaccine given concomitantly with routine EPI
vaccinations (including DTPw [licensed combined diphtheria and tetanus toxoids and
whole-cell pertussis vaccine], HBV [licensed hepatitis type B vaccine], Hib [licensed H.
influenzae type b vaccine] and OPV [oral polio vaccine]) in healthy infants”
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “The ATP cohort for immunogenicity in-
cluded all vaccinated subjects: - who had
received at least one dose of study vaccine/
control according to their random assign-
ment, - for whom the randomization code
had not been broken”
Allocation concealment (selection bias) Unclear risk No details
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk No details; “Double blind, randomized (2:
1) and placebo controlled study with 2 par-
allel groups”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Insufficient reporting of attrition/exclu-
sions
Selective reporting (reporting bias) Unclear risk No details
Other bias Unclear risk No details
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Methods RCT
Length of follow-up: 1 month after dose 2
Adverse event data collection methods: not reported
Participants Number: 228 enrolled; 203 evaluable
Age range: 1 to 3 months (beginning); 3 to 6 months (end)
Inclusion criteria: healthy infants, born after a normal gestation period of ≥ 36 weeks;
6 to 12 weeks of age at the time of the first dose of the study vaccination course, free
of obvious health problems as established by medical history and clinical examination
before entering into the study
Exclusion criteria: any clinically significant history of chronic gastrointestinal disease
including any uncorrected congenital malformation of the gastrointestinal tract or other
serious medical condition as determined by the investigator and previous confirmed
occurrence of rotavirus gastroenteritis
Interventions RV1
1. RIX4414 (RV1): 106.5 PFU*; 730 participants (randomized)
1.1. Received RV1 vaccine Lot A
1.2. Received RV1 vaccine Lot B
1.3. Received RV1 vaccine Lot C
*Dose unclear, some use 106.5 PFU and some 105 PFU
2. Placebo: 124 participants (randomized)
Schedule: 2 oral doses given at 2 and 4 months; visits 1, 2, and 3 correspond to months
0, 2, and 4 in the schedule
Outcomes Clinical outcome measures (safety and efficacy)
1. Reactogenicity: for each type of solicited symptom, occurrence of the symptomwithin
the 8-day (days 0 to 7) solicited follow-upperiod after each dose; occurrence of unsolicited
adverse events within 31 days (days 0 to 30) after each dose, according to MedDRA
classification; measured up to 31 days after vaccine/placebo
2. Serious adverse events: occurrence throughout entire study period; measured up to 31
days after vaccine/placebo
3. Drop-outs: measured up to 31 days after vaccine/placebo
4. All-cause death
5. Adverse events resulting in discontinuation
Outcomes to measure immunogenicity
6. Vaccine virus shedding: presence of rotavirus antigen in stool samples collected on
day of vaccination and on planned days following each dose in a subset of participants
[review includes data from combined time points]
7. Seroconversion: appearance of serum anti-rotavirus IgA antibody concentrations ≥
20 U/mL [review includes data from 2 months after dose 2]
Immunization status Use of other vaccines not mentioned
Location 7 study centres (2 in Colombia, 1 in Mexico, and 4 in Peru)
WHO mortality strata B, D
Notes Date: 8 August 2003 to 29 January 2004
Source of funding: GlaxoSmithKline Biologicals
Study rationale: “to assess the clinical consistency of 3 production lots of human ro-
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tavirus vaccine in terms of immunogenicity and safety when given to healthy infants at
2 and 4 months of age”
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No details
Allocation concealment (selection bias) Unclear risk No details; “treatment allocation of 2:2:2:
1”
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk No details
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Insufficient reporting of attrition/exclu-
sions
Selective reporting (reporting bias) Unclear risk No details
Other bias Unclear risk No details
RV1 GSK[041] 2007-KOR
Methods RCT
Length of follow-up: 2 months after dose 2
Adverse event data collection methods: not reported
Participants Number: 400 enrolled; 391 evaluable
Age range: 1 to 3 months (beginning); 3 to 6 months (end)
Inclusion criteria: full-term infants; healthy infants aged between 6 and 12 weeks (42
to 90 days) at the time of the first vaccination for whom the vaccination history was
available
Exclusion criteria: previous confirmed occurrence of rotavirus gastroenteritis
Interventions RV1
1. RIX4414 (RV1): 106.5 PFU; 103 participants (randomized)
2. Placebo: 52 participants (randomized)
Schedule: 2 oral doses starting at about 2 months of age; second dose at 4 months of
age
Outcomes Clinical outcome measures (safety and efficacy)
1. Reactogenicity: for each type of solicited symptom, occurrence of the symptomwithin
the 15-day (days 0 to 14) solicited follow-up period after each dose; occurrence of
unsolicited adverse events within 43 days (days 0 to 42) after each dose, according to
MedDRA classification; up to 43 days after vaccine/placebo
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2. Serious adverse events: no definition; occurrence throughout the entire study period
(up to 2 months after dose 2)
3. Drop-outs: measured up to 2 months after dose 2
4. Rotavirus diarrhoea: presence of rotavirus in gastroenteritis episode stools collected
from dose 1 of vaccine/placebo up to 2 months after dose 2
5. All-cause death
6. Adverse events resulting in discontinuation
Outcomes to measure immunogenicity
7. Seroconversion: appearance of anti-rotavirus immunoglobulin A antibody concentra-
tion 20 U/mL in participants who were seronegative before vaccination [review includes
data from 2 months after dose 2]
Immunization status H. influenzae type b vaccine administered concomitantly along with the 2 doses of
vaccine/placebo and at 2 months after dose 2; other routine childhood vaccines were to
be given at least 14 days before trial vaccine/placebo
Location 6 centres in Korea
WHO mortality stratum B
Notes Date: 15 July 2005 to 11 May 2006
Source of funding: GlaxoSmithKline Biologicals
Study rationale: “to assess immunogenicity and safety of 2 doses of the HRV [human
rotavirus] vaccine in Korean infants aged approximately 2 months at the time of the first
dose”
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “The ATP cohort for immunogenicity in-
cluded all vaccinated subjects: - who had
received at least one dose of study vaccine/
control according to their random assign-
ment, - for whom the randomization code
had not been broken”
Allocation concealment (selection bias) Unclear risk No details
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk No details; “Randomized (2:1), double-
blind, placebo-controlled study with 2 par-
allel groups”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Insufficient reporting of attrition/exclu-
sions
Selective reporting (reporting bias) Unclear risk No details
Other bias Unclear risk No details
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Methods RCT
Length of follow-up: outcomes measured 1 month after last dose of vaccine/placebo
Adverse event data collection methods: not reported
Participants Number: 150 enrolled; 145 evaluable
Age range: 6 to 12 weeks
Inclusion criteria: healthy, full-term infants aged 6 to 12 weeks; male or female infants
between, and including, 6 and 12 weeks of age at the time of the first vaccination, free
of obvious health problems, born after a normal gestation period (between 36 and 42
weeks) or with a birth weight > 2000 g
Exclusion criteria: infants with previous confirmed occurrence of rotavirus gastroen-
teritis
Interventions RV1
1. RIX4414 (RV1): 106.5; 100 participants*
1.1 Licensed formulation
1.2 Lyophilized formulation
2. Placebo: 50 participants*
2.1 Normal placebo
2.2 Lyophilized formulation
Schedule: 2 doses given 2 months
*Data from the lyophilized formulation, which is not yet approved or marketed, are not
reported in review
Outcomes Clinical outcome measures (safety and efficacy)
1. Reactogenicity: for each type of solicited symptom, occurrence of the symptomwithin
the 15-day (day 0 to 14) solicited follow-up period after each dose; occurrence of un-
solicited adverse events within 31 (day 0 to 30) days after any doses of RV1 vaccine or
placebo, according to MedDRA classification
2. Serious adverse events: occurrence throughout entire study period (up to 31 days after
final dose of vaccine/placebo)
3. Drop-outs: measured up to 31 days after final dose of vaccine/placebo
4. Rotavirus diarrhoea: presence of rotavirus in gastroenteritis stools collected until 1
month after dose 2
5. All-cause death
6. Adverse events resulting in discontinuation
Outcomes to measure immunogenicity
7. Vaccine viral shedding in stool (review includes data from combined time points)
8. Seroconversion: appearance of anti-rotavirus IgA antibody concentration ≥ 20 U/
mL in participants initially (ie before first dose of vaccine/placebo) negative for rotavirus
(review includes data from 2 months after dose 1, 1 month after dose 2, and combined
dose 1 and 2 at 1 month after dose 2)
Immunization status Use of other vaccines not mentioned
Location 1 study centre in the Philippines
WHO mortality stratum B
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Notes Date: 11 May 2004 to 13 September 2004
Source of funding: GlaxoSmithKline Biologicals
Trial objective: “To assess the immunogenicity and safety of 2 different formulations of
live attenuated HRV [human rotavirus] vaccine given as a two-dose primary vaccination
in healthy infants previously uninfected with HRV”
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “The ATP cohort for immunogenicity in-
cluded all vaccinated subjects: - who had
received at least one dose of study vaccine/
control according to their random assign-
ment, - for whom the randomization code
had not been broken”
Allocation concealment (selection bias) Unclear risk No details
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk No details; “Double-blind with respect to
each HRV [RV1] vaccine formulation and
its respective placebo”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Insufficient reporting of attrition/exclu-
sions
Selective reporting (reporting bias) Unclear risk No details
Other bias Unclear risk No details
RV1 Kawamura 2010-JPN
Methods RCT
Length of follow-up: up to the age of 2 years
Adverse event data collection methods: not reported
Participants Number: 765
Age range: 6 to 14 weeks
Inclusion criteria: full-term healthy infants aged 6 to 14 weeks at the time of the first
dose
Exclusion criteria: use of any other investigational or non-registered product (drug or
vaccine) within 30 days preceding the first dose of human rotavirus vaccine; history of
use of experimental rotavirus vaccine; chronic administration of immunosuppressants
or other immune-modifying drugs since birth; concurrently participating in another
clinical study; any clinically significant history of a serious medical condition; previous
confirmed occurrence of rotavirus gastroenteritis
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Interventions 1. RV1, 508 participants
2. Placebo, 257 participants
Schedule: 2 doses according to a 0, 1 month schedule
Outcomes Clinical outcome measures (safety and efficacy)
1. Any rotavirus gastroenteritis leading to medical intervention and caused by the circu-
lating wild-type rotavirus strains, from 2 weeks after dose 2 up to 2 years of age, stool
sample collected as soon as possible but preferably not later than 7 days after the start of
the episode
2. Severe rotavirus gastroenteritis (≥11 on the Vesikari scale) leading to a medical inter-
vention and caused by the circulating wild-type rotavirus strains (a) of G1 type, (b) of
non-G1 types, from 2 weeks after dose 2 up to 2 years of age
3. Each type of solicited symptom (including: cough, diarrhoea, fever, irritability, loss of
appetite and vomiting), during the 8-day follow-up period after each dose
4. Adverse events leading to discontinuation of the trial
5. Serious adverse events, including intussusception, up to 2 years of age
6. Fatal serious adverse events
7. Drop-outs before the end of the trial
Outcomes to measure immunogenicity
8. Seroconversion in terms of anti-rotavirus IgA antibody, from 2 months after dose
2. Seroconversion was defined as the appearance of anti-rotavirus immunoglobulin A
antibody concentration over 20 units (U)/millilitre (mL) in subjects initially (ie prior to
the first dose of RV1) seronegative
Immunization status Combined diphtheria and tetanus toxoids and acellular pertussis (DTPa) and Hepatitis
B (HBV) vaccines were allowed to be co-administered along with RV1 vaccine/placebo
Location Japan
WHO mortality stratum A
Notes Date: June 2007 - November 2009
Source of funding: GlaxoSmithKline
Registration number: NCT00480324
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomized, no further information given
Allocation concealment (selection bias) Unclear risk No details provided
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk “Double Blind (Subject, Caregiver, Investi-
gator, Outcomes Assessor)”, no further de-
tails
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Incomplete outcome data (attrition bias)
All outcomes
Low risk Attrition/exclusions balanced between
groups
Selective reporting (reporting bias) Low risk Protocol published a priori, all pre-pub-
lished outcomes reported
Other bias Unclear risk Study sponsor and collaborator: Glaxo-
SmithKline
RV1 Kerdpanich 2010-THA
Methods RCT
Length of follow-up: 2 months post dose 2
Adverse event data collection methods: passive; “Diary cards were provided to the
parents/guardians of infants to record the solicited general symptoms occurring during
the 15 day follow up period after each vaccine dose. The solicited general symptoms
were loss of appetite, fussiness/irritability, fever, diarrhoea, vomiting and cough/runny
nose. The intensity of each of these symptoms was graded on a 3-point scale where “0”
indicates normal and “3” indicates severe”
Participants Number: 450 enrolled; ATP safety cohort: 447; ATP immunogenicity cohort: 339
Inclusion criteria: healthy infants aged 6 to 12 weeks at the time of the first vaccination
Exclusion criteria: any other investigational drug or vaccine; a history of gastrointestinal
disease or rotavirus gastroenteritis; allergy to any of the vaccine components; a history
of immunosuppressive or immunodeficient condition
Interventions 1. RIX4414* vaccine reconstituted in buffer stored at 2°C-8°C, n = 174
2. RIX4414* vaccine reconstituted in water stored at 2°C-8°C, n = 174
3. RIX4414* vaccine reconstituted in buffer stored at 37°C for seven days, n = 50
4. Placebo reconstituted in buffer, n = 26
5. Placebo reconstituted in water, n = 26
* Lyophilized formulation containing at least 106.0 CCID50 of the RIX4414 strain
Schedule: Two doses at month 0 and 2
Outcomes Clinical outcome measures
1. * Rotavirus diarrhoea, stool sample collected during diarrhoea episode, up to 2months
post dose 2
2. * All-cause diarrhoea, up to 2 months post dose 2
3. Reactogenicity, including fever, vomiting and diarrhoea, 15 day follow-up period after
each dose (collected from GSK report)
4. Serious adverse events, up to 2 months post dose 2
5. Fatal serious adverse events
6. Adverse events resulting in discontinuation (collected from GSK report)
7. Drop-outs: measured up to 2 months after dose 2 (collected from GSK report)
Outcomes to measure immunogenicity
8. Seroconversion, anti-rotavirus IgA antibody levels (cut off: ≥ 20 U/mL by ELISA ),
two months post dose 2
9. Rotavirus antigen shedding in stool [review includes data from combined time points]
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(collected from GSK report)
* Outcome reported as proportion (P) with 95% CI. Events (n) and totals (N) were
estimated by using the values when two formulas for the standard error (SE) converged
Immunization status “During the study period, participating infants were offered commercially available GSK
Biologicals’ diphtheria toxoid, tetanus toxoid, acellular pertussis, inactivated polio andH.
influenzae type b combination vaccine (InfanrixTM -IPV/Hib) at two and four months
of age and diphtheria toxoid, tetanus toxoid, acellular pertussis, hepatitis B, inactivated
polio and H. influenzae type b combination vaccine (Infanrix hexaT M ) at six months of
age”
Location Two centres in Thailand
WHO mortality stratum B
Notes Study known as RIX GSK[039] 2007-AS in previously published versions of this review.
Date: March to December 2005
Source of funding: GSK Biologicals
Study rationale: This study evaluated the stability of lyophilized RIX4414 vaccine in
terms of immunogenicity when reconstituted in water instead of regular buffer, and
when stored at tropical room temperature (37 °C) for 7 days before reconstitution
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Randomized”, no further details reported
Allocation concealment (selection bias) Unclear risk No details reported
Blinding (performance bias and detection
bias)
All outcomes
High risk Partially blind study “Single blind”, not re-
ported whether personnel or participants
were blinded
“The placebo was identical in appearance
and composition to the active vaccine”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Attrition balanced across groups with rea-
sons for withdrawal reported
Selective reporting (reporting bias) Low risk All pre-specified outcomes reported
Other bias Unclear risk Funded by GSK Biologicals
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Methods RCT
Length of follow-up: outcomes measured 2 weeks after last dose to 1 year of age, and
at two years
Adverse event data collection methods: active surveillance for all gastroenteritis
episodes was conducted by members of the study staff through weekly visits to parents
or guardians to collect diary cards and through the collection of data from health clinics
that served the study populations
Participants Number: 4939 enrolled; 4417 evaluable
Age range: 1 to 6 months
Inclusion criteria: healthy infants aged 6 to 10 weeks for the group receiving 3 doses
and 10 to 14 weeks for the group receiving 2 doses of RV1
Exclusion criteria: children HIV positive that were immunosuppressed at < 6 weeks
before vaccination
Interventions RV1
1. RIX4414 (RV1): dose same as commercial; 3298 participants
1.1 2 doses
1.2 3 doses
2. Placebo: 1641 participants
2.1 Normal placebo
Schedule: 2 to 3 doses given 1 month apart
Outcomes Clinical outcome measures (safety and efficacy)
1. All-cause diarrhoea
2. Rotavirus diarrhoea: stool samples were tested for rotavirus with the use of an enzyme-
linked immunosorbent assay (ELISA) (Rotaclone, Meridian Bioscience)
3. Severe rotavirus diarrhoea: the severity of each episode of gastroenteritis was evaluated
with the use of the Vesikari scale 13 (on which scores range from 1 to 20, with higher
scores indicating greater severity) and was categorized as severe if the score was 11 or
more *
4. Severe all-cause diarrhoea: the severity of each episode of gastroenteritis was evaluated
with the use of the Vesikari scale 13 (on which scores range from 1 to 20, with higher
scores indicating greater severity) and was categorized as severe if the score was 11 or
more
5. All-cause mortality: all serious adverse events including deaths were recorded for the
period between the date the first dose of vaccine or placebo was administered and the
date the child reached 1 year of age
6. Serious adverse events: all serious adverse events including deaths were recorded for
the period between the date the first dose of vaccine or placebo was administered and
the date the child reached 1 year of age
Outcomes to measure immunogenicity
7. Immunogenicity: ELISA - 1 month after the last dose to determine the serum con-
centrations of antirotavirus IgA antibody
Immunization status Vaccines that are administered routinely according to the guidelines of the Expanded
Program on Immunization (EPI) were concomitantly administered with the vaccine or
placebo, including oral polio vaccine
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Location South Africa and Malawi
WHO mortality stratum E
Notes This trial was conducted inMalawi andSouthAfrica, data reported separately per country
can be found under RV1 Madhi 2010-MWI and RV1 Madhi 2010-ZAF
Date: October 2005 to February 2007 (South Africa); October 2006 to July 2007
(Malawi)
Source of funding: PATH Rotavirus Vaccine Program and GlaxoSmithKline
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk A randomizations list was generated at
GSK Biologicals, Rixensart, using a stan-
dard SAS® (Statistical Analysis System)
program and this was used to number the
vaccines
Allocation concealment (selection bias) Low risk The vaccine doses were distributed to each
study centre while respecting the random-
izations block size
Blinding (performance bias and detection
bias)
All outcomes
Low risk The site investigator, who was unaware of
the group assignments of the children
Incomplete outcome data (attrition bias)
All outcomes
Low risk Missing data balanced across groups
Selective reporting (reporting bias) Low risk All expected outcomes reported
Other bias Unclear risk Sponsored by industry
RV1 Madhi 2010-MWI
Methods RCT
Length of follow-up: outcomes measured 2 weeks after last dose to 1 year of age, and
at two years
Adverse event data collection methods: active surveillance for all gastroenteritis
episodes was conducted by members of the study staff through weekly visits to parents
or guardians to collect diary cards and through the collection of data from health clinics
that served the study populations
Participants Number: 1773 enrolled
Age range: 1 to 6 months
Inclusion criteria: healthy infants aged 6 to 10 weeks for the group receiving 3 doses
and 10 to 14 weeks for the group receiving 2 doses of RV1
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Exclusion criteria: children HIV positive that were immunosuppressed at < 6 weeks
before vaccination
Interventions RV1
1. RIX4414 (RV1): dose same as commercial; 1182 participants
1.1 2 doses
1.2 3 doses
2. Placebo: 591 participants
2.1 Normal placebo
Schedule: 2 to 3 doses given 1 month apart
Outcomes Clinical outcome measures (safety and efficacy)
1. All-cause diarrhoea
2. Rotavirus diarrhoea: stool samples were tested for rotavirus with the use of an ELISA
(Rotaclone, Meridian Bioscience)
3. Severe rotavirus diarrhoea: the severity of each episode of gastroenteritis was evaluated
with the use of the Vesikari scale 13 (on which scores range from 1 to 20, with higher
scores indicating greater severity) and was categorized as severe if the score was 11 or
more*
4. Severe all-cause diarrhoea: the severity of each episode of gastroenteritis was evaluated
with the use of the Vesikari scale 13 (on which scores range from 1 to 20, with higher
scores indicating greater severity) and was categorized as severe if the score was 11 or
more
5. All-cause mortality: all serious adverse events including deaths were recorded for the
period between the date the first dose of vaccine or placebo was administered and the
date the child reached 1 year of age
6. Serious adverse events: all serious adverse events including deaths were recorded for
the period between the date the first dose of vaccine or placebo was administered and
the date the child reached 1 year of age
Outcomes to measure immunogenicity
7. Immunogenicity: ELISA - 1 month after the last dose to determine the serum con-
centrations of antirotavirus IgA antibody
Immunization status Vaccines that are administered routinely according to the guidelines of the Expanded
Program on Immunization (EPI) were concomitantly administered with the vaccine or
placebo, including oral polio vaccine
Location Malawi
WHO mortality stratum E
Notes This trial was conducted in Malawi and South Africa, this part presents data reported
for the Malawi cohort, data reported for South Africa can be found under RV1 Madhi
2010-ZAF, data reported for both countries under RV1 Madhi 2010-AF
Date: October 2006 to July 2007
Source of funding: PATH Rotavirus Vaccine Program and GlaxoSmithKline
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Low risk A randomizations list was generated at
GSK Biologicals, Rixensart, using a stan-
dard SAS® (Statistical Analysis System)
program and this was used to number the
vaccines
Allocation concealment (selection bias) Low risk The vaccine doses were distributed to each
study centre while respecting the random-
izations block size
Blinding (performance bias and detection
bias)
All outcomes
Low risk The site investigator, who was unaware of
the group assignments of the children
Incomplete outcome data (attrition bias)
All outcomes
Low risk Missing data balanced across groups
Selective reporting (reporting bias) Low risk All expected outcomes reported
Other bias Unclear risk Sponsored by industry
RV1 Madhi 2010-ZAF
Methods RCT
Length of follow-up: outcomes measured 2 weeks after last dose to 1 year of age, and
at two years (only Cohort 2)
Adverse event data collection methods: active surveillance for all gastroenteritis
episodes was conducted by members of the study staff through weekly visits to parents
or guardians to collect diary cards and through the collection of data from health clinics
that served the study populations
Participants Number: 3166 enrolled
Age range: 1 to 6 months
Inclusion criteria: healthy infants aged 6 to 10 weeks for the group receiving 3 doses
and 10 to 14 weeks for the group receiving 2 doses of RV1
Exclusion criteria: children HIV positive that were immunosuppressed at < 6 weeks
before vaccination
Interventions RV1
1. RIX4414 (RV1): dose same as commercial; 2116 participants
1.1 2 doses
1.2 3 doses
2. Placebo: 1050 participants
2.1 Normal placebo
Schedule: 2 to 3 doses given 1 month apart
Outcomes Clinical outcome measures (safety and efficacy)
1. All-cause diarrhoea
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2. Rotavirus diarrhoea: stool samples were tested for rotavirus with the use of an ELISA
(Rotaclone, Meridian Bioscience)
3. Severe rotavirus diarrhoea: the severity of each episode of gastroenteritis was evaluated
with the use of the Vesikari scale 13 (on which scores range from 1 to 20, with higher
scores indicating greater severity) and was categorized as severe if the score was 11 or
more*
4. Severe all-cause diarrhoea: the severity of each episode of gastroenteritis was evaluated
with the use of the Vesikari scale 13 (on which scores range from 1 to 20, with higher
scores indicating greater severity) and was categorized as severe if the score was 11 or
more
5. All-cause mortality: all serious adverse events including deaths were recorded for the
period between the date the first dose of vaccine or placebo was administered and the
date the child reached 1 year of age
6. Serious adverse events: all serious adverse events including deaths were recorded for
the period between the date the first dose of vaccine or placebo was administered and
the date the child reached 1 year of age
Outcomes to measure immunogenicity
7. Immunogenicity: ELISA - 1 month after the last dose to determine the serum con-
centrations of antirotavirus IgA antibody
*G types for severe rotavirus diarrhoea for the first year follow-up was reported and added
to the analyses, G types for any rotavirus diarrhoea was reported for the second year only,
and was not added to the analysis
Immunization status Vaccines that are administered routinely according to the guidelines of the Expanded
Program on Immunization (EPI) were concomitantly administered with the vaccine or
placebo, including oral polio vaccine
Location South Africa
WHO mortality stratum E
Notes This trial was conducted in Malawi and South Africa, this part presents data reported
for the South Africa cohorts, data reported for Malawi can be found under RV1 Madhi
2010-MWI, data reported for both countries under RV1 Madhi 2010-AF
Date: October 2005 to February 2007
Source of funding: PATH Rotavirus Vaccine Program and GlaxoSmithKline
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk A randomizations list was generated at
GSK Biologicals, Rixensart, using a stan-
dard SAS® (Statistical Analysis System)
program and this was used to number the
vaccines
Allocation concealment (selection bias) Low risk The vaccine doses were distributed to each
study centre while respecting the random-
izations block size
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Blinding (performance bias and detection
bias)
All outcomes
Low risk The site investigator, who was unaware of
the group assignments of the children
Incomplete outcome data (attrition bias)
All outcomes
Low risk Missing data balanced across groups
Selective reporting (reporting bias) Low risk All expected outcomes reported
Other bias Unclear risk Sponsored by industry
RV1 Narang 2009-IND
Methods RCT
Length of follow-up: 1 month after dose 2
Adverse event data collection methods: passive, parents/guardians filled in diary cards
of any symptoms
Participants Number: 363 enrolled; 344 evaluable
Age range: 1 to 3 months (beginning); 3 to 6 months (end)
Inclusion criteria: healthy male or female infant between and including, 8 to 10 weeks
of age at the time of first vaccination; free of obvious health problems as established by
medical history and clinical examination before entering into the study; subjects had been
administered the first dose of diphtheria, tetanus, pertussis, hepatitis B, H. influenzae
type b, oral poliovirus vaccine as per the local universal immunization programme at age
6 weeks (given with a 2-week separation from the first and subsequent dose of the RV1
vaccine or placebo)
Exclusion criteria: history of confirmed rotavirus gastroenteritis or with prior adminis-
tration of experimental rotavirus vaccine
Interventions RV1
1. RIX4414 (RV1): 106.5 PFU; 182 participants (randomized)
2. Placebo: 181 participants (randomized)
Schedule: 2 oral doses given at age 2 and 4 months
Outcomes Clinical outcome measures (safety and efficacy)
1. Reactogenicity: for each type of solicited symptom, occurrence of the symptomwithin
the 8-day (days 0 to 7) solicited follow-upperiod after each dose; occurrence of unsolicited
adverse events within 31 days (days 0 to 30) after each dose, according to MedDRA
classification; measured up to 31 days after vaccine/placebo
2. Serious adverse events: no definition; occurrence throughout entire study period (up
to 31 days after vaccine/placebo)
3. Drop-outs: no definition; measured up to 31 days after vaccine/placebo
4. Rotavirus diarrhoea: presence of rotavirus in gastroenteritis episode stools collected
from dose 1 of RV1 vaccine/placebo up to 2 months after dose 2; measured up to 31
days after vaccine/placebo
5. All-cause death
6. Adverse events resulting in discontinuation
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Outcomes to measure immunogenicity
7. Seroconversion: appearance of anti-rotavirus immunoglobulin A (IgA) antibody con-
centration≥ 20 U/mL in participants who were seronegative before vaccination [review
includes data from 1 month after dose 2]
Immunization status Routine vaccinations (diphtheria-tetanus-whole cell pertussis-hepatitis b, H. influenzae
type b, and oral poliovirus vaccine) were administered at 6, 10, and 14 weeks of age
(given with a 2-week separation from the first and subsequent dose of the RV1 vaccine
or placebo)
Location 4 centres in India
WHO mortality stratum D
Notes Date: 10 February 2006 to 8 September 2006
Source of funding: GlaxoSmithKline Biologicals
Study rationale: “to assess the immunogenicity and safety of 2 doses of oral live atten-
uated human rotavirus vaccine in healthy infants in India”
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “The ATP cohort for immunogenicity in-
cluded all vaccinated subjects: - who had
received at least one dose of study vaccine/
control according to their random assign-
ment, - for whom the randomization code
had not been broken”, no further details
Allocation concealment (selection bias) Unclear risk No details
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk “Double-blind”, no further details
Incomplete outcome data (attrition bias)
All outcomes
Low risk Attrition/exclusions balanced between
groups
Selective reporting (reporting bias) Unclear risk Not enough details were provided
Other bias Unclear risk Funded by industry
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Methods RCT
Length of follow-up: 30 to 83 days after dose two
Adverse events data collection methods: active surveillance: at each study visit parens
were asked about AEs; passive surveillance: throughout the trial, parents were asked to
immediately report AEs to the investigator
Participants Number: 1009
Age range: 6 to 12 weeks of age at the time of the first study vaccination
Inclusion criteria: medically stable pre-term infants, born within a gestational period
of 27-36 weeks, planned to be discharged from hospital’s neonatal stay on or before the
day of the first human rotavirus vaccine/placebo administration
Exclusion criteria: use of any investigational or non-registered product (drug or vaccine)
other than the human rotavirus vaccine within 30 days preceding the first dose of human
rotavirus vaccine; any clinically significant history of chronic gastrointestinal disease; any
confirmed or suspected immunosuppressive or immunodeficient condition; history of
allergic disease; major congenital defects or serious chronic illness
Notes: each study group is further stratified into two subgroups depending on the
gestational age at birth of the subject: Stratum I: very pre-term infants, born after a
gestational period of 27 to 30 weeks (189 to 216 days) (20% of enrolment); Stratum
II: mild pre-term infants born after a gestational period of 31 to 36 weeks (217 to 258
days) (80% of enrolment)
Interventions 1. RV1, 670 participants
2. Placebo, 339 participants
Schedule: 2 oral doses of vaccine or placebo, 1 dose at Day 0 and 1 dose at month 1 or
2, depending on the country
Outcomes Clinical outcome measures
1. Serious adverse events, including fatal events and intussusception, from Day 0 up to
83 days after dose 2 of RV1 vaccine/placebo
2. Solicited symptoms, within 15 days after each RV1 vaccine/placebo dose. Solicited
symptoms included diarrhoea (3 or more looser than normal stools/day), fever (axillary
temperature over 37.5 °C), irritability, loss of appetite, and vomiting
3. All-cause gastroenteritis and rotavirus gastroenteritis, from Dose 1 up to 83 days after
Dose 2 of RV1 vaccine/placebo. Gastroenteritis: diarrhoea with or without vomiting.
Rotavirus gastroenteritis: a gastroenteritis episode was a rotavirus gastroenteritis episode
if a stool sample taken during or not later than 7 days after the episode was rotavirus
positive by ELISA
4. Drop-outs before the end of the trial
Outcomes to measure immunogenicity
5. Seroconversion to anti-rotavirus IgA antibody, at Visit 3, 1month after Dose 2 of RV1
vaccine/placebo. Number of subjects with anti-rotavirus IgA antibody concentration
over 20 Units/mL
Immunization status In accordance with the local National Plan of Immunisation schedule in each of the
respective participating countries, GSK Biologicals’ Infanrix Hexa® (DTPa-HBV-IPV/
Hib), InfanrixQuinta® (DTPa-IPV-Hib), Infanrix®+IPV+Hib (DTPa+IPV+Hib) and/
or Engerix-B® (HBV) will be co-administered (at a maximum interval of two days from
each other) with each human rotavirus vaccine or placebo dose
Hepatitis B and Bacille Calmette-Guérin vaccines (BCG) at birth are allowed if included
83Vaccines for preventing rotavirus diarrhoea: vaccines in use (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
RV1 Omenaca 2012-EU (Continued)
in the local National Plan of Immunisation schedule in participating countries
At the discretion of the investigator the following vaccines may be administered during
each subject’s study participation:
• Vaccine against S. pneumoniae (Prevenar®) in France and Spain (concomitantly
with human rotavirus vaccine/placebo).
• Vaccine against Neisseria meningitidis (Neis Vacc C®) is allowed if there is at least
14-days interval with respect to the administration of the human rotavirus vaccine/
placebo.
Location France, Poland, Portugal, Spain
WHO mortality strata A, B
Notes Study known as RV1 NCT00420745 2009-EU in previously published versions of this
review.
Date: January 2007 to March 2008
Source of funding: GlaxoSmithKline
Registration number: NCT00420745
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer generated block randomizations
Allocation concealment (selection bias) Unclear risk No details given
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk “Double Blind (Subject, Caregiver, Investi-
gator, Outcomes Assessor)”, no further in-
formation
Incomplete outcome data (attrition bias)
All outcomes
Low risk Missing data balanced between groups
Selective reporting (reporting bias) Low risk All expected outcomes included
Other bias Unclear risk Sponsor: GlaxoSmithKline
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Methods RCT
Length of follow-up: until infants aged 18 months (ie about 13 to 15 months of follow-
up)
Adverse events data collection methods: “diary cards during a 15-day follow-up period
after each vaccine dose was administered, and the symptoms were graded according to
severity. AEs occurring up to 42 days after administration of each study vaccine was
recorded” (passive method)
Participants Number: 2464 enrolled; 2365 evaluable
Age range: 3 to 6 months
Inclusion criteria:male or female infants, born after a normal gestation period of 36 to
42 weeks; aged 11 to 17 weeks at time of first dose of study vaccine; free of obvious health
problems as established by medical history and clinical examination before entering into
the study
Exclusion criteria: “Subjects with previous confirmed occurrence of rotavirus gastroen-
teritis, previous vaccination against or history of diphtheria, tetanus, pertussis, polio and/
or Hib, had a history of allergic reaction to any vaccine component, were immunocom-
promised or had contact with immunosuppressed individual or pregnant women in their
household, had any clinically significant history of chronic gastrointestinal (GI) disease
including any uncorrected congenital malformation of GI tract or subjects with use of
antibiotics within 7 days preceding Dose 1”
Interventions RV1
1. RIX4414 (RV1)
1.1. 104.7 focus forming units (FFU); 510 participants
1.2. 105.2 FFU; 648 participants
1.3. 106.1 FFU; 653 participants
2. Placebo; 653 participants
All vaccines given in 2 doses with a 1-month interval
Outcomes measured at 15 months (efficacy data from 2 weeks after second dose to 18 months
of age)
Outcomes Clinical outcome measures
1. All-cause diarrhoea: episodes of acute gastroenteritis; parents instructed to record
(diary cards) body temperature, the number of episodes of vomiting, the number of
looser-than-normal stools, and whether they sought medical intervention or medication,
and were asked to obtain at least 2 stool samples on 2 different days within 7 days of the
onset of symptoms; measured at 2 weeks to 18 months
2. Rotavirus diarrhoea: see all-cause diarrhoea; “Rotavirus gastroenteritis was confirmed
if at least 1 of the 2 stool specimens was found to be positive for rotavirus by ELISA.
Rotavirus isolates were G-typed by use of reverse-transcriptase polymerase chain reaction
(RT-PCR)”; measured at 2 weeks to 18 months
3. Severe all-cause diarrhoea: severity of each episode of gastroenteritis graded using a
20-point scoring system described by Ruuska 1990
4. Severe rotavirus diarrhoea: see severe all-cause diarrhoea
5. All-cause death
6. All-cause hospital admission
7. Emergency department visit
8. Serious adverse events
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9. Reactogenicity: fever if rectal temperature > 38 ºC
10. Adverse events requiring discontinuation
11. Rotavirus diarrhoea requiring hospitalization
12. Drop-outs
Outcomes to measure immunogenicity
11. Shedding of vaccine virus: in stool samples on day of each vaccination and on days
7 and 15 after each vaccination (from 50 participants/group, the “stool sample subset”)
[review includes data from 1 month after dose 1 and 1 month after dose 2]
12. Seroconversion: serum anti-rotavirus IgA antibody seroconversion rate; “seroconver-
sion” “defined by an anti-rotavirus IgA antibody concentration of ≥ 20 U/mL, for in-
fants who were initially (i.e. before administration of the first vaccine dose) seronegative
for anti-rotavirus IgA antibodies (i.e. a concentration of <20 U/mL) and/or who had a
stool sample that was negative for rotavirus antigen. Any detection of RIX4414 antigen
in stool samples was taken as evidence of a vaccine response”
Immunization status Hepatitis B vaccine, diphtheria-tetanus-acellular pertussis, poliovirus, and H. influenzae
type b co-administered with interventions
Location 8 centres in Singapore
WHO mortality stratum A
Notes Date: 4 January 2001 to 15 April 2003
Funding: GlaxoSmithKline Biologicals
Other: 93% of population were Asian
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No details: “Infants were randomly as-
signed (on a 1:1:1 basis)”; “randomized,
double-blind, placebo-controlled study”
Allocation concealment (selection bias) Unclear risk No details: “randomized, double-blind,
placebo-controlled study”
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk No details: “double-blind, placebo-con-
trolled study”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Missing data imputed appropriately
Selective reporting (reporting bias) Unclear risk Reasons for low number of rotavirus gas-
troenteritis; “A smaller number of ro-
tavirus-related gastroenteritis cases than ex-
pected were documented during the study.
For 41% (160/387) of the reported gas-
troenteritis episodes, stool sampleswere not
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available for determination of the etiology
of the gastroenteritis. No results were avail-
able for 6% (24/387) of the gastroenteritis
episodes because of an insufficient quantity
of stool samples collected or because of in-
valid results”
Other bias Unclear risk See above
RV1 Phua 2009-AS
Methods RCT
Length of follow-up: 2 weeks post dose 2 to 3 years
Adverse events data collection methods: passive method, using diary cards
Participants Number: 10,708 enrolled; 10,519 evaluable
Age range: 3 to 6 months
Inclusion criteria: healthy infants 6 to 12 weeks of age in Hong Kong and Taiwan, or
11 to 17 weeks of age in Singapore at the time of the first dose
Exclusion criteria: “they did not have a history of chronic administration of immuno-
suppressants since birth, any confirmed or suspected immunosuppressive or immunod-
eficient condition, history of allergic disease or reaction likely to be exacerbated by any
vaccine component, had not received any investigational drugs/vaccines from 30 days
before Dose 1 or planned use during the study, had not received immunoglobulins and/
or blood products since birth or planned administration during the study period, did
not have any clinically significant history of chronic gastrointestinal disease including
any uncorrected congenital malformation of the gastrointestinal tract or other serious
medical condition as determined by the investigator, and did not have first or second
degree of consanguinity of parents”
Interventions RV1
1. RIX4414 (RV1) 106 FFU; 5359 participants
2. Placebo; 5349 participants
All vaccines given in 2 doses with a 1 to 2 month interval
Outcomes Clinical outcome measures
1. All-cause diarrhoea: a gastroenteritis episode was defined as occurrence of diarrhoea
with or without vomiting (diarrhoea was defined as the passage of three or more looser
than normal stool within a 24 h period)
2. Severe all-cause diarrhoea: severe gastroenteritis was defined as an episode of diarrhoea
with or without vomiting that required overnight hospitalization and/or rehydration
therapy (equivalent to WHO plan B or C) in a medical facility and with a score 11
points on the 20-point Vesikari scale
3. Rotavirus diarrhoea: stool samples collected during gastroenteritis episodes were tested
for the presence of rotavirus using ELISA method (RotacloneT M , Meridian Bioscience)
atGlaxoSmithKline Biologicals’ laboratories inRixensart, Belgium. All rotavirus-positive
stool samples were tested by reverse transcriptase polymerase chain reaction (RT-PCR)
followed by reverse hybridization assay, and optional sequencing, at Delft Diagnostic
Laboratory, The Netherlands to determine G and P types, and differentiation of G1P[8]
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vaccine type
4. Severe rotavirus diarrhoea*: see above
5. Emergency department visit: active surveillance was conducted at hospitals and medi-
cal facilities in the study area to capture gastroenteritis episodes requiring hospitalization
and/or re-hydration therapy (equivalent toWHO plan B or C) in a medical facility from
day of the first vaccine or placebo dose until the follow-up visit at 24 months of age
6. Serious adverse events: intussusception and serious adverse events (SAEs)were followed
during the study duration. A case of definite intussusception required confirmation at
surgery or autopsy or by using imaging techniques such as gas or liquid contrast enema
or abdominal ultrasound. Abstractable data for all serious adverse events and Kawasaki
disease were only provided for the third year of follow-up Intussusception data for the
third year follow-up was not included in the analysis as the follow-up population was
smaller (RV1: 2/4272; Placebo: 1/4226)
7. All-cause deaths
Outcomes to measure immunogenicity
None
*G types for severe rotavirus diarrhoea up to two years follow-up was reported and added
to the analyses, data for the third year was reported but not included in the analysis as
the follow-up population was smaller
Immunization status Infants received other routine paediatric immunisations (combined diphtheria toxoid-
tetanus toxoid-acellular pertussis [DTPa] inactivated poliovirus [IPV] andH. influenzae
type b [HiB] vaccine and hepatitis B vaccine [HBV]) during the study period according
to local schedules. Almost all infants received BCG dose at birth. If oral polio vaccine
(OPV) was given as part of the routine schedule in the participating countries, a time
interval of 2 weeks was observed between the OPV doses and RIX4414 vaccine/placebo
doses. One dose of oral polio vaccine (OPV) was given at birth in Hong Kong (99.
8% subjects) and Taiwan (0.7% subjects). However, during the study period, >95% of
infants in the three countries received DTPa-IPV-HiB concomitantly with both doses
of RIX4414 vaccine/placebo as per local schedules 50.9% of subjects were male and the
study population was predominantly Chinese (76.3%)
Location Hong Kong, Singapore, Taiwan
WHO mortality stratum A
Notes Date: 8 December 2003 to 31 August 2005
Funding: GlaxoSmithKline
Other: all enrolled infants received the first dose of RIX4414 vaccine or placebo, and
10,551 (98.5%) received both doses
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk A randomization list was generated at GSK
Biologicals, Rixensart, using a standard
SAS® program and was used to number
the vaccines
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Allocation concealment (selection bias) Low risk A randomizationblocking schemewas used
to ensure that the balance between treat-
ments was maintained. Treatment alloca-
tion at the investigator sites was performed
using a central randomization system on
the Internet
Blinding (performance bias and detection
bias)
All outcomes
Low risk Data analysis was performed at GSK Bi-
ologicals. The treatment code remains
masked, except for statisticians and the
database administrator
Incomplete outcome data (attrition bias)
All outcomes
Low risk Primary analysis of efficacy was performed
from2weeks post dose 2 until 2 years of age
on the “according-to-protocol” (ATP) co-
hort that included participants who com-
pleted the full two-dose vaccination course
and complied with the protocol. The to-
tal vaccinated cohort was used to calculate
vaccine efficacy starting from the first dose
onwards
Selective reporting (reporting bias) Low risk All expected outcomes included
Other bias Unclear risk Study sponsored by GlaxoSmithKline Bio-
logicals
RV1 Rivera 2011-DOM
Methods RCT
Length of follow-up: 17 weeks
Adverse events data collection methods: not reported
Participants Number: 200
Age range: 6 to 14 weeks of age at the time of the first study vaccination
Inclusion criteria: healthy infants with a live twin living in the same household who is
also enrolled in this study, born after a gestation period of over 32 weeks
Exclusion criteria: use of any investigational or non-registered product other than the
study vaccine(s); any confirmed or suspected immunosuppressive or immunodeficient
condition; any clinically significant history of chronic gastrointestinal disease; history of
allergic disease; acute disease at time of enrolment; gastroenteritis within 7 days preceding
the first study vaccine administration; documented HIV-positive subject
Interventions 1. RV1 (RIX 4414) Vaccine, 100 participants
2. Placebo, 100 participants
Schedule: both vaccine and placebo 2 doses at Day 0 (Visit 1) and Week 7 (Visit 2)
Notes: one complimentary dose of RV1 was administered to all infants enrolled in this
study (both study groups) who are aged less than 6 months at Visit 3 (Week 13) as a
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benefit to the placebo group for participation in the study
Outcomes Clinical outcome measures (safety and efficacy)
1. Gastroenteritis, up to week 17
2. Rotavirus gastroenteritis, up to week 13. Rotavirus gastroenteritis episodes were de-
fined as gastroenteritis episodes for which the stool sample temporally closest to the onset
day of the gastroenteritis episode was positive for rotavirus by ELISA
3. Serious adverse events, including fatal serious adverse events and intussusception, up
to week 17
4. Drop-outs from the study
Outcomes to measure immunogenicity
5. Anti-rotavirus IgA antibody seroconversion and concentration in each group, at visit
3
Immunization status All infants received three doses of combined diphtheria, tetanus, acellular pertussis,
hepatitis B, inactivated poliovirus and H. influenzae vaccine
Location Dominican Republic
WHO mortality stratum B
Notes Study known as RV1 NCT00396630 2009-LA in previously published versions of this
review.
Date: January 2007 to February 2008
Source of funding: GlaxoSmithKline
Registration number: NCT00396630
Aim: “to explore horizontal transmission of the HRV [human rotavirus] vaccine strain
within a family from the twin vaccinated with Rotarix to the twin receiving placebo”
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “A randomization list was generated at
GlaxoSmithKline (GSK) Biologicals, Rix-
ensart, using a standard SAS® program.
A randomization blocking scheme (1:1 ra-
tio, block size = 2) was used to ensure bal-
ance between the treatment arms; a treat-
ment number uniquely identified the vac-
cine doses to be administered to the same
infant”
Allocation concealment (selection bias) Low risk “No investigator or any person involved in
the clinical trial (including laboratory per-
sonnel, statisticians and data management)
was aware of the treatment groups during
the course of the study”
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Blinding (performance bias and detection
bias)
All outcomes
Low risk “The study was double-blinded and the
parents/guardians of infants, investigator
and the study personnel were unaware of
the study vaccine administered”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Attrition/exclusions balanced between
groups
Selective reporting (reporting bias) Low risk Trial report does not provide enough details
Other bias Unclear risk Study sponsor: GlaxoSmithKline
RV1 Ruiz-Palac 06-LA/EU
Methods RCT
Length of follow-up: 9 to 10 months
Adverse events data collection methods: active surveillance system established at hos-
pital and medical facilities in study areas to capture intussusceptions and severe gastroen-
teritis episodes (active method)
Participants Number: 63,225 enrolled for safety and 20,169 enrolled for efficacy; 59,308 evaluable
for safety, and 17,882 evaluable for first year efficacy and 14,615 for second year efficacy
Age range: 1 to 3 months (start) and 3 to 6 months (end)
Inclusion criteria: healthy infants aged 6 to 12 weeks (in all countries except Chile)
or 6 to 13 weeks (in Chile) at time of first dose of RV1 or placebo; “healthy infants 6-
13 weeks of age at the time of the first study vaccination whose parent/guardian sign
a written informed consent and whose parents/guardians can and will comply with the
requirements of the protocol (eg, completion of the diary cards, return for follow-up
visits)”
Exclusion criteria (from NCT00140673): use of any investigational or non-registered
product (drug or vaccine) other than the study vaccine(s) within 30 days preceding the
first dose of study vaccine or placebo, or planned use during the study period; chronic
administration (defined as > 14 days) of immunosuppressants or other immune-modi-
fying drugs since birth (topical steroids allowed); child unlikely to remain in the study
area for the duration of the study; any confirmed or suspected immunosuppressive or
immunodeficient condition, including human immunodeficiency virus (HIV) infec-
tion; history of allergic disease or reaction likely to be exacerbated by any component
of the vaccine; administration of immunoglobulins and/or blood products since birth
or planned administration during the study period; any clinically significant history of
chronic gastrointestinal disease including any uncorrected congenital malformation of
the gastrointestinal tract or other serious medical condition as determined by the inves-
tigator
Interventions RV1
1. RIX4414 (RV1): 106.5 PFU; 31,673 participants (safety), 10,159 participants (effi-
cacy)
2. Placebo; 31,552 participants (safety), 10,010 participants (efficacy)
Both vaccine and placebo given in 2 doses with 4 to 8 weeks interval
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Both vaccine and placebo reconstituted in 1.3 mL of liquid calcium carbonate buffer
Outcomes Clinical outcome measures
1. Serious adverse events: “defined as any new health-related problems that resulted
in death, were life-threatening, necessitated hospitalization or prolongation of existing
hospitalization, or resulted in disability or incapacity”; “case of definite intussusception
required confirmation at surgery or autopsy or with the use of imaging techniques,
such as imaging with gas- or liquid-contrast enema or abdominal ultrasonography”;
measured up to 30 days after vaccination and during the first year follow-up for efficacy;
intussusception measured up to 100 days after dose 1. Final intussusception results taken
from CDC report (CDC 2010)
2. Severe all-cause diarrhoea: severe gastroenteritis measured as an “episode of diarrhoea
with or without vomiting that required hospitalization and/or re-hydration therapy
(equivalent to WHealth O plan B or C) in a medical facility”; measured from 2 weeks
after second dose up to 2 years follow-up
3. All-cause diarrhoea; measured from 2 weeks after second dose up to 2 years follow-up
4. Rotavirus diarrhoea; measured from 2 weeks after second dose up to 2 years follow-
up
5. Severe rotavirus diarrhoea: severe rotavirus gastroenteritis defined as an “an episode of
severe gastroenteritis occurring at least 2 weeks after the full vaccination course in which
rotavirus other than vaccine strain was identified in a stool sample collected during the
episode of severe gastroenteritis”; measured from 2 weeks after second dose up to 2 years
follow-up
6. All-cause death; measured up to 30 days after vaccination
7. All-cause hospital admission; from 2 weeks after second dose up to 2 years follow-up
8. Reactogenicity; up to 30 days after vaccination
9. Drop-outs; measured up to 2 years follow-up
11. Rotavirus diarrhoea requiring hospitalizations
12. Adverse events resulting in discontinuation
Outcomes to measure immunogenicity
13. Seroconversion: serum rotavirus IgA antibody concentrations in a subset of 100
participants per country (except in Finland) at Visits 1 and 3 [data not included in review
because it was not a random sample]
Outcomes measured up to 30 days after second dose of vaccine (safety outcomes) and up to 2
years (efficacy outcomes)
Immunization status Routine immunizations according to local regulations; oral poliovirus vaccination at least
2 weeks before or after rotavirus vaccine
Location Latin America and Europe (Argentina, Brazil, Chile, Colombia, Dominican Republic,
Finland, Honduras, Mexico, Nicaragua, Panama, Peru, and Venezuela); second year
follow-up in all locations except Finland and Peru
WHO mortality strata A, B, D
Notes Date: 5 August 2003 to 20 October 2005
Source of funding: GlaxoSmithKline Biologicals
Data extracted from appendix accompanying main report and GlaxoSmithKline com-
panion reports
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Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “GlaxoSmithKline Biologicals provided
vaccine supplies that were numbered with
a computer-generated randomization list.
We used a blocking scheme randomization.
GSK did the masking and concealment”
Allocation concealment (selection bias) Low risk “Randomization was done by a central In-
ternet randomization system”
Blinding (performance bias and detection
bias)
All outcomes
Low risk “Treatment allocation remained concealed
from investigators and parents of partici-
pating infants throughout the study. GSK
did the masking and concealment”
Incomplete outcome data (attrition bias)
All outcomes
Low risk “full GSK report account for all with-
drawals regardless of reason”
Selective reporting (reporting bias) High risk The trial reported only on severe episodes
of rotavirus diarrhoea and all-cause diar-
rhoea, and not on diarrhoea of any severity,
which is unusual in these trials
Other bias Unclear risk Study sponsored by GlaxoSmithKline Bio-
logicals
RV1 Salinas 2005-LA
Methods RCT
Length of follow-up: up to 2 years (stated in GlaxoSmithKline report)
Adverse event data collection methods: diary cards were supplied to the parents to
record occurrence of specific solicited symptoms for 15 days after each vaccination (pas-
sive method); any other unsolicited symptoms were recorded during 43 days after each
vaccination (passive method); serious adverse events were recorded throughout the study
Participants Number: 2155 enrolled; 2004 evaluable
Age range: 1 to 3 months (beginning); 3 to 6 months (end)
Inclusion criteria: healthy infants, born after a normal gestation period of 36 to 42
weeks or with a birth weight > 2000 g; aged 6 to 12 weeks at the time of the first
vaccination; free of obvious health problems as established bymedical history and clinical
examination before entering into the study
Exclusion criteria: previous confirmed occurrence of rotavirus gastroenteritis; previous
vaccination against or history of diphtheria, tetanus, pertussis, polio and/orH. influenzae
type b vaccine (HiB); any clinically significant history of chronic gastrointestinal disease
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including any uncorrected congenital malformation of gastrointestinal tract; use of an-
tibiotics within 7 days preceding dose 1; immunocompromised or were in household
contact with an immunosuppressed individual or pregnant woman
Interventions RV1
1. RIX4414 (RV1)
1.1. 104.7 PFU; 538 participants (randomized)
1.2. 105.2 PFU; 540 participants (randomized)
1.3. 105.8 PFU; 540 participants (randomized)
2. Placebo: 537 participants (randomized)
Schedule: 2 doses given every 2 months
An additional 200 participants were randomized to RV1 x placebo to receive 3 doses. This
is not mentioned on the main publication, only in the GlaxoSmithKline report (no data
available)
Outcomes Clinical outcome measures (safety and efficacy)
1. Serious adverse events: no definition; measured during follow-up (2 years)
2. Reactogenicity: no definition; measured up to 43 days after vaccination
3. All-cause diarrhoea: gastroenteritis defined as diarrhoea characterized by ≥ 3 looser
than normal stools within a day; minimum of 5 days required between episodes for them
to be considered as separate events; measured during follow-up (2 years)
4. Severe all-cause diarrhoea: information on diary cards was used to assess the severity
of each gastroenteritis episode according to a 20-point scoring system; measured during
follow-up (2 years)
5. Rotavirus diarrhoea: all rotavirus-positive specimens were tested by reverse transcrip-
tion-polymerase chain reaction at GlaxoSmithKline to determine the G type; any G1
rotavirus detected until 2 months after the second dose were analysed to differentiate
between vaccine strain and wild G1 strains; only gastroenteritis episodes in which wild
rotavirus other than the vaccine strain was identified in a stool specimen were included
in the efficacy analysis; measured during follow-up (2 years)
6. Severe rotavirus diarrhoea: see above; measured during follow-up (2 years)
7. All-cause hospital admission: no definition; measured during follow-up (2 years)
8. All-cause mortality: no definition; measured during follow-up (2 years)
9. Rotavirus diarrhoea resulting in hospitalization
Outcomes to measure immunogenicity
10. Vaccine take: rotavirus shedding in stool specimens [review includes data from day
7 after dose 2]
11. Seroconversion: “percentages of infants with post-antirotavirus IgA antibody con-
centration 20 units/mL in infants who were negative for rotavirus before the first dose
of RIX4414 or placebo” [review includes data from 2 months after dose 1 and 2 months
after dose 2]
Immunization status Oral polio vaccine given after 2 weeks, not together with RV1
Location Belem (Brazil), Mexico City (Mexico), Valencia (Venezuela)
WHO mortality stratum B
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Notes Date: 25 May 2001 to 8 November 2003
Source of funding: GlaxoSmithKline Biologicals
Malnutrition: reported in “Journal of Infectious Disease, 2007, 196(4): 537-40”
Other: main publication did not report that the trial included 2 subsets:
• 2 doses of human rotavirus or placebo subset: these participants received 2 oral
doses of RV1 vaccine or placebo according to a 0, 2 months schedule, and routine
vaccinations (DTPw- Hepatitis B vaccine (HBV) + Hib vaccine) at a 0, 2, and 4
months schedule
• 3 doses of RV1 or placebo subset: these participants received 3 oral doses of RV1
vaccine or placebo, and routine vaccinations (DTPw-HBV + Hib vaccine)
concomitantly with each dose of human rotavirus vaccine and placebo at a 0, 2, and 4
months schedule
Immunogenicity sampling: “A subset of infants (N 800) provided blood samples 2
months after the first dose (serology for antirotavirus IgA antibodies) and 2 months
after the second dose (serology for antirotavirus IgA antibodies and antibodies against
antigens of routine infant vaccines). The first 200 enrolled infants in each participating
country constituted this subset, and the remaining 200 infants were included according
to the order of enrolment irrespective of country”
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer generated; “The participating
infants were randomly assigned to one of
the 4 study groups (3 vaccine groups and a
placebo group) following a 1:1:1:1 alloca-
tion ratio according to a computer-gener-
ated randomization list”
Allocation concealment (selection bias) Unclear risk Not reported
Blinding (performance bias and detection
bias)
All outcomes
Low risk “Double blinding was maintained during
the entire study period”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Missing data balanced across groups
Selective reporting (reporting bias) High risk Not all pre-specified outcomes reported
Other bias Unclear risk GlaxoSmithKline final report stated that
part of the population received 3 doses of
rotavirus vaccine. This was not mentioned
on the original published report
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Methods RCT
Length of follow-up: up to 6 months after last vaccine given
Adverse event data collection methods: ”The infants were monitored for at least 30
min after each vaccination. Parents received a diary card to record information daily
about solicited general symptoms (fever, fussiness/irritability, diarrhoea, vomiting, loss
of appetite or cough/runny nose) for 15 days after each dose of RIX4414 or placebo, and
any other adverse events occurring until the next study visit.Weekly supervisionwas done
by Health Care Workers fromMadibeng District Health Centre. The study physician or
his staff questioned the parents on their child’s health and verified the completed diary
card at each visit
Participants Number: 450 enrolled; 406 evaluable
Two cohorts were vaccinated: 1st cohort before the rotavirus season (271 participants);
2nd cohort after the rotavirus season (179) participants
Age range: 1 to 3 months (beginning); 3 to 6 months (end)
Inclusion criteria: healthy infants, born after a normal gestation period of ≥ 36 weeks;
5 to 10 weeks of age at the time of the first study visit; free of obvious health problems as
established by medical history and clinical examination before entering into the study.
There were no restrictions on feeding the infants before or after vaccination
Exclusion criteria: infants were excluded if they had a clinically significant history of
gastrointestinal disease or malformation, had received vaccines or treatment prohibited
by the protocol, were immuno-compromised or were in household contact with an im-
muno-suppressed individual or pregnant woman. Bacillus Calmette-Guerin (BCG) and
OPV vaccinations at birth were allowed according to the local EPI schedule. Vaccination
was postponed if the infant had fever (≥37.5C axillary or≥38C rectal) or gastroenteritis
within the previous 7 days
Interventions RV1
1. RIX4414 (RV1): 105 FFU; 2 doses given 1 month apart; 300 participants (random-
ized)
1.1. RV1 vaccine + oral polio vaccine + diphtheria-tetanus-acellular pertussis/H. influen-
zae type b vaccine
1.2. RV1 vaccine + oral polio vaccine placebo + diphtheria-tetanus-acellular pertussis
inactivated polio-H. influenzae type b vaccine
1.3. RV1 placebo + diphtheria-tetanus-acellular pertussis inactivated polio-H. influenzae
type b vaccine
2. Placebo: 2 doses given 1 month apart; 150 participants (randomized)
Outcomes Clinical outcome measures (safety and efficacy)
1. Reactogenicity (see Adverse event data collection methods above)
2. Serious adverse events: Infants who experienced a serious adverse event and required
hospitalization were admitted at the local district hospital in the study sites or at Ga-
Rankuwa Hospital, the referral hospital for the study site and surrounding areas. Parents
were informed on the symptoms of intussusception and were instructed to contact the
study physician or clinic if any signs of intussusception became apparent. Any suspected
cases were immediately referred to Ga-Rankuwa Hospital. All serious adverse events
were reported to the sponsor and the Ethics committees and followed-up until resolved.
Parents were contacted 6 months after the second
dose of RIX4414 or placebo to obtain information on any serious adverse events since the
final study visit. All serious adverse events were reviewed periodically by an independent
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safety monitoring committee
3. All-cause death
4. Drop-outs
5. Adverse events resulting in discontinuation
Outcomes to measure immunogenicity
6. Vaccine virus shedding: vaccine virus in stool sample (review includes data from
combined time points)
7. Seroconversion: appearance of anti-rotavirus IgA antibody (concentration ≥ 20 U/
mL) in participants negative for rotavirus before vaccination (review includes data from
289 participants)
Immunization status Diphtheria-tetanus-acellular pertussis, polio virus, and H. influenzae type b co-admin-
istered in trial
Location Madibeng District, North West Province, South Africa
WHO mortality stratum E
Notes Date: 1st cohort started from 22 November 2001; 2nd cohort from 23 October 2002
to 15 October 2003
Source of funding: The study (e-Track 444563-014/NCT00346892) was sponsored by
a public-private partnership RAPID and GSK Biologicals. The RAPID partnership con-
sists of public sector partners (including the WHO, US Agency for International Devel-
opment, National Institutes of Health, Children’s Vaccine Programme and the Centers
for Disease Control), academic institutions (International Centre for Diarrhoeal Disease
Research, Bangladesh and Medical University of Southern Africa) and GlaxoSmithKline
Biologicals
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Very likely; “This study was conducted un-
der the WHO RAPID (Rotavirus Action
Partnership for Immunization and Devel-
opment) programme that facilitates con-
duct of rotavirus vaccine trials in devel-
oping countries, specifically in Africa and
Asia, to address specific developing country
needs. The RAPID partnership consists of
public sector partners (including the
WHO, US Agency for International De-
velopment, National Institutes of Health,
Children’s Vaccine Programme and the
Centers for Disease Control), academic in-
stitutions (International Centre for Diar-
rhoeal Disease Research, Bangladesh and
Medical University of Southern Africa) and
GlaxoSmithKline Biologicals”
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Allocation concealment (selection bias) Unclear risk No details; “balanced allocation (1:1:1)”
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Blinding of oral polio vaccine co-adminis-
tration not completely blinded. “OPV and
its placebo used in the first cohort were
identical in appearance allowing for double
blinding while this was not possible in the
second cohort due to differences in appear-
ance of OPV and its placebo”
Incomplete outcome data (attrition bias)
All outcomes
Low risk “All infants who had received at least one
dose of RIX4414 or placebo (total vacci-
nated cohort) were included in the primary
analysis of reactogenicity”
Selective reporting (reporting bias) Low risk All pre-specified outcomes reported
Other bias Unclear risk Funded by RAPID partnership and Glaxo-
SmithKlineBiologicals. Protocol published
a prior with ClinicalTrials.gov, number
NCT00346892. “The public sector part-
ners provided co-funding and technical ex-
pertise for clinical evaluation. GSKBiolog-
icals supplied all vaccine doses, handled the
study design, the collection and analysis of
data, the monitoring and implementation
of the study in collaboration with the study
centres, which are WHO reference centres.
In addition, GSK Biologicals also coordi-
nated the report writing and took part in
the decision to submit the paper for publi-
cation”
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Methods RCT
Length of follow-up: up to 31 days after each vaccine dose and 42 days after the last
vaccine dose
Adverse event data collection methods: all solicited general symptoms (fever, fussiness
/irritability, diarrhoea, vomiting, loss of appetite, cough/runny nose) and unsolicited
symptomswere recorded during the 15-day and 31-day postvaccination follow-up period
after each RIX4414/placebo
dose, respectively. The intensity of adverse events was assessed on a 4-point scale, where
“0” indicated no symptoms; “1,” mild; “2,” moderate; and “3” severe symptoms. Symp-
toms of Grade 3 intensity were defined as follows: rectal temperature ≥39.5°C (fever),
≥6 looser than normal stools per day (diarrhoea),≥3 episodes of vomiting per day (vom-
iting), refusing food intake (loss of appetite), and preventing normal activity (cough/
runny nose, fussiness/irritability). Grade 2 symptoms were defined as rectal temperature
of 38.5°C to 39.5°C (fever), 4 to 5 looser than normal stools/d (diarrhoea), 2 episodes
of vomiting/d (vomiting), eating lesser than usual, which interfered with normal activity
(loss of appetite), and interfering with normal activity (cough/runny nose, fussiness /
irritability). Occurrence of SAEs was recorded throughout the study period
Participants Number: 100 enrolled; 100 evaluable for safety, 50 for immunogenicity
Age range: 1 to 3 months (beginning); 3 to 6 months (end)
Inclusion criteria: only HIV-positive infants (confirmed at screening) who were clini-
cally asymptomatic or mildly symptomatic (clinical stages I and II according to WHO
classification) and aged 6 to 10 weeks at the time of Dose 1 of RIX4414/placebo were
enrolled. There were no restrictions on feeding the infants before or after vaccination
Exclusion criteria: infants were not included in the study if they were confirmed HIV
negative, had received any other investigational drug or vaccine 30 days before receiving
the first dose of study vaccine, or had a history of chronic gastroenteritis or previous
documented rotavirus gastroenteritis
Interventions 1. RV1: 3 doses at least 106.0 CCID50 viral concentration
2. Placebo
Outcomes Clinical outcome measures (safety and efficacy)
1. Reactogenicity (see Adverse event data collection methods above)
2. All-cause diarrhoea; A GE episode was defined as diarrhoea (3 or more, loose than
normal stools per day) with or without vomiting. Stool samples were collected on Days
0, 7, 15, and 22 of Doses 1 and 2 and on Days 0, 7, 15, 30, 45, and 60 of Dose 3
3. Rotavirus diarrhoea; measured from 1 week after second dose up to 2 months’ follow-
up
4. Serious adverse events: infants who experienced a serious adverse event and required
hospitalization were admitted at the local district hospital in the study sites or at Ga-
Rankuwa Hospital, the referral hospital for the study site and surrounding areas. Parents
were informed on the symptoms of intussusception and were instructed to contact the
study physician or clinic if any signs of intussusception became apparent. Any suspected
cases were immediately referred to Ga-Rankuwa Hospital. All serious adverse events
were reported to the sponsor and the Ethics committees and followed-up until resolved.
Parents were contacted 6 months after the second dose of RIX4414 or placebo to obtain
information on any serious adverse events since the final study visit. All serious adverse
events were reviewed periodically by an independent safety monitoring committee
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5. All-cause death
6. Drop-outs
Outcomes to measure immunogenicity
7. Vaccine take: defined as serum antirotavirus IgA concentration 20 U/mL in postvac-
cination sera or rotavirus vaccine shedding in any stool sample collected from Dose 1 to
2 months post-Dose 3 for infants initially negative for rotavirus
8. Seroconversion: appearance of anti-rotavirus IgA antibody (concentration ≥ 20 U/
mL) in participants negative for rotavirus before vaccination (review includes data from
289 participants)
Immunization status RV1 vaccine was concomitantly administered with 3 doses of combined diphtheria,
tetanus and whole-cell pertussis, hepatitis B, and H. influenzae type b vaccine (Tritan-
rixHepBHib) and OPV (PolioSabin)
Location Pretoria, South Africa
WHO mortality stratum E
Notes Registration number: ISRCTN11877362/NCT00263666
Source of funding: RAPID trials (USA); WHO (Switzerland) and GlaxoSmithKline
Biologicals
For infants who developed clinical symptoms of HIV (WHO stages III or IV disease)
anytime after enrolment, access to antiretroviral therapy (cotrimoxazole) according to
the South African national guidelines was facilitated. Infants who needed treatment were
referred to antiretroviral therapy centres by the investigators
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Very likely; “This study was conducted un-
der the WHO RAPID (Rotavirus Action
Partnership for Immunization and Devel-
opment) programme that facilitates con-
duct of rotavirus vaccine trials in devel-
oping countries, specifically in Africa and
Asia, to address specific developing coun-
try needs. The RAPID partnership con-
sists of public sector partners (including the
WHO, US Agency for International De-
velopment, National Institutes of Health,
Children’s Vaccine Programme and the
Centers for Disease Control), academic in-
stitutions (International Centre for Diar-
rhoeal Disease Research, Bangladesh and
Medical University of Southern Africa) and
GlaxoSmithKline Biologicals”
Allocation concealment (selection bias) Unclear risk 1:1 randomization, no further details
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Blinding (performance bias and detection
bias)
All outcomes
Low risk “The placebo was similar to RIX4414 in
appearance and contained the same con-
stituents as the active vaccine except that it
did not contain the vaccine virus”
Incomplete outcome data (attrition bias)
All outcomes
Low risk “All infants who had received at least one
dose of RIX4414 or placebo (total vacci-
nated cohort) were included in the primary
analysis of reactogenicity”
Selective reporting (reporting bias) Low risk All pre-specified outcomes reported
Other bias Unclear risk Supported by research grants from theWH
O (V27/181/173), the Program for Appro-
priate Technology in Health (PATHGrant
GAV.1142-01-07211-SPS), the Norwe-
gian Program for Development, Research
andHigher Education research grant (PRO
48/2002), and the South African Medical
Research Council. GlaxoSmithKline Bio-
logicals was also the funding source and
was involved in all stages of the study con-
duct and analysis. GSK Biologicals also
took in charge all costs associated with
the development and the publishing of
the presentmanuscript. Protocol published
a priori with ClinicalTrials.gov, number
NCT00263666
RV1 Steele 2010b-ZAF
Methods RCT
Length of follow-up: up to 6 months after last dose of vaccine or placebo
Adverse event data collection methods: ”The infants were monitored for at least 30
min after each vaccination. Parents received a diary card to record information daily
about solicited general symptoms (fever, fussiness/irritability, diarrhoea, vomiting, loss
of appetite or cough/runny nose) for 15 days after each dose of RIX4414 or placebo, and
any other adverse events occurring until the next study visit.Weekly supervisionwas done
by Health Care Workers fromMadibeng District Health Centre. The study physician or
his staff questioned the parents on their child’s health and verified the completed diary
card at each visit
Participants Number: 475 participants enrolled; 420 evaluable
Age range: 1 to 3 months (beginning); 3 to 6 months (end)
Inclusion criteria: healthy infants, born after a normal gestation period of ≥ 36 weeks;
6 to 10 weeks of age at the time of the first study visit; free of obvious health problems as
established by medical history and clinical examination before entering into the study,
and mothers had confirmed negative HIV status
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Exclusion criteria: infants were excluded if they had a clinically significant history of
gastrointestinal disease or malformation, had received vaccines or treatment prohibited
by the protocol, were immuno-compromised or were in household contact with an im-
muno-suppressed individual or pregnant woman. Bacillus Calmette-Guerin (BCG) and
OPV vaccinations at birth were allowed according to the local EPI schedule. Infants with
acute disease at the time of enrolment or gastroenteritis (diarrhoea) within 7 days before
administration of the study vaccine were also excluded. In addition, vaccination was
postponed if the infant had fever (≥37.5 °C axillary or ≥38 °C rectal) or gastroenteritis
within the previous 7 days
Interventions RV1
1. RIX4414 (RV1): at least 106.0 PFU CCID50
1.1. 2 doses, 1 month apart (at 10 and 14 weeks) plus 1 dose of placebo (at 6 weeks);
190 participants (randomized)
1.2. 3 doses, 1month apart (at 6, 10, and 14weeks of age); 189 participants (randomized)
2. Placebo: 3 doses, 1 month apart (at 6, 10, and 14 weeks of age); 96 participants
(randomized)
Schedule: Visits 1 (Dose 1), 2 (Dose 2), 3 (Dose 3), 4 and 5 correspond to months 0,
1, 2, 4, and 8 to 11 in the schedule
Outcomes Clinical outcome measures (safety and efficacy)
1. Reactogenicity: for each type of solicited symptom, occurrence of the symptomwithin
the 15-day (days 0 to 14) solicited follow-up period after each dose; occurrence of
unsolicited adverse events within 43 days (days 0 to 42) after each dose, according to
MedDRA classification; measured up to 43 days after vaccine/placebo
2. Serious adverse events: occurrence throughout entire study period; measured up to 6
months
5. All-cause death: fatal adverse events measured up to 6 months
6. Drop-outs: measured up to 6 months
7. Adverse events resulting in discontinuation
Outcomes to measure immunogenicity
8. Viral shedding: presence of rotavirus in any stool sample (review includes data from
combined time points (these combined data for 2 and 3 doses))
9. Seroconversion: appearance of anti-rotavirus IgA antibody concentration ≥ 20 U/
mL in participants negative for rotavirus before first dose (review includes data from 1
month after dose 1 and 2 months after dose 3)
Immunization status Infants received routine vaccinations according to the local EPI schedule in South Africa.
Bacille Calmette-Guerin and OPV vaccinations were given at birth; all other routine
vaccinations (including diphtheria-tetanus toxoids-whole cell pertussis, hepatitis B, H.
influenzae type b, and OPV) were administered concomitantly with the study vaccine.
All of the infants received a dose of OPV concomitantly with each dose of study vaccine
or placebo at all administration times
Location 7 centres in South Africa
WHO mortality stratum E
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Notes Study known as RIX GSK[013] 2007-AF in previously published versions of this review
Date: 5 September 2003 to 25 October 2004
Source of funding: GlaxoSmithKline Biologicals
Study rationale: “The aim of this study was to determine if there was a difference in
immune response between the two different schedules that were tested”
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Very likely. This study was conducted un-
der the auspices of WHO (eTrack 444563/
013/NCT00383903)
Allocation concealment (selection bias) Unclear risk 2:2:1 randomization, no further details
Blinding (performance bias and detection
bias)
All outcomes
Low risk “The placebo was similar to RIX4414 in
appearance and contained the same con-
stituents as the active vaccine except that it
did not contain the vaccine virus”
Incomplete outcome data (attrition bias)
All outcomes
Low risk “All infants who had received at least one
dose of RIX4414 or placebo (total vacci-
nated cohort) were included in the primary
analysis of reactogenicity”
Selective reporting (reporting bias) Low risk All pre-specified outcomes reported
Other bias Unclear risk Supported by research grants from theWH
O (V27/181/173), the Program for Appro-
priate Technology in Health (PATHGrant
GAV.1142-01-07211-SPS), the Norwe-
gian Program for Development, Research
andHigher Education research grant (PRO
48/2002), and the South African Medical
Research Council. GlaxoSmithKline Bio-
logicals was also the funding source andwas
involved in all stages of the study conduct
and analysis. GSK Biologicals also took in
charge all costs associated with the devel-
opment and the publishing of the present
manuscript
Pro-
tocol published a prior with ClinicalTrials.
gov (eTrack 444563/013/NCT00383903)
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Methods RCT
Length of follow-up: 8 to 30 days after each dose
Adverse event data collection methods: diary cards provided to participants or par-
ticipants’ parents/guardians to record solicited general symptoms on the day of each
vaccination and for 7 subsequent days (passive method)
Participants Number: 192 enrolled; 178 evaluable
Age range: 1 to 3 months (beginning); 3 to 6 months (end)
Inclusion criteria: healthy infants, born after a normal gestation period of 36 to 42
weeks; 6 to 12 weeks of age at the time of the first dose of the study vaccination course;
free of obvious health problems as established bymedical history and clinical examination
before entering into the study
Exclusion criteria: participating in any other clinical trial; acute disease; history of
allergic reaction to any vaccine component; history of chronic gastrointestinal disease
or other serious medical condition; undergone immunosuppressive therapy; received
antibiotics within 14 days preceding the study vaccine administration and during the
first 7 days after vaccine administration; any confirmed or suspected immunosuppressive
or immunodeficient condition, had received any immunoglobulin therapy or blood
products before start or during the trial; abnormal stool pattern or household contact
with an immunosuppressed individual or pregnant woman; for the infants, previous
confirmed occurrence of rotavirus gastroenteritis
Interventions RV1
1. RIX4414 (RV1)
1.1. 104.1 PFU; 32 participants (randomized)
1.2. 104.7 PFU; 64 participants (randomized) *
1.3. 105.8 PFU; 32 participants (randomized)
2. Placebo: 64 participants (randomized)
Schedule: 2 doses given 2 months apart
*Half of infants receiving 104.7 PFU ofRV1were tested with prior administration ofMylanta
as buffer; in the other half vaccine was diluted in a buffer containing calcium carbonate
Feeding was not allowed for an hour before and after study vaccine administration
Outcomes Clinical outcome measures (safety and efficacy)
1. Adverse events requiring discontinuation: no definition; measured at 31 days follow-
up after each dose
2. Serious adverse events: no definition; measured at 31 days follow-up after each dose
3. Reactogenicity: no definition; measured at 31 days follow-up after each dose
4. Drop-outs: no definition; measured at 31 days follow-up after each dose
5. All-cause mortality: no definition; measured at 31 days follow-up after each dose
Outcomes to measure immunogenicity
6. Rotavirus shedding in stool (review includes data from day 7 to 9 after dose 2)
7. Seroconversion: appearance of serum anti-rotavirus IgA antibody to rotavirus in post-
vaccination sera at a titre of ≥ 20 U/mL in previously uninfected infants; measured in
infants only (review includes data from 2 months after dose 1 and 1 month after dose 2)
Immunization status Infant routine vaccinations were separated from the study vaccines by 2 weeks
104Vaccines for preventing rotavirus diarrhoea: vaccines in use (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
RV1 Vesikari 2004a-FIN (Continued)
Location 2 centres in Finland
WHO mortality stratum A
Notes Date: 29 May to 18 December 2000
Source of funding: GlaxoSmithKline Biologicals
Trial report also includes results for a study in adults and in previously rotavirus infected
children; neither included in this review
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not reported
Allocation concealment (selection bias) Unclear risk Not reported
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk “The study was performed under double-
blindwith respect to the groupswithin each
study part”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk “Fourteen subjects did not complete the
study including one infant from 10*4.7
FFU with Mylanta® group who failed to
complete the study due to anunrelated SAE
(allergic reaction to DTP vaccine)”
“15 subjects were eliminated from ATP
analysis for non-compliance with the pro-
tocol (nine subjects) or seropositivity be-
fore vaccination (six subjects)”
Selective reporting (reporting bias) Unclear risk No information
Other bias Unclear risk No information
RV1 Vesikari 2004b-FIN
Methods RCT
Unbalanced randomization (2:1)
Length of follow-up: 1 and 2 years of follow-up are reported
Adverse event data collection methods: to assess reactogenicity, parents recorded daily
on diary cards rectal temperature, any diarrhoea, vomiting, irritability, and loss of appetite
for 15 days after each vaccination. Any other symptoms or signs occurring during a 43-
day follow-up period after each vaccination were recorded as unsolicited symptoms (or
signs) (passive method)
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Participants Number: 405 enrolled; 372 evaluable
Age range: 1 to 3 months (beginning); 3 to 6 months (end)
Inclusion criteria: healthy infants, born after a normal gestation period of 36 to 42
weeks; 6 to 12 weeks of age at the time of the first dose of the study vaccination course;
free of obvious health problems as established bymedical history and clinical examination
before entering into the study
Exclusion criteria: premature labour; vaccination was delayed if infant had fever (rectal
temperature > 38 °C) or had gastroenteritis within the previous 7 days
Interventions RV1
1. RIX4414 (RV1): 104.7 PFU; 2 doses given 2 months apart; 270 participants (ran-
domized)
2. Placebo: 2 doses given 2 months apart; 135 participants (randomized)
Feeding was not allowed for 1 h before administration of the study vaccine
Outcomes Clinical outcome measures (safety and efficacy)
1. Rotavirus diarrhoea: occurrence of rotavirus gastroenteritis during the period starting
from2weeks after dose 2until the endof the first rotavirus season following vaccination as
detected by reverse transcription-polymerase chain reaction (RT-PCR) in stool samples;
occurrence of asymptomatic rotavirus infections during the period starting from1month
after dose 2 until the end of each rotavirus season following vaccination; G type of the
wild rotavirus strain by RT-PCR; measured at 1 year (first report) and 2 years (second
report)
2. Reactogenicity: for each type of solicited symptom, occurrence of the symptomwithin
the 15-day solicited follow-up period after each dose; measured at 15 days after each
dose
3. Adverse events requiring discontinuation: occurrence of unsolicited symptoms within
42 days after each dose, according to WHO’s classification; measured 42 days after each
dose
4. Serious adverse events: no definition; measured at all follow-up
5. All-cause diarrhoea: gastroenteritis was defined as diarrhoea (≥ 3 looser than normal
stools within any day) and/or vomiting (≥ 1 episodes of forceful emptying of partially
digested stomach contents > 1 h after feeding within any day; 2 occurrences of gastroen-
teritis were classified as separate episodes if there were ≥ 5 symptom-free days between
them
6. Severe rotavirus diarrhoea: score of < 7 prospectively defined as mild; score of 7 to 10
as moderate; and a score > 11 as severe
7. Rotavirus diarrhoea resulting in hospitalization
8. All-cause death
9. Drop outs
Outcomes to measure immunogenicity
10. Seroconversion: anti-rotavirus antibody IgA concentration of ≥ 20 units/mL in
infants negative for this before the first dose (review includes data from 1 month after
dose 2)
Immunization status Infant routine vaccinations (diphtheria tetanus toxoids-pertussis, H. influenzae type b,
and inactivated poliovirus vaccines) were separated from the study vaccines by at least 2
weeks
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Location 6 centres in Finland
WHO mortality stratum A
Notes Date: 21 August 2000 to 11 July 2002
Source of funding: GlaxoSmithKline Biologicals
Other: GSK 444663/004 (rota-004annex) reports a second year extension of the study
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Eligible infants were randomly assigned
(2:1 ratio) to 2 study groups according to a
computer-generated randomization list to
receive the vaccine or placebo by mouth”
Allocation concealment (selection bias) Unclear risk Not reported
Blinding (performance bias and detection
bias)
All outcomes
Low risk “The placebo had the same constituents
and identical appearance as the active vac-
cine, but did not contain the vaccine virus”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 44 subjectswere eliminated fromATPanal-
ysis for non-compliance with the protocol
(five subjects) or unknown rotavirus status
(one subject) or reason not stated (38 sub-
jects)
Selective reporting (reporting bias) Low risk All pre-specified outcomes reported
Other bias Unclear risk No information
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Methods RCT
Length of follow-up: 1 and 2 years of follow-up in all countries, and a third year follow-
up in Finland (GSK109810)
Adverse event data collection methods: “active surveillance for gastroenteritis episodes
and serious adverse events from the day of the first vaccine or placebo dose (8 September
2004) until the follow-up visit at the end of the second rotavirus epidemic season (10
August 2006) ... Study staff contacted parents every week” (active method); “During
every episode, we asked parents to record in a daily diary card the number of looser
than normal stools, axillary or rectal temperature, number of vomiting episodes, any
rehydration or other medication administered, and any medical attention (defined as
medical personnel contact, advice, or visit; emergency roomcontact or visit; or admission)
” (passive method)
Participants Number: 3994 enrolled; 3848 evaluable
Age range: 1 to 3 months (beginning); 3 to 6 months (end)
Inclusion criteria: healthy infants aged 6 to 14 weeks who weighed > 2000 g at birth
Exclusion criteria: acute disease at the time of enrolment; history of chronic administra-
tion of immunosuppressants since birth; received any vaccines or treatments prohibited
by the protocol; or had any disorders or illnesses excluded by the protocol
Interventions RV1
1. RIX4414 (RV1): 106.5 PFU; 2 doses given 1 or 2 months apart; 2646 participants
(randomized)
2. Placebo: 2 doses given 1 or 2 months apart; 1348 participants (randomized)
Outcomes Clinical outcome measures (safety and efficacy)
1. All-cause diarrhoea: gastroenteritis defined as diarrhoea characterized by at least 3
looser than normal stools within a day, with or without vomiting; measured 2 weeks
after dose 2 until end of 2 years follow-up
2. Rotavirus diarrhoea: trialists deemed a gastroenteritis episode to be caused by rotavirus
if a rotavirus strain was identified in a stool sample collected during the episode or within
7 days after resolution of symptoms, or before the next episode if fewer than 7 days
had fallen between the end of 1 episode and the start of the next, in cases of multiple
episodes; measured 2 weeks after dose 2 until end of 2 years follow-up
3. Severe rotavirus diarrhoea: score < 7 was defined prospectively as mild, score of 7 to
10 as moderate, and a score of ≥ 11 as severe
4. Severe all-cause diarrhoea: as for severe rotavirus diarrhoea
5. Emergency department visit: no definition
6. All-cause hospitalization admission: no definition
7. Serious adverse events: no definition
8. Rotavirus diarrhoea resulting in hospitalization
9. Rotavirus diarrhoea requiring medical attention (defined as “medical personnel con-
tact, advice, or visit; emergency room contact or visit; or admission”)
10. Reactogenicity
Outcomes to measure immunogenicity
11. Seroconversion: appearance of anti-rotavirus IgA antibody concentration ≥ 20 U/
mL in participants seronegative for rotavirus before vaccination (review includes data
from 1 to 2 months after dose 2)
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Immunization status Concomitant vaccines included 7 valent pneumococcal polysaccharide conjugate vac-
cine (Prevenar) and meningococcal group c conjugate vaccine (Meningitec); Hepatitis
B vaccine, diphtheria-tetanus-acellular pertussis, polio virus, and H. influenzae type b
vaccines were co-administered
Location 98 centres in six European countries (Czech Republic, Finland, France, Germany, Italy,
and Spain)
WHO mortality stratum A
Notes Date: 12 February 2007 to 08 August 2007
Source of funding: funded by GlaxoSmithKline Biologicals
Other: vaccination postponed if baby either had a temperature of ≥ 37.5 °C (axillary)
or of 38.0 °C (rectal) or had gastroenteritis within 7 days before planned vaccination
Study aim: “to assess the efficacy and safety of HRV [RV1] vaccine during the 3rd year
of age in subjects primed with a 2-dose schedule in study 102247, with the first dose
administered at the age of 6 to 14 weeks”
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “GSK Biologicals provided vaccine sup-
plies that were numbered with a computer-
generated randomization list”
Allocation concealment (selection bias) Low risk “randomization was done by a central In-
ternet randomization system. Infants were
randomly allocated in a 2/1 ratio two doses
of either RIX4414 or placebo”
Blinding (performance bias and detection
bias)
All outcomes
Low risk “Treatment allocation remained concealed
from investigators and the parents of par-
ticipating infants throughout the study”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Missing data imputed appropriately
Selective reporting (reporting bias) Unclear risk Data are provided only rotavirus gastroen-
teritis and for severe gastroenteritis, not for
all gastroenteritis episodes
Other bias Unclear risk No information
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Methods RCT
Length of follow-up: 2 months
Adverse event data collection methods: passive. “Parents/guardians of infants were
provided diary cards to record solicited general symptoms (loss of appetite, fussiness/
irritability, fever, diarrhoea, vomiting, and cough/runny nose) during a 15-day post-
vaccination follow-up period. The intensity of each adverse event was assessed using a
4-point scale where ”0“ refers to ‘absent’ and ”3“ refers to ‘severe”’
Participants Number: 250 enrolled and randomized; ATP safety cohort: 240; ATP immunogenicity
cohort: 237
Inclusion criteria: healthy infants aged 6 to 10 weeks with a birth weight > 2 kg
Exclusion criteria: any other investigational drug or vaccine 30 days prior to the ad-
ministration of the first dose of the study vaccine; a history of allergy; rotavirus gastroen-
teritis; infants with acute illness at the time of enrolment could not receive the vaccine
until the condition was resolved
Interventions 1. Liquid formulation of RIX4414*/(RV1), 1.5 mL
2. Placebo corresponding to liquid vaccine formulation
3. Lyophilized formulation RIX4414*/(RV1), 1 mL
4. Placebo corresponding to lyophilized vaccine formulation
* vaccine containing at least 106 median CCID50 of live attenuated RIX4414 human
rotavirus strain
Schedule: 2 oral doses at month 0 and 1 (minimum time interval between doses: 14
days)
Outcomes Clinical outcome measures (safety and efficacy)
1. Reactogenicity, occurrence of the symptom within the 15-day solicited follow-up
period after each dose (collected from GSK report)
2. Serious adverse events, occurrence throughout study period
3. * Rotavirus diarrhoea, stool samples collected during diarrhoea episodes tested for
rotavirus strains
4. * All-cause diarrhoea, up to 1 month post dose 2
5. Drop outs: up to 2 months after dose 2 (collected from GSK report)
6. All-cause death (collected from GSK report)
7. Adverse events resulting in discontinuation (collected from GSK report)
Outcomes to measure immunogenicity
8. Seroconversion, antirotavirus IgA antibody concentration > 20 U/mL, 1 month after
each dose (collected from GSK report)
9. Rotavirus vaccine virus shedding in stools, reported at peak (day 7 post dose 1)
* Outcome reported as proportion (P) with 95% CI. Events (n) and totals (N) were
estimated by using the value when two formulas for the standard error (SE) converged
Immunization status Routine childhood vaccinations were allowed according to local practice, but at least 14
days apart from each dose of study vaccine
Location Five centres in Finland
WHO mortality stratum A
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Notes Study known as RIX GSK[048] 2007-EU in previously published versions of this review
Date: August to November 2005
Source of funding: GlaxoSmithKline Biologicals
Study rationale: the immunogenicity, reactogenicity and safety of the RV1 liquid for-
mulation were compared with lyophilized formulation and placebo
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer generated “A standard SAS®
program was used for generating the ran-
domization list and a block randomization
was used in order to ensure that the balance
between the treatment arms were main-
tained”
Allocation concealment (selection bias) Unclear risk Unique treatment number “A unique
treatment number identified the vaccine/
placebo doses that were to be administered
to the infants”. No details reported how
allocation of treatment number was con-
cealed
Blinding (performance bias and detection
bias)
All outcomes
Low risk Participants and key personnel were
blinded as far as technically possible. “The
study was double blind with respect to each
of the vaccine formulation and their respec-
tive placebo; however, blinding between
the two vaccine formulations was not tech-
nically possible because of the difference in
appearance of the vaccines”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Attrition balanced across study groupswith
reasons for drop-out/exclusion reported
Selective reporting (reporting bias) Low risk All pre-published outcomes reported
Other bias Unclear risk Funded by GlaxoSmithKline Biologicals
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Methods RCT
Length of follow-up: 7 days following each vaccination; 3 to 5 weeks after second
vaccination
Adverse event data collection methods: unclear
Participants Number: 117 enrolled; 111 evaluable
Age range: 3 to 6 months (beginning); 3 to 6 months (end)
Inclusion criteria: not specified
Exclusion criteria: not specified
Interventions RV1
1. RIX4414 (RV1)
1.1. 1 x 105 dose; 41 participants (randomized)
1.2. 1 x 106 dose; 39 participants (randomized)
2. Placebo: 37 participants
Schedule: 2 doses given at a 6 to 10 week interval
Outcomes Clinical outcome measures (safety and efficacy)
1. Reactogenicity*: symptoms of rotavirus illness, including fever, diarrhoea, and vom-
iting; measured for 7 days after each dose
*Although mentioned in the methods, no results are presented
Outcomes to measure immunogenicity
2. Vaccine take: faecal shedding of rotavirus antigen (review includes data from after
either dose 1 or 2)
3. Seroconversion: serum rotavirus IgA responses (increases in level of serum rotavirus
IgA ≥ 4 fold) (review includes data from after either dose 1 or 2)
Immunization status Not specified
Location Cincinnati and Baltimore, USA
WHO mortality stratum A
Notes Date: July to December 1996
Source of funding: “Avant Immunotherapeutics, to which the 89-12 vaccine candidate
was licensed and which sublicensed its product to GlaxoSmithKline (which developed
Rotarix from 89-12).”
89-12 was the precursor to RV1
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No information
Allocation concealment (selection bias) Unclear risk “double-blinded, placebo-controlled study
designed”
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RV1 Ward 2006-USA (Continued)
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk “double-blinded, placebo-controlled study
designed”
Incomplete outcome data (attrition bias)
All outcomes
Low risk No impact on intervention effect estimate;
“Of the 80 vaccine recipients in this trial,
2 had evidence of natural rotavirus infec-
tion before administration of the first dose,
determined on the basis of rotavirus IgA in
their serum. These, along with the 3 who
received only 1 dose of vaccine, were elim-
inated from further analyses”
Selective reporting (reporting bias) Unclear risk No information
Other bias Unclear risk No information
RV1 Zaman 2009-BGD
Methods RCT
Length of follow-up: 31 days after each vaccination (total of 14 weeks)
Adverse event data collection methods: “active surveillance for reactogenicity and
safety was conducted via daily home visits by study personnel for 8 days after each dose
of vaccine or placebo dose and bi-weekly home visits thereafter until one month after
last dose” (active method); “During every episode, parents were asked to record in a
daily diary card the number of looser than normal stools, axillary or rectal temperature,
number of vomiting episodes, any rehydration or other medication administered, and
any medical attention (defined as medical personnel contact, advice, or visit; emergency
room contact or visit; or admission)” (passive method); serious adverse events were
reviewed periodically by an independent committee
Participants Number: 300 enrolled; 290 evaluable
Age range: 1 to 3 months (beginning); 3 to 6 months (end)
Inclusion criteria: healthy infants aged 6 to 7 weeks
Exclusion criteria: acute disease at the time of enrolment;malnourished children; history
of chronic administration of immunosuppressants since birth; received any vaccines or
treatments prohibited by the protocol; or had any disorders or illnesses excluded by the
protocol
Interventions RV1
1. RIX4414 (RV1)
1.1. 1 x 106.5 dose + OPV; 100 participants (randomized)
1.2. 1 x 106.5 dose; 100 participants (randomized)
2. Placebo:
2.1. Placebo + OPV; 50 participants (randomized)
2.2. Placebo; 50 participants (randomized)
Schedule: 2 doses given at a 6 to 12 week interval
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Outcomes Clinical outcome measures (safety and efficacy)
1. Reactogenicity: for each type of solicited symptom, occurrence of the symptomwithin
the 8 day (Day 0 to 7) solicited follow-up period after each dose; occurrence of unsolicited
adverse events within 31 days (Day 0 to 30) after each dose, according to MedDRA
classification; measured up to 31 days after vaccine/placebo
2. Serious adverse events: occurrence throughout entire study period (up to 105 days
after vaccine/placebo)
3. Drop outs: measured up to 105 days after vaccine/placebo
4. Rotavirus diarrhoea: presence of rotavirus in gastroenteritis episode stools collected
from dose 1 of vaccine/placebo up to 2 months after dose 2; measured up to 105 days
after vaccine/placebo
5. All-cause death
6. Adverse events resulting in discontinuation
Outcomes to measure immunogenicity
7. Viral shedding: % participants with rotavirus antigen in stool samples collected at pre-
determined time points (ATP cohort for immunogenicity, stool analysis subset) (review
includes data from combined time points)
8. Seroconversion: appearance of anti-rotavirus immunoglobulin A antibody concen-
tration ≥ 20 U/mL in participants who were negative for rotavirus before vaccination
(review includes data from 1 month after dose 2)
Immunization status All children in the study received the standard EPI vaccines starting at 6 weeks of age,
including oral polio vaccine for one RV1 vaccine arm and one placebo arm
Location Single site in urban Dhaka at Mirpur, Bangladesh
WHO mortality stratum D
Notes Date: June 2005 to January 2006
Source of funding: funded by GlaxoSmithKline Biologicals and the Rotavirus Vaccine
Program (RVP) at the Program for Appropriate Technology in Health (PATH)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No information
Allocation concealment (selection bias) Unclear risk “double-blinded, placebo-controlled study
designed”
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk “double-blinded, placebo-controlled study
designed”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Missing data imputed appropriately
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Selective reporting (reporting bias) Unclear risk No information
Other bias Unclear risk No information
RV5 Armah 2010-AF
Methods RCT
Length of follow-up: up to 43 days for safety outcomes, and up to 21 months for
efficacy outcomes
Adverse event data collection methods: “Study physicians reported and documented
all serious adverse events occurring within 14 days of any dose and deaths or vaccine-
related serious adverse events occurring at any time during the study”
A subset had active surveillance: “A subset of 300 participants enrolled in Kenya was
followed up for 42 days for all adverse events, including vomiting, diarrhoea, and high
temperature. Home visits were attempted on days 3, 5, 7, 14, 21, and 42 after all
vaccinations”
Participants Number: 5560 enrolled; 5468 randomized, 5225 evaluable
Age range: 1 to 3 months (beginning); 3 to 6 months (end)
Inclusion criteria: healthy infants aged 4 to 12 weeks; “no symptoms of active gastroin-
testinal disease and could be adequately followed up for safety by home visit or telephone
contact (1 week and 2 weeks after any dose of vaccine or placebo)”; breastfeeding was
not restricted; no enrolment restrictions based on HIV status - infants in Kenya were
offered routine HIV testing, and a subset were followed up for safety
All children exposed to or infected with HIV were referred for appropriate HIV care
and treatment; voluntary counselling and testing were also offered to mothers of infants
exposed to HIV
Exclusion criteria: see above
Special group:HIV-infected participants
Interventions RV5
1. WC3 (RV5): 2 mL (every dose had an estimated potency of 107 infectious units per
reassortant rotavirus); 3 doses given 4 weeks apart; 2733 participants (randomized)
2. Placebo: 2 mL; 3 doses given 4 weeks apart; 2735 participants (randomized)
Schedule: 3 doses given at a 4-week interval
Outcomes Clinical outcome measures (safety and efficacy)
1. Serious adverse events (including intussusception)
2. Death due to serious adverse events
3. Rotavirus diarrhoea: case definition for rotavirus gastroenteritis required participants
to meet both of the following criteria: (1) ≥ 3 watery or looser-than-normal stools
within a 24-h period and/or forceful vomiting, and (2) rotavirus detected by enzyme
immunoassay (EIA) in a stool specimen taken within 14 days after the onset of symptoms
4. Severe rotavirus diarrhoea: an established clinical scoring system based on the intensity
and duration of fever, vomiting, diarrhoea, and changes in behaviour used to categorize
episodes of rotavirus gastroenteritis on a 20-point severity scale; scores > 11 were con-
sidered to indicate severe disease; measured up to 2 years follow-up
5. All-cause diarrhoea
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RV5 Armah 2010-AF (Continued)
6. All-cause diarrhoea - severe
7. Reactogenicity*: symptoms of rotavirus illness, including fever, diarrhoea, and vomit-
ing; measured for 7 days after each dose (review includes data from for the end of follow-
up)
*Data on fever and vomiting are provided only on figure 2 and data could not be extracted
reliably
Outcomes to measure immunogenicity
8. Seroconversion: serum rotavirus IgA responses (increases in level of serum rotavirus
IgA ≥ 4 fold) (review includes data from after dose 2)
Immunization status All children in the study received the standard EPI vaccines (including oral poliovirus
vaccine) starting at 6 weeks of age
Location Sites in rural Kassena-Nankana district (Ghana), rural Karemo division, Siaya district
(Kenya), and urban area of Bamako (Mali)
WHO mortality strata D, E
Notes This trial was conducted in Ghana, Kenya andMali, data reported separately per country
can be found under RV5 Armah 2010-GHA; RV5 Armah 2010-KEN and RV5 Armah
2010-MLI.
Date: 28 April 2007 to 31 March 2009
Source of funding: funded by PATH (GAVI Alliance grant) and Merck
Registration number: NCT00362648
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Unique allocation numbers were desig-
nated atMerck as pentavalent rotavirus vac-
cine or placebo with computer generated
block randomization, with block sizes of
six”
Allocation concealment (selection bias) Low risk “Vaccine and placebo packages were then
labelled with allocation numbers and pro-
vided to sites in identical presentations.
Sites were instructed to assign allocation
numbers to participants in sequential order
as they were enrolled”
Blinding (performance bias and detection
bias)
All outcomes
Low risk Participants and staff: “Participants were
enrolled by study staff, who remained
masked to treatment assignment through-
out the trial”
Researchers: “The statistician from Merck
who analysed the data and the Merck
and PATH protocol teams were masked to
treatment assignment”
116Vaccines for preventing rotavirus diarrhoea: vaccines in use (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
RV5 Armah 2010-AF (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Missing data balanced across groups
Selective reporting (reporting bias) Low risk Pre-specified outcomes reported
Other bias Low risk Funded by PATH (GAVI Alliance grant)
andMerck. Protocol published a prior with
ClinicalTrials.gov, number
NCT00362648. “The study was designed
by scientists from Merck, with substantial
input from PATH staff and site investiga-
tors. Merck had direct oversight or partic-
ipation in every stage of the study. Merck
also participated in pharmacovigilance, or-
ganised and led the data and safety mon-
itoring board meetings, and did the data
analysis. Staff from PATH independently
monitored study execution at sites and par-
ticipated in pharmacovigilance, data anal-
ysis, and data and safety monitoring board
meetings. All authors had full access to the
data, and the corresponding author had fi-
nal responsibility for the decision to submit
for publication”
RV5 Armah 2010-GHA
Methods RCT
Length of follow-up: up to 43 days for safety outcomes, and up to 21 months for
efficacy outcomes
Adverse event data collection methods: “Study physicians reported and documented
all serious adverse events occurring within 14 days of any dose and deaths or vaccine-
related serious adverse events occurring at any time during the study”
Participants Number: 2200 randomized
Age range: 1 to 3 months (beginning); 3 to 6 months (end)
Inclusion criteria: healthy infants aged 4 to 12 weeks; “no symptoms of active gastroin-
testinal disease and could be adequately followed up for safety by home visit or telephone
contact (1 week and 2 weeks after any dose of vaccine or placebo)”; breastfeeding was
not restricted; no enrolment restrictions based on HIV status
All children exposed to or infected with HIV were referred for appropriate HIV care
and treatment; voluntary counselling and testing were also offered to mothers of infants
exposed to HIV
Exclusion criteria: see above
Interventions RV5
1. WC3 (RV5): 2 mL (every dose had an estimated potency of 107 infectious units per
reassortant rotavirus); 3 doses given 4 weeks apart; 1098 participants (randomized)
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RV5 Armah 2010-GHA (Continued)
2. Placebo: 2 mL; 3 doses given 4 weeks apart; 1102 participants (randomized)
Schedule: 3 doses given at a 4-week interval
Outcomes Clinical outcome measures (safety and efficacy)
1. Serious adverse events (including intussusception)
2. Death due to serious adverse events
3. Rotavirus diarrhoea: case definition for rotavirus gastroenteritis required participants
to meet both of the following criteria: (1)≥ 3 watery or looser-than-normal stools within
a 24-h period and/or forceful vomiting, and (2) rotavirus detected by EIA in a stool
specimen taken within 14 days after the onset of symptoms
4. Severe rotavirus diarrhoea: an established clinical scoring system based on the intensity
and duration of fever, vomiting, diarrhoea, and changes in behaviour used to categorize
episodes of rotavirus gastroenteritis on a 20-point severity scale; scores > 11 were con-
sidered to indicate severe disease; measured up to 2 years follow-up
5. All-cause diarrhoea
6. All-cause diarrhoea - severe
7. Reactogenicity*: symptoms of rotavirus illness, including fever, diarrhoea, and vomit-
ing; measured for 7 days after each dose [review includes data from for the end of follow-
up]
*Data on fever and vomiting are provided only on figure 2 and data could not be extracted
reliably
Outcomes to measure immunogenicity
8. Seroconversion: serum rotavirus IgA responses (increases in level of serum rotavirus
IgA ≥ 4 fold) (review includes data from after dose 2)
Immunization status All children in the study received the standard EPI vaccines (including oral poliovirus
vaccine) starting at 6 weeks of age
Location Sites in rural Kassena-Nankana district, Ghana
WHO mortality stratum D
Notes This trial was conducted in Ghana, Kenya and Mali, this part presents data for the
Ghana cohort, data reported separately for the other countries can be found under RV5
Armah 2010-KEN and RV5 Armah 2010-MLI data reported for all countries under
RV5 Armah 2010-AF
Date: 28 April 2007 to 31 March 2009
Source of funding: funded by PATH (GAVI Alliance grant) and Merck
Registration number: NCT00362648
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Unique allocation numbers were desig-
nated atMerck as pentavalent rotavirus vac-
cine or placebo with computer generated
block randomization, with block sizes of
six”
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Allocation concealment (selection bias) Low risk “Vaccine and placebo packages were then
labelled with allocation numbers and pro-
vided to sites in identical presentations.
Sites were instructed to assign allocation
numbers to participants in sequential order
as they were enrolled”
Blinding (performance bias and detection
bias)
All outcomes
Low risk Participants and staff: “Participants were
enrolled by study staff, who remained
masked to treatment assignment through-
out the trial”
Researchers: “The statistician from Merck
who analysed the data and the Merck
and PATH protocol teams were masked to
treatment assignment”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Missing data balanced across groups
Selective reporting (reporting bias) Low risk Pre-specified outcomes reported
Other bias Low risk Funded by PATH (GAVI Alliance grant)
andMerck. Protocol published a prior with
ClinicalTrials.gov, number
NCT00362648. “The study was designed
by scientists from Merck, with substantial
input from PATH staff and site investiga-
tors. Merck had direct oversight or partic-
ipation in every stage of the study. Merck
also participated in pharmacovigilance, or-
ganised and led the data and safety mon-
itoring board meetings, and did the data
analysis. Staff from PATH independently
monitored study execution at sites and par-
ticipated in pharmacovigilance, data anal-
ysis, and data and safety monitoring board
meetings. All authors had full access to the
data, and the corresponding author had fi-
nal responsibility for the decision to submit
for publication”
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RV5 Armah 2010-KEN
Methods RCT
Length of follow-up: up to 43 days for safety outcomes, and up to 21 months for
efficacy outcomes
Adverse event data collection methods: “Study physicians reported and documented
all serious adverse events occurring within 14 days of any dose and deaths or vaccine-
related serious adverse events occurring at any time during the study”
A subset had active surveillance: “A subset of 300 participants enrolled in Kenya was
followed up for 42 days for all adverse events, including vomiting, diarrhoea, and high
temperature. Home visits were attempted on days 3, 5, 7, 14, 21, and 42 after all
vaccinations”
Participants Number: 5560 enrolled; 5468 randomized, 5225 evaluable
Age range: 1 to 3 months (beginning); 3 to 6 months (end)
Inclusion criteria: healthy infants aged 4 to 12 weeks; “no symptoms of active gastroin-
testinal disease and could be adequately followed up for safety by home visit or telephone
contact (1 week and 2 weeks after any dose of vaccine or placebo)”; breastfeeding was
not restricted; no enrolment restrictions based on HIV status - infants in Kenya were
offered routine HIV testing, and a subset were followed up for safety
All children exposed to or infected with HIV were referred for appropriate HIV care
and treatment; voluntary counselling and testing were also offered to mothers of infants
exposed to HIV
Exclusion criteria: see above
Special group:HIV-infected participants
Interventions RV5
1. WC3 (RV5): 2 mL (every dose had an estimated potency of 107 infectious units per
reassortant rotavirus); 3 doses given 4 weeks apart; 656 participants (randomized)
2. Placebo: 2 mL; 3 doses given 4 weeks apart; 652 participants (randomized)
Schedule: 3 doses given at a 4 week interval
Outcomes Clinical outcome measures (safety and efficacy)
1. Serious adverse events (including intussusception)
2. Death due to serious adverse events
3. Rotavirus diarrhoea: case definition for rotavirus gastroenteritis required participants
to meet both of the following criteria: (1)≥ 3 watery or looser-than-normal stools within
a 24-h period and/or forceful vomiting, and (2) rotavirus detected by EIA in a stool
specimen taken within 14 days after the onset of symptoms
4. Severe rotavirus diarrhoea: an established clinical scoring system based on the intensity
and duration of fever, vomiting, diarrhoea, and changes in behaviour used to categorize
episodes of rotavirus gastroenteritis on a 20-point severity scale; scores > 11 were con-
sidered to indicate severe disease; measured up to 2 years follow-up
5. All-cause diarrhoea
6. All-cause diarrhoea - severe
7. Reactogenicity*: symptoms of rotavirus illness, including fever, diarrhoea, and vomit-
ing; measured for 7 days after each dose [review includes data from for the end of follow-
up]
*Data on fever and vomiting are provided only on figure 2 and data could not be extracted
reliably
Outcomes to measure immunogenicity
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8. Seroconversion: serum rotavirus IgA responses (increases in level of serum rotavirus
IgA ≥ 4 fold) (review includes data from after dose 2)
Immunization status All children in the study received the standard EPI vaccines (including oral poliovirus
vaccine) starting at 6 weeks of age
Location Sites in rural Karemo division, Siaya district, Kenya
WHO mortality stratum E
Notes This trial was conducted in Ghana, Kenya and Mali, this part presents data for the
Kenya cohort, data reported separately for the other countries can be found under RV5
Armah 2010-GHA and RV5 Armah 2010-MLI data reported for all countries under
RV5 Armah 2010-AF
Date: 28 April 2007 to 31 March 2009
Source of funding: funded by PATH (GAVI Alliance grant) and Merck
Registration number: NCT00362648
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Unique allocation numbers were desig-
nated atMerck as pentavalent rotavirus vac-
cine or placebo with computer generated
block randomization, with block sizes of
six”
Allocation concealment (selection bias) Low risk “Vaccine and placebo packages were then
labelled with allocation numbers and pro-
vided to sites in identical presentations.
Sites were instructed to assign allocation
numbers to participants in sequential order
as they were enrolled”
Blinding (performance bias and detection
bias)
All outcomes
Low risk Participants and staff: “Participants were
enrolled by study staff, who remained
masked to treatment assignment through-
out the trial”
Researchers: “The statistician from Merck
who analysed the data and the Merck
and PATH protocol teams were masked to
treatment assignment”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Missing data balanced across groups
Selective reporting (reporting bias) Low risk Pre-specified outcomes reported
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Other bias Low risk Funded by PATH (GAVI Alliance grant)
andMerck. Protocol published a prior with
ClinicalTrials.gov, number
NCT00362648. “The study was designed
by scientists from Merck, with substantial
input from PATH staff and site investiga-
tors. Merck had direct oversight or partic-
ipation in every stage of the study. Merck
also participated in pharmacovigilance, or-
ganised and led the data and safety mon-
itoring board meetings, and did the data
analysis. Staff from PATH independently
monitored study execution at sites and par-
ticipated in pharmacovigilance, data anal-
ysis, and data and safety monitoring board
meetings. All authors had full access to the
data, and the corresponding author had fi-
nal responsibility for the decision to submit
for publication”
RV5 Armah 2010-MLI
Methods RCT
Length of follow-up: up to 43 days for safety outcomes, and up to 21 months for
efficacy outcomes
Adverse event data collection methods: “Study physicians reported and documented
all serious adverse events occurring within 14 days of any dose and deaths or vaccine-
related serious adverse events occurring at any time during the study”
Participants Number: 5560 enrolled; 5468 randomized, 5225 evaluable
Age range: 1 to 3 months (beginning); 3 to 6 months (end)
Inclusion criteria: healthy infants aged 4 to 12 weeks; “no symptoms of active gastroin-
testinal disease and could be adequately followed up for safety by home visit or telephone
contact (1 week and 2 weeks after any dose of vaccine or placebo)”; breastfeeding was
not restricted; no enrolment restrictions based on HIV status
All children exposed to or infected with HIV were referred for appropriate HIV care
and treatment; voluntary counselling and testing were also offered to mothers of infants
exposed to HIV
Exclusion criteria: see above
Interventions RV5
1. WC3 (RV5): 2 mL (every dose had an estimated potency of 107 infectious units per
reassortant rotavirus); 3 doses given 4 weeks apart; 979 participants (randomized)
2. Placebo: 2 mL; 3 doses given 4 weeks apart; 981 participants (randomized)
Schedule: 3 doses given at a 4 week interval
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Outcomes Clinical outcome measures (safety and efficacy)
1. Serious adverse events (including intussusception)
2. Death due to serious adverse events
3. Rotavirus diarrhoea: case definition for rotavirus gastroenteritis required participants
to meet both of the following criteria: (1)≥ 3 watery or looser-than-normal stools within
a 24-h period and/or forceful vomiting, and (2) rotavirus detected by EIA in a stool
specimen taken within 14 days after the onset of symptoms
4. Severe rotavirus diarrhoea: an established clinical scoring system based on the intensity
and duration of fever, vomiting, diarrhoea, and changes in behaviour used to categorize
episodes of rotavirus gastroenteritis on a 20-point severity scale; scores > 11 were con-
sidered to indicate severe disease; measured up to 2 years follow-up
5. All-cause diarrhoea
6. All-cause diarrhoea - severe
7. Reactogenicity *: symptoms of rotavirus illness, including fever, diarrhoea, and vomit-
ing; measured for 7 days after each dose [review includes data from for the end of follow-
up]
* Data on fever and vomiting are provided only on figure 2 and data could not be extracted
reliably
Outcomes to measure immunogenicity
8. Seroconversion: serum rotavirus IgA responses (increases in level of serum rotavirus
IgA ≥ 4 fold) (review includes data from after dose 2)
Immunization status All children in the study received the standard EPI vaccines (including oral poliovirus
vaccine) starting at 6 weeks of age
Location Sites in urban area of Bamako, Mali
WHO mortality stratum D
Notes This trial was conducted in Ghana, Kenya and Mali, this part presents data for the Mali
cohort
Date: 28 April 2007 to 31 March 2009
Source of funding: funded by PATH (GAVI Alliance grant) and Merck
Registration number: NCT00362648
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Unique allocation numbers were desig-
nated atMerck as pentavalent rotavirus vac-
cine or placebo with computer generated
block randomization, with block sizes of
six”
Allocation concealment (selection bias) Low risk “Vaccine and placebo packages were then
labelled with allocation numbers and pro-
vided to sites in identical presentations.
Sites were instructed to assign allocation
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numbers to participants in sequential order
as they were enrolled”
Blinding (performance bias and detection
bias)
All outcomes
Low risk Participants and staff: “Participants were
enrolled by study staff, who remained
masked to treatment assignment through-
out the trial”
Researchers: “The statistician from Merck
who analysed the data and the Merck
and PATH protocol teams were masked to
treatment assignment”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Missing data balanced across groups
Selective reporting (reporting bias) Low risk
Other bias Low risk Funded by PATH (GAVI Alliance grant)
andMerck. Protocol published a prior with
ClinicalTrials.gov, number
NCT00362648. “The study was designed
by scientists from Merck, with substantial
input from PATH staff and site investiga-
tors. Merck had direct oversight or partic-
ipation in every stage of the study. Merck
also participated in pharmacovigilance, or-
ganised and led the data and safety mon-
itoring board meetings, and did the data
analysis. Staff from PATH independently
monitored study execution at sites and par-
ticipated in pharmacovigilance, data anal-
ysis, and data and safety monitoring board
meetings. All authors had full access to the
data, and the corresponding author had fi-
nal responsibility for the decision to submit
for publication”
RV5 Block 2007-EU/USA
Methods RCT
Length of follow-up: up to 42 days for safety/immunogenicity; up to 1 year for efficacy
Adverse event data collection methods: parents or guardians contacted by the study site
on day 7, day 14, and day 42 after each vaccination and asked about serious adverse events
(active method); parents or guardians were provided diary cards and were instructed to
record daily temperatures for the infant for 7 days after each vaccination (passive method)
Participants Number: 1312 enrolled; 1200 evaluable
Age range: 1 to 3 months (beginning); 3 to 6 months (end)
124Vaccines for preventing rotavirus diarrhoea: vaccines in use (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
RV5 Block 2007-EU/USA (Continued)
Inclusion criteria: healthy infants, 6 through 12 weeks of age, who had no known
history of congenital abdominal disorders, intussusception, or abdominal surgery; no
known or suspected impairment of immunological function; no known hypersensitivity
to any component of the rotavirus vaccine; no prior receipt of any rotavirus vaccine; no
fever, with a rectal temperature ≥ 38.1 °C (≥ 100.5 °F) at the time of immunization;
no history of known prior rotavirus disease, chronic diarrhoea, or failure to thrive; no
clinical evidence of active gastrointestinal illness; no receipt of intramuscular, oral, or
intravenous corticosteroid treatment within the 2 weeks before vaccination; did not
reside in a household with an immunocompromised person; no prior receipt of a blood
transfusion or blood products, including immunoglobulins; no receipt of oral poliovirus
vaccine during the course of the study or within 42 days before first dose of vaccine/
placebo; any infant who could not be adequately followed for safety by telephone or home
visit; and no condition, which, in the opinion of the investigator, may have interfered
with the evaluation of the study objectives
Exclusion criteria: see above
Interventions RV5
1. WC3 (RV5): 1.1 x 107 PFU; 651 participants (randomized)
2. Placebo: 661 participants (randomized)
Schedule: 3 doses given 4 to 10 weeks apart
Outcomes Clinical outcome measures (safety and efficacy)
1. Serious adverse events: potential cases of intussusception were adjudicated by an
independent blinded committee; all study personnel remained blinded to the treatment
arm and adjudication results of the potential intussusception cases; data on cases of
intussusception, deaths, or other serious adverse events determined to be vaccine-related
by the investigator were collected throughout the trial; measured up to 42 days, and up
to 1 year (for vaccine-related serious adverse events)
2. Reactogenicity: no definition; measured up to 42 days
3. Drop outs: no definition: measured up to 1 year
4. Rotavirus diarrhoea: case of rotavirus gastroenteritis defined as meeting both of the
following criteria: (a) > 3 watery or looser than normal stools within a 24-h period and/
or forceful vomiting; and (b) rotavirus antigen detection by EIA in the stool sample.
Primary analysis of efficacy included only cases caused by naturally occurring rotavirus
of serotypes G1, G2, G3, or G4 as confirmed by reverse-transcriptase polymerase chain
reaction (RT-PCR) occurring at least 14 days after the third dose
5. Severe rotavirus diarrhoea: each episode graded on a 24-point scale, where a score < 8
designated as mild, > 8 as moderate-and-severe, and > 16 as a severe disease
6. All-cause death
7. Adverse events resulting in discontinuation
Outcomes to measure immunogenicity
8. Seroconversion: pre-vaccination and post-vaccination sera analysed for serotype-spe-
cific rotavirus neutralizing antibody and for serum anti-rotavirus immunoglobulin A
(IgA) (review includes data from after dose 3)
Immunization status Use of oral poliovirus vaccine during the course of the study or within 42 days before
first dose of vaccine/placebo was an exclusion criterion; administration of other vaccines
permitted
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Location 30 sites; 27 in USA, and 3 in Finland
WHO mortality stratum A
Notes Date: 24 September 2002 (first patient in) to 11 February 2004
Source of funding: Merck & Co., Inc.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Enrolled infants were randomly assigned
1:1 by using computer-generated alloca-
tion schedules to receive either vaccine or
visibly indistinguishable placebo in a su-
crose citrate buffer administered orally as
three 2-mL doses 4 to 10 weeks apart”
Allocation concealment (selection bias) Low risk Sequential identical containers (see quote
above)
Blinding (performance bias and detection
bias)
All outcomes
Low risk “This randomized, clinical trial blinded to
investigator, parent or guardian, and spon-
sor”
“The placebo was identical to the vaccine
except that it did not contain the rotavirus
reassortants or trace trypsin”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Missing data balanced across groups
Selective reporting (reporting bias) High risk Key expected outcome (episodes of gas-
troenteritis) not included
Other bias Unclear risk Relevant information needed for assess-
ment not provided
RV5 Ciarlet 2009-EU
Methods RCT
Length of follow-up: up to 42 days after last dose
Adverse event data collection methods: see outcome measures; passive method used
for reactogenicity, and active method used for serious adverse events
Participants Number: 403 enrolled; 403 evaluable
Age range: 1 to 3 months (beginning); 3 to 6 months (end)
Inclusion criteria: healthy infants, aged 6 to 12 weeks; mothers negative for hepatitis B
surface antigen; no known history of congenital abdominal disorders; intussusception, or
abdominal surgery; no known or suspected impairment of immunological function; no
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history of seizure with or without fever; no known hypersensitivity to any component of
rotavirus vaccine or INFANRIX hexa; no prior receipt of any rotavirus, DTaP, DTP, H.
influenzae type b, Hepatitis B, injectable poliovirus vaccine, or oral polio vaccine during
the course of the study, within 42 days before first dose of RV5 or before final blood
draw (42 days after dose 3); no fever, with a rectal temperature < 38.1 °C (< 100.5 °F)
at the time of immunization; no history of known rotavirus disease, chronic diarrhoea,
or failure to thrive; no clinical evidence of active gastrointestinal illness; no prior receipt
of intramuscular, oral, or intravenous corticosteroids treatment within 2 weeks before
vaccination; did not reside in a household with an immunocompromised person; no
receipt of a blood transfusion or blood products, including immunoglobulin; did not
participate in another clinical study within 42 days before or during current study; could
be adequately followed for safety
Exclusion criteria: as above
Interventions RV5
1. WC3 (RV5) plus Infanrix hexa: RV5 (2 mL; 3 doses given 4 to 6 weeks apart); 201
participants (randomized)
2. Placebo plus Infanrix hexa: placebo (2 mL; 3 doses given 4 to 6 weeks apart); 202
participants (randomized)
Infanrix hexa: comes in 2 parts; first part is a white, milky liquid (0.5 mL) in a pre-
filled syringe that consists of the combined diphtheria, tetanus, pertussis, hepatitis b,
and inactivated poliovirus vaccine; second part is the H. influenzae type b vaccine and
is a white pellet in a separate glass vial; both parts mixed together before being injected
intramuscularly
Outcomes Clinical outcome measures (safety and efficacy)
1. Reactogenicity: in both groups, at each study visit, parents/legal guardians received
Vaccination Report Cards (VRCs) which they completed for 7 days with information
regarding fever, diarrhoea, and vomiting starting from the day of office visit and returned
completed VRCs to the study site at the next visit
2. Serious adverse events: parents/legal guardians of all participants were contacted by
telephone or home visit on approximately day 14 after each office visit in either group
for safety follow-up and asked about all serious adverse experiences; measured up to 42
days
3. All-cause death
4. Adverse events resulting in discontinuation
Outcomes to measure immunogenicity
None specific to review
Immunization status Hepatitis B vaccine, diphtheria-tetanus-acellular pertussis, polio virus, andH. influenzae
type b co-administered
Location 26 study sites in Austria, Belgium, and Germany
WHO mortality stratum A
Notes Date: 22 February 2006 to 13 November 2006
Source of funding: Merck & Co., Inc.
Other: only data about serious adverse events and adverse events leading to discontinu-
ation are provided
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Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer generated randomized 1:1 to
receive hexavalent vaccine concomitantly
with either RV5 (RotaTeq) or placebo
(Merck 2012)
Allocation concealment (selection bias) Low risk Allocation numbers were generated for par-
ticipants, investigators, adults, and par-
ents/guardians of children were blinded
throughout trial (Merck 2012)
Blinding (performance bias and detection
bias)
All outcomes
Low risk RV5 was visibly indistinguishable from
placebo, investigators, parents/guardians
and study personnel (internal and exter-
nal) were blinded throughout trial (Merck
2012)
Incomplete outcome data (attrition bias)
All outcomes
Low risk “In
both treatment groups (RV5+Hexavalent
and Placebo+Hexavalent), 84% of the in-
fants reported 1 or more adverse events
within 14 days after vaccination. One sub-
ject discontinued in the concomitant-use
group because of abdominal pain (consid-
ered non-serious)” (Merck 2012)
Selective reporting (reporting bias) High risk Not all pre-specified outcomes reported
Other bias Unclear risk No details
RV5 Clark 2003-USA
Methods RCT
Length of follow-up: up to 1 year
Adverse event data collection methods: parents/guardians recorded temperatures 4 to
6 h after each dose and then daily thereafter for 7 days and the number of episodes of
vomiting and diarrhoea daily for 7 days (passive method); also recorded any behavioral
or systemic adverse experience on a vaccination report card and was asked to report any
serious adverse experience immediately to the study site; telephone call made to each
parent/guardian 14 days after each dose to verify that no serious adverse experiences had
occurred (active)
Participants Number: 731 enrolled; 681 evaluable
Age range: 1 to 3 months (beginning); 3 to 6 months (end)
Special groups: breast fed; infants in the vaccine control group (Group 1) received
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the reassortants as administered in previous studies within 30 min of feeding Enfamil
formula (30 ml) or Mylanta Double Strength (0.5 ml/kg). Infants in a corresponding
placebo group (Group 2) were pre-fed as in Group 1
Inclusion criteria: healthy infants 2 to 4 months of age
Exclusion criteria: known hypersensitivity to any component of the rotavirus vaccine;
known or suspected immunologic impairment; prior administration of any rotavirus
vaccine; fever at the time of vaccination; history of chronic diarrhoea; failure to thrive or
gastrointestinal illness; recent receipt of oral polio vaccine or blood products; residence
in the household with an immunocompromised person; and failure to fast for 1 h before
vaccination
Interventions RV5
1. WC3 (RV5): 107 PFU; 581 participants (randomized)
2. Placebo: 581 participants (randomized)
Schedule: 3 doses given 42 to 56 days apart
Outcomes Clinical outcome measures (safety and efficacy)
1. Reactogenicity: parents/guardians recorded temperatures 4 to 6 h after each dose and
then daily thereafter for 7 days and the number of episodes of vomiting and diarrhoea
daily for 7 days; fever defined as 38.1°C (rectal) or 37.5°C (oral, otic, or axillary);
measured up to 42 days after vaccine/placebo
2. Rotavirus diarrhoea: case of rotavirus gastroenteritis defined as ≥ 3 watery or looser
than normal stools within a 24-h period and/or forceful vomiting occurring at least 14
days after the third dose of vaccine/placebo and detection by ELISA of wild-type G1
and/or G2 rotavirus in a stool specimen collected within 14 days of symptom onset;
measured up to 1 year
3. Severe rotavirus diarrhoea: clinical scoring system used to assess severity of illness for
each episode of rotavirus acute gastroenteritis; measured up to 1 year
4. Serious adverse events: defined as: death; life-threatening events; experiences that
resulted in hospitalization, persistent disability, or that prolonged a hospitalization; and
other importantmedical events. Data on deaths or any serious adverse experiences judged
to be vaccine related were collected for the duration of the study; measured up to 1 year
5. Intussusception, data from correspondence with Merck (Merck 2012)
6. Drop outs
Outcomes to measure immunogenicity
7. Viral shedding: at least a 3-fold rise in serum-neutralizing antibody to total stool IgA
(review includes data from after dose 3)
8. Seroconversion: at least a 3-fold rise in serum-neutralizing antibody to serum IgA
(review includes data from after dose 3)
Immunization status Children that had recently received oral polio vaccine were excluded from the study
Location 19 centres in the USA
WHO mortality stratum A
Notes Date: September 1997 through September 1998
Source of funding: Merck & Co., Inc.
Other: active surveillance for cases of rotavirus gastroenteritis at each study site began
when the local laboratory confirmed at least 3 cases of rotavirus gastroenteritis or on 31
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January 1998, whichever came first
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No details; “Children who met all eligibil-
ity criteria were randomized to one of eight
treatment groups”
Allocation concealment (selection bias) Unclear risk No details
Blinding (performance bias and detection
bias)
All outcomes
Low risk Participants and key personnel; “Parents of
participating infants and study personnel
were blinded to receipt of vaccine/placebo
but not to the volume administered or to
the prefeeding requirement”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Insufficient reporting of attrition/exclu-
sions
Selective reporting (reporting bias) High risk Not all pre-specified outcomes reported;
“Because there were relatively few con-
firmed cases of RV [rotavirus] caused by
serotypes G1 and G2, the evidence is in-
sufficient to declare that the efficacy of any
buffered formulation is > 0.0%”
Other bias High risk Poor reporting of efficacy data
RV5 Clark 2004-USA
Methods RCT
Length of follow-up: up to 1 year (season)
Adverse event data collectionmethods: episodes of fever (subjective assessment of fever)
, vomiting, diarrhoea, behavioural changes, and any other adverse experiences during the
14 days after each dose also were reported on the diary card (passive method); parents
were asked to report any serious adverse experience immediately to the study site (passive
method); telephone call made to each participant 14 days after each vaccination to ask
about serious adverse experiences (active method)
Participants Number: 439 enrolled; 416 evaluable
Age range: 1 to 3 months (beginning); 3 to 6 months (end)
Inclusion criteria: healthy infants approximately 2 to 6 months of age were enrolled
and followed for episodes of acute gastroenteritis
Exclusion criteria: known hypersensitivity to any component of the rotavirus vaccine;
known or suspected immunologic impairment; prior administration of any rotavirus
vaccine; fever at time of vaccination (> 38.1 °C rectal); history of chronic diarrhoea or
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failure to thrive; clinical evidence of gastrointestinal illness; receipt of any other vaccines
within 14 days; immunocompromised resident in the home; or any condition, which, in
the opinion of the investigator, might interfere with the evaluation of the study objectives
Interventions RV5
1.WC3 (RV5): 107 PFU; 3 doses at 6 to 8 week intervals; 218 participants (randomized)
2. Placebo: 3 doses at 6 to 8 week intervals; 221 participants (randomized)
Outcomes Clinical outcome measures (safety and efficacy)
1. Rotavirus diarrhoea: case of rotavirus disease in a study participant defined as ≥
3 watery or looser than normal stools within a 24-h period and/or forceful vomiting
occurring at least 14 days after the third dose of vaccine/placebo and identification of
rotavirus in a stool specimen obtained within 14 days of symptom onset; measured up
to 1 year
2. Severe rotavirus diarrhoea: based on a clinical scoring system for evaluating the severity
of an episode of infant acute gastroenteritis (0 to 24 points) they consider severe above
16 points; measured up to 1 year
3. Drop outs: measured up to 1 year
4. Serious adverse events: serious adverse experiences included death, life-threatening
events, and experiences that resulted in hospitalization, persistent disability, or that pro-
longed a hospitalization; deaths or any serious adverse experiences judged to be vaccine-
related were recorded for the duration of the study; measured up to 1 year, including
intussusception (data from correspondence with Merck, Merck 2012).
5. Reactogenicity: all participants were followed for clinical adverse experiences for 14
days after each vaccination
6. Adverse events requiring discontinuation; measured up to 1 year
Outcomes to measure immunogenicity
7. Viral shedding: stools were collected to evaluate vaccine strain shedding among subsets
of infants at different time periods after each dose [review includes data from after dose
3]
8. Seroconversion: pre-vaccination and post-vaccination sera assayed for anti-rotavirus
immunoglobulin A (IgA) and anti-rotavirus IgG (units/mL, based on pooled human
serum standards); ≥ 3-fold rise in titre from baseline to after dose 3 (review includes
data from after dose 3)
Immunization status Receipt of any other vaccines within 14 days was not allowed
Location 10 study sites in the USA
WHO mortality stratum A
Notes Date: August 1993 to June 1994
Source of funding: Merck & Co., Inc.
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Unclear risk “Infants whomet all eligibility criteria were
randomly assigned in a 1:1 ratio”. No fur-
ther details
Allocation concealment (selection bias) Unclear risk No details
Blinding (performance bias and detection
bias)
All outcomes
Low risk “The vials of vaccine and placebo were vis-
ibly indistinguishable”
“The placebo was identical to the vaccine
except that it did not contain the rotavirus
reassortants”. Investigators, study person-
nel (internal and external), and parents/
guardians were blinded throughout trial.
(Merck 2012)
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Insufficient reporting of attrition/exclu-
sions
Selective reporting (reporting bias) High risk ≥ 1 outcome of interest reported incom-
pletely; “Only wild-type (ie, non-vaccine
related) rotavirus cases were considered for
the primary case definition”
Other bias Unclear risk Not enough detail to make a judgment
RV5 Kim 2008-KOR
Methods RCT
Length of follow-up: up to 42 days after last dose
Adverse event data collection methods: diary cards (passive method)
Participants Number: 178 enrolled; 171 evaluable
Age range: 1 to 3 months (beginning); 3 to 6 months (end)
Inclusion criteria: healthy infants; 6 to 12 weeks of age
Exclusion criteria: history of congenital abdominal disorders, intussusception, or ab-
dominal surgery; known or suspected impairment of immunological function; known
hypersensitivity to any component of the rotavirus vaccine; prior receipt of any rotavirus
vaccine; fever, with a rectal temperature ≥ 38.1 °C (≥ 100.5 °F) at the time of im-
munization; history of known prior rotavirus disease, chronic diarrhoea, or failure to
thrive; clinical evidence of active gastrointestinal illness (infants with gastro-oesophageal
reflux disease were permitted to participate in the study as long as the gastro-oesophageal
reflux disease was well controlled with or without medication); receipt of intramuscular,
oral, or intravenous corticosteroid treatment between the 2 weeks before first vaccination
and 2 weeks after last vaccination; reside in a household with an immunocompromised
person; prior receipt of a blood transfusion or blood products, including immunoglob-
ulins; receipt of OPV during the course of the study or within 42 days before first dose
of vaccine/placebo; and condition, which, in the opinion of the investigator, may have
interfered with the evaluation of the study objectives
132Vaccines for preventing rotavirus diarrhoea: vaccines in use (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
RV5 Kim 2008-KOR (Continued)
Interventions RV5
1.WC3 (RV5): 6.9 to 8.6 x 107 PFU; 3 doses given 4 to 10 weeks apart; 115 participants
(randomized)
2. Placebo: 3 doses given 4 to 10 weeks apart; 3 participants (randomized)
Outcomes Clinical outcome measures (safety and efficacy)
1. Serious adverse events: no definition; measured up to 42 days
2. Reactogenicity: no definition; measured up to 14 days
3. Adverse events resulting in discontinuation
Outcomes to measure immunogenicity
4. Seroconversion: seroresponse serum anti-rotavirus immunoglobulin A (IgA) defined
as an increase in antibody titre by a factor of ≥ 3 from baseline (data could not be
extracted for review)
Immunization status Infants excluded if they had or were to receive oral poliovirus vaccine at any time during
the study or in the 42 days before the first dose; concomitant administration of other
licensed vaccines and breastfeeding was not restricted
Location 8 study centres in South Korea
WHO mortality stratum B
Notes Date: 2 August 2005 (first patient in) to 25 May 2006 (last dose given); last participant
completed follow-up on 5 July 2006
Source of funding: Merck & Co., Inc.
Other: most of the outcome data is not provided in the reports
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer generated randomized 2:1 to
receive hexavalent vaccine concomitantly
with either RV5 (RotaTeq) or placebo
(Merck 2012)
Allocation concealment (selection bias) Low risk Allocation numbers were generated for par-
ticipants, investigators, adults, and par-
ents/guardians of children were blinded
throughout trial (Merck 2012)
Blinding (performance bias and detection
bias)
All outcomes
Low risk RV5 was visibly indistinguishable from
placebo, investigators, study personnel (in-
ternal and external), and parents/guardians
were blinded throughout trial (Merck
2012)
Incomplete outcome data (attrition bias)
All outcomes
High risk Reason related to outcome
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Selective reporting (reporting bias) High risk Key expected outcome not included
Other bias Unclear risk Information not provided
RV5 Merck[009] 2005-USA
Methods RCT
Length of follow-up: up to 42 days after vaccination
Adverse event data collection methods: not reported
Participants Number: 793 enrolled; 706 evaluable
Age range: 1 to 3 months (beginning); 3 to 6 months (end)
Inclusion criteria: healthy infants; 6 to 12 weeks of age
Exclusion criteria: history of congenital abdominal disorders, intussusception, or ab-
dominal surgery; known or suspected impairment of immunological function; known
hypersensitivity to any component of the rotavirus vaccine; prior receipt of any rotavirus
vaccine; fever, with a rectal temperature ≥ 38.1 °C (≥ 100.5 °F) at the time of immu-
nization; history of known prior rotavirus disease, chronic diarrhoea, or failure to thrive;
clinical evidence of active gastrointestinal illness (infants with gastro-oesophageal reflux
disease were permitted to participate in the study as long as the gastro-oesophageal reflux
disease was well controlled with or without medication); receipt of intramuscular, oral,
or intravenous corticosteroid treatment between the 2 weeks before first vaccination and
2 weeks after last vaccination; reside in a household with an immunocompromised per-
son; prior receipt of a blood transfusion or blood products, including immunoglobulins;
receipt of oral polio vaccine during the course of the study or within 42 days before first
dose of vaccine/placebo; and condition, which, in the opinion of the investigator, may
have interfered with the evaluation of the study objectives
Interventions RV5
1.WC3 (RV5): 2mL (10.7PFU); 3 doses given at 4 to 10week intervals; 680 participants
(randomized)
2. Placebo: 3 doses given at 28 to 70 day intervals; 113 participants (randomized)
Outcomes Clinical outcome measures (safety and efficacy)
1. Reactogenicity: no definition; measured 7 days after vaccination
2. Drop outs: measured up to 42 days
3. Adverse events requiring discontinuations: measured up to 42 days, (data from corre-
spondence with Merck; Merck 2012).
4. Serious adverse events: not defined; measured up to 42 days, including intussusception
(data from correspondence with Merck; Merck 2012).
5. Number of deaths (data from correspondence with Merck; Merck 2012).
Outcomes to measure immunogenicity
None
Immunization status Infants were excluded if they had or were to receive oral poliovirus vaccine at any time
during the study or in the 42 days before the first dose; concomitant administration of
other licensed vaccines and breastfeeding was not reported
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Location 10 centres in USA
WHO mortality stratum A
Notes Date: 9 May 2003 to 13 August 2004
Source of funding: Merck & Co., Inc.
Study objective: “Comparison of the Immunogenicity and Safety of Three Consistency
Lots of RotaTeq in Healthy Infants”
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer generated randomization to 1
of 4 treatment groups. A randomization
scheme of 2:2:2:1, with a blocking factor
of 14, was used and subjects received either
1 of 3 lots of RV5 or placebo (Merck 2012)
Allocation concealment (selection bias) Low risk Allocation numbers were generated for par-
ticipants, investigators, adults, and par-
ents/guardians of children were blinded
throughout trial (Merck 2012)
Blinding (performance bias and detection
bias)
All outcomes
Low risk RV5 was visibly indistinguishable from
placebo, investigators, study personnel (in-
ternal and external) and parents/guardians
were blinded throughout trial (Merck
2012)
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Insufficient reporting of attrition/exclu-
sions
Selective reporting (reporting bias) Unclear risk Insufficient information
Other bias Unclear risk Insufficient information
RV5 NCT00718237 2010-JPN
Methods RCT
Length of follow-up: 25 months
Adverse event data collection methods: any death, vaccine-related serious adverse
events and intussusception were collected during the study period; parents/guardians
asked to record adverse events on a standardized vaccine report card during 14 days after
each vaccination
Participants Number: 762
Age range: 6 to 12 weeks
Inclusion criteria: healthy Japanese Infants
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Exclusion criteria: history of known prior rotavirus gastroenteritis; subjects who are
concurrently participating in or are anticipated to participate in other studies of investi-
gational products at any time during the study period
Interventions 1. Rotavirus vaccine, live, oral, pentavalent [RV5], 381 participants
2. Placebo (unspecified), 381 participants
Schedule: 3 doses, 28 to 70 days apart, with 14 days of safety follow-up after each
vaccination, and follow-up for acute gastroenteritis episodes until the end of the study
Outcomes 1. Efficacy against rotavirus gastroenteritis of any severity, at least 14 days following the
3rd vaccination
2. Efficacy against moderate to severe and severe rotavirus gastroenteritis, at least 14 days
following the 3rd vaccination
3. Serious adverse events, including intussusception (data from correspondence with
Merck; Merck 2012).
4. Reactogenicity (fever, vomiting, diarrhoea)
5. Drop-outs before the end of the trial
6. Adverse events leading to discontinuation of the trial
7. Number of deaths (data from correspondence with Merck; Merck 2012).
Immunization status No information about other vaccines given
Location 32 sites in Japan
WHO mortality stratum A
Notes Date: August 2008 to September 2009
Registration number: NCT00718237
Source of funding: Merck Sharp & Dohme Corp
Rationale: “to evaluate whether V260 is effective and well tolerated in Japanese healthy
infants”
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Allocation number was assigned and the
subject was randomized to the group re-
ceiving RV5 or the group receiving placebo
in a 1:1 ratio according to the randomiza-
tion code prepared by a computer at theUS
MerckHeadquarters Office” (Merck 2012)
Allocation concealment (selection bias) Low risk Allocation numbers were generated and al-
located centrally for participants (Merck
2012)
Blinding (performance bias and detection
bias)
All outcomes
Low risk RV5 was visibly indistinguishable from
placebo, investigators, study personnel (in-
ternal and external) and parents/guardians
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were blinded throughout trial (Merck
2012)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Attrition/exclusions balanced across groups
Selective reporting (reporting bias) Unclear risk Insufficient information
Other bias Unclear risk Sponsor: Merck
RV5 NCT00953056 2010-CHI
Methods RCT
Length of follow-up: two weeks after last dose
Adverse event data collection methods: not reported
Participants Number: Infant cohort: 48 enrolled and randomized
Inclusion criteria: healthy infants aged 6 to 12 weeks
Exclusion criteria: receiving other live vaccines 14 days before or after study vaccine;
prior administration of any rotavirus vaccine; elevated temperature, with axillary tem-
perature ≥ 37.1 °C 24-h before study vaccine; Prior or active gastrointestinal illnesses;
immunodeficiency
Interventions 1. 2.0 mL doses of RV5 (V260) administered orally. The vaccine consists of an oral
solution of 5 live human-bovine reassortant rotaviruses
2. 2.0 mL doses of matching placebo to RV5 administered orally
Schedule: 3 doses of RV5/placebo at 3 separate visits scheduled 28 to 70 days apart. The
third dose was administered by 32 weeks of age
Outcomes Clinical outcome measures
1. Serious adverse events, up to 14 days post vaccination, including intussusception (data
from correspondence with Merck; Merck 2012).
2. Adverse events requiring discontinuation
3. Drop outs from the trial
4. Number of deaths (data from correspondence with Merck; Merck 2012).
Outcomes to measure immunogenicity
4. Vaccine virus shedding in stools, day 3 to day 7 following each of the 3 doses of RV5/
placebo
Immunization status Other live vaccines 14 days before or after study vaccine were not allowed
Location China
WHO mortality stratum B
Notes Date: September 2009 to March 2010
Source of funding: Merck Sharp & Dohme Corp
Study rationale: “This study will assess the safety and tolerability of RV5 (V260) in
the healthy Chinese populations. Approximately 144 participants will be enrolled and
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equally stratified into three age cohorts, Cohort I ages 19-47 years, Cohort II ages 2-6
years, and Cohort III ages 6-12 weeks”
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk All subjects were randomized according to
a computer generated allocation schedule
(Merck 2012)
Allocation concealment (selection bias) Low risk Allocation numbers were generated for par-
ticipants, investigators, adults, and par-
ents/guardians of children were blinded
throughout trial (Merck 2012)
Blinding (performance bias and detection
bias)
All outcomes
Low risk RV5 was visibly indistinguishable from
placebo, investigators, study personnel (in-
ternal and external) and parents/guardians
were blinded throughout trial (Merck
2012)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Attrition balanced across groups with rea-
sons reported for withdrawal
Selective reporting (reporting bias) Unclear risk Trial report does not provide enough infor-
mation
Other bias Unclear risk Funded by Merck Sharp & Dohme Corp
RV5 Vesikari 2006a-FIN
Methods RCT
Length of follow-up: 1 to 3 rotavirus seasons (1 to 3 years)
Adverse event data collection methods: diary cards (passive method); telephone calls
to parents/legal guardians to ask about serious adverse events (active method)
Note: the per-protocol population used for the primary efficacy analysis included 1496
participants after exclusion of 450 participants (23.1%). The modified intention-to-
treat population used in a secondary efficacy analysis consisted of the 1647 participants,
including protocol violators, who had any valid post-dose 3 efficacy data
Participants Number: 1946 enrolled; 1496 evaluable (after 2 years)
Age range: 3 to 6 months (beginning); > 6 months (end)
Inclusion criteria: healthy infants between 2 and 8 months of age
Exclusion criteria: not described
Interventions RV5
1. WC3 (RV5)
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1.1. G1-4, P1A (2.69 x 107 , 7.92 x 106, 2.41 x 106); 3 doses given 4 to 8 weeks apart;
1027 participants (randomized)
1.2. G1-4 (2.9 x 107); 3 doses given 4 to 8 weeks apart; 270 participants (randomized)
1.3. P1A (9.24 x 107); 3 doses given 4 to 8 weeks apart; 327 participants (randomized)
2. Placebo: 3 doses given 4 to 8 weeks apart; 322 participants (randomized)
We excluded the two arms dealing with different G or P serotypes and compared a single arm
to placebo
Outcomes Clinical outcome measures (safety and efficacy)
1. Rotavirus diarrhoea: case definition for rotavirus gastroenteritis required: (1) ≥ 3
watery or looser-than-normal stools within a 24-h period and/or forceful vomiting;
and (2) rotavirus antigen detection by EIA. The primary analysis of efficacy considered
episodes as positive only when caused by wild-type rotavirus with a vaccine G serotype
(G1, G2, G3, or G4) confirmed by polymerase chain reaction (PCR) occurring at least
14 days after the third dose of vaccine; measured 1 to 3 years
2. Severe rotavirus diarrhoea: clinical scoring system based on the intensity and duration
of symptoms of fever, vomiting, diarrhoea, and behavioural changes was used to rate
the severity of gastroenteritis, using a 24-point severity scale where a score of 1 to 8 was
designated as mild, > 8 was designated as moderate-and-severe, and > 16 was designated
as severe; measured 1 to 3 years
3. Reactogenicity: not definedother than all participantswere followed for clinical adverse
events for 42 days after each dose of vaccine or placebo; parents/guardians were provided
with diary cards to record adverse events
4. Serious adverse events: not defined; noted that they were to be reported immediately.
Parents/legal guardians were contacted by phone approximately 14 days after each dose
and asked about serious adverse events. Data on deaths and serious adverse events judged
by the investigator to be vaccine related were collected for the duration of the study (up
to 42 days)
5. All-cause diarrhoea
6. All-cause diarrhoea - severe
7. All-cause death
Outcomes to measure immunogenicity
8. Seroconversion: prevaccination and postvaccination sera assayed for rotavirus-specific
IgA by ELISAwith seroconversion defined as≥ 3-fold rise in antibody titre frombaseline
to 2 weeks after dose 3 (review includes data from 14 days after dose 3)
Immunization status Licensed vaccines could be administered throughout the study, but were not given on the
same day as study vaccine; inactivated poliovirus vaccine was exclusively used in Finland
at the time of the study
Location 4 sites (Tampere, Espoo, Lahti, Pori) in Finland
WHO mortality stratum A
Notes Date: June 1998 and June 2001
Source of funding: Merck & Co., Inc.
Other: in total, 1946 infants (1300 in the first year and 646 in the second year of
the study) were enrolled in the study and received at least the first dose of 1 of the 5
active vaccines or placebo. Overall, 1813 (93.2%) participants received 3 three doses
and were followed for ≥ 42 days after the final dose. 1800 participants (92.5%) were
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followed through the first rotavirus season after vaccination; 1740 participants (89.4%)
were followed through a second rotavirus season. Of the 1300 participants enrolled in
the first year, 880 (67.7%) were followed through a third rotavirus season
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer generated (Merck 2012)
Allocation concealment (selection bias) Low risk Allocation numbers were generated for
participants, investigators and parents/
guardians were blinded throughout trial
(Merck 2012)
Blinding (performance bias and detection
bias)
All outcomes
Low risk Sequential identical containers; “The vials
containing either vaccine or placebo were
visibly indistinguishable.” Participants and
key personnel; “This randomized clini-
cal trial blinded to subject, investigator,
parent/legal guardian, and sponsor. The
placebo was identical to the vaccine except
that it did not contain rotavirus reassortants
or trace trypsin”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Insufficient reporting of attrition/exclu-
sions
Selective reporting (reporting bias) High risk ≥1 outcome of interest reported incom-
pletely
Other bias Unclear risk Insufficient information to assess
RV5 Vesikari 2006b-INT
Methods RCT
Length of follow-up: up to 43 days for safety outcomes, and up to 2 years for efficacy
outcomes
Adverse event data collection methods: active surveillance was used to obtain safety
data; parents or legal guardians were contacted on days 7, 14, and 42 after each dose and
every 6 weeks thereafter for 1 year after the first dose with respect to intussusception and
serious adverse events (active method)
Participants Number: 70,301 enrolled and 69,274 randomized (efficacy study subpopulation of
5673); 57,134 evaluable for safety outcomes; for efficacy outcomes, 4512 evaluable in
year 1 and 1569 evaluable in year 2
Age range: 1 to 3 months (beginning); 3 to 6 months (end)
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Inclusion criteria: healthy infants between 6 and 12 weeks of chronological age were el-
igible regardless of gestational age; no known history of congenital abdominal disorders,
intussusception, or abdominal surgery; no known or suspected impairment of immuno-
logical function; no known hypersensitivity to any component of the rotavirus vaccine;
no prior receipt of any rotavirus vaccine; no fever, with a rectal temperature ≥ 38.1 °C
(≥ 100.5 °F) at the time of immunization; no history of known prior rotavirus disease,
chronic diarrhoea, or failure to thrive; no clinical evidence of active gastrointestinal ill-
ness; no receipt of intramuscular, oral, or intravenous corticosteroid treatment within
the 2 weeks before vaccination; did not reside in a household with an immunocom-
promised person; no prior receipt of a blood transfusion or blood products, including
immunoglobulins; no receipt of oral poliovirus vaccine during the course of the study
or within 42 days prior to the first dose of vaccine/placebo
Exclusion criteria: see above for details
Special group: infants born at < 36 weeks of gestational age were considered premature
and infants born at < 32 weeks of gestational age were considered extremely premature;
no formal safety or efficacy hypotheses were prespecified for premature infants
Interventions RV5
1. WC3 (RV5): 2 mL (6.7 to 12.4 x 107 PFU); 3 doses given 4 to 10 weeks apart; 34,
644 participants (randomized)
2. Placebo: 2 mL; 3 doses given 4 to 10 weeks apart; 34,630 participants (randomized)
Outcomes Clinical outcome measures (safety and efficacy)
1. Rotavirus diarrhoea: case definition for rotavirus gastroenteritis required participants
to meet both of the following criteria: (1)≥ 3 watery or looser-than-normal stools within
a 24-h period and/or forceful vomiting, and (2) rotavirus detected by EIA in a stool
specimen taken within 14 days after the onset of symptoms. Only naturally occurring
“rotavirus AGEs” caused by the composite of the human rotavirus G-serotypes in the
vaccine (G1, G2, G3, and G4) occurring through the first rotavirus season that began
at least 14 days following the third vaccination were included in the primary analysis;
measured up to 2 years follow-up
2. Severe rotavirus diarrhoea: an established clinical scoring system based on the intensity
and duration of fever, vomiting, diarrhoea, and changes in behaviour used to categorize
episodes of rotavirus gastroenteritis on a 24-point severity scale; scores > 16 were con-
sidered to indicate severe disease; measured up to 2 years follow-up
3. Emergency department visit: hospitalizations and emergency department visits for
acute gastroenteritis; measured up to 1 year of follow-up
4. All-cause hospital admission: see above; measured up to 1 year of follow-up
5. All-cause mortality: measured up to 1 year of follow-up
6. Drop outs: no definition; measured up to 2 years follow-up
7. Serious adverse events: monitored for at least 42 days after each dose for serious adverse
events, including intussusception. All suspected cases of intussusception were reported to
an independent, blinded adjudication committee, which included a paediatric surgeon,
a paediatric radiologist, and a paediatrician with extensive experience in emergency
medicine. The committee adjudicated potential cases of intussusception according to a
prespecified case definition that required confirmation of the diagnosis by radiography or
at surgery or autopsy; measured up to 1 year of follow-up. Final intussusception results
taken from CDC report (CDC 2010).
8. Reactogenicity: not defined; measured up to 43 days after vaccine
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9. Adverse events requiring discontinuation: not defined;measured up to 1 year of follow-
up
10. Rotavirus diarrhoea resulting in hospitalization
Outcomes to measure immunogenicity
11. Seroconversion: defined as an increase in the antibody titre by a factor of ≥ 3 from
baseline (review includes data from 14 days after dose 3)
Immunization status Administration of other licensed childhood vaccines and breastfeeding were not re-
stricted; for a subset of subjects in the USA (U.A. concomitant use cohort), Merck also
provided the licensed paediatric vaccines that were administered concomitantly (same
day) with RV5 or placebo, which included Comvax, Infanrix, Ipol, and Prevnar
Location 356 primary study sites in Belgium, Costa Rica, Finland, Germany, Guatemala, Italy,
Jamaica, Mexico, Puerto Rico, Sweden, Taiwan, and the USA
WHO mortality strata A, B, D
Notes Date: 12 January 2001 to 6 October 2004
Source of funding: Merck & Co., Inc.
Other: there is a full report on premature babies that will be data extracted separately
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer generated randomized 1:1 to
receive either RV5 (RotaTeq) or placebo
(Merck 2012)
Allocation concealment (selection bias) Low risk Allocation numbers were generated for
participants, investigators and parents/
guardians were blinded throughout trial
(Merck 2012)
Blinding (performance bias and detection
bias)
All outcomes
Low risk Participants and key personnel; “Random-
ized, multicenter, double blinded (oper-
ated under in-house blinding procedures),
placebo controlled, safety and efficacy trial.
The placebo was an exact match minus the
virus”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Missing data balanced across groups
Selective reporting (reporting bias) Low risk Pre-specified outcomes reported
Other bias Unclear risk Difficult to judge, as some important in-
formation about randomization/allocation
concealment are not provided
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Methods RCT
Length of follow-up: up to 43 days for safety outcomes, and up to 2 years for efficacy
outcomes
Adverse event data collection methods: active surveillance was used to obtain safety
data; parents or legal guardians were contacted on the first 14 days after each dose and
every month thereafter for 1 year after the first dose with respect to intussusception
and serious adverse events (active method). “Serious adverse events were classified with
the US regulatory definition, in line with ICH guidance, and identified by monthly
query and parental reporting at any time or identification by study staff in hospitals or
clinics. Intussusception at any time was assessed with an additional detailed protocol. All
these events were monitored by an independent, unmasked, data and safety monitoring
board that met about twice a year during the course of the investigation. The board also
provided guidance about enrolment and severity scoring”
Participants Number: 2119 enrolled; 2036 randomized, 2016 evaluable
Age range: 1 to 3 months (beginning); 3 to 6 months (end)
Inclusion criteria: healthy infants aged 4 to 12 weeks. Breastfeeding was not restricted
and there was no enrolment restrictions based on HIV status, although HIV testing was
not done
Exclusion criteria: see above
Interventions RV5
1. WC3 (RV5): 2 mL (6.7 to 12.4 x 107 PFU); 3 doses given 4 weeks apart; 1,018
participants (randomized)
2. Placebo: 2 mL; 3 doses given 4 weeks apart; 1,018 participants (randomized)
Schedule: 3 doses given at a 4 week interval
Outcomes Clinical outcome measures (safety and efficacy)
1. Serious adverse events
2. Death due to serious adverse events
3. Rotavirus diarrhoea: case definition for rotavirus gastroenteritis required participants
to meet both of the following criteria: (1)≥ 3 watery or looser-than-normal stools within
a 24-h period and/or forceful vomiting, and (2) rotavirus detected by EIA in a stool
specimen taken within 14 days after the onset of symptoms
4. Severe rotavirus diarrhoea: an established clinical scoring system based on the intensity
and duration of fever, vomiting, diarrhoea, and changes in behaviour used to categorize
episodes of rotavirus gastroenteritis on a 20-point severity scale; scores > 11 were con-
sidered to indicate severe disease; measured up to 2 years follow-up
5. All-cause diarrhoea
6. All-cause diarrhoea - severe
7. Reactogenicity *: symptoms of rotavirus illness, including fever, diarrhoea, and vomit-
ing; measured for 7 days after each dose (review includes data from for the end of follow-
up)
Data on fever and vomiting are provided only on figure 2 and data could not be extracted
reliably
Outcomes to measure immunogenicity
8. Seroconversion: serum rotavirus IgA responses (increases in level of serum rotavirus
IgA ≥ 4 fold) (review includes data from after dose 2)
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Immunization status All children in the study received the standard EPI vaccines (including oral poliovirus
vaccine) starting at 6 weeks of age
Location Sites in rural Matlab (Bangladesh) and urban and peri-urban Nha Trang (Vietnam)
WHO mortality strata B, D
Notes This trial was conducted inBangladesh andVietnam, data reported separately per country
can be found under RV5 Zaman 2010-BGD and RV5 Zaman 2010-VNM.
Date: March 29, 2007 to March 31, 2009
Source of funding: funded by PATH (GAVI Alliance grant) and Merck
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Unique allocation numbers were desig-
nated atMerck as pentavalent rotavirus vac-
cine or placebo with computer generated
block randomization, with block sizes of
six”
Allocation concealment (selection bias) Low risk “Vaccine and placebo packages were then
labelled with allocation numbers and pro-
vided to sites in identical presentations.
Sites were instructed to assign allocation
numbers to participants in sequential order
as they were enrolled”
Blinding (performance bias and detection
bias)
All outcomes
Low risk Participants and staff: “Participants were
enrolled by study staff, who remained
masked to treatment assignment through-
out the trial”
Researchers: “The statistician from Merck
who analysed the data and the Merck
and PATH protocol teams were masked to
treatment assignment”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Missing data balanced across groups
Selective reporting (reporting bias) Low risk Pre-specified outcomes reported
Other bias Low risk Funded by PATH (GAVI Alliance grant)
andMerck. Protocol published a prior with
ClinicalTrials.gov, number
NCT00362648. The study was designed
by scientists from Merck, with substantial
input from PATH staff and site investiga-
144Vaccines for preventing rotavirus diarrhoea: vaccines in use (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
RV5 Zaman 2010-AS (Continued)
tors. Merck had direct oversight or partic-
ipation in every stage of the study. Merck
also participated in pharmacovigilance, or-
ganised and led the data and safety mon-
itoring board meetings, and did the data
analysis. Staff from PATH independently
monitored study execution at sites and par-
ticipated in pharmacovigilance, data anal-
ysis, and data and safety monitoring board
meetings. All authors had full access to the
data, and the corresponding author had fi-
nal responsibility for the decision to submit
for publication
RV5 Zaman 2010-BGD
Methods RCT
Length of follow-up: up to 43 days for safety outcomes, and up to 2 years for efficacy
outcomes
Adverse event data collection methods: active surveillance was used to obtain safety
data; parents or legal guardians were contacted on the first 14 days after each dose and
every month thereafter for 1 year after the first dose with respect to intussusception
and serious adverse events (active method). “Serious adverse events were classified with
the US regulatory definition, in line with ICH guidance, and identified by monthly
query and parental reporting at any time or identification by study staff in hospitals or
clinics. Intussusception at any time was assessed with an additional detailed protocol. All
these events were monitored by an independent, unmasked, data and safety monitoring
board that met about twice a year during the course of the investigation. The board also
provided guidance about enrolment and severity scoring”
Participants Number: 1136 randomized
Age range: 1 to 3 months (beginning); 3 to 6 months (end)
Inclusion criteria: healthy infants aged 4 to 12 weeks. Breastfeeding was not restricted
and there was no enrolment restrictions based on HIV status, although HIV testing was
not done
Exclusion criteria: see above
Interventions RV5
1. WC3 (RV5): 2 mL (6.7 to 12.4 x 107 PFU); 3 doses given 4 weeks apart; 568
(randomized)
2. Placebo: 2 mL; 3 doses given 4 weeks apart; 568 participants (randomized)
Schedule: 3 doses given at a 4-week interval
Outcomes Clinical outcome measures (safety and efficacy)
1. Serious adverse events
2. Death due to serious adverse events
3. Rotavirus diarrhoea: case definition for rotavirus gastroenteritis required participants
to meet both of the following criteria: (1)≥ 3 watery or looser-than-normal stools within
a 24-h period and/or forceful vomiting, and (2) rotavirus detected by EIA in a stool
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specimen taken within 14 days after the onset of symptoms
4. Severe rotavirus diarrhoea: an established clinical scoring system based on the intensity
and duration of fever, vomiting, diarrhoea, and changes in behaviour used to categorize
episodes of rotavirus gastroenteritis on a 20-point severity scale; scores > 11 were con-
sidered to indicate severe disease; measured up to 2 years follow-up
5. All-cause diarrhoea
6. All-cause diarrhoea - severe
7. Reactogenicity *: symptoms of rotavirus illness, including fever, diarrhoea, and vomit-
ing; measured for 7 days after each dose [review includes data from for the end of follow-
up]
Data on fever and vomiting are provided only on figure 2 and data could not be extracted
reliably
Outcomes to measure immunogenicity
8. Seroconversion: serum rotavirus IgA responses (increases in level of serum rotavirus
IgA ≥ 4 fold) [review includes data from after dose 2]
Immunization status All children in the study received the standard EPI vaccines (including oral poliovirus
vaccine) starting at 6 weeks of age
Location Sites in rural Matlab, Bangladesh
WHO mortality stratum D
Notes This trial was conducted in Bangladesh and Vietnam, this part presents data for the
Bangladesh cohort, data reported separately for Vietnam can be found under RV5 Zaman
2010-VNM and data for both countries under RV5 Zaman 2010-AS
Date: March 29, 2007 to March 31, 2009
Source of funding: funded by PATH (GAVI Alliance grant) and Merck
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Unique allocation numbers were desig-
nated atMerck as pentavalent rotavirus vac-
cine or placebo with computer generated
block randomization, with block sizes of
six”
Allocation concealment (selection bias) Low risk “Vaccine and placebo packages were then
labelled with allocation numbers and pro-
vided to sites in identical presentations.
Sites were instructed to assign allocation
numbers to participants in sequential order
as they were enrolled”
Blinding (performance bias and detection
bias)
All outcomes
Low risk Participants and staff: “Participants were
enrolled by study staff, who remained
masked to treatment assignment through-
out the trial”
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Researchers: “The statistician from Merck
who analysed the data and the Merck
and PATH protocol teams were masked to
treatment assignment”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Missing data balanced across groups
Selective reporting (reporting bias) Low risk Pre-specified outcomes reported
Other bias Low risk Funded by PATH (GAVI Alliance grant)
andMerck. Protocol published a prior with
ClinicalTrials.gov, number
NCT00362648. The study was designed
by scientists from Merck, with substantial
input from PATH staff and site investiga-
tors. Merck had direct oversight or partic-
ipation in every stage of the study. Merck
also participated in pharmacovigilance, or-
ganised and led the data and safety mon-
itoring board meetings, and did the data
analysis. Staff from PATH independently
monitored study execution at sites and par-
ticipated in pharmacovigilance, data anal-
ysis, and data and safety monitoring board
meetings. All authors had full access to the
data, and the corresponding author had fi-
nal responsibility for the decision to submit
for publication
RV5 Zaman 2010-VNM
Methods RCT
Length of follow-up: up to 43 days for safety outcomes, and up to 2 years for efficacy
outcomes
Adverse event data collection methods: active surveillance was used to obtain safety
data; parents or legal guardians were contacted on the first 14 days after each dose and
every month thereafter for 1 year after the first dose with respect to intussusception
and serious adverse events (active method). “Serious adverse events were classified with
the US regulatory definition, in line with ICH guidance, and identified by monthly
query and parental reporting at any time or identification by study staff in hospitals or
clinics. Intussusception at any time was assessed with an additional detailed protocol. All
these events were monitored by an independent, unmasked, data and safety monitoring
board that met about twice a year during the course of the investigation. The board also
provided guidance about enrolment and severity scoring”
Participants Number: 900 randomized
Age range: 1 to 3 months (beginning); 3 to 6 months (end)
Inclusion criteria: healthy infants aged 4 to 12 weeks. Breastfeeding was not restricted
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and there was no enrolment restrictions based on HIV status, although HIV testing was
not done
Exclusion criteria: see above
Interventions RV5
1. WC3 (RV5): 2 mL (6.7 to 12.4 x 107 PFU); 3 doses given 4 weeks apart; 450
participants (randomized)
2. Placebo: 2 mL; 3 doses given 4 weeks apart; 450 participants (randomized)
Schedule: 3 doses given at a 4 week interval
Outcomes Clinical outcome measures (safety and efficacy)
1. Serious adverse events
2. Death due to serious adverse events
3. Rotavirus diarrhoea: case definition for rotavirus gastroenteritis required participants
to meet both of the following criteria: (1)≥ 3 watery or looser-than-normal stools within
a 24-h period and/or forceful vomiting, and (2) rotavirus detected by EIA in a stool
specimen taken within 14 days after the onset of symptoms
4. Severe rotavirus diarrhoea: an established clinical scoring system based on the intensity
and duration of fever, vomiting, diarrhoea, and changes in behaviour used to categorize
episodes of rotavirus gastroenteritis on a 20-point severity scale; scores > 11 were con-
sidered to indicate severe disease; measured up to 2 years follow-up
5. All-cause diarrhoea
6. All-cause diarrhoea - severe
7. Reactogenicity*: symptoms of rotavirus illness, including fever, diarrhoea, and vomit-
ing; measured for 7 days after each dose [review includes data from for the end of follow-
up]
Data on fever and vomiting are provided only on figure 2 and data could not be extracted
reliably.
Outcomes to measure immunogenicity
8. Seroconversion: serum rotavirus IgA responses (increases in level of serum rotavirus
IgA ≥ 4 fold) [review includes data from after dose 2]
Immunization status All children in the study received the standard EPI vaccines (including oral poliovirus
vaccine) starting at 6 weeks of age
Location Sites in urban and peri-urban Nha Trang, Vietnam
WHO mortality stratum B
Notes This trial was conducted in Bangladesh and Vietnam, this part presents data for the
Vietnam cohort, data reported separately for Bangladesh can be found under RV5 Zaman
2010-BGD and data for both countries under RV5 Zaman 2010-AS
Date: March 29, 2007 to March 31, 2009
Source of funding: funded by PATH (GAVI Alliance grant) and Merck
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Low risk “Unique allocation numbers were desig-
nated atMerck as pentavalent rotavirus vac-
cine or placebo with computer generated
block randomization, with block sizes of
six”
Allocation concealment (selection bias) Low risk “Vaccine and placebo packages were then
labelled with allocation numbers and pro-
vided to sites in identical presentations.
Sites were instructed to assign allocation
numbers to participants in sequential order
as they were enrolled”
Blinding (performance bias and detection
bias)
All outcomes
Low risk Participants and staff: “Participants were
enrolled by study staff, who remained
masked to treatment assignment through-
out the trial”
Researchers: “The statistician from Merck
who analysed the data and the Merck
and PATH protocol teams were masked to
treatment assignment”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Missing data balanced across groups
Selective reporting (reporting bias) Low risk Pre-specified outcomes reported
Other bias Low risk Funded by PATH (GAVI Alliance grant)
andMerck. Protocol published a prior with
ClinicalTrials.gov, number
NCT00362648. The study was designed
by scientists from Merck, with substantial
input from PATH staff and site investiga-
tors. Merck had direct oversight or partic-
ipation in every stage of the study. Merck
also participated in pharmacovigilance, or-
ganised and led the data and safety mon-
itoring board meetings, and did the data
analysis. Staff from PATH independently
monitored study execution at sites and par-
ticipated in pharmacovigilance, data anal-
ysis, and data and safety monitoring board
meetings. All authors had full access to the
data, and the corresponding author had fi-
nal responsibility for the decision to submit
for publication
RCT = Randomized controlled trial; ELISA = Enzyme Linked Immunosorbent Assay.
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MedDRA: Medical Dictionary for Regulatory Activities.
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
OTHER Bucher 2012 Diagnostic test accuracy study
OTHER Chatterjee 2012 RCT, not rotavirus vaccine
OTHER Davidson 2007 Review article about RV5 and RV1
OTHER de Palma 2010 Case-control study
OTHER Diness 2010 Study of vitamin A supplementation with Bacille Calmette-Guerin vaccine for rotavirus diarrhoea
outcomes
OTHER Dutta 2011 RCT, not rotavirus vaccine
OTHER Freedman 2007 Review article about acute infectious pediatric gastroenteritis
OTHER Gagneur 2011 Observational study (IVANHOE)
OTHER Glass 2004 Review article about rotavirus vaccines
OTHER Kapikian 1989 Review article about rotavirus vaccines
OTHER Kempe 2007 Survey of paediatricians about rotavirus disease and rotavirus vaccines
OTHER Muhsen 2010 Case-control study
OTHER NCT01195844 Ongoing observational study
OTHER NCT01236066 Ongoing observational study
OTHER NCT01375907 Ongoing study with adult participants
OTHER Prymula 2009 Review article about febrile reactions and vaccination
OTHER Rivera 2011 RCT, no placebo comparison
OTHER Tate 2012 Meta-analysis
OTHER Thyagarajan 2011 Procedural codes for rotavirus vaccination in the US
RV1 Anonymous 2004 Review article of the RV1 vaccine
150Vaccines for preventing rotavirus diarrhoea: vaccines in use (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(Continued)
RV1 Araujo 2007 Partial report of the Brazilian population in an included RV1 trial (RV1 Salinas 2005-LA)
RV1 Cervantes 2006 Letter to the Editor about RV1 trials
RV1 Cheuvart 2009 Review article of the RV1 vaccine
RV1 Correia 2010 Case-control study
RV1 CTRI/2012/02/002454 Ongoing RCT with no placebo group
RV1 De Vos 2006 Review article of the RV1 vaccine
RV1 De Vos 2009 Review article of the RV1 vaccine
RV1 Dennehy 2008 RCT of RV1 vaccine, but no placebo group reported
RV1 GSK[107077-057] 2008 RCT of RV1 vaccine, but no placebo group reported
RV1 GSK[107876-061] 2008 RCT of RV1 vaccine, but no placebo group reported
RV1 GSK[444563-020] 2007 RCT, but excludedbecause reportmentioned that “4 groups received an investigational vaccination
regimen”, but no details are provided about this vaccine (may be related to GlaxoSmithKline’s
RV1 vaccine)
RV1 NCT00353366 Ongoing non-randomized study
RV1 NCT00382772 2008 RCT comparing RV1 liquid formulation to lyophilized formulation, no placebo
RV1 NCT00653198 Ongoing case-control study
RV1 NCT00655187 Ongoing case-control study
RV1 NCT01162590 Ongoing study with adult participants
RV1 NCT01177826 Ongoing observational study
RV1 NCT01273077 Ongoing observational study
RV1 NCT01339221 Ongoing observational study
RV1 PLOSKER 2011 Economic analysis
RV1 Rojas 2007 Viral conversion on the same population of RV1 Ruiz-Palac 06-LA/EU (included trial)
RV1 Suryakiran 2011 Not RCT, integrated safety summary
RV1 Vesikari 2006 Review article about RV1
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RV5 [NCT00130832] 2010 Not RCT; open label study investigating different schedules of rotavirus and polio vaccine com-
binations without placebo
RV5 ACTRN12611000559910 Ongoing observational study
RV5 Bernstein 2008 Letter questioning the level of efficacy of RV5
RV5 Caple 2006 Review article about RV5
RV5 Ciarlet 2008 RCT of RV5 vaccine, but no placebo group reported
RV5 Clark 2006 Review article about RV5
RV5 El Khoury 2011 Mathematical model in Brazil
RV5 El Khoury 2011a Mathematical model in six Asian countries
RV5 Goveia 2008 Retrospective analysis to check percentage of babies that were breastfeeding while participating in
RV5 Vesikari 2006b-INT (included trial)
RV5 Goveia 2010 Post-hoc analysis of the Merck RV5 trials (mainly REST)
RV5 Heyse 2008 Review article about RV5
RV5 Keating 2006 Review article about RV5
RV5 NCT00496054 Ongoing non-randomized study
RV5 Tom-Revzon 2007 Review article about RV5
RV5 Tugcu 2009 RCT of RV5 vaccine, no placebo group reported
RV5 van der Wielen 2008 Review article about RV5
RV5 Vesikari 2011 RCT of RV5 and MenCC vaccines - concomitant or sequential administration, no placebo group
reported
Characteristics of ongoing studies [ordered by study ID]
Other ACTRN12610000525088
Trial name or title “A Phase 1 double-blind, randomized study to compare the safety, tolerability and immunogenicity of oral
RV3-BB rotavirus vaccine and placebo in infants, children and male adults”
Methods “Randomized controlled trial, parallel assignment”
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Participants Number: 60 (target)
Description: cohort 3: infants (males and females) aged 6 to 8 weeks inclusive in good health
Interventions 1 mL oral dose administered once
1. live attenuated human rotavirus vaccine RV3-BB
2. Placebo
Outcomes 1. Adverse events
2. Serologic markers of rotavirus immunity (immunoglobulin G (IgG) and immunoglobulin A (IgA), neu-
tralising antibodies (NA’s))
3. Presence of RV3-BB rotavirus vaccine in faecal extracts
Starting date 27 January 2010
Completion: not stated
Contact information Dr Carl Kirkwood, Murdoch Childrens Research Institute 4th Floor, Front Entry Building Royal Children’s
Hospital Flemington Road Parkville, Victoria 3052, Australia carl.kirkwood@mcri.edu.au
Notes Location: Australia
Registration number: ACTRN12610000525088 (Australian New Zealand Clinical Trials Registry)
Source of funding: Murdoch Childrens Research Institute
Other ACTRN12611001212943
Trial name or title A Phase IIa double-blind, randomized, placebo controlled study of the immunogenicity, safety, tolerability
and reactogenicity of three doses of oral RV3-BB rotavirus vaccine, with the first dose of vaccine administered
either at birth (0 to 5 days of age) or in infancy
Methods Randomized, parallel assignment, blinded
Participants Number: 93 (target)
Description: healthy, full-term infants, 0 to 5 days of age
Interventions 1. Neonatal schedule arm: RV3-BB rotavirus vaccine at 0 to 5 days, 9 weeks, and 15 weeks of age + placebo
at 23 weeks of age
2. Infant schedule arm: RV3-BB rotavirus vaccine at 9 weeks, 15 weeks, and 23 weeks of age + placebo at 0
to 5 days of age
3. Placebo
Outcomes 1. Vaccine shedding in stool
2. Solicited adverse events
3. Serious adverse events
Starting date December 2011
Contact information Professor Julie Bines; jebines@unimelb.edu.au
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Notes Location: New Zealand
Registration number: ACTRN12611001212943
Source of funding: Australian National Health and Medical Research Council; Australian Health Research
Council; Murdoch Children’s Research Institute
Other CTRI-091-000102
Trial name or title “A Phase III, Randomized, Double blind, Placebo Controlled Trial to Evaluate the protective efficacy of three
doses of Oral Rotavirus Vaccine (ORV) 116E, against severe Rotavirus gastroenteritis in infants ”
Methods “Randomized, Parallel Group, Placebo Controlled, Double-Blind Trial”
Participants Number: 6800 (target)
Description: infants aged 6 to 7 weeks at recruitment
Interventions 3 doses of 0.5 mL at 4 week intervals
1. Oral rotavirus vaccine 116E (ORV 116E)
2. Placebo
Outcomes 1. Severe rotavirus gastroenteritis (>/= 11 on the 20 point Vesikari scoring scale)
2. Any severity of gastroenteritis caused by non vaccine rotavirus
3. Any severity of gastroenteritis irrespective of etiology
4. Severe (>/= 11 on the 20 point Vesikari scoring scale) gastroenteritis irrespective of etiology
5. Hospitalization and/or supervised re-hydration therapy (equivalent to WHO plan B or C) in a treatment
facility/hospital for gastroenteritis
6. Very severe rotavirus gastroenteritis (>/= 16 on the 20-point Vesikari scoring system)
Starting date 1 February 2011
Completion: not stated
Contact information Dr. G.V.J.A. Harshavardhan, Bharat Biotech International Limited, Genome valley, Shameerpet 500078
Hyderabad, ANDHRA PRADESH, India, kmohan@bharatbiotech.com
Notes Location: India
Registration number: Clinical Trials Registry-India (CTRI/2010/091/000102)
Source of funding: 1) Department of Biotechnology (DBT), Ministry of Science and Technology, Gov-
ernment of India CGO Complex, Lodhi Road, New Delhi, India 2) Bharat Biotech International Limited
(BBIL), Genome Valley, Shameerpet, Hyderabad, Andhra Pradesh, India 3) PATH, 2201 Westlake Avenue,
Suite 200, Seattle, WA 98121, USA & A-9, Qutab Institutional Area, New Delhi, India
Other CTRI-091-003064
Trial name or title “ARandomized,Double-Blind, PlaceboControlled Study toAssess Safety andTolerability of RotaVacVaccine
(Live Attenuated Bovine-Human (UK) Reassortant Pentavalent Rotavirus Vaccine)”
Methods “Randomized, Parallel Group assignment, Placebo Controlled, Double-Blind Study”
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Other CTRI-091-003064 (Continued)
Participants Number: 60 (target)
Description: healthy male or female infants 8-10 weeks of age at the time of first dose of vaccination
Interventions 3 Oral doses with 28 days interval between each dose
1. Rotavirus vaccine
2. Placebo
Outcomes 1. Unsolicited and serious adverse events
2. Solicited symptom within 14 day
3. Rotavirus-specific IgA antibody titre
4. Viral Shedding
Starting date 10 January 2011
Completion: not stated
Contact information Dr. Sajjad Desai, Serum Institute of India Ltd, 212/2 Off Soli Poonawalla road, Hadapsar, 411028 Pune,
MAHARASHTRA India, sajjad.desai@seruminstitute.com
Notes Location: India
Registration number: Clinical Trials Registry-India (CTRI/2010/091/003064)
Source of funding: Serum Institute of India Ltd.
Other CTRI2009-091-000821
Trial name or title “A Randomized, Double-Blind, Placebo Controlled Study To Assess the Safety And Tolerability Of RotaVac
Vaccine (Live Attenuated Bovine-Human (UK) Reassortant Pentavalent Rotavirus Vaccine)”
Methods “Randomized, parallel group, placebo controlled trial”
Participants Number: not stated
Description: healthy adults (aged between 18 and 45 years); healthy toddlers; and healthy infants
Interventions RotaVac
1. RotaVac vaccine (live attenuated bovine-human (UK) reassortant pentavalent rotavirus vaccine): “Single
oral dose in Part I of the study and three doses in Part II of the study”
2. Placebo: “Schedule matching with Rotavirus vaccine”
Outcomes 1. “Occurrence of any solicited symptom within 7-day solicited follow-up period” (Primary outcome)
2. “Occurrence of unsolicited and serious adverse events within 7 days after vaccination” (Primary outcome)
3. “Rotavirus-specific IgA antibody titre” (Secondary outcome)
4. “Presence of rotavirus antigen in any diarrhoeal stools during the 7-day solicited follow-up period” (Sec-
ondary outcome)
Starting date 21 October 2009
Completion: not stated
Contact information Dr Anand Pandit, KEM Hospital, Pune, Maharashtra, India
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Other CTRI2009-091-000821 (Continued)
Notes Location: KEM Hospital, Pune, Maharashtra, India
Registration number: Clinical Trials Registry India (CTRI/2009/091/000821, 15-10-2009); temporary
unique trial identification number (UTRI) (104944555-0610200913021785)
Source of funding: Serum Institute of India, Pune, India
Other NCT00981669
Trial name or title “Evaluation of Rotavirus Vaccine Produced by Butantan Institute. Phase I - Safety, Tolerability and Immuno-
genicity Evaluation”
Methods “Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Placebo Control, Parallel
Assignment, Safety Study”
Participants Target number: 80
Description: healthy males aged 18 to 40 years
Interventions “An agreement between Path Foundation and Butantan Institute has made possible the transfer of technology
to Butantan Institute to produce, at a reduced cost, a pentavalent rotavirus vaccine including the rotavirus
serotypes more frequent in Brazil”
1. Rotavirus vaccine (3 doses with 6 weeks interval); other name: Brazilian rotavirus vaccine
2. Placebo ( 3 doses with 6 weeks interval); other name: Butantan placebo
Outcomes “Titers of anti-rotavirus IgA and the presence of neutralizing antibodies anti-rotavirus”
Starting date March 2009
Anticipated completion date: March 2010 [primary outcome], still ongoing
Contact information Alexander R Precioso (Study Director), Butantan Institute, Brazil
Notes Location: Brazil
Registration number: NCT00981669
Source of funding: Butantan Institute, Brazil
Other NCT01061658
Trial name or title “Phase I/II, Randomized, Double-blind, Placebo-controlled, Dosage Selection (10e5.5 or 10e6.25 FFU of
Each Constituent Serotype Per 0.5 mL) Study to Evaluate the Safety, Tolerability, and Immunogenicity of a
3-dose Series of Live Attenuated Tetravalent (G1-G4) Bovine-Human Reassortant Rotavirus Vaccine [BRV-
TV] Administered to Healthy Indian Infants”
Methods “Randomized, Placebo Control, Safety Study, Parallel Assignment, Double Blind (Subject, Caregiver, Inves-
tigator)”
Participants Number: 90 (target)
Description: healthy infants 6 to 8 weeks of age at time of enrolment of either sex
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Other NCT01061658 (Continued)
Interventions 1. Live attenuated tetravalent (G1-G4) bovine-human reassortant rotavirus vaccine
2. Placebo
Outcomes 1. Reactogenicity
2. Adverse events
3. Shedding of vaccine rotavirus in stool samples
4. Seroconversion rate
5. Sero-response rate
6. GMT of serum IgA antibody against rotavirus
Starting date 1 July 2010
Completion: not stated
Contact information Gagandeep Kang, MD PhD, gkang@cmcvellore.ac.in
Notes Location: India
Registration number: NCT01061658 (http://clinicaltrials.gov)
Source of funding: Shantha Biotechnics Limited
Other NCT01266850
Trial name or title “Safety and Immunogenicity of Sequential Rotavirus Vaccine Schedules With RotaTeq® and Rotarix®”
Methods “Randomized, Efficacy Study, Parallel Assignment, Open Label”
Participants Number: 1266 (target)
Description: male or female infants who are at least 6 weeks of age and no more than 14 weeks
Interventions 1. RV1
2. RV5
Outcomes 1. Geometric mean titer (GMT) serum anti-rotavirus immunoglobulin (Ig)A
2. Seroresponse rate
3. Comparison of systemic reaction incidences
4. GMT of neutralizing rotavirus antibody to the most common rotavirus serotypes (G1-G4 and G9)
Starting date March 2011
Estimated completion: June 2013
Contact information Kathryn M Edwards, kathryn.edwards@vanderbilt.edu
Notes Location: US
Registration number: NCT01266850 (http://clinicaltrials.gov)
Source of funding: National Institute of Allergy and Infectious Diseases (NIAID)
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Other NCT01305109
Trial name or title “A Phase III, Randomized, Double Blind, Placebo Controlled Trial to Evaluate the Protective Efficacy of
Three Doses of Oral Rotavirus Vaccine (ORV) 116E, Against Severe Rotavirus Gastroenteritis in Infants”
Methods “randomized, placebo control, efficacy study, parallel assignment, double blind”
Participants Number: 6800 (target)
Description: infants aged 6 to 7 weeks at recruitment
Interventions 1. ORV 116E
2. Placebo
Outcomes 1. Severe rotavirus gastroenteritis (>= 11 on the 20 point Vesikari scoring scale)
2. Adverse events
Starting date March 2011
Estimated completion: April 2014
Contact information Dr. Nita Bhandari, MD, PhD, nita.bhandari@sas.org.in
Notes Location: India
Registration number: NCT01305109 (http://clinicaltrials.gov)
Source of funding: Bharat Biotech International Limited
Other NCT01571505
Trial name or title Exploration of the biologic basis for underperformance of oral polio and rotavirus vaccines in India (PRO-
VIDE)
Methods Randomized, efficacy study, parallel assignment, single blind
Participants Number: 372
Description: healthy infants 0 to 49 days old with no obvious congenital abnormalities or birth defects
Interventions 1. Rotavirus vaccine (unspecified) with OPV + IPV booster
2. Rotavirus vaccine (unspecified) with OPV + OPV booster
Outcomes 1. Systemic immune responses
2. Mucosal immune responses
Starting date March 2012
Estimated completion: February 2015
Contact information Dipika Sur, M.D.; dipikasur@hotmail.com
Notes Location: India
Registration number: NCT01571505, CTRI/2012/03/002504
Source of funding: International Vaccine Institute
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RV1 ISRCTN37373664
Trial name or title “A double blind, randomized placebo controlled study of the safety, reactogenicity and immunogenicity of
two doses of orally administered human rotavirus vaccine (RIX4414) in healthy infants in South Africa”
Methods “A double blind, randomized placebo controlled study”
Participants Target number: 285
Description: healthy infants aged 6 to 10 weeks
Interventions 1. RV1: 2 doses at 106.5 CCID50 viral concentration
2. Placebo
Outcomes 1. Seroconversion
2. Immunogenicity: vaccine take; serum rotavirus immunoglobulin A (IgA) antibody concentrations; anti-
poliovirus antibody titres; viral shedding
3. Safety: solicited symptom; unsolicited adverse events; presence of rotavirus in diarrhoeal stool; serious
adverse events
4. Efficacy: rotavirus gastroenteritis/severe rotavirus gastroenteritis; severe rotavirus gastroenteritis
Starting date 1 January 2002
Anticipated end date: 25 October 2004, completed
Contact information Dr Duncan Steele (steeled@who.int), WHO
Notes Location: South Africa
Registration number: ISRCTN37373664
Source of funding: RAPID trials (USA); WHO (Switzerland)
RV1 ISRCTN86632774
Trial name or title “A phase II, double blind randomized, placebo controlled study to assess the safety reactogenicity and im-
munogenicity of three doses of GSK Biologicals (South Africa)”
Methods “randomized, controlled study with three parallel groups with balanced allocation (1:1:1)”
Participants Target number: 271
Description: participants’ parents/guardians who could comply with the protocol requirements (eg comple-
tion of diary cards, return for follow-up visits); male or female aged 6 to 10 weeks of age at the time of first
vaccination; written informed consent from parents/guardians; born after a gestation period of 36 to 42 weeks
Interventions 1. RIX4414 (RV1): 2 doses vaccine at 106.5 CCID50 viral concentration plus 1 dose of placebo
2. Placebo: 3 doses
Outcomes 1. Seroprotection for each polio serotype (primary)
2. Vaccine take
3. Viral shedding
4. Presence of rotavirus in diarrhoeal stools
5. Anti-poliovirus antibody titres
6. Serum anti-rotavirus immunoglobulin A (IgA) antibody titres
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RV1 ISRCTN86632774 (Continued)
7. Solicited symptoms
8. Unsolicited adverse events
9. Serious adverse events
Starting date 1 January 2001
Anticipated end date: 1 January 2003, completed
Contact information Dr Duncan Steele (steeled@who.int), WHO
Notes Location: South Africa
Registration number: ISRCTN86632774
Source of funding: RAPID trials (USA); WHO (Switzerland)
RV1 NCT00134732
Trial name or title “Assess the Immunogenicity, Safety & Reactogenicity of 2 Doses of GSK Biologicals’ Oral Live Attenuated
Human Rotavirus (HRV) Vaccine inHealthy Infants (6-12Weeks of Age at First Dose) Previously Uninfected
With Human Rotavirus”
Methods “Prevention, Randomized, Double-Blind, Parallel Assignment, Safety Study”
Participants Target number: 150
Description: healthy infants aged between 6 and 12 weeks (42 to 90 days) of age at the time of the first
vaccination
Interventions 1. Human rotavirus vaccine [RV1]
2. Placebo
Both administered starting at 2 months of age according to a two dose schedule (0, 2 months)
Outcomes 1. Percent who seroconverted (anti-rota serum IgA, 2 months post dose 2) (primary)
2. Grade 2 and 3 fever, vomiting, diarrhoea, solicited symptoms
3. Unsolicited events
4. Serious adverse events
5. Presence of rotavirus in gastroenteritis
6. Concentration IgA 2 months post dose 2
Starting date July 2005
Completion date: not stated, completed
Contact information GSK Clinical Trials, GlaxoSmithKline
Notes Location: Republic of Korea
Registration number: NCT00134732
Source of funding: GlaxoSmithKline
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RV1 NCT00158756
Trial name or title “Assess Immunogenicity&Reactogenicity of 2 Formulations ofGSK’sDTPw-HBVVaccines vs Concomitant
Admn of CSL’s DTPw [diphtheria-tetanus-pertussis] & GSK’s HBV [Hepatitis B] Vaccine, co-Admnd With
GSK’s Rotavirus Vaccine, to Infants at 3, 4½ & 6 Mths, After Birth Dose of HBV Vaccine”
Methods “Prevention, Randomized, Open Label, Active Control, Parallel Assignment”
Participants Number: 330
Description: healthy infants aged 11 to 17 weeks of age at the time of the first DTPw vaccination
Interventions 5 groups
1. RV1 plus DTPw-HBVs
2 to 5. One of the two formulations of GSK Biologicals’ DTPw-HBV + Placebo CSL’s DTPw + GSK
Biologicals’ HBV
Outcomes 1. Anti-diphtheria antibody concentration (primary)
2. Antibody concentrations or titres against all vaccine antigens (diphtheria, tetanus, pertussis, hepatitis B,
rotavirus, and poliovirus antigens)
3. Reactogenicity and safety: solicited symptoms; unsolicited symptoms; serious adverse events
Starting date September 2005
Anticipated completion date: November 2006, completed
Contact information Clinical Trials, GlaxoSmithKline
Notes Location: Moscow, Russian Federation
Registration number: NCT00158756
Source of funding: GlaxoSmithKline
RV1 NCT00289172
Trial name or title “A Multicenter Study of the Immunogenicity & Safety of 2 Doses of GSK Biologicals’ Oral Live Attenuated
Human Rotavirus Vaccine (RIX4414) as Primary Dosing of Healthy Infants in India Aged Approximately 8
Wks at the Time of the First Dose”
Methods “Prevention, Randomized, Double-Blind, Parallel Assignment, Safety Study”
Participants Number: 360
Description: healthy infants in India aged 8 to 10 weeks at time of first vaccination
Interventions 1. Human rotavirus [RV1] vaccine
2. Placebo
Both administered starting at age 8 to 12 weeks of age, according to a 2- dose schedule (0, 1 months schedule)
Participants should have been administered the first dose of diphtheria, pertussis, and tetanus/ oral polio
vaccine/Hepatitis B vaccines as per the local universal immunization program at 6 weeks of age
Outcomes 1. Percentage of seroconversion (anti-rota serum immunoglobulin A (IgA)) (primary)
2. Fever, vomiting, diarrhoea
3. Solicited symptoms
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RV1 NCT00289172 (Continued)
4. Unsolicited events
5. Serious adverse events
6. Presence of rotavirus in gastroenteritis stools
Starting date February 2006
Status: completed
Contact information Not stated
Notes Location: India
Registration number: NCT00289172
Source of funding: GlaxoSmithKline
RV1 NCT00383903
Trial name or title “A Study of the Safety, Reactogenicity and Immunogenicity of 2 or 3 Doses of GSK Biologicals’ Oral Live
Attenuated Human Rotavirus (HRV) Vaccine in Healthy Infants (Approximately 5-10 Weeks Old) in South
Africa”
Methods “Prevention, Randomized, Double-Blind, Parallel Assignment, Safety/Efficacy Study”
Participants Number: 475
Inclusion criteria: healthy infants aged between 5 and 10 weeks with confirmed negative HIV status of the
participant’s mother
Interventions Oral live attenuated human rotavirus vaccine: 2 or 3 doses (“to determine the appropriate regimen of GSK
human rotavirus vaccine for concomitant administration with EPI vaccines”)
Outcomes 1. Seroconversion after human rotavirus vaccination (primary)
2. Shedding
3. Serum anti-rota IgA antibody concentrations
4. Anti-polio 1, 2 and 3 seroprotection rates
5. Reactogenicity
6. Safety
Starting date September 2003
Status: completed
Contact information GSK Clinical Trials, GlaxoSmithKline
Notes Location: South Africa
Registration number: NCT00383903
Source of funding: GlaxoSmithKline
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RV1 NCT00420316
Trial name or title “To Assess Long-Term Efficacy & Safety of Subjects Approximately 3 Years After Priming With 2 Doses of
GlaxoSmithKline (GSK) Biologicals’ Oral Live Attenuated Human Rotavirus (HRV) Vaccine (Rotarix) in
the Primary Vaccination Study (102247)”
Methods “Prevention, Randomized, Open Label, Parallel Assignment, Safety/Efficacy Study”
Participants Number: 2601
Description:male or female who has completed the second year efficacy follow-up of the primary vaccination
study in Finland
Interventions “To assess the long-term efficacy and safety of the subjects during the third year after priming with 2 doses of
GSK Biologicals’ oral live attenuated HRV [human rotavirus] vaccine (Rotarix) in the primary vaccination
study (102247). TheRotarix vaccine was administered in the primary vaccination study. There was no vaccine/
intervention in this long-term efficacy study”
Outcomes 1. Any rotavirus gastroenteritis (primary)
2. Severe rotavirus gastroenteritis
3. Severe gastroenteritis
4. Mortality
5. Serious adverse events (full study)
6. Intussusception (retrospective)
Starting date February 2007
Anticipated completion date: August 2007, completed
Contact information GSK Clinical Trials, GlaxoSmithKline
Notes Location: Finland
Registration number: NCT00420316
Source of funding: GlaxoSmithKline
RV1 NCT00425737
Trial name or title “A Study to Assess the Efficacy, Immunogenicity and Safety of Two Doses of Oral Live Attenuated Human
Rotavirus (HRV) Vaccine (Rotarix) in Healthy Infants”
Methods “Prevention, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study”
Participants Number: 405
Description: healthy infants aged 6 to 12 weeks
Interventions 1. Two doses of oral live attenuated human rotavirus vaccine
Outcomes 1. Rotavirus gastroenteritis
2. Severe rotavirus gastroenteritis
3. Solicited symptoms
4. Unsolicited adverse events
5. Serious adverse events
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RV1 NCT00425737 (Continued)
6. Presence of rotavirus antigen in stool samples
7. Immunogenicity
Starting date August 2002
Completion date: December 2002
Contact information Clinical Trials, GlaxoSmithKline
Notes Location: Finland
Registration number: NCT00425737
Source of funding: GlaxoSmithKline
RV1 NCT00429481
Trial name or title “A Study to Assess the Efficacy, Immunogenicity and Safety of 2 Doses of Oral Live Attenuated Human
Rotavirus Vaccine (Rotarix) at Different Viral Concentrations in Healthy Infants”
Methods “Prevention, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study”
Participants Number: 2460
Description: healthy infants aged 11 to 17 weeks
Interventions 1. RV1: 2 doses (at different concentrations)
2. Placebo
Outcomes 1. Rotavirus gastroenteritis
2. Severe rotavirus gastroenteritis
3. Rotavirus IgA antibody titres
4. Solicited symptoms
5. Unsolicited adverse events
6. Serious adverse events
Starting date December 2000
Completion date: not stated, completed
Contact information Clinical Trials, GlaxoSmithKline
Notes Location: Singapore
Registration number: NCT00429481
Source of funding: GlaxoSmithKline
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RV1 NCT01171963
Trial name or title “Efficacy, Immunogenicity and Safety of Two Doses of GlaxoSmithKline (GSK) Biologicals’ Oral Live At-
tenuated Liquid Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants”
Methods “Randomized, Efficacy Study, Parallel Assignment, Double Blind”
Participants Number: 3250
Description: male or female infant of Chinese origin between, and including, 6 and 16 weeks of age at the
time of the first vaccination
Interventions Co-administered with Infanrix™ and oral poliovirus vaccine
1. GSK Biologicals’ liquid human rotavirus vaccine 444563
2. Placebo
Outcomes 1. Severe rotavirus gastroenteritis caused by the circulating wild-type rotavirus strains
2. Anti-rotavirus Immunoglobulin A antibody concentrations
3. Any and hospitalized rotavirus gastroenteritis caused by circulating wild type rotavirus
4. Any and severe all cause gastroenteritis
5. Solicited symptoms
6. Serious adverse events
7. Unsolicited symptoms
Starting date August 2010
Estimated completion: December 2011
Contact information GSK Clinical Trials, GlaxoSmithKline
Notes Location: China
Registration number: NCT01171963
Source of funding: GlaxoSmithKline
RV1 NCT01199874
Trial name or title “The Immunogenicity of Rotavirus Vaccine Under Different Age Schedules and the Impact of Withholding
Breast Feeding Around the Time of Vaccination on the Immunogenicity of Rotarix Vaccine”
Methods “Randomized, Efficacy Study, Parallel Assignment, Open Label”
Participants Number: 1100 (target)
Description: healthy infants, 6 weeks 0 days to 6 weeks 6 days age at the time of enrolment, free of chronic
or serious medical condition as determined by history and physical exam at time of enrolment into in the
study
Interventions Rotavirus vaccine
Outcomes 1. Seropositivity as anti-rotavirus IgA concentration >/= 20 U/ml
Starting date April 2011
Estimated completion: April 2012
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RV1 NCT01199874 (Continued)
Contact information S. Asad Ali, MBBS, Aga Khan University, asad.ali@aku.edu
Notes Location: Pakistan
Registration number: NCT01199874
Source of funding: Program for Appropriate Technology in Health
RV1 NCT01375647
Trial name or title “Exploration of the biologic basis for underperformance of oral polio and rotavirus vaccines in Bangladesh
(PROVIDE)”
Methods “Randomized, single blind, efficacy study, factorial assignment”
Participants Number: 700
Description: healthy infant aged 0 to 7 days
Interventions 1. RV1
2. RV1 + IPV
3. IPV
Outcomes 1. Differences in episodes of Rotavirus diarrhoea between rotavirus vaccinees and non-vaccinees
2. Immunogenicity measures-IgA response to rota and polio virus vaccines
Starting date May 2011
Estimated completion: October 2014
Contact information Masud Alam, M.D., masud@icddrb.org
Notes Location: Bangladesh
Registration number: NCT01375647
Source of funding: University of Vermont; Bill and Melinda Gates Foundation; Centers for Disease Control
and Prevention; International Centre for Diarrhoeal Disease Research, Bangladesh
RV1 NCT01575197
Trial name or title Evaluation of the human rotavirus vaccine when given at varying schedules in rural Ghana
Methods Randomized, parallel assignment, open label
Participants Number: 456
Description: healthy infants 42 days to 55 days at enrolment, free of chronic or serious medical condition
Interventions 1. RV1 at 6 and 10 weeks of age
2. RV1 at 10 and 14 weeks of age
3. RV1 at 6, 10 and 14 weeks of age
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RV1 NCT01575197 (Continued)
Outcomes 1. IgA seroconversion
2. IgA GMT’s
3. Vaccine-type rotavirus shedding in stool
4. Serious adverse events
Starting date April 2012
Estimated completion: October 2012
Contact information George E Armah, PhD; GArmah@noguchi.mimcom.org
Notes Location: Ghana
Registration number: NCT01575197
Source of funding: PATH
RV1 Tatochenko 2008
Trial name or title Co-administration of a human rotavirus vaccine Rix4414 with DTPw-HBv Vaccines: immunogenicity and
reactogenicity in healthy infants
Methods Randomized controlled trial
Participants Number: 308
Description: healthy infants 11 to 17 weeks of age
Interventions 1. RIX4414 vaccine
2. Placebo
Outcomes 1. Immunogenicity
2. Safety
Starting date Not reported
Contact information GlaxoSmithKline
Notes Location: not reported
Registration number: not reported
Source of funding: GlaxoSmithKline
RV5 NCT00880698
Trial name or title “Safety and Immunogenicity of a Live, Attenuated Rotavirus (RotaTeq) in HIV-1 Infected and Uninfected
Children Born to HIV-1-Infected Mothers”
Methods “Randomized, Double Blind (Subject, Investigator), Parallel Assignment, Safety/Efficacy Study”
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RV5 NCT00880698 (Continued)
Participants Number: 320
Description: HIV-1 uninfected children (Group 1) and infected children (Group 2), up to 14 weeks, born
to HIV-1-infected mothers
Interventions 1. RV5
2. Placebo
Outcomes 1. Safety
2. Immunogenicity
Starting date December 2009
Anticipated completion date: July 2012 (final data collection date for primary outcome measure)
Contact information Myron J Levin (Study Chair), University of Colorado at Denver Health Sciences Center
Notes Location: Botswana
Registration number: NCT00880698
Source of funding: National Institute of Allergy and Infectious Diseases (NIAID)
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D A T A A N D A N A L Y S E S
Comparison 1. RV1 versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Rotavirus diarrhoea: severe (up
to 1 year follow-up)
9 46045 Risk Ratio (M-H, Random, 95% CI) 0.20 [0.11, 0.35]
1.1 Low-mortality countries
(WHO strata A & B)
6 40631 Risk Ratio (M-H, Random, 95% CI) 0.14 [0.07, 0.26]
1.2 High-mortality countries
(WHO stratum E)
3 5414 Risk Ratio (M-H, Random, 95% CI) 0.37 [0.18, 0.75]
2 Rotavirus diarrhoea: severe (up
to 2 years follow-up)
10 35618 Risk Ratio (M-H, Fixed, 95% CI) 0.24 [0.19, 0.29]
2.1 Low-mortality countries
(WHO strata A & B)
8 32854 Risk Ratio (M-H, Fixed, 95% CI) 0.15 [0.12, 0.20]
2.2 High-mortality countries
(WHO stratum E)
2 2764 Risk Ratio (M-H, Fixed, 95% CI) 0.58 [0.42, 0.79]
3 All-cause diarrhoea: severe cases
(up to 1 year follow-up)
3 8813 Risk Ratio (M-H, Random, 95% CI) 0.59 [0.42, 0.83]
3.1 Low-mortality countries
(WHO strata A & B)
1 3874 Risk Ratio (M-H, Random, 95% CI) 0.48 [0.37, 0.61]
3.2 High-mortality countries
(WHO stratum E)
2 4939 Risk Ratio (M-H, Random, 95% CI) 0.66 [0.44, 0.98]
4 All-cause diarrhoea: severe cases
(up to 2 years follow-up)
4 9033 Risk Ratio (M-H, Fixed, 95% CI) 0.68 [0.60, 0.76]
4.1 Low-mortality countries
(WHO strata A & B)
2 6269 Risk Ratio (M-H, Fixed, 95% CI) 0.49 [0.40, 0.60]
4.2 High-mortality countries
(WHO stratum E)
2 2764 Risk Ratio (M-H, Fixed, 95% CI) 0.82 [0.71, 0.95]
5 All-cause diarrhoea: severe
episodes (up to 1 year
follow-up)
1 Rate Ratio (Fixed, 95% CI) Subtotals only
5.1 Low-mortality countries
(WHO strata A & B)
1 Rate Ratio (Fixed, 95% CI) 0.60 [0.50, 0.72]
6 All-cause diarrhoea: severe
episodes (up to 2 years
follow-up)
2 Rate Ratio (Fixed, 95% CI) Subtotals only
6.1 Low-mortality countries
(WHO strata A & B)
2 Rate Ratio (Fixed, 95% CI) 0.63 [0.56, 0.71]
7 All-cause death 25 100802 Risk Ratio (M-H, Fixed, 95% CI) 1.04 [0.82, 1.32]
7.1 Low-mortality countries
(WHO strata A & B)
18 93321 Risk Ratio (M-H, Fixed, 95% CI) 1.27 [0.89, 1.81]
7.2 High-mortality countries
(WHO strata D & E)
7 7481 Risk Ratio (M-H, Fixed, 95% CI) 0.88 [0.64, 1.22]
8 All serious adverse events 27 99438 Risk Ratio (M-H, Fixed, 95% CI) 0.90 [0.85, 0.95]
8.1 Low-mortality countries
(WHO strata A & B)
20 91957 Risk Ratio (M-H, Fixed, 95% CI) 0.90 [0.84, 0.95]
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8.2 High-mortality countries
(WHO strata D & E)
7 7481 Risk Ratio (M-H, Fixed, 95% CI) 0.89 [0.76, 1.04]
9 Serious adverse events:
intussusception
13 97246 Risk Ratio (M-H, Fixed, 95% CI) 0.88 [0.53, 1.47]
9.1 Low-mortality countries
(WHO strata A & B)
11 91832 Risk Ratio (M-H, Fixed, 95% CI) 0.87 [0.52, 1.46]
9.2 High-mortality countries
(WHO stratum E)
2 5414 Risk Ratio (M-H, Fixed, 95% CI) 1.49 [0.06, 36.63]
10 Serious adverse events:
Kawasaki disease
3 13117 Risk Ratio (M-H, Fixed, 95% CI) 1.79 [0.30, 10.61]
11 Serious adverse events requiring
hospitalization
2 63675 Risk Ratio (M-H, Fixed, 95% CI) 0.88 [0.81, 0.96]
12 Rotavirus diarrhoea: of any
severity (up to 2 months
follow-up)
11 3610 Risk Ratio (M-H, Fixed, 95% CI) 1.17 [0.69, 2.00]
12.1 Low-mortality countries
(WHO strata A & B)
8 2853 Risk Ratio (M-H, Fixed, 95% CI) 1.28 [0.66, 2.50]
12.2 High-mortality countries
(WHO strata D & E)
3 757 Risk Ratio (M-H, Fixed, 95% CI) 1.0 [0.41, 2.41]
13 Rotavirus diarrhoea: of any
severity (up to 1 year follow-up)
6 11349 Risk Ratio (M-H, Random, 95% CI) 0.31 [0.19, 0.50]
13.1 Low-mortality countries
(WHO strata A & B)
3 5935 Risk Ratio (M-H, Random, 95% CI) 0.19 [0.08, 0.47]
13.2 High-mortality countries
(WHO stratum E)
3 5414 Risk Ratio (M-H, Random, 95% CI) 0.45 [0.28, 0.73]
14 Rotavirus diarrhoea: of
any severity (up to 2 years
follow-up)
6 8544 Risk Ratio (M-H, Random, 95% CI) 0.35 [0.25, 0.48]
14.1 Low-mortality countries
(WHO strata A & B)
5 7293 Risk Ratio (M-H, Random, 95% CI) 0.33 [0.21, 0.50]
14.2 High-mortality countries
(WHO stratum E)
1 1251 Risk Ratio (M-H, Random, 95% CI) 0.41 [0.28, 0.62]
15 All-cause diarrhoea: all cases
(up to 2 months follow-up)
6 2448 Risk Ratio (M-H, Fixed, 95% CI) 0.89 [0.71, 1.13]
15.1 Low-mortality countries
(WHO strata A & B)
5 2348 Risk Ratio (M-H, Fixed, 95% CI) 0.86 [0.66, 1.12]
15.2 High-mortality countries
(WHO stratum E)
1 100 Risk Ratio (M-H, Fixed, 95% CI) 1.04 [0.69, 1.58]
16 All-cause diarrhoea: all cases
(up to 1 year follow-up)
2 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
16.1 Low-mortality countries
(WHO strata A & B)
2 2204 Risk Ratio (M-H, Fixed, 95% CI) 0.92 [0.82, 1.03]
17 All-cause diarrhoea: all cases
(up to 2 years follow-up)
2 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
17.1 Low-mortality countries
(WHO strata A & B)
2 2789 Risk Ratio (M-H, Fixed, 95% CI) 0.81 [0.66, 1.00]
18 All-cause diarrhoea: all episodes
(up to 1 year follow-up)
2 Rate Ratio (Fixed, 95% CI) Subtotals only
18.1 Low-mortality countries
(WHO strata A & B)
2 Rate Ratio (Fixed, 95% CI) 0.98 [0.88, 1.10]
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19 All-cause diarrhoea: all episodes
(up to 2 years follow-up)
1 Rate Ratio (Fixed, 95% CI) Subtotals only
19.1 Low-mortality countries
(WHO strata A & B)
1 Rate Ratio (Fixed, 95% CI) 1.02 [0.78, 1.33]
20 All-cause hospitalizations (up
to 2 years follow-up)
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
20.1 Low-mortality countries
(WHO strata A & B)
1 2421 Risk Ratio (M-H, Fixed, 95% CI) 0.36 [0.15, 0.86]
21 Rotavirus diarrhoea: requiring
hospitalization
9 Risk Ratio (M-H, Random, 95% CI) Subtotals only
21.1 Up to 1 year follow-up
(at least 1 rotavirus season)
6 39260 Risk Ratio (M-H, Random, 95% CI) 0.19 [0.08, 0.43]
21.2 Second year follow-up
(at least 2 rotavirus seasons)
6 32183 Risk Ratio (M-H, Random, 95% CI) 0.14 [0.09, 0.23]
22 Rotavirus diarrhoea: requiring
medical attention
3 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
22.1 Up to 1 year follow-up
(at least 1 rotavirus season)
1 3874 Risk Ratio (M-H, Fixed, 95% CI) 0.08 [0.04, 0.16]
22.2 Second year follow-up
(at least 2 rotavirus seasons)
3 7017 Risk Ratio (M-H, Fixed, 95% CI) 0.22 [0.16, 0.31]
23 All-cause diarrhoea: cases
requiring hospitalization
2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
23.1 Up to one year of
follow-up (at least 1 rotavirus
season)
2 14393 Risk Ratio (M-H, Random, 95% CI) 0.43 [0.17, 1.11]
23.2 Second year of follow-up
(at least 2 rotavirus seasons)
2 14367 Risk Ratio (M-H, Random, 95% CI) 0.52 [0.27, 0.99]
24 All-cause diarrhoea: episodes
requiring hospitalization
1 Rate Ratio (Fixed, 95% CI) Subtotals only
24.1 Up to 1 year of follow-up
(at least 1 rotavirus season)
1 Rate Ratio (Fixed, 95% CI) 0.58 [0.47, 0.71]
24.2 Second year of follow-up
(at least 2 rotavirus seasons)
1 Rate Ratio (Fixed, 95% CI) 0.53 [0.46, 0.61]
25 Reactogenicity: fever 23 Risk Ratio (M-H, Random, 95% CI) Subtotals only
25.1 After dose 1 20 11563 Risk Ratio (M-H, Random, 95% CI) 1.08 [0.98, 1.18]
25.2 After dose 2 19 11156 Risk Ratio (M-H, Random, 95% CI) 0.98 [0.91, 1.06]
25.3 After dose 3 4 1390 Risk Ratio (M-H, Random, 95% CI) 0.98 [0.86, 1.13]
25.4 End of follow-up 16 8799 Risk Ratio (M-H, Random, 95% CI) 0.97 [0.93, 1.01]
26 Reactogenicity: diarrhoea 22 Risk Ratio (M-H, Random, 95% CI) Subtotals only
26.1 After dose 1 20 14103 Risk Ratio (M-H, Random, 95% CI) 1.01 [0.86, 1.20]
26.2 After dose 2 19 11156 Risk Ratio (M-H, Random, 95% CI) 0.93 [0.76, 1.14]
26.3 After dose 3 4 1390 Risk Ratio (M-H, Random, 95% CI) 0.69 [0.35, 1.36]
26.4 End of follow-up 15 11178 Risk Ratio (M-H, Random, 95% CI) 0.92 [0.80, 1.07]
27 Reactogenicity: vomiting 22 Risk Ratio (M-H, Random, 95% CI) Subtotals only
27.1 After dose 1 20 14103 Risk Ratio (M-H, Random, 95% CI) 1.06 [0.96, 1.17]
27.2 After dose 2 19 11156 Risk Ratio (M-H, Random, 95% CI) 0.92 [0.78, 1.09]
27.3 After dose 3 4 1390 Risk Ratio (M-H, Random, 95% CI) 1.34 [0.71, 2.50]
27.4 End of follow-up 15 11178 Risk Ratio (M-H, Random, 95% CI) 0.93 [0.82, 1.05]
28 Adverse events requiring
discontinuation (end of
follow-up)
21 90604 Risk Ratio (M-H, Fixed, 95% CI) 1.07 [0.86, 1.34]
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29 Immunogenicity: rotavirus
vaccine shedding (end of
follow-up)
15 2606 Risk Ratio (M-H, Random, 95% CI) 12.07 [5.23, 27.85]
30 Immunogenicity:
seroconversion
24 Risk Ratio (M-H, Random, 95% CI) Subtotals only
30.1 After dose 1 9 2537 Risk Ratio (M-H, Random, 95% CI) 20.39 [8.48, 49.01]
30.2 After dose 2 21 6416 Risk Ratio (M-H, Random, 95% CI) 11.04 [7.03, 17.34]
30.3 After dose 3 4 1094 Risk Ratio (M-H, Random, 95% CI) 8.43 [4.16, 17.11]
31 Drop outs before the end of the
trial
22 25005 Risk Ratio (M-H, Fixed, 95% CI) 0.91 [0.81, 1.02]
32 Subgroup analysis: rotavirus
diarrhoea of any severity (by G
type)
4 Risk Ratio (M-H, Random, 95% CI) Subtotals only
32.1 G1 4 24335 Risk Ratio (M-H, Random, 95% CI) 0.14 [0.08, 0.26]
32.2 G2 3 23587 Risk Ratio (M-H, Random, 95% CI) 0.43 [0.24, 0.75]
32.3 G3 2 5720 Risk Ratio (M-H, Random, 95% CI) 0.15 [0.05, 0.48]
32.4 G4 2 5720 Risk Ratio (M-H, Random, 95% CI) 0.20 [0.07, 0.59]
32.5 G9 2 5720 Risk Ratio (M-H, Random, 95% CI) 0.40 [0.17, 0.91]
33 Subgroup analysis: severe cases
of rotavirus diarrhoea (by G
type)
6 Risk Ratio (M-H, Random, 95% CI) Subtotals only
33.1 G1 5 36100 Risk Ratio (M-H, Random, 95% CI) 0.20 [0.11, 0.37]
33.2 G2 4 37117 Risk Ratio (M-H, Random, 95% CI) 0.40 [0.16, 0.98]
33.3 G3 2 12940 Risk Ratio (M-H, Random, 95% CI) 0.26 [0.01, 8.16]
33.4 G4 1 2421 Risk Ratio (M-H, Random, 95% CI) 0.12 [0.00, 2.95]
33.5 G9 3 19250 Risk Ratio (M-H, Random, 95% CI) 0.15 [0.07, 0.33]
34 Subgroup analysis: rotavirus
diarrhoea in malnourished
children
1 287 Risk Ratio (M-H, Fixed, 95% CI) 0.39 [0.19, 0.79]
34.1 Up to 1 year of follow-up
(at least 1 rotavirus season)
1 287 Risk Ratio (M-H, Fixed, 95% CI) 0.39 [0.19, 0.79]
35 Subgroup analysis: rotavirus
diarrhoea in HIV-infected
children
1 100 Risk Ratio (M-H, Fixed, 95% CI) 1.0 [0.26, 3.78]
36 Subgroup analysis: serious
adverse events in premature
babies
1 1009 Risk Ratio (M-H, Fixed, 95% CI) 0.75 [0.45, 1.25]
37 Subgroup analysis: severe
rotavirus diarrhoea in breast
fed and formula fed infants
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
37.1 Severe rotavirus
diarrhoea (2 year follow-up)
breast fed infants
1 3046 Risk Ratio (M-H, Fixed, 95% CI) 0.09 [0.06, 0.14]
37.2 Severe rotavirus
diarrhoea (2 year follow-up):
formula fed infants
1 828 Risk Ratio (M-H, Fixed, 95% CI) 0.02 [0.00, 0.14]
38 Sensitivity analysis: allocation
concealment
6 Risk Ratio (M-H, Random, 95% CI) Subtotals only
38.1 Rotavirus diarrhoea:
severe, up to 1 year follow-up
(low-mortality countries)
4 32475 Risk Ratio (M-H, Random, 95% CI) 0.10 [0.04, 0.23]
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38.2 Rotavirus diarrhoea:
severe, up to 1 year follow-up
(high-mortality countries)
2 4939 Risk Ratio (M-H, Random, 95% CI) 0.36 [0.15, 0.88]
38.3 All-cause diarrhoea:
severe, up to 1 year follow-up
(high-mortality countries)
2 4939 Risk Ratio (M-H, Random, 95% CI) 0.66 [0.44, 0.98]
Comparison 2. RV5 versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Rotavirus diarrhoea: severe (up
to 1 year follow-up)
7 8260 Risk Ratio (M-H, Fixed, 95% CI) 0.37 [0.26, 0.53]
1.1 Low-mortality countries
(WHO strata A & B)
3 2344 Risk Ratio (M-H, Fixed, 95% CI) 0.13 [0.04, 0.45]
1.2 High-mortality countries
(WHO strata D & E)
4 5916 Risk Ratio (M-H, Fixed, 95% CI) 0.43 [0.29, 0.62]
2 Rotavirus diarrhoea: severe (up
to 2 years follow-up)
7 9075 Risk Ratio (M-H, Random, 95% CI) 0.46 [0.30, 0.70]
2.1 Low-mortality countries
(WHO strata A & B)
3 3190 Risk Ratio (M-H, Random, 95% CI) 0.18 [0.07, 0.50]
2.2 High-mortality countries
(WHO strata D & E)
4 5885 Risk Ratio (M-H, Random, 95% CI) 0.59 [0.43, 0.82]
3 All-cause diarrhoea: severe cases
(up to 1 year follow-up)
4 5114 Risk Ratio (M-H, Random, 95% CI) 0.64 [0.39, 1.06]
3.1 Low-mortality countries
(WHO stratum A)
1 1029 Risk Ratio (M-H, Random, 95% CI) 0.28 [0.16, 0.48]
3.2 High-mortality countries
(WHO strata D & E)
3 4085 Risk Ratio (M-H, Random, 95% CI) 0.80 [0.58, 1.11]
4 All-cause diarrhoea: severe cases
(up to 2 years follow-up)
5 7006 Risk Ratio (M-H, Fixed, 95% CI) 0.84 [0.73, 0.96]
4.1 Low-mortality countries
(WHO strata A & B)
1 1029 Risk Ratio (M-H, Fixed, 95% CI) 0.04 [0.00, 0.70]
4.2 High-mortality countries
(WHO strata D & E)
4 5977 Risk Ratio (M-H, Fixed, 95% CI) 0.85 [0.75, 0.98]
5 All-cause death 12 80207 Risk Ratio (M-H, Fixed, 95% CI) 0.98 [0.75, 1.28]
5.1 Low-mortality countries
(WHO strata A & B)
8 73603 Risk Ratio (M-H, Fixed, 95% CI) 1.18 [0.67, 2.08]
5.2 High-mortality countries
(WHO strata D & E)
4 6604 Risk Ratio (M-H, Fixed, 95% CI) 0.93 [0.69, 1.25]
6 All serious adverse events 11 78226 Risk Ratio (M-H, Fixed, 95% CI) 0.92 [0.85, 1.01]
6.1 Low-mortality countries
(WHO strata A & B)
7 71638 Risk Ratio (M-H, Fixed, 95% CI) 0.92 [0.84, 1.01]
6.2 High-mortality countries
(WHO strata D & E)
4 6588 Risk Ratio (M-H, Fixed, 95% CI) 0.93 [0.66, 1.33]
7 Serious adverse events:
intussusception
15 81462 Risk Ratio (M-H, Fixed, 95% CI) 0.67 [0.34, 1.31]
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7.1 Low-mortality countries
(WHO strata A & B)
11 74874 Risk Ratio (M-H, Fixed, 95% CI) 0.67 [0.34, 1.31]
7.2 High-mortality countries
(WHO strata D & E)
4 6588 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
8 Rotavirus diarrhoea: of any
severity (up to 1 year follow-up)
7 12420 Risk Ratio (M-H, Random, 95% CI) 0.36 [0.26, 0.52]
8.1 Low-mortality countries
(WHO strata A & B)
4 7614 Risk Ratio (M-H, Random, 95% CI) 0.27 [0.22, 0.33]
8.2 High-mortality countries
(WHO strata D & E)
3 4806 Risk Ratio (M-H, Random, 95% CI) 0.52 [0.28, 0.94]
9 Rotavirus diarrhoea: of any
severity (up to 2 years
follow-up)
6 9024 Risk Ratio (M-H, Random, 95% CI) 0.51 [0.36, 0.70]
9.1 Low-mortality countries
(WHO strata A & B)
2 2280 Risk Ratio (M-H, Random, 95% CI) 0.36 [0.25, 0.50]
9.2 High-mortality countries
(WHO strata D & E)
4 6744 Risk Ratio (M-H, Random, 95% CI) 0.61 [0.45, 0.83]
10 All-cause diarrhoea: of any
severity (up to 1 year follow-up)
2 2089 Risk Ratio (M-H, Fixed, 95% CI) 0.64 [0.51, 0.81]
10.1 Low-mortality countries
(WHO strata A & B)
1 1030 Risk Ratio (M-H, Fixed, 95% CI) 0.41 [0.28, 0.60]
10.2 High-mortality countries
(WHO stratum E)
1 1059 Risk Ratio (M-H, Fixed, 95% CI) 0.82 [0.61, 1.11]
11 All-cause diarrhoea: of
any severity (up to 2 years
follow-up)
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
11.1 High-mortality countries
(WHO stratum E)
1 1059 Risk Ratio (M-H, Fixed, 95% CI) 0.89 [0.68, 1.16]
12 Rotavirus diarrhoea: requiring
hospitalization
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
12.1 Up to 1 year of follow-up 1 57134 Risk Ratio (M-H, Fixed, 95% CI) 0.04 [0.02, 0.10]
13 Rotavirus diarrhoea: requiring
medical attention
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
13.1 Up to 1 year of follow-up 1 57134 Risk Ratio (M-H, Fixed, 95% CI) 0.07 [0.04, 0.12]
14 Reactogenicity: fever 8 Risk Ratio (M-H, Random, 95% CI) Subtotals only
14.1 After dose 1 3 3090 Risk Ratio (M-H, Random, 95% CI) 1.28 [1.04, 1.58]
14.2 After dose 2 1 417 Risk Ratio (M-H, Random, 95% CI) 0.75 [0.47, 1.19]
14.3 After dose 3 1 416 Risk Ratio (M-H, Random, 95% CI) 1.10 [0.77, 1.59]
14.4 End of follow-up 7 14067 Risk Ratio (M-H, Random, 95% CI) 1.03 [0.93, 1.15]
15 Reactogenicity: diarrhoea 6 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
15.1 After dose 1 1 711 Risk Ratio (M-H, Fixed, 95% CI) 0.99 [0.71, 1.39]
15.2 End of follow-up 6 12763 Risk Ratio (M-H, Fixed, 95% CI) 1.04 [0.98, 1.12]
16 Reactogenicity: vomiting 5 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
16.1 After dose 1 1 711 Risk Ratio (M-H, Fixed, 95% CI) 0.87 [0.59, 1.29]
16.2 End of follow-up 5 11970 Risk Ratio (M-H, Fixed, 95% CI) 1.00 [0.91, 1.09]
17 Adverse events requiring
discontinuation (end of
follow-up)
9 11437 Risk Ratio (M-H, Fixed, 95% CI) 0.67 [0.38, 1.19]
18 Immunogenicity: rotavirus
vaccine shedding (after dose 3)
3 Risk Ratio (M-H, Random, 95% CI) Subtotals only
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19 Immunogenicity:
seroconversion (after dose 3)
8 Risk Ratio (M-H, Random, 95% CI) Subtotals only
20 Drop outs before the end of the
trial
10 81573 Risk Ratio (M-H, Random, 95% CI) 0.97 [0.88, 1.07]
21 Subgroup analysis: rotavirus
diarrhoea of any severity (by G
type)
3 Risk Ratio (M-H, Random, 95% CI) Subtotals only
21.1 G1 3 7158 Risk Ratio (M-H, Random, 95% CI) 0.26 [0.21, 0.33]
21.2 G2 2 6043 Risk Ratio (M-H, Random, 95% CI) 0.37 [0.16, 0.88]
21.3 G3 3 7158 Risk Ratio (M-H, Random, 95% CI) 0.27 [0.03, 2.29]
21.4 G4 2 6043 Risk Ratio (M-H, Random, 95% CI) 0.47 [0.13, 1.67]
21.5 G9 1 5673 Risk Ratio (M-H, Random, 95% CI) 0.33 [0.03, 3.21]
22 Subgroup analysis: severe cases
of rotavirus diarrhoea (by G
type)
2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
22.1 G1 2 72743 Risk Ratio (M-H, Random, 95% CI) 0.18 [0.01, 2.97]
22.2 G2 2 72743 Risk Ratio (M-H, Random, 95% CI) 0.41 [0.08, 2.09]
22.3 G3 2 72743 Risk Ratio (M-H, Random, 95% CI) 0.19 [0.03, 1.06]
22.4 G4 2 72743 Risk Ratio (M-H, Random, 95% CI) 0.11 [0.03, 0.48]
22.5 G9 2 72743 Risk Ratio (M-H, Random, 95% CI) 0.15 [0.01, 2.37]
23 Subgroup analysis:
HIV-infected children
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
23.1 Rotavirus diarrhoea:
severe (up to two years
follow-up)
1 38 Risk Ratio (M-H, Fixed, 95% CI) 2.45 [0.11, 56.68]
23.2 All-cause diarrhoea:
severe (up to two years
follow-up)
1 38 Risk Ratio (M-H, Fixed, 95% CI) 4.05 [0.52, 31.43]
23.3 All-cause death 1 38 Risk Ratio (M-H, Fixed, 95% CI) 1.62 [0.59, 4.47]
23.4 Serious adverse events
(up to 14 days after each dose)
1 37 Risk Ratio (M-H, Fixed, 95% CI) 1.90 [0.42, 8.58]
24 Subgroup analysis: rotavirus
diarrhoea of any severity
in premature babies (1 year
follow-up)
1 170 Risk Ratio (M-H, Fixed, 95% CI) 0.39 [0.15, 1.06]
25 Sensitivity analysis: allocation
concealment
3 Risk Ratio (M-H, Random, 95% CI) Subtotals only
25.1 Rotavirus diarrhoea:
severe, up to 2 years follow-up
(high-mortality countries)
3 4748 Risk Ratio (M-H, Random, 95% CI) 0.62 [0.44, 0.87]
25.2 All-cause diarrhoea:
severe, up to 1 year follow-up
(high-mortality countries)
2 3127 Risk Ratio (M-H, Random, 95% CI) 0.77 [0.49, 1.21]
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Analysis 1.1. Comparison 1 RV1 versus placebo, Outcome 1 Rotavirus diarrhoea: severe (up to 1 year
follow-up).
Review: Vaccines for preventing rotavirus diarrhoea: vaccines in use
Comparison: 1 RV1 versus placebo
Outcome: 1 Rotavirus diarrhoea: severe (up to 1 year follow-up)
Study or subgroup RV1 Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Low-mortality countries (WHO strata A % B)
RV1 Bernstein 1999-USA 2/108 9/107 7.6 % 0.22 [ 0.05, 1.00 ]
RV1 GSK[024] 2008-LA 7/4211 19/2099 11.9 % 0.18 [ 0.08, 0.44 ]
RV1 Phua 2009-AS 0/5263 15/5256 3.2 % 0.03 [ 0.00, 0.54 ]
RV1 Ruiz-Palac 06-LA/EU (1) 12/9009 77/8858 13.8 % 0.15 [ 0.08, 0.28 ]
RV1 Salinas 2005-LA 27/1392 34/454 14.6 % 0.26 [ 0.16, 0.42 ]
RV1 Vesikari 2007a-EU 5/2572 60/1302 11.5 % 0.04 [ 0.02, 0.10 ]
Subtotal (95% CI) 22555 18076 62.6 % 0.14 [ 0.07, 0.26 ]
Total events: 53 (RV1), 214 (Placebo)
Heterogeneity: Tau2 = 0.35; Chi2 = 14.68, df = 5 (P = 0.01); I2 =66%
Test for overall effect: Z = 6.14 (P < 0.00001)
2 High-mortality countries (WHO stratum E)
RV1 Madhi 2010-MWI (2) 52/1182 47/591 15.3 % 0.55 [ 0.38, 0.81 ]
RV1 Madhi 2010-ZAF (3) 16/2116 36/1050 14.0 % 0.22 [ 0.12, 0.40 ]
RV1 Steele 2010b-ZAF 5/379 3/96 8.1 % 0.42 [ 0.10, 1.74 ]
Subtotal (95% CI) 3677 1737 37.4 % 0.37 [ 0.18, 0.75 ]
Total events: 73 (RV1), 86 (Placebo)
Heterogeneity: Tau2 = 0.25; Chi2 = 6.70, df = 2 (P = 0.04); I2 =70%
Test for overall effect: Z = 2.74 (P = 0.0061)
Total (95% CI) 26232 19813 100.0 % 0.20 [ 0.11, 0.35 ]
Total events: 126 (RV1), 300 (Placebo)
Heterogeneity: Tau2 = 0.51; Chi2 = 39.36, df = 8 (P<0.00001); I2 =80%
Test for overall effect: Z = 5.61 (P < 0.00001)
Test for subgroup differences: Chi2 = 4.15, df = 1 (P = 0.04), I2 =76%
0.001 0.01 0.1 1 10 100 1000
Favours RV1 Favours placebo
(1) This multinational study includes 12 Latin America countries, two of them with high mortality (Nicaragua and Peru)
(2) Data taken from main paper Supplementary Appendix, Table 3 - total vaccinated cohort in Malawi
(3) Data taken from main paper Supplementary Appendix, Table 3 - total vaccinated cohort in South Africa
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Analysis 1.2. Comparison 1 RV1 versus placebo, Outcome 2 Rotavirus diarrhoea: severe (up to 2 years
follow-up).
Review: Vaccines for preventing rotavirus diarrhoea: vaccines in use
Comparison: 1 RV1 versus placebo
Outcome: 2 Rotavirus diarrhoea: severe (up to 2 years follow-up)
Study or subgroup RV1 Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Low-mortality countries (WHO strata A % B)
RV1 Bernstein 1999-USA 3/108 19/107 4.3 % 0.16 [ 0.05, 0.51 ]
RV1 Kawamura 2010-JPN 2/498 12/250 3.6 % 0.08 [ 0.02, 0.37 ]
RV1 Phua 2005-SGP 0/1779 1/642 0.5 % 0.12 [ 0.00, 2.95 ]
RV1 Phua 2009-AS 2/5263 51/5256 11.4 % 0.04 [ 0.01, 0.16 ]
RV1 Ruiz-Palac 06-LA/EU (1) 32/7205 161/7081 36.3 % 0.20 [ 0.13, 0.29 ]
RV1 Salinas 2005-LA 2/332 3/109 1.0 % 0.22 [ 0.04, 1.29 ]
RV1 Vesikari 2004b-FIN 3/245 10/123 3.0 % 0.15 [ 0.04, 0.54 ]
RV1 Vesikari 2007a-EU 19/2554 67/1302 19.9 % 0.14 [ 0.09, 0.24 ]
Subtotal (95% CI) 17984 14870 79.9 % 0.15 [ 0.12, 0.20 ]
Total events: 63 (RV1), 324 (Placebo)
Heterogeneity: Chi2 = 6.09, df = 7 (P = 0.53); I2 =0.0%
Test for overall effect: Z = 13.65 (P < 0.00001)
2 High-mortality countries (WHO stratum E)
RV1 Madhi 2010-MWI (2) 70/1030 53/483 16.1 % 0.62 [ 0.44, 0.87 ]
RV1 Madhi 2010-ZAF (3) 11/843 13/408 3.9 % 0.41 [ 0.19, 0.91 ]
Subtotal (95% CI) 1873 891 20.1 % 0.58 [ 0.42, 0.79 ]
Total events: 81 (RV1), 66 (Placebo)
Heterogeneity: Chi2 = 0.88, df = 1 (P = 0.35); I2 =0.0%
Test for overall effect: Z = 3.44 (P = 0.00058)
Total (95% CI) 19857 15761 100.0 % 0.24 [ 0.19, 0.29 ]
Total events: 144 (RV1), 390 (Placebo)
Heterogeneity: Chi2 = 46.39, df = 9 (P<0.00001); I2 =81%
Test for overall effect: Z = 14.18 (P < 0.00001)
Test for subgroup differences: Chi2 = 40.38, df = 1 (P = 0.00), I2 =98%
0.001 0.01 0.1 1 10 100 1000
Favours RV1 Favours placebo
(1) This multinational study includes 12 Latin America countries, two of them with high mortality (Nicaragua and Peru)
(2) Data from Malawi cohort only
(3) Assessment of vaccine effiicacy up to two years follow-up available from cohort 2 subjects only in South Africa
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Analysis 1.3. Comparison 1 RV1 versus placebo, Outcome 3 All-cause diarrhoea: severe cases (up to 1 year
follow-up).
Review: Vaccines for preventing rotavirus diarrhoea: vaccines in use
Comparison: 1 RV1 versus placebo
Outcome: 3 All-cause diarrhoea: severe cases (up to 1 year follow-up)
Study or subgroup RV1 Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Low-mortality countries (WHO strata A % B)
RV1 Vesikari 2007a-EU 116/2572 123/1302 33.1 % 0.48 [ 0.37, 0.61 ]
Subtotal (95% CI) 2572 1302 33.1 % 0.48 [ 0.37, 0.61 ]
Total events: 116 (RV1), 123 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 5.92 (P < 0.00001)
2 High-mortality countries (WHO stratum E)
RV1 Madhi 2010-MWI (1) 221/1182 139/591 35.7 % 0.79 [ 0.66, 0.96 ]
RV1 Madhi 2010-ZAF (2) 92/2116 86/1050 31.2 % 0.53 [ 0.40, 0.71 ]
Subtotal (95% CI) 3298 1641 66.9 % 0.66 [ 0.44, 0.98 ]
Total events: 313 (RV1), 225 (Placebo)
Heterogeneity: Tau2 = 0.07; Chi2 = 5.42, df = 1 (P = 0.02); I2 =82%
Test for overall effect: Z = 2.06 (P = 0.039)
Total (95% CI) 5870 2943 100.0 % 0.59 [ 0.42, 0.83 ]
Total events: 429 (RV1), 348 (Placebo)
Heterogeneity: Tau2 = 0.07; Chi2 = 12.28, df = 2 (P = 0.002); I2 =84%
Test for overall effect: Z = 3.03 (P = 0.0024)
Test for subgroup differences: Chi2 = 1.85, df = 1 (P = 0.17), I2 =46%
0.001 0.01 0.1 1 10 100 1000
Favours RV1 Favours placebo
(1) Data taken from main paper Supplementary Appendix, Table 6 - total vaccinated cohort in Malawi
(2) Data taken from main paper Supplementary Appendix, Table 6 - total vaccinated cohort in South Africa
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Analysis 1.4. Comparison 1 RV1 versus placebo, Outcome 4 All-cause diarrhoea: severe cases (up to 2 years
follow-up).
Review: Vaccines for preventing rotavirus diarrhoea: vaccines in use
Comparison: 1 RV1 versus placebo
Outcome: 4 All-cause diarrhoea: severe cases (up to 2 years follow-up)
Study or subgroup RV1 Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Low-mortality countries (WHO strata A % B)
RV1 Phua 2005-SGP 11/1779 10/642 2.9 % 0.40 [ 0.17, 0.93 ]
RV1 Vesikari 2007a-EU 149/2554 153/1294 40.6 % 0.49 [ 0.40, 0.61 ]
Subtotal (95% CI) 4333 1936 43.5 % 0.49 [ 0.40, 0.60 ]
Total events: 160 (RV1), 163 (Placebo)
Heterogeneity: Chi2 = 0.24, df = 1 (P = 0.63); I2 =0.0%
Test for overall effect: Z = 6.76 (P < 0.00001)
2 High-mortality countries (WHO stratum E)
RV1 Madhi 2010-MWI (1) 287/1030 160/483 43.5 % 0.84 [ 0.72, 0.99 ]
RV1 Madhi 2010-ZAF (2) 76/843 48/408 12.9 % 0.77 [ 0.54, 1.08 ]
Subtotal (95% CI) 1873 891 56.5 % 0.82 [ 0.71, 0.95 ]
Total events: 363 (RV1), 208 (Placebo)
Heterogeneity: Chi2 = 0.24, df = 1 (P = 0.63); I2 =0.0%
Test for overall effect: Z = 2.60 (P = 0.0093)
Total (95% CI) 6206 2827 100.0 % 0.68 [ 0.60, 0.76 ]
Total events: 523 (RV1), 371 (Placebo)
Heterogeneity: Chi2 = 17.33, df = 3 (P = 0.00060); I2 =83%
Test for overall effect: Z = 6.41 (P < 0.00001)
Test for subgroup differences: Chi2 = 16.39, df = 1 (P = 0.00), I2 =94%
0.001 0.01 0.1 1 10 100 1000
Favours RV1 Favours placebo
(1) Data from Malawi cohort only
(2) Data from South Africa cohort only
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Analysis 1.5. Comparison 1 RV1 versus placebo, Outcome 5 All-cause diarrhoea: severe episodes (up to 1
year follow-up).
Review: Vaccines for preventing rotavirus diarrhoea: vaccines in use
Comparison: 1 RV1 versus placebo
Outcome: 5 All-cause diarrhoea: severe episodes (up to 1 year follow-up)
Study or subgroup log [Rate Ratio] Rate Ratio Weight Rate Ratio
(SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 Low-mortality countries (WHO strata A % B)
RV1 Ruiz-Palac 06-LA/EU (1) -0.511 (0.094) 100.0 % 0.60 [ 0.50, 0.72 ]
Subtotal (95% CI) 100.0 % 0.60 [ 0.50, 0.72 ]
Heterogeneity: not applicable
Test for overall effect: Z = 5.44 (P < 0.00001)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours RV1 Favours Placebo
(1) This multinational study includes 12 Latin America countries, two of them with high mortality (Nicaragua and Peru)
Analysis 1.6. Comparison 1 RV1 versus placebo, Outcome 6 All-cause diarrhoea: severe episodes (up to 2
years follow-up).
Review: Vaccines for preventing rotavirus diarrhoea: vaccines in use
Comparison: 1 RV1 versus placebo
Outcome: 6 All-cause diarrhoea: severe episodes (up to 2 years follow-up)
Study or subgroup log [Rate Ratio] Rate Ratio Weight Rate Ratio
(SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 Low-mortality countries (WHO strata A % B)
RV1 Phua 2009-AS -0.361 (0.11) 28.2 % 0.70 [ 0.56, 0.86 ]
RV1 Ruiz-Palac 06-LA/EU (1) -0.494 (0.069) 71.8 % 0.61 [ 0.53, 0.70 ]
Subtotal (95% CI) 100.0 % 0.63 [ 0.56, 0.71 ]
Heterogeneity: Chi2 = 1.05, df = 1 (P = 0.31); I2 =5%
Test for overall effect: Z = 7.81 (P < 0.00001)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours RV1 Favours Placebo
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(1) This multinational study includes 12 Latin America countries, two of them with high mortality (Nicaragua and Peru)
Analysis 1.7. Comparison 1 RV1 versus placebo, Outcome 7 All-cause death.
Review: Vaccines for preventing rotavirus diarrhoea: vaccines in use
Comparison: 1 RV1 versus placebo
Outcome: 7 All-cause death
Study or subgroup RV1 Placebo Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Low-mortality countries (WHO strata A % B)
RV1 Anh 2011-PHL 1/281 0/64 0.69 [ 0.03, 16.78 ]
RV1 Anh 2011-VNM 0/279 0/73 0.0 [ 0.0, 0.0 ]
RV1 Bernstein 1999-USA 1/108 0/107 2.97 [ 0.12, 72.16 ]
RV1 GSK[021] 2007-PAN 0/177 0/51 0.0 [ 0.0, 0.0 ]
RV1 GSK[024] 2008-LA 10/4376 2/2192 2.50 [ 0.55, 11.42 ]
RV1 GSK[041] 2007-KOR 0/103 0/52 0.0 [ 0.0, 0.0 ]
RV1 GSK[101555] 2008-PHL 0/100 0/50 0.0 [ 0.0, 0.0 ]
RV1 Kawamura 2010-JPN 0/507 0/257 0.0 [ 0.0, 0.0 ]
RV1 Kerdpanich 2010-THA 0/395 0/26 0.0 [ 0.0, 0.0 ]
RV1 Omenaca 2012-EU 0/670 1/339 0.17 [ 0.01, 4.14 ]
RV1 Phua 2005-SGP 3/1779 0/642 2.53 [ 0.13, 48.89 ]
RV1 Phua 2009-AS 1/5263 3/5256 0.33 [ 0.03, 3.20 ]
RV1 Rivera 2011-DOM 0/100 0/100 0.0 [ 0.0, 0.0 ]
RV1 Ruiz-Palac 06-LA/EU (1) 56/31673 43/31552 1.30 [ 0.87, 1.93 ]
RV1 Salinas 2005-LA 2/1618 1/537 0.66 [ 0.06, 7.31 ]
RV1 Vesikari 2004b-FIN 0/267 0/133 0.0 [ 0.0, 0.0 ]
RV1 Vesikari 2007a-EU 0/2613 0/1331 0.0 [ 0.0, 0.0 ]
RV1 Vesikari 2011-FIN 0/200 0/50 0.0 [ 0.0, 0.0 ]
Subtotal (95% CI) 50509 42812 1.27 [ 0.89, 1.81 ]
Total events: 74 (RV1), 50 (Placebo)
Heterogeneity: Chi2 = 4.56, df = 7 (P = 0.71); I2 =0.0%
0.01 0.1 1 10 100
Favours RV1 Favours placebo
(Continued . . . )
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(. . . Continued)
Study or subgroup RV1 Placebo Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Test for overall effect: Z = 1.30 (P = 0.19)
2 High-mortality countries (WHO strata D % E)
RV1 GSK[033] 2007-LA (2) 3/730 0/124 1.20 [ 0.06, 23.03 ]
RV1 Madhi 2010-AF 83/3298 43/1641 0.96 [ 0.67, 1.38 ]
RV1 Narang 2009-IND 0/182 0/181 0.0 [ 0.0, 0.0 ]
RV1 Steele 2008-ZAF 3/300 5/150 0.30 [ 0.07, 1.24 ]
RV1 Steele 2010a-ZAF 6/50 9/50 0.67 [ 0.26, 1.73 ]
RV1 Steele 2010b-ZAF 3/379 0/96 1.79 [ 0.09, 34.30 ]
RV1 Zaman 2009-BGD 1/200 0/100 1.51 [ 0.06, 36.68 ]
Subtotal (95% CI) 5139 2342 0.88 [ 0.64, 1.22 ]
Total events: 99 (RV1), 57 (Placebo)
Heterogeneity: Chi2 = 3.13, df = 5 (P = 0.68); I2 =0.0%
Test for overall effect: Z = 0.76 (P = 0.45)
Total (95% CI) 55648 45154 1.04 [ 0.82, 1.32 ]
Total events: 173 (RV1), 107 (Placebo)
Heterogeneity: Chi2 = 9.82, df = 13 (P = 0.71); I2 =0.0%
Test for overall effect: Z = 0.36 (P = 0.72)
Test for subgroup differences: Chi2 = 2.17, df = 1 (P = 0.14), I2 =54%
0.01 0.1 1 10 100
Favours RV1 Favours placebo
(1) This multinational study includes 12 Latin America countries, two of them with high mortality (Nicaragua and Peru)
(2) This study was conducted in four study centres in a high mortality country (Peru), but also in three study centres in two low mortality countries (Colombia and
Mexico)
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Analysis 1.8. Comparison 1 RV1 versus placebo, Outcome 8 All serious adverse events.
Review: Vaccines for preventing rotavirus diarrhoea: vaccines in use
Comparison: 1 RV1 versus placebo
Outcome: 8 All serious adverse events
Study or subgroup RV1 Placebo Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Low-mortality countries (WHO strata A % B)
RV1 Anh 2011-PHL 1/281 1/64 0.23 [ 0.01, 3.59 ]
RV1 Anh 2011-VNM 15/279 1/73 3.92 [ 0.53, 29.23 ]
RV1 Bernstein 1998-USA 0/21 0/20 0.0 [ 0.0, 0.0 ]
RV1 Dennehy 2005-NA 15/421 8/108 0.48 [ 0.21, 1.10 ]
RV1 GSK[021] 2007-PAN 18/177 9/51 0.58 [ 0.28, 1.20 ]
RV1 GSK[024] 2008-LA 505/4376 265/2192 0.95 [ 0.83, 1.10 ]
RV1 GSK[041] 2007-KOR 0/103 0/52 0.0 [ 0.0, 0.0 ]
RV1 GSK[101555] 2008-PHL 5/100 0/50 5.55 [ 0.31, 98.50 ]
RV1 Kawamura 2010-JPN 72/508 44/257 0.83 [ 0.59, 1.17 ]
RV1 Kerdpanich 2010-THA 11/396 4/51 0.35 [ 0.12, 1.07 ]
RV1 Omenaca 2012-EU 34/670 23/339 0.75 [ 0.45, 1.25 ]
RV1 Phua 2005-SGP 144/1811 40/653 1.30 [ 0.93, 1.82 ]
RV1 Phua 2009-AS 10/4272 11/4226 0.90 [ 0.38, 2.12 ]
RV1 Rivera 2011-DOM 5/100 6/100 0.83 [ 0.26, 2.64 ]
RV1 Ruiz-Palac 06-LA/EU (1) 928/31673 1047/31552 0.88 [ 0.81, 0.96 ]
RV1 Salinas 2005-LA 156/1618 64/537 0.81 [ 0.62, 1.06 ]
RV1 Vesikari 2004a-FIN 2/128 1/64 1.00 [ 0.09, 10.82 ]
RV1 Vesikari 2004b-FIN 28/267 9/133 1.55 [ 0.75, 3.19 ]
RV1 Vesikari 2007a-EU 290/2646 176/1348 0.84 [ 0.70, 1.00 ]
RV1 Vesikari 2011-FIN 3/193 0/47 1.73 [ 0.09, 32.97 ]
Subtotal (95% CI) 50040 41917 0.90 [ 0.84, 0.95 ]
Total events: 2242 (RV1), 1709 (Placebo)
Heterogeneity: Chi2 = 20.49, df = 17 (P = 0.25); I2 =17%
Test for overall effect: Z = 3.43 (P = 0.00061)
2 High-mortality countries (WHO strata D % E)
RV1 GSK[033] 2007-LA (2) 3/730 0/124 1.20 [ 0.06, 23.03 ]
0.001 0.01 0.1 1 10 100 1000
Favours RV1 Favours placebo
(Continued . . . )
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(. . . Continued)
Study or subgroup RV1 Placebo Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
RV1 Madhi 2010-AF 319/3298 189/1641 0.84 [ 0.71, 1.00 ]
RV1 Narang 2009-IND 3/182 2/181 1.49 [ 0.25, 8.82 ]
RV1 Steele 2008-ZAF 30/300 14/150 1.07 [ 0.59, 1.96 ]
RV1 Steele 2010a-ZAF 17/50 12/50 1.42 [ 0.76, 2.65 ]
RV1 Steele 2010b-ZAF 19/379 5/96 0.96 [ 0.37, 2.51 ]
RV1 Zaman 2009-BGD 1/200 0/100 1.51 [ 0.06, 36.68 ]
Subtotal (95% CI) 5139 2342 0.89 [ 0.76, 1.04 ]
Total events: 392 (RV1), 222 (Placebo)
Heterogeneity: Chi2 = 3.42, df = 6 (P = 0.75); I2 =0.0%
Test for overall effect: Z = 1.50 (P = 0.13)
Total (95% CI) 55179 44259 0.90 [ 0.85, 0.95 ]
Total events: 2634 (RV1), 1931 (Placebo)
Heterogeneity: Chi2 = 23.90, df = 24 (P = 0.47); I2 =0.0%
Test for overall effect: Z = 3.74 (P = 0.00019)
Test for subgroup differences: Chi2 = 0.01, df = 1 (P = 0.91), I2 =0.0%
0.001 0.01 0.1 1 10 100 1000
Favours RV1 Favours placebo
(1) This multinational study includes 12 Latin America countries, two of them with high mortality (Nicaragua and Peru)
(2) This study was conducted in four study centres in a high mortality country (Peru), but also in three study centres in two low mortality countries (Colombia and
Mexico)
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Analysis 1.9. Comparison 1 RV1 versus placebo, Outcome 9 Serious adverse events: intussusception.
Review: Vaccines for preventing rotavirus diarrhoea: vaccines in use
Comparison: 1 RV1 versus placebo
Outcome: 9 Serious adverse events: intussusception
Study or subgroup RV1 Placebo Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Low-mortality countries (WHO strata A % B)
RV1 Dennehy 2005-NA 0/421 0/108 0.0 [ 0.0, 0.0 ]
RV1 GSK[024] 2008-LA 4/4376 2/2192 1.00 [ 0.18, 5.47 ]
RV1 Kawamura 2010-JPN 0/507 0/257 0.0 [ 0.0, 0.0 ]
RV1 Omenaca 2012-EU 0/670 0/339 0.0 [ 0.0, 0.0 ]
RV1 Phua 2005-SGP 1/1811 1/653 0.36 [ 0.02, 5.76 ]
RV1 Phua 2009-AS 8/5263 4/5256 2.00 [ 0.60, 6.63 ]
RV1 Rivera 2011-DOM 0/100 0/100 0.0 [ 0.0, 0.0 ]
RV1 Ruiz-Palac 06-LA/EU (1) 13/31673 20/31552 0.65 [ 0.32, 1.30 ]
RV1 Salinas 2005-LA 1/1618 0/537 1.00 [ 0.04, 24.44 ]
RV1 Vesikari 2004b-FIN 0/270 0/135 0.0 [ 0.0, 0.0 ]
RV1 Vesikari 2007a-EU 2/2646 1/1348 1.02 [ 0.09, 11.23 ]
Subtotal (95% CI) 49355 42477 0.87 [ 0.52, 1.46 ]
Total events: 29 (RV1), 28 (Placebo)
Heterogeneity: Chi2 = 2.97, df = 5 (P = 0.70); I2 =0.0%
Test for overall effect: Z = 0.53 (P = 0.59)
2 High-mortality countries (WHO stratum E)
RV1 Madhi 2010-AF 1/3298 0/1641 1.49 [ 0.06, 36.63 ]
RV1 Steele 2010b-ZAF 0/379 0/96 0.0 [ 0.0, 0.0 ]
Subtotal (95% CI) 3677 1737 1.49 [ 0.06, 36.63 ]
Total events: 1 (RV1), 0 (Placebo)
Heterogeneity: Chi2 = 0.0, df = 0 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 0.25 (P = 0.81)
Total (95% CI) 53032 44214 0.88 [ 0.53, 1.47 ]
Total events: 30 (RV1), 28 (Placebo)
Heterogeneity: Chi2 = 3.08, df = 6 (P = 0.80); I2 =0.0%
Test for overall effect: Z = 0.48 (P = 0.63)
Test for subgroup differences: Chi2 = 0.11, df = 1 (P = 0.74), I2 =0.0%
0.001 0.01 0.1 1 10 100 1000
Favours RV1 Favours placebo
from www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm134142.htm
(1) This multinational study includes 12 Latin America countries, two of them with high mortality (Nicaragua and Peru). Data updated
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Analysis 1.10. Comparison 1 RV1 versus placebo, Outcome 10 Serious adverse events: Kawasaki disease.
Review: Vaccines for preventing rotavirus diarrhoea: vaccines in use
Comparison: 1 RV1 versus placebo
Outcome: 10 Serious adverse events: Kawasaki disease
Study or subgroup RV1 Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
RV1 Phua 2005-SGP 2/1811 0/653 37.0 % 1.80 [ 0.09, 37.54 ]
RV1 Phua 2009-AS 1/4272 0/4226 25.3 % 2.97 [ 0.12, 72.83 ]
RV1 Salinas 2005-LA 1/1618 0/537 37.8 % 1.00 [ 0.04, 24.44 ]
Total (95% CI) 7701 5416 100.0 % 1.79 [ 0.30, 10.61 ]
Total events: 4 (RV1), 0 (Placebo)
Heterogeneity: Chi2 = 0.22, df = 2 (P = 0.89); I2 =0.0%
Test for overall effect: Z = 0.64 (P = 0.52)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours RV1 Favours placebo
Analysis 1.11. Comparison 1 RV1 versus placebo, Outcome 11 Serious adverse events requiring
hospitalization.
Review: Vaccines for preventing rotavirus diarrhoea: vaccines in use
Comparison: 1 RV1 versus placebo
Outcome: 11 Serious adverse events requiring hospitalization
Study or subgroup RV1 Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
RV1 Ruiz-Palac 06-LA/EU 886/31673 1003/31552 99.9 % 0.88 [ 0.81, 0.96 ]
RV1 Steele 2008-ZAF 1/300 0/150 0.1 % 1.50 [ 0.06, 36.72 ]
Total (95% CI) 31973 31702 100.0 % 0.88 [ 0.81, 0.96 ]
Total events: 887 (RV1), 1003 (Placebo)
Heterogeneity: Chi2 = 0.11, df = 1 (P = 0.74); I2 =0.0%
Test for overall effect: Z = 2.81 (P = 0.0050)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours RV1 Favours placebo
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Analysis 1.12. Comparison 1 RV1 versus placebo, Outcome 12 Rotavirus diarrhoea: of any severity (up to 2
months follow-up).
Review: Vaccines for preventing rotavirus diarrhoea: vaccines in use
Comparison: 1 RV1 versus placebo
Outcome: 12 Rotavirus diarrhoea: of any severity (up to 2 months follow-up)
Study or subgroup RV1 Placebo Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Low-mortality countries (WHO strata A % B)
RV1 Anh 2011-PHL 1/270 1/66 0.24 [ 0.02, 3.86 ]
RV1 Anh 2011-VNM 0/275 0/71 0.0 [ 0.0, 0.0 ]
RV1 GSK[041] 2007-KOR 1/103 1/52 0.50 [ 0.03, 7.91 ]
RV1 GSK[101555] 2008-PHL 4/100 1/50 2.00 [ 0.23, 17.43 ]
RV1 Kerdpanich 2010-THA 4/392 0/52 1.21 [ 0.07, 22.23 ]
RV1 Omenaca 2012-EU 3/670 2/339 0.76 [ 0.13, 4.52 ]
RV1 Rivera 2011-DOM 10/100 6/100 1.67 [ 0.63, 4.41 ]
RV1 Vesikari 2011-FIN 4/169 0/44 2.38 [ 0.13, 43.44 ]
Subtotal (95% CI) 2079 774 1.28 [ 0.66, 2.50 ]
Total events: 27 (RV1), 11 (Placebo)
Heterogeneity: Chi2 = 2.78, df = 6 (P = 0.84); I2 =0.0%
Test for overall effect: Z = 0.72 (P = 0.47)
2 High-mortality countries (WHO strata D % E)
RV1 Narang 2009-IND 0/182 0/181 0.0 [ 0.0, 0.0 ]
RV1 Steele 2010a-ZAF 4/50 4/50 1.00 [ 0.26, 3.78 ]
RV1 Zaman 2009-BGD 8/196 4/98 1.00 [ 0.31, 3.24 ]
Subtotal (95% CI) 428 329 1.00 [ 0.41, 2.41 ]
Total events: 12 (RV1), 8 (Placebo)
Heterogeneity: Chi2 = 0.0, df = 1 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 0.0 (P = 1.0)
Total (95% CI) 2507 1103 1.17 [ 0.69, 2.00 ]
Total events: 39 (RV1), 19 (Placebo)
Heterogeneity: Chi2 = 2.92, df = 8 (P = 0.94); I2 =0.0%
Test for overall effect: Z = 0.58 (P = 0.56)
Test for subgroup differences: Chi2 = 0.19, df = 1 (P = 0.66), I2 =0.0%
0.001 0.01 0.1 1 10 100 1000
Favours RV1 Favours placebo
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Analysis 1.13. Comparison 1 RV1 versus placebo, Outcome 13 Rotavirus diarrhoea: of any severity (up to 1
year follow-up).
Review: Vaccines for preventing rotavirus diarrhoea: vaccines in use
Comparison: 1 RV1 versus placebo
Outcome: 13 Rotavirus diarrhoea: of any severity (up to 1 year follow-up)
Study or subgroup RV1 Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Low-mortality countries (WHO strata A % B)
RV1 Bernstein 1999-USA 2/108 18/107 7.7 % 0.11 [ 0.03, 0.46 ]
RV1 Salinas 2005-LA 58/1392 51/454 19.4 % 0.37 [ 0.26, 0.53 ]
RV1 Vesikari 2007a-EU 24/2572 94/1302 18.5 % 0.13 [ 0.08, 0.20 ]
Subtotal (95% CI) 4072 1863 45.6 % 0.19 [ 0.08, 0.47 ]
Total events: 84 (RV1), 163 (Placebo)
Heterogeneity: Tau2 = 0.49; Chi2 = 14.80, df = 2 (P = 0.00061); I2 =86%
Test for overall effect: Z = 3.60 (P = 0.00031)
2 High-mortality countries (WHO stratum E)
RV1 Madhi 2010-MWI (1) 109/1182 85/591 20.4 % 0.64 [ 0.49, 0.84 ]
RV1 Madhi 2010-ZAF (2) 91/2116 128/1050 20.5 % 0.35 [ 0.27, 0.46 ]
RV1 Steele 2010b-ZAF 13/379 9/96 13.6 % 0.37 [ 0.16, 0.83 ]
Subtotal (95% CI) 3677 1737 54.4 % 0.45 [ 0.28, 0.73 ]
Total events: 213 (RV1), 222 (Placebo)
Heterogeneity: Tau2 = 0.13; Chi2 = 10.33, df = 2 (P = 0.01); I2 =81%
Test for overall effect: Z = 3.26 (P = 0.0011)
Total (95% CI) 7749 3600 100.0 % 0.31 [ 0.19, 0.50 ]
Total events: 297 (RV1), 385 (Placebo)
Heterogeneity: Tau2 = 0.29; Chi2 = 41.47, df = 5 (P<0.00001); I2 =88%
Test for overall effect: Z = 4.67 (P < 0.00001)
Test for subgroup differences: Chi2 = 2.73, df = 1 (P = 0.10), I2 =63%
0.001 0.01 0.1 1 10 100 1000
Favours RV1 Favours placebo
(1) Data taken from main paper Supplementary Appendix, Table 5 - total vaccinated cohort in Malawi
(2) Data taken from main paper Supplementary Appendix, Table 5 - total vaccinated cohort in South Africa
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Analysis 1.14. Comparison 1 RV1 versus placebo, Outcome 14 Rotavirus diarrhoea: of any severity (up to 2
years follow-up).
Review: Vaccines for preventing rotavirus diarrhoea: vaccines in use
Comparison: 1 RV1 versus placebo
Outcome: 14 Rotavirus diarrhoea: of any severity (up to 2 years follow-up)
Study or subgroup RV1 Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Low-mortality countries (WHO strata A % B)
RV1 Bernstein 1999-USA 8/108 33/107 13.7 % 0.24 [ 0.12, 0.50 ]
RV1 Phua 2005-SGP 2/1779 4/642 3.6 % 0.18 [ 0.03, 0.98 ]
RV1 Salinas 2005-LA 23/332 9/109 13.3 % 0.84 [ 0.40, 1.76 ]
RV1 Vesikari 2004b-FIN 13/245 23/123 15.8 % 0.28 [ 0.15, 0.54 ]
RV1 Vesikari 2007a-EU 61/2554 110/1294 28.9 % 0.28 [ 0.21, 0.38 ]
Subtotal (95% CI) 5018 2275 75.3 % 0.33 [ 0.21, 0.50 ]
Total events: 107 (RV1), 179 (Placebo)
Heterogeneity: Tau2 = 0.11; Chi2 = 8.30, df = 4 (P = 0.08); I2 =52%
Test for overall effect: Z = 5.08 (P < 0.00001)
2 High-mortality countries (WHO stratum E)
RV1 Madhi 2010-ZAF (1) 41/843 48/408 24.7 % 0.41 [ 0.28, 0.62 ]
Subtotal (95% CI) 843 408 24.7 % 0.41 [ 0.28, 0.62 ]
Total events: 41 (RV1), 48 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 4.33 (P = 0.000015)
Total (95% CI) 5861 2683 100.0 % 0.35 [ 0.25, 0.48 ]
Total events: 148 (RV1), 227 (Placebo)
Heterogeneity: Tau2 = 0.08; Chi2 = 9.84, df = 5 (P = 0.08); I2 =49%
Test for overall effect: Z = 6.22 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.61, df = 1 (P = 0.44), I2 =0.0%
0.001 0.01 0.1 1 10 100 1000
Favours RV1 Favours placebo
(1) Data from South Africa cohort only
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Analysis 1.15. Comparison 1 RV1 versus placebo, Outcome 15 All-cause diarrhoea: all cases (up to 2
months follow-up).
Review: Vaccines for preventing rotavirus diarrhoea: vaccines in use
Comparison: 1 RV1 versus placebo
Outcome: 15 All-cause diarrhoea: all cases (up to 2 months follow-up)
Study or subgroup RV1 Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Low-mortality countries (WHO strata A % B)
RV1 Anh 2011-PHL 29/270 8/66 10.6 % 0.89 [ 0.42, 1.85 ]
RV1 Anh 2011-VNM 44/275 11/71 14.4 % 1.03 [ 0.56, 1.89 ]
RV1 Kerdpanich 2010-THA 51/392 7/52 10.2 % 0.97 [ 0.46, 2.02 ]
RV1 Omenaca 2012-EU 55/670 36/339 39.4 % 0.77 [ 0.52, 1.15 ]
RV1 Vesikari 2011-FIN 15/169 5/44 6.5 % 0.78 [ 0.30, 2.03 ]
Subtotal (95% CI) 1776 572 81.1 % 0.86 [ 0.66, 1.12 ]
Total events: 194 (RV1), 67 (Placebo)
Heterogeneity: Chi2 = 0.77, df = 4 (P = 0.94); I2 =0.0%
Test for overall effect: Z = 1.11 (P = 0.27)
2 High-mortality countries (WHO stratum E)
RV1 Steele 2010a-ZAF 24/50 23/50 18.9 % 1.04 [ 0.69, 1.58 ]
Subtotal (95% CI) 50 50 18.9 % 1.04 [ 0.69, 1.58 ]
Total events: 24 (RV1), 23 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.20 (P = 0.84)
Total (95% CI) 1826 622 100.0 % 0.89 [ 0.71, 1.13 ]
Total events: 218 (RV1), 90 (Placebo)
Heterogeneity: Chi2 = 1.38, df = 5 (P = 0.93); I2 =0.0%
Test for overall effect: Z = 0.96 (P = 0.34)
Test for subgroup differences: Chi2 = 0.59, df = 1 (P = 0.44), I2 =0.0%
0.001 0.01 0.1 1 10 100 1000
Favours RV1 Favours placebo
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Analysis 1.16. Comparison 1 RV1 versus placebo, Outcome 16 All-cause diarrhoea: all cases (up to 1 year
follow-up).
Review: Vaccines for preventing rotavirus diarrhoea: vaccines in use
Comparison: 1 RV1 versus placebo
Outcome: 16 All-cause diarrhoea: all cases (up to 1 year follow-up)
Study or subgroup RV1 Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Low-mortality countries (WHO strata A % B)
RV1 Rivera 2011-DOM 32/100 31/100 8.8 % 1.03 [ 0.69, 1.55 ]
RV1 Salinas 2005-LA 573/1498 214/506 91.2 % 0.90 [ 0.80, 1.02 ]
Subtotal (95% CI) 1598 606 100.0 % 0.92 [ 0.82, 1.03 ]
Total events: 605 (RV1), 245 (Placebo)
Heterogeneity: Chi2 = 0.37, df = 1 (P = 0.54); I2 =0.0%
Test for overall effect: Z = 1.49 (P = 0.14)
0.001 0.01 0.1 1 10 100 1000
Favours RV1 Favours placebo
Analysis 1.17. Comparison 1 RV1 versus placebo, Outcome 17 All-cause diarrhoea: all cases (up to 2 years
follow-up).
Review: Vaccines for preventing rotavirus diarrhoea: vaccines in use
Comparison: 1 RV1 versus placebo
Outcome: 17 All-cause diarrhoea: all cases (up to 2 years follow-up)
Study or subgroup RV1 Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Low-mortality countries (WHO strata A % B)
RV1 Phua 2005-SGP 231/1779 100/642 90.9 % 0.83 [ 0.67, 1.04 ]
RV1 Vesikari 2004b-FIN 12/245 11/123 9.1 % 0.55 [ 0.25, 1.21 ]
Subtotal (95% CI) 2024 765 100.0 % 0.81 [ 0.66, 1.00 ]
Total events: 243 (RV1), 111 (Placebo)
Heterogeneity: Chi2 = 1.01, df = 1 (P = 0.31); I2 =1%
Test for overall effect: Z = 2.01 (P = 0.045)
0.001 0.01 0.1 1 10 100 1000
Favours RV1 Favours placebo
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Analysis 1.18. Comparison 1 RV1 versus placebo, Outcome 18 All-cause diarrhoea: all episodes (up to 1
year follow-up).
Review: Vaccines for preventing rotavirus diarrhoea: vaccines in use
Comparison: 1 RV1 versus placebo
Outcome: 18 All-cause diarrhoea: all episodes (up to 1 year follow-up)
Study or subgroup log [Rate Ratio] Rate Ratio Weight Rate Ratio
(SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 Low-mortality countries (WHO strata A % B)
RV1 Rivera 2011-DOM 0.032 (0.252) 4.9 % 1.03 [ 0.63, 1.69 ]
RV1 Salinas 2005-LA -0.02 (0.057) 95.1 % 0.98 [ 0.88, 1.10 ]
Subtotal (95% CI) 100.0 % 0.98 [ 0.88, 1.10 ]
Heterogeneity: Chi2 = 0.04, df = 1 (P = 0.84); I2 =0.0%
Test for overall effect: Z = 0.31 (P = 0.75)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours RV1 Favours placebo
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Analysis 1.19. Comparison 1 RV1 versus placebo, Outcome 19 All-cause diarrhoea: all episodes (up to 2
years follow-up).
Review: Vaccines for preventing rotavirus diarrhoea: vaccines in use
Comparison: 1 RV1 versus placebo
Outcome: 19 All-cause diarrhoea: all episodes (up to 2 years follow-up)
Study or subgroup log [Rate Ratio] Rate Ratio Weight Rate Ratio
(SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 Low-mortality countries (WHO strata A % B)
RV1 Vesikari 2004b-FIN 0.016 (0.137) 100.0 % 1.02 [ 0.78, 1.33 ]
Subtotal (95% CI) 100.0 % 1.02 [ 0.78, 1.33 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.12 (P = 0.91)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours RV1 Favours placebo
Analysis 1.20. Comparison 1 RV1 versus placebo, Outcome 20 All-cause hospitalizations (up to 2 years
follow-up).
Review: Vaccines for preventing rotavirus diarrhoea: vaccines in use
Comparison: 1 RV1 versus placebo
Outcome: 20 All-cause hospitalizations (up to 2 years follow-up)
Study or subgroup RV1 Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Low-mortality countries (WHO strata A % B)
RV1 Phua 2005-SGP 10/1779 10/642 100.0 % 0.36 [ 0.15, 0.86 ]
Subtotal (95% CI) 1779 642 100.0 % 0.36 [ 0.15, 0.86 ]
Total events: 10 (RV1), 10 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 2.29 (P = 0.022)
0.001 0.01 0.1 1 10 100 1000
Favours RV1 Favours placebo
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Analysis 1.21. Comparison 1 RV1 versus placebo, Outcome 21 Rotavirus diarrhoea: requiring
hospitalization.
Review: Vaccines for preventing rotavirus diarrhoea: vaccines in use
Comparison: 1 RV1 versus placebo
Outcome: 21 Rotavirus diarrhoea: requiring hospitalization
Study or subgroup RV1 Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Up to 1 year follow-up (at least 1 rotavirus season)
RV1 Bernstein 1999-USA 0/108 2/107 6.0 % 0.20 [ 0.01, 4.08 ]
RV1 Madhi 2010-AF (1) 20/3298 19/1641 28.4 % 0.52 [ 0.28, 0.98 ]
RV1 Phua 2009-AS 0/5263 13/5256 6.7 % 0.04 [ 0.00, 0.62 ]
RV1 Ruiz-Palac 06-LA/EU 9/9009 59/8858 27.2 % 0.15 [ 0.07, 0.30 ]
RV1 Salinas 2005-LA 9/1392 14/454 25.1 % 0.21 [ 0.09, 0.48 ]
RV1 Vesikari 2007a-EU 0/2572 12/1302 6.7 % 0.02 [ 0.00, 0.34 ]
Subtotal (95% CI) 21642 17618 100.0 % 0.19 [ 0.08, 0.43 ]
Total events: 38 (RV1), 119 (Placebo)
Heterogeneity: Tau2 = 0.51; Chi2 = 13.57, df = 5 (P = 0.02); I2 =63%
Test for overall effect: Z = 4.02 (P = 0.000059)
2 Second year follow-up (at least 2 rotavirus seasons)
RV1 Kawamura 2010-JPN 1/498 2/250 4.2 % 0.25 [ 0.02, 2.75 ]
RV1 Phua 2005-SGP 0/1779 1/642 2.4 % 0.12 [ 0.00, 2.95 ]
RV1 Phua 2009-AS 3/5263 48/5256 16.3 % 0.06 [ 0.02, 0.20 ]
RV1 Ruiz-Palac 06-LA/EU 22/7205 127/7081 64.2 % 0.17 [ 0.11, 0.27 ]
RV1 Vesikari 2004b-FIN 1/241 0/120 2.4 % 1.50 [ 0.06, 36.55 ]
RV1 Vesikari 2007a-EU 2/2554 13/1294 10.5 % 0.08 [ 0.02, 0.34 ]
Subtotal (95% CI) 17540 14643 100.0 % 0.14 [ 0.09, 0.23 ]
Total events: 29 (RV1), 191 (Placebo)
Heterogeneity: Tau2 = 0.05; Chi2 = 5.49, df = 5 (P = 0.36); I2 =9%
Test for overall effect: Z = 7.64 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.34, df = 1 (P = 0.56), I2 =0.0%
0.001 0.01 0.1 1 10 100 1000
Favours RV1 Favours placebo
(1) Data taken from main paper Supplementary Appendix, Table 3 - total vaccinated cohort.
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Analysis 1.22. Comparison 1 RV1 versus placebo, Outcome 22 Rotavirus diarrhoea: requiring medical
attention.
Review: Vaccines for preventing rotavirus diarrhoea: vaccines in use
Comparison: 1 RV1 versus placebo
Outcome: 22 Rotavirus diarrhoea: requiring medical attention
Study or subgroup RV1 Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Up to 1 year follow-up (at least 1 rotavirus season)
RV1 Vesikari 2007a-EU 10/2572 62/1302 100.0 % 0.08 [ 0.04, 0.16 ]
Subtotal (95% CI) 2572 1302 100.0 % 0.08 [ 0.04, 0.16 ]
Total events: 10 (RV1), 62 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 7.39 (P < 0.00001)
2 Second year follow-up (at least 2 rotavirus seasons)
RV1 Kawamura 2010-JPN 14/498 34/250 32.8 % 0.21 [ 0.11, 0.38 ]
RV1 Phua 2005-SGP 0/1779 3/642 3.7 % 0.05 [ 0.00, 1.00 ]
RV1 Vesikari 2007a-EU 31/2554 66/1294 63.5 % 0.24 [ 0.16, 0.36 ]
Subtotal (95% CI) 4831 2186 100.0 % 0.22 [ 0.16, 0.31 ]
Total events: 45 (RV1), 103 (Placebo)
Heterogeneity: Chi2 = 1.09, df = 2 (P = 0.58); I2 =0.0%
Test for overall effect: Z = 8.67 (P < 0.00001)
0.001 0.01 0.1 1 10 100 1000
Favours RV1 Favours placebo
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Analysis 1.23. Comparison 1 RV1 versus placebo, Outcome 23 All-cause diarrhoea: cases requiring
hospitalization.
Review: Vaccines for preventing rotavirus diarrhoea: vaccines in use
Comparison: 1 RV1 versus placebo
Outcome: 23 All-cause diarrhoea: cases requiring hospitalization
Study or subgroup RV1 Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Up to one year of follow-up (at least 1 rotavirus season)
RV1 Phua 2009-AS 60/5263 90/5256 55.8 % 0.67 [ 0.48, 0.92 ]
RV1 Vesikari 2007a-EU 11/2572 22/1302 44.2 % 0.25 [ 0.12, 0.52 ]
Subtotal (95% CI) 7835 6558 100.0 % 0.43 [ 0.17, 1.11 ]
Total events: 71 (RV1), 112 (Placebo)
Heterogeneity: Tau2 = 0.39; Chi2 = 5.75, df = 1 (P = 0.02); I2 =83%
Test for overall effect: Z = 1.74 (P = 0.082)
2 Second year of follow-up (at least 2 rotavirus seasons)
RV1 Phua 2009-AS 164/5263 240/5256 59.4 % 0.68 [ 0.56, 0.83 ]
RV1 Vesikari 2007a-EU 18/2554 26/1294 40.6 % 0.35 [ 0.19, 0.64 ]
Subtotal (95% CI) 7817 6550 100.0 % 0.52 [ 0.27, 0.99 ]
Total events: 182 (RV1), 266 (Placebo)
Heterogeneity: Tau2 = 0.17; Chi2 = 4.31, df = 1 (P = 0.04); I2 =77%
Test for overall effect: Z = 2.00 (P = 0.046)
0.1 0.2 0.5 1 2 5 10
Favours RV1 Favours placebo
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Analysis 1.24. Comparison 1 RV1 versus placebo, Outcome 24 All-cause diarrhoea: episodes requiring
hospitalization.
Review: Vaccines for preventing rotavirus diarrhoea: vaccines in use
Comparison: 1 RV1 versus placebo
Outcome: 24 All-cause diarrhoea: episodes requiring hospitalization
Study or subgroup log [Rate Ratio] Rate Ratio Weight Rate Ratio
(SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 Up to 1 year of follow-up (at least 1 rotavirus season)
RV1 Ruiz-Palac 06-LA/EU -0.546 (0.105) 100.0 % 0.58 [ 0.47, 0.71 ]
Subtotal (95% CI) 100.0 % 0.58 [ 0.47, 0.71 ]
Heterogeneity: not applicable
Test for overall effect: Z = 5.20 (P < 0.00001)
2 Second year of follow-up (at least 2 rotavirus seasons)
RV1 Ruiz-Palac 06-LA/EU -0.636 (0.076) 100.0 % 0.53 [ 0.46, 0.61 ]
Subtotal (95% CI) 100.0 % 0.53 [ 0.46, 0.61 ]
Heterogeneity: not applicable
Test for overall effect: Z = 8.37 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.48, df = 1 (P = 0.49), I2 =0.0%
0.01 0.1 1 10 100
Favours RV1 Favours placebo
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Analysis 1.25. Comparison 1 RV1 versus placebo, Outcome 25 Reactogenicity: fever.
Review: Vaccines for preventing rotavirus diarrhoea: vaccines in use
Comparison: 1 RV1 versus placebo
Outcome: 25 Reactogenicity: fever
Study or subgroup RV1 Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 After dose 1
RV1 Anh 2011-PHL 239/300 54/75 14.0 % 1.11 [ 0.95, 1.29 ]
RV1 Anh 2011-VNM 182/297 44/78 10.4 % 1.09 [ 0.88, 1.35 ]
RV1 Bernstein 1998-USA 3/21 6/20 0.6 % 0.48 [ 0.14, 1.65 ]
RV1 Bernstein 1999-USA 21/108 5/107 1.0 % 4.16 [ 1.63, 10.63 ]
RV1 Dennehy 2005-NA 83/421 21/108 4.1 % 1.01 [ 0.66, 1.56 ]
RV1 GSK[021] 2007-PAN 91/177 18/51 4.6 % 1.46 [ 0.98, 2.17 ]
RV1 GSK[033] 2007-LA 98/730 15/124 3.1 % 1.11 [ 0.67, 1.85 ]
RV1 GSK[041] 2007-KOR 10/100 3/52 0.6 % 1.73 [ 0.50, 6.03 ]
RV1 GSK[101555] 2008-PHL 39/100 11/50 2.5 % 1.77 [ 1.00, 3.16 ]
RV1 Kerdpanich 2010-THA 68/348 6/52 1.4 % 1.69 [ 0.77, 3.70 ]
RV1 Narang 2009-IND 14/182 6/181 1.0 % 2.32 [ 0.91, 5.90 ]
RV1 Phua 2005-SGP 497/1811 183/653 14.6 % 0.98 [ 0.85, 1.13 ]
RV1 Salinas 2005-LA 1002/1618 346/537 19.3 % 0.96 [ 0.89, 1.03 ]
RV1 Steele 2008-ZAF 37/297 21/150 3.2 % 0.89 [ 0.54, 1.46 ]
RV1 Steele 2010b-ZAF 62/189 30/96 5.4 % 1.05 [ 0.73, 1.50 ]
RV1 Vesikari 2004a-FIN 8/122 3/62 0.5 % 1.36 [ 0.37, 4.93 ]
RV1 Vesikari 2004b-FIN 32/265 14/133 2.3 % 1.15 [ 0.63, 2.07 ]
RV1 Vesikari 2007a-EU 166/914 91/490 9.6 % 0.98 [ 0.78, 1.23 ]
RV1 Vesikari 2011-FIN 9/200 1/50 0.2 % 2.25 [ 0.29, 17.35 ]
RV1 Zaman 2009-BGD 16/196 12/98 1.7 % 0.67 [ 0.33, 1.35 ]
Subtotal (95% CI) 8396 3167 100.0 % 1.08 [ 0.98, 1.18 ]
Total events: 2677 (RV1), 890 (Placebo)
Heterogeneity: Tau2 = 0.01; Chi2 = 29.53, df = 19 (P = 0.06); I2 =36%
Test for overall effect: Z = 1.48 (P = 0.14)
2 After dose 2
RV1 Anh 2011-PHL 197/296 45/75 10.6 % 1.11 [ 0.91, 1.36 ]
0.01 0.1 1 10 100
Favours RV1 Favours placebo
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198Vaccines for preventing rotavirus diarrhoea: vaccines in use (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(. . . Continued)
Study or subgroup RV1 Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
RV1 Anh 2011-VNM 141/286 36/73 7.0 % 1.00 [ 0.77, 1.30 ]
RV1 Bernstein 1998-USA 4/21 5/20 0.4 % 0.76 [ 0.24, 2.44 ]
RV1 Dennehy 2005-NA 82/394 31/101 4.2 % 0.68 [ 0.48, 0.96 ]
RV1 GSK[021] 2007-PAN 57/168 13/47 2.1 % 1.23 [ 0.74, 2.04 ]
RV1 GSK[033] 2007-LA 129/683 28/112 4.1 % 0.76 [ 0.53, 1.08 ]
RV1 GSK[041] 2007-KOR 8/99 6/52 0.6 % 0.70 [ 0.26, 1.91 ]
RV1 GSK[101555] 2008-PHL 29/98 22/50 2.8 % 0.67 [ 0.43, 1.04 ]
RV1 Kerdpanich 2010-THA 69/342 12/52 1.9 % 0.87 [ 0.51, 1.50 ]
RV1 Narang 2009-IND 18/175 12/173 1.1 % 1.48 [ 0.74, 2.98 ]
RV1 Phua 2005-SGP 536/1779 186/642 17.3 % 1.04 [ 0.90, 1.20 ]
RV1 Salinas 2005-LA 826/1534 288/522 26.5 % 0.98 [ 0.89, 1.07 ]
RV1 Steele 2008-ZAF 34/282 12/143 1.4 % 1.44 [ 0.77, 2.69 ]
RV1 Steele 2010b-ZAF 91/369 13/90 1.9 % 1.71 [ 1.00, 2.91 ]
RV1 Vesikari 2004a-FIN 5/111 4/60 0.3 % 0.68 [ 0.19, 2.42 ]
RV1 Vesikari 2004b-FIN 69/255 31/124 3.9 % 1.08 [ 0.75, 1.56 ]
RV1 Vesikari 2007a-EU 244/905 142/486 13.0 % 0.92 [ 0.77, 1.10 ]
RV1 Vesikari 2011-FIN 10/196 3/49 0.4 % 0.83 [ 0.24, 2.91 ]
RV1 Zaman 2009-BGD 14/195 6/97 0.7 % 1.16 [ 0.46, 2.93 ]
Subtotal (95% CI) 8188 2968 100.0 % 0.98 [ 0.91, 1.06 ]
Total events: 2563 (RV1), 895 (Placebo)
Heterogeneity: Tau2 = 0.00; Chi2 = 21.03, df = 18 (P = 0.28); I2 =14%
Test for overall effect: Z = 0.45 (P = 0.65)
3 After dose 3
RV1 Anh 2011-PHL 182/293 48/75 50.0 % 0.97 [ 0.80, 1.18 ]
RV1 Anh 2011-VNM 146/283 40/73 32.8 % 0.94 [ 0.74, 1.19 ]
RV1 GSK[021] 2007-PAN 63/168 18/46 10.9 % 0.96 [ 0.64, 1.44 ]
RV1 Steele 2010b-ZAF 76/364 13/88 6.3 % 1.41 [ 0.82, 2.43 ]
Subtotal (95% CI) 1108 282 100.0 % 0.98 [ 0.86, 1.13 ]
Total events: 467 (RV1), 119 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.03, df = 3 (P = 0.57); I2 =0.0%
Test for overall effect: Z = 0.25 (P = 0.80)
4 End of follow-up
RV1 Dennehy 2005-NA 136/421 38/108 2.3 % 0.92 [ 0.69, 1.23 ]
RV1 GSK[033] 2007-LA 199/730 33/124 2.0 % 1.02 [ 0.75, 1.40 ]
0.01 0.1 1 10 100
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(. . . Continued)
Study or subgroup RV1 Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
RV1 GSK[041] 2007-KOR 17/100 8/52 0.3 % 1.11 [ 0.51, 2.39 ]
RV1 GSK[101555] 2008-PHL 47/100 24/50 1.6 % 0.98 [ 0.69, 1.40 ]
RV1 Kawamura 2010-JPN 62/508 22/257 0.9 % 1.43 [ 0.90, 2.26 ]
RV1 Kerdpanich 2010-THA 114/348 16/52 1.0 % 1.06 [ 0.69, 1.64 ]
RV1 Narang 2009-IND 29/182 18/181 0.7 % 1.60 [ 0.92, 2.78 ]
RV1 Omenaca 2012-EU 54/203 29/100 1.3 % 0.92 [ 0.63, 1.34 ]
RV1 Rivera 2011-DOM 32/100 32/100 1.2 % 1.00 [ 0.67, 1.50 ]
RV1 Salinas 2005-LA 1238/1618 425/537 75.5 % 0.97 [ 0.92, 1.02 ]
RV1 Steele 2008-ZAF 64/297 28/150 1.2 % 1.15 [ 0.78, 1.72 ]
RV1 Vesikari 2004a-FIN 8/122 6/62 0.2 % 0.68 [ 0.25, 1.87 ]
RV1 Vesikari 2004b-FIN 86/265 33/133 1.7 % 1.31 [ 0.93, 1.84 ]
RV1 Vesikari 2007a-EU 310/914 192/490 9.7 % 0.87 [ 0.75, 1.00 ]
RV1 Vesikari 2011-FIN 18/200 4/50 0.2 % 1.13 [ 0.40, 3.18 ]
RV1 Zaman 2009-BGD 10/196 3/49 0.1 % 0.83 [ 0.24, 2.91 ]
Subtotal (95% CI) 6304 2495 100.0 % 0.97 [ 0.93, 1.01 ]
Total events: 2424 (RV1), 911 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 13.64, df = 15 (P = 0.55); I2 =0.0%
Test for overall effect: Z = 1.31 (P = 0.19)
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Analysis 1.26. Comparison 1 RV1 versus placebo, Outcome 26 Reactogenicity: diarrhoea.
Review: Vaccines for preventing rotavirus diarrhoea: vaccines in use
Comparison: 1 RV1 versus placebo
Outcome: 26 Reactogenicity: diarrhoea
Study or subgroup RV1 Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 After dose 1
RV1 Anh 2011-PHL 9/300 6/75 2.8 % 0.38 [ 0.14, 1.02 ]
RV1 Anh 2011-VNM 21/297 5/78 3.2 % 1.10 [ 0.43, 2.83 ]
RV1 Bernstein 1998-USA 2/21 1/20 0.5 % 1.90 [ 0.19, 19.40 ]
RV1 Bernstein 1999-USA 18/108 9/107 4.9 % 1.98 [ 0.93, 4.21 ]
RV1 Dennehy 2005-NA 28/421 10/108 5.9 % 0.72 [ 0.36, 1.43 ]
RV1 GSK[021] 2007-PAN 33/177 2/51 1.4 % 4.75 [ 1.18, 19.14 ]
RV1 GSK[033] 2007-LA 42/730 5/124 3.4 % 1.43 [ 0.58, 3.54 ]
RV1 GSK[041] 2007-KOR 5/100 3/52 1.5 % 0.87 [ 0.22, 3.49 ]
RV1 GSK[101555] 2008-PHL 6/100 3/50 1.6 % 1.00 [ 0.26, 3.83 ]
RV1 Kerdpanich 2010-THA 7/348 1/52 0.7 % 1.05 [ 0.13, 8.33 ]
RV1 Narang 2009-IND 11/182 8/181 3.6 % 1.37 [ 0.56, 3.32 ]
RV1 Phua 2005-SGP 31/1811 13/653 6.8 % 0.86 [ 0.45, 1.63 ]
RV1 Salinas 2005-LA 111/1618 45/537 25.4 % 0.82 [ 0.59, 1.14 ]
RV1 Steele 2008-ZAF 29/297 14/150 7.6 % 1.05 [ 0.57, 1.92 ]
RV1 Steele 2010b-ZAF 19/189 11/96 5.7 % 0.88 [ 0.44, 1.77 ]
RV1 Vesikari 2004a-FIN 11/122 5/62 2.7 % 1.12 [ 0.41, 3.08 ]
RV1 Vesikari 2004b-FIN 20/265 7/133 4.0 % 1.43 [ 0.62, 3.31 ]
RV1 Vesikari 2007a-EU 68/2613 29/1331 15.2 % 1.19 [ 0.78, 1.84 ]
RV1 Vesikari 2011-FIN 10/200 2/50 1.3 % 1.25 [ 0.28, 5.53 ]
RV1 Zaman 2009-BGD 5/196 4/98 1.7 % 0.63 [ 0.17, 2.28 ]
Subtotal (95% CI) 10095 4008 100.0 % 1.01 [ 0.86, 1.20 ]
Total events: 486 (RV1), 183 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 17.94, df = 19 (P = 0.53); I2 =0.0%
Test for overall effect: Z = 0.14 (P = 0.89)
2 After dose 2
RV1 Anh 2011-PHL 4/296 0/75 0.5 % 2.30 [ 0.13, 42.31 ]
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Study or subgroup RV1 Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
RV1 Anh 2011-VNM 8/286 0/73 0.5 % 4.38 [ 0.26, 75.08 ]
RV1 Bernstein 1998-USA 2/21 1/20 0.8 % 1.90 [ 0.19, 19.40 ]
RV1 Dennehy 2005-NA 16/394 5/101 4.3 % 0.82 [ 0.31, 2.19 ]
RV1 GSK[021] 2007-PAN 21/168 9/47 8.1 % 0.65 [ 0.32, 1.33 ]
RV1 GSK[033] 2007-LA 35/683 6/112 5.8 % 0.96 [ 0.41, 2.22 ]
RV1 GSK[041] 2007-KOR 5/99 6/52 3.2 % 0.44 [ 0.14, 1.37 ]
RV1 GSK[101555] 2008-PHL 6/98 4/50 2.8 % 0.77 [ 0.23, 2.59 ]
RV1 Kerdpanich 2010-THA 15/342 1/52 1.0 % 2.28 [ 0.31, 16.90 ]
RV1 Narang 2009-IND 5/175 8/173 3.4 % 0.62 [ 0.21, 1.85 ]
RV1 Phua 2005-SGP 36/1779 7/642 6.3 % 1.86 [ 0.83, 4.15 ]
RV1 Salinas 2005-LA 116/1534 46/522 38.3 % 0.86 [ 0.62, 1.19 ]
RV1 Steele 2008-ZAF 22/282 9/143 7.3 % 1.24 [ 0.59, 2.62 ]
RV1 Steele 2010b-ZAF 33/369 7/90 6.7 % 1.15 [ 0.53, 2.51 ]
RV1 Vesikari 2004a-FIN 3/111 2/60 1.3 % 0.81 [ 0.14, 4.72 ]
RV1 Vesikari 2004b-FIN 11/255 2/124 1.8 % 2.67 [ 0.60, 11.88 ]
RV1 Vesikari 2007a-EU 15/905 9/486 6.1 % 0.90 [ 0.39, 2.03 ]
RV1 Vesikari 2011-FIN 5/196 2/49 1.6 % 0.63 [ 0.12, 3.13 ]
RV1 Zaman 2009-BGD 0/195 1/97 0.4 % 0.17 [ 0.01, 4.05 ]
Subtotal (95% CI) 8188 2968 100.0 % 0.93 [ 0.76, 1.14 ]
Total events: 358 (RV1), 125 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 13.38, df = 18 (P = 0.77); I2 =0.0%
Test for overall effect: Z = 0.69 (P = 0.49)
3 After dose 3
RV1 Anh 2011-PHL 3/293 1/75 8.3 % 0.77 [ 0.08, 7.28 ]
RV1 Anh 2011-VNM 3/283 4/73 17.2 % 0.19 [ 0.04, 0.85 ]
RV1 GSK[021] 2007-PAN 18/168 4/46 29.3 % 1.23 [ 0.44, 3.46 ]
RV1 Steele 2010b-ZAF 28/364 9/88 45.2 % 0.75 [ 0.37, 1.54 ]
Subtotal (95% CI) 1108 282 100.0 % 0.69 [ 0.35, 1.36 ]
Total events: 52 (RV1), 18 (Placebo)
Heterogeneity: Tau2 = 0.13; Chi2 = 4.11, df = 3 (P = 0.25); I2 =27%
Test for overall effect: Z = 1.07 (P = 0.28)
4 End of follow-up
RV1 Dennehy 2005-NA 41/421 14/108 6.6 % 0.75 [ 0.43, 1.33 ]
RV1 GSK[033] 2007-LA 74/730 11/124 5.9 % 1.14 [ 0.62, 2.09 ]
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Study or subgroup RV1 Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
RV1 GSK[041] 2007-KOR 9/100 9/52 2.9 % 0.52 [ 0.22, 1.23 ]
RV1 GSK[101555] 2008-PHL 11/100 7/50 2.7 % 0.79 [ 0.32, 1.90 ]
RV1 Kawamura 2010-JPN 43/508 14/257 6.3 % 1.55 [ 0.87, 2.79 ]
RV1 Kerdpanich 2010-THA 20/348 2/52 1.1 % 1.49 [ 0.36, 6.21 ]
RV1 Narang 2009-IND 16/182 15/181 4.7 % 1.06 [ 0.54, 2.08 ]
RV1 Omenaca 2012-EU 9/203 5/100 1.9 % 0.89 [ 0.31, 2.58 ]
RV1 Salinas 2005-LA 206/1618 85/537 39.6 % 0.80 [ 0.64, 1.02 ]
RV1 Steele 2008-ZAF 45/297 20/150 9.0 % 1.14 [ 0.70, 1.85 ]
RV1 Vesikari 2004a-FIN 11/122 7/62 2.7 % 0.80 [ 0.33, 1.96 ]
RV1 Vesikari 2004b-FIN 30/265 8/133 3.8 % 1.88 [ 0.89, 3.99 ]
RV1 Vesikari 2007a-EU 44/2613 25/1331 9.1 % 0.90 [ 0.55, 1.46 ]
RV1 Vesikari 2011-FIN 7/193 2/47 0.9 % 0.85 [ 0.18, 3.97 ]
RV1 Zaman 2009-BGD 11/196 8/98 2.8 % 0.69 [ 0.29, 1.65 ]
Subtotal (95% CI) 7896 3282 100.0 % 0.92 [ 0.80, 1.07 ]
Total events: 577 (RV1), 232 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 12.60, df = 14 (P = 0.56); I2 =0.0%
Test for overall effect: Z = 1.10 (P = 0.27)
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Analysis 1.27. Comparison 1 RV1 versus placebo, Outcome 27 Reactogenicity: vomiting.
Review: Vaccines for preventing rotavirus diarrhoea: vaccines in use
Comparison: 1 RV1 versus placebo
Outcome: 27 Reactogenicity: vomiting
Study or subgroup RV1 Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 After dose 1
RV1 Anh 2011-PHL 56/300 5/75 1.3 % 2.80 [ 1.16, 6.74 ]
RV1 Anh 2011-VNM 39/297 6/78 1.5 % 1.71 [ 0.75, 3.89 ]
RV1 Bernstein 1998-USA 4/21 2/20 0.4 % 1.90 [ 0.39, 9.28 ]
RV1 Bernstein 1999-USA 16/108 10/107 1.8 % 1.59 [ 0.75, 3.33 ]
RV1 Dennehy 2005-NA 56/421 19/108 4.4 % 0.76 [ 0.47, 1.22 ]
RV1 GSK[021] 2007-PAN 36/177 10/51 2.5 % 1.04 [ 0.55, 1.94 ]
RV1 GSK[033] 2007-LA 115/730 22/124 5.8 % 0.89 [ 0.59, 1.34 ]
RV1 GSK[041] 2007-KOR 18/100 11/52 2.2 % 0.85 [ 0.43, 1.66 ]
RV1 GSK[101555] 2008-PHL 15/100 9/50 1.7 % 0.83 [ 0.39, 1.77 ]
RV1 Kerdpanich 2010-THA 103/348 13/52 4.0 % 1.18 [ 0.72, 1.95 ]
RV1 Narang 2009-IND 24/182 24/181 3.6 % 0.99 [ 0.59, 1.68 ]
RV1 Phua 2005-SGP 102/1811 39/653 7.7 % 0.94 [ 0.66, 1.35 ]
RV1 Salinas 2005-LA 285/1618 89/537 21.0 % 1.06 [ 0.86, 1.32 ]
RV1 Steele 2008-ZAF 55/297 21/150 4.6 % 1.32 [ 0.83, 2.10 ]
RV1 Steele 2010b-ZAF 24/189 14/96 2.6 % 0.87 [ 0.47, 1.61 ]
RV1 Vesikari 2004a-FIN 20/122 14/62 2.7 % 0.73 [ 0.39, 1.34 ]
RV1 Vesikari 2004b-FIN 23/265 6/133 1.3 % 1.92 [ 0.80, 4.61 ]
RV1 Vesikari 2007a-EU 290/2613 141/1331 27.4 % 1.05 [ 0.87, 1.27 ]
RV1 Vesikari 2011-FIN 39/200 7/50 1.8 % 1.39 [ 0.66, 2.93 ]
RV1 Zaman 2009-BGD 22/196 8/98 1.7 % 1.38 [ 0.64, 2.98 ]
Subtotal (95% CI) 10095 4008 100.0 % 1.06 [ 0.96, 1.17 ]
Total events: 1342 (RV1), 470 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 17.35, df = 19 (P = 0.57); I2 =0.0%
Test for overall effect: Z = 1.08 (P = 0.28)
2 After dose 2
RV1 Anh 2011-PHL 32/296 5/75 2.9 % 1.62 [ 0.65, 4.02 ]
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Study or subgroup RV1 Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
RV1 Anh 2011-VNM 27/286 7/73 3.7 % 0.98 [ 0.45, 2.17 ]
RV1 Bernstein 1998-USA 4/21 0/20 0.4 % 8.59 [ 0.49, 150.00 ]
RV1 Dennehy 2005-NA 30/394 15/101 5.8 % 0.51 [ 0.29, 0.92 ]
RV1 GSK[021] 2007-PAN 33/168 6/47 3.6 % 1.54 [ 0.69, 3.45 ]
RV1 GSK[033] 2007-LA 82/683 17/112 7.3 % 0.79 [ 0.49, 1.28 ]
RV1 GSK[041] 2007-KOR 21/99 10/52 4.7 % 1.10 [ 0.56, 2.16 ]
RV1 GSK[101555] 2008-PHL 8/98 1/50 0.7 % 4.08 [ 0.53, 31.73 ]
RV1 Kerdpanich 2010-THA 65/342 15/52 7.4 % 0.66 [ 0.41, 1.06 ]
RV1 Narang 2009-IND 12/175 13/173 4.0 % 0.91 [ 0.43, 1.94 ]
RV1 Phua 2005-SGP 77/1779 26/642 8.2 % 1.07 [ 0.69, 1.65 ]
RV1 Salinas 2005-LA 189/1534 59/522 12.0 % 1.09 [ 0.83, 1.43 ]
RV1 Steele 2008-ZAF 47/282 14/143 6.1 % 1.70 [ 0.97, 2.99 ]
RV1 Steele 2010b-ZAF 60/369 17/90 7.2 % 0.86 [ 0.53, 1.40 ]
RV1 Vesikari 2004a-FIN 16/111 12/60 4.6 % 0.72 [ 0.37, 1.42 ]
RV1 Vesikari 2004b-FIN 16/255 11/124 4.1 % 0.71 [ 0.34, 1.48 ]
RV1 Vesikari 2007a-EU 53/905 46/486 9.4 % 0.62 [ 0.42, 0.90 ]
RV1 Vesikari 2011-FIN 31/196 6/49 3.5 % 1.29 [ 0.57, 2.92 ]
RV1 Zaman 2009-BGD 17/195 12/97 4.5 % 0.70 [ 0.35, 1.42 ]
Subtotal (95% CI) 8188 2968 100.0 % 0.92 [ 0.78, 1.09 ]
Total events: 820 (RV1), 292 (Placebo)
Heterogeneity: Tau2 = 0.04; Chi2 = 27.17, df = 18 (P = 0.08); I2 =34%
Test for overall effect: Z = 0.96 (P = 0.34)
3 After dose 3
RV1 Anh 2011-PHL 18/293 1/75 8.6 % 4.61 [ 0.63, 33.96 ]
RV1 Anh 2011-VNM 27/283 3/73 20.3 % 2.32 [ 0.72, 7.44 ]
RV1 GSK[021] 2007-PAN 23/168 5/46 27.9 % 1.26 [ 0.51, 3.13 ]
RV1 Steele 2010b-ZAF 45/364 13/88 43.3 % 0.84 [ 0.47, 1.48 ]
Subtotal (95% CI) 1108 282 100.0 % 1.34 [ 0.71, 2.50 ]
Total events: 113 (RV1), 22 (Placebo)
Heterogeneity: Tau2 = 0.15; Chi2 = 4.79, df = 3 (P = 0.19); I2 =37%
Test for overall effect: Z = 0.90 (P = 0.37)
4 End of follow-up
RV1 Dennehy 2005-NA 79/421 27/108 7.1 % 0.75 [ 0.51, 1.10 ]
RV1 GSK[033] 2007-LA 168/730 34/124 8.8 % 0.84 [ 0.61, 1.15 ]
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Study or subgroup RV1 Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
RV1 GSK[041] 2007-KOR 27/100 17/52 4.8 % 0.83 [ 0.50, 1.37 ]
RV1 GSK[101555] 2008-PHL 21/100 9/50 2.8 % 1.17 [ 0.58, 2.36 ]
RV1 Kawamura 2010-JPN 74/508 36/257 7.4 % 1.04 [ 0.72, 1.50 ]
RV1 Kerdpanich 2010-THA 131/348 20/52 7.4 % 0.98 [ 0.68, 1.42 ]
RV1 Narang 2009-IND 29/182 32/181 5.6 % 0.90 [ 0.57, 1.43 ]
RV1 Omenaca 2012-EU 52/203 27/100 6.7 % 0.95 [ 0.64, 1.41 ]
RV1 Salinas 2005-LA 403/1618 129/537 14.1 % 1.04 [ 0.87, 1.23 ]
RV1 Steele 2008-ZAF 82/297 31/150 7.5 % 1.34 [ 0.93, 1.92 ]
RV1 Vesikari 2004a-FIN 30/122 21/62 5.4 % 0.73 [ 0.46, 1.16 ]
RV1 Vesikari 2004b-FIN 34/265 14/133 3.8 % 1.22 [ 0.68, 2.19 ]
RV1 Vesikari 2007a-EU 154/2613 126/1331 11.9 % 0.62 [ 0.50, 0.78 ]
RV1 Vesikari 2011-FIN 34/193 6/47 2.2 % 1.38 [ 0.62, 3.09 ]
RV1 Zaman 2009-BGD 36/196 16/98 4.4 % 1.13 [ 0.66, 1.92 ]
Subtotal (95% CI) 7896 3282 100.0 % 0.93 [ 0.82, 1.05 ]
Total events: 1354 (RV1), 545 (Placebo)
Heterogeneity: Tau2 = 0.02; Chi2 = 23.32, df = 14 (P = 0.06); I2 =40%
Test for overall effect: Z = 1.15 (P = 0.25)
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Analysis 1.28. Comparison 1 RV1 versus placebo, Outcome 28 Adverse events requiring discontinuation
(end of follow-up).
Review: Vaccines for preventing rotavirus diarrhoea: vaccines in use
Comparison: 1 RV1 versus placebo
Outcome: 28 Adverse events requiring discontinuation (end of follow-up)
Study or subgroup RV1 Placebo Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
RV1 Anh 2011-PHL 1/300 0/75 0.76 [ 0.03, 18.41 ]
RV1 Anh 2011-VNM 1/297 0/78 0.80 [ 0.03, 19.34 ]
RV1 Bernstein 1998-USA 1/21 0/20 2.86 [ 0.12, 66.44 ]
RV1 Dennehy 2005-NA 5/421 1/108 1.28 [ 0.15, 10.86 ]
RV1 GSK[021] 2007-PAN 0/177 1/51 0.10 [ 0.00, 2.35 ]
RV1 GSK[024] 2008-LA 12/4376 3/2192 2.00 [ 0.57, 7.09 ]
RV1 GSK[033] 2007-LA 4/730 0/122 1.51 [ 0.08, 27.95 ]
RV1 GSK[041] 2007-KOR 0/103 0/52 0.0 [ 0.0, 0.0 ]
RV1 GSK[101555] 2008-PHL 0/100 0/50 0.0 [ 0.0, 0.0 ]
RV1 Kawamura 2010-JPN 1/508 1/257 0.51 [ 0.03, 8.06 ]
RV1 Kerdpanich 2010-THA 0/348 0/52 0.0 [ 0.0, 0.0 ]
RV1 Narang 2009-IND 1/182 0/181 2.98 [ 0.12, 72.76 ]
RV1 Phua 2009-AS 7/5263 12/5256 0.58 [ 0.23, 1.48 ]
RV1 Ruiz-Palac 06-LA/EU 118/31673 104/31552 1.13 [ 0.87, 1.47 ]
RV1 Steele 2008-ZAF 4/300 4/150 0.50 [ 0.13, 1.97 ]
RV1 Steele 2010b-ZAF 4/379 1/95 1.00 [ 0.11, 8.87 ]
RV1 Vesikari 2004a-FIN 5/128 0/64 5.54 [ 0.31, 98.71 ]
RV1 Vesikari 2004b-FIN 6/270 2/135 1.50 [ 0.31, 7.33 ]
RV1 Vesikari 2007a-EU 7/2646 6/1348 0.59 [ 0.20, 1.77 ]
RV1 Vesikari 2011-FIN 1/200 0/50 0.76 [ 0.03, 18.41 ]
RV1 Zaman 2009-BGD 1/196 0/98 1.51 [ 0.06, 36.67 ]
Total (95% CI) 48618 41986 1.07 [ 0.86, 1.34 ]
Total events: 179 (RV1), 135 (Placebo)
Heterogeneity: Chi2 = 9.97, df = 17 (P = 0.91); I2 =0.0%
Test for overall effect: Z = 0.62 (P = 0.53)
Test for subgroup differences: Not applicable
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Analysis 1.29. Comparison 1 RV1 versus placebo, Outcome 29 Immunogenicity: rotavirus vaccine shedding
(end of follow-up).
Review: Vaccines for preventing rotavirus diarrhoea: vaccines in use
Comparison: 1 RV1 versus placebo
Outcome: 29 Immunogenicity: rotavirus vaccine shedding (end of follow-up)
Study or subgroup RV1 Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
RV1 Bernstein 1998-USA 17/20 0/20 5.0 % 35.00 [ 2.25, 544.92 ]
RV1 Bernstein 1999-USA 75/100 1/107 6.7 % 80.25 [ 11.37, 566.35 ]
RV1 Dennehy 2005-NA 184/328 2/78 8.3 % 21.88 [ 5.55, 86.22 ]
RV1 GSK[021] 2007-PAN 35/88 0/26 4.9 % 21.54 [ 1.37, 339.58 ]
RV1 GSK[033] 2007-LA 14/26 1/6 7.1 % 3.23 [ 0.52, 20.02 ]
RV1 GSK[101555] 2008-PHL 50/86 7/40 10.0 % 3.32 [ 1.66, 6.67 ]
RV1 Kerdpanich 2010-THA 198/337 1/51 6.8 % 29.96 [ 4.29, 209.08 ]
RV1 Salinas 2005-LA 44/267 1/93 6.7 % 15.33 [ 2.14, 109.68 ]
RV1 Steele 2008-ZAF 19/76 0/39 4.9 % 20.26 [ 1.26, 326.90 ]
RV1 Steele 2010a-ZAF 15/23 7/22 10.0 % 2.05 [ 1.04, 4.05 ]
RV1 Steele 2010b-ZAF 41/109 0/23 5.0 % 18.11 [ 1.15, 284.20 ]
RV1 Vesikari 2004a-FIN 9/122 0/62 4.8 % 9.73 [ 0.58, 164.51 ]
RV1 Vesikari 2011-FIN 101/193 0/46 4.9 % 49.18 [ 3.11, 777.27 ]
RV1 Ward 2006-USA 74/75 0/36 5.0 % 72.54 [ 4.62, 1138.35 ]
RV1 Zaman 2009-BGD 45/71 7/36 10.0 % 3.26 [ 1.64, 6.49 ]
Total (95% CI) 1921 685 100.0 % 12.07 [ 5.23, 27.85 ]
Total events: 921 (RV1), 27 (Placebo)
Heterogeneity: Tau2 = 1.70; Chi2 = 61.54, df = 14 (P<0.00001); I2 =77%
Test for overall effect: Z = 5.84 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 1.30. Comparison 1 RV1 versus placebo, Outcome 30 Immunogenicity: seroconversion.
Review: Vaccines for preventing rotavirus diarrhoea: vaccines in use
Comparison: 1 RV1 versus placebo
Outcome: 30 Immunogenicity: seroconversion
Study or subgroup RV1 Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 After dose 1
RV1 Bernstein 1998-USA 16/20 0/21 6.9 % 34.57 [ 2.21, 540.36 ]
RV1 GSK[021] 2007-PAN 59/140 2/38 14.3 % 8.01 [ 2.05, 31.29 ]
RV1 GSK[101555] 2008-PHL 34/77 4/39 17.3 % 4.31 [ 1.65, 11.26 ]
RV1 Phua 2005-SGP 357/442 3/155 16.1 % 41.73 [ 13.60, 128.09 ]
RV1 Salinas 2005-LA 157/405 1/139 10.5 % 53.88 [ 7.61, 381.29 ]
RV1 Steele 2008-ZAF 72/201 2/110 14.2 % 19.70 [ 4.93, 78.76 ]
RV1 Steele 2010b-ZAF 30/283 0/65 6.8 % 14.18 [ 0.88, 228.86 ]
RV1 Vesikari 2004a-FIN 85/122 0/62 6.9 % 87.59 [ 5.53, 1388.36 ]
RV1 Vesikari 2011-FIN 130/176 0/42 6.9 % 63.41 [ 4.02, 998.86 ]
Subtotal (95% CI) 1866 671 100.0 % 20.39 [ 8.48, 49.01 ]
Total events: 940 (RV1), 12 (Placebo)
Heterogeneity: Tau2 = 0.91; Chi2 = 18.72, df = 8 (P = 0.02); I2 =57%
Test for overall effect: Z = 6.74 (P < 0.00001)
2 After dose 2
RV1 Bernstein 1998-USA 19/21 0/20 2.0 % 37.23 [ 2.40, 578.09 ]
RV1 Bernstein 1999-USA 98/107 0/106 2.0 % 195.18 [ 12.28, 3102.13 ]
RV1 Dennehy 2005-NA 197/271 4/63 5.7 % 11.45 [ 4.42, 29.64 ]
RV1 GSK[021] 2007-PAN 96/139 2/37 4.5 % 12.78 [ 3.30, 49.41 ]
RV1 GSK[024] 2008-LA 108/176 14/89 6.9 % 3.90 [ 2.38, 6.40 ]
RV1 GSK[033] 2007-LA 355/494 9/91 6.6 % 7.27 [ 3.90, 13.54 ]
RV1 GSK[041] 2007-KOR 32/48 1/24 3.2 % 16.00 [ 2.32, 110.13 ]
RV1 GSK[101555] 2008-PHL 60/76 6/39 6.3 % 5.13 [ 2.44, 10.81 ]
RV1 Kawamura 2010-JPN 29/34 1/20 3.2 % 17.06 [ 2.51, 115.83 ]
RV1 Kerdpanich 2010-THA 290/352 0/51 2.0 % 85.59 [ 5.42, 1350.73 ]
RV1 Narang 2009-IND 67/115 7/112 6.3 % 9.32 [ 4.48, 19.42 ]
RV1 Omenaca 2012-EU 126/147 13/81 6.9 % 5.34 [ 3.23, 8.83 ]
0.001 0.01 0.1 1 10 100 1000
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(. . . Continued)
Study or subgroup RV1 Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
RV1 Phua 2005-SGP 379/445 4/151 5.6 % 32.15 [ 12.22, 84.62 ]
RV1 Rivera 2011-DOM 50/80 17/80 7.0 % 2.94 [ 1.87, 4.63 ]
RV1 Salinas 2005-LA 246/391 5/132 5.9 % 16.61 [ 7.01, 39.37 ]
RV1 Steele 2008-ZAF 86/182 5/106 5.9 % 10.02 [ 4.20, 23.89 ]
RV1 Vesikari 2004a-FIN 106/122 0/62 2.0 % 109.10 [ 6.89, 1726.59 ]
RV1 Vesikari 2004b-FIN 168/209 0/112 2.0 % 181.34 [ 11.40, 2883.75 ]
RV1 Vesikari 2007a-EU 687/794 28/422 7.2 % 13.04 [ 9.11, 18.67 ]
RV1 Vesikari 2011-FIN 144/166 0/44 2.0 % 77.87 [ 4.94, 1226.73 ]
RV1 Zaman 2009-BGD 83/135 13/70 6.9 % 3.31 [ 1.99, 5.50 ]
Subtotal (95% CI) 4504 1912 100.0 % 11.04 [ 7.03, 17.34 ]
Total events: 3426 (RV1), 129 (Placebo)
Heterogeneity: Tau2 = 0.70; Chi2 = 110.09, df = 20 (P<0.00001); I2 =82%
Test for overall effect: Z = 10.43 (P < 0.00001)
3 After dose 3
RV1 Anh 2011-PHL 155/240 3/52 23.8 % 11.19 [ 3.72, 33.71 ]
RV1 Anh 2011-VNM 178/247 10/65 41.2 % 4.68 [ 2.63, 8.33 ]
RV1 GSK[021] 2007-PAN 111/130 3/37 24.2 % 10.53 [ 3.55, 31.23 ]
RV1 Steele 2010b-ZAF 117/264 1/59 10.7 % 26.15 [ 3.73, 183.41 ]
Subtotal (95% CI) 881 213 100.0 % 8.43 [ 4.16, 17.11 ]
Total events: 561 (RV1), 17 (Placebo)
Heterogeneity: Tau2 = 0.23; Chi2 = 5.49, df = 3 (P = 0.14); I2 =45%
Test for overall effect: Z = 5.91 (P < 0.00001)
0.001 0.01 0.1 1 10 100 1000
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Analysis 1.31. Comparison 1 RV1 versus placebo, Outcome 31 Drop outs before the end of the trial.
Review: Vaccines for preventing rotavirus diarrhoea: vaccines in use
Comparison: 1 RV1 versus placebo
Outcome: 31 Drop outs before the end of the trial
Study or subgroup RV1 Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
RV1 Anh 2011-PHL 8/300 1/75 0.3 % 2.00 [ 0.25, 15.75 ]
RV1 Anh 2011-VNM 16/297 5/78 1.4 % 0.84 [ 0.32, 2.22 ]
RV1 GSK[021] 2007-PAN 19/177 6/51 1.6 % 0.91 [ 0.38, 2.16 ]
RV1 GSK[024] 2008-LA 142/4376 77/2192 17.5 % 0.92 [ 0.70, 1.21 ]
RV1 GSK[033] 2007-LA 47/730 12/124 3.5 % 0.67 [ 0.36, 1.22 ]
RV1 GSK[041] 2007-KOR 4/103 0/52 0.1 % 4.59 [ 0.25, 83.60 ]
RV1 GSK[101555] 2008-PHL 5/100 0/50 0.1 % 5.55 [ 0.31, 98.50 ]
RV1 Kawamura 2010-JPN 32/508 16/257 3.6 % 1.01 [ 0.57, 1.81 ]
RV1 Kerdpanich 2010-THA 9/348 0/52 0.1 % 2.89 [ 0.17, 48.85 ]
RV1 Madhi 2010-AF 324/3298 198/1641 45.2 % 0.81 [ 0.69, 0.96 ]
RV1 Narang 2009-IND 9/182 10/181 1.7 % 0.90 [ 0.37, 2.15 ]
RV1 Omenaca 2012-EU 15/670 6/339 1.4 % 1.26 [ 0.50, 3.23 ]
RV1 Phua 2005-SGP 69/1811 25/653 6.3 % 1.00 [ 0.64, 1.56 ]
RV1 Rivera 2011-DOM 5/100 5/100 0.9 % 1.00 [ 0.30, 3.35 ]
RV1 Steele 2008-ZAF 30/300 14/150 3.2 % 1.07 [ 0.59, 1.96 ]
RV1 Steele 2010a-ZAF 14/50 12/50 2.1 % 1.17 [ 0.60, 2.27 ]
RV1 Steele 2010b-ZAF 42/379 13/96 3.5 % 0.82 [ 0.46, 1.46 ]
RV1 Vesikari 2004a-FIN 12/128 2/64 0.5 % 3.00 [ 0.69, 13.00 ]
RV1 Vesikari 2004b-FIN 21/270 12/135 2.7 % 0.88 [ 0.44, 1.72 ]
RV1 Vesikari 2007a-EU 33/2646 17/1348 3.8 % 0.99 [ 0.55, 1.77 ]
RV1 Vesikari 2011-FIN 5/200 1/50 0.3 % 1.25 [ 0.15, 10.46 ]
RV1 Zaman 2009-BGD 3/196 1/98 0.2 % 1.50 [ 0.16, 14.23 ]
Total (95% CI) 17169 7836 100.0 % 0.91 [ 0.81, 1.02 ]
Total events: 864 (RV1), 433 (Placebo)
Heterogeneity: Chi2 = 11.33, df = 21 (P = 0.96); I2 =0.0%
Test for overall effect: Z = 1.65 (P = 0.099)
Test for subgroup differences: Not applicable
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Analysis 1.32. Comparison 1 RV1 versus placebo, Outcome 32 Subgroup analysis: rotavirus diarrhoea of any
severity (by G type).
Review: Vaccines for preventing rotavirus diarrhoea: vaccines in use
Comparison: 1 RV1 versus placebo
Outcome: 32 Subgroup analysis: rotavirus diarrhoea of any severity (by G type)
Study or subgroup RV1 Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 G1
RV1 Kawamura 2010-JPN 5/498 19/250 20.2 % 0.13 [ 0.05, 0.35 ]
RV1 Ruiz-Palac 06-LA/EU 3/9009 36/8858 16.3 % 0.08 [ 0.03, 0.27 ]
RV1 Salinas 2005-LA 25/1392 30/454 31.5 % 0.27 [ 0.16, 0.46 ]
RV1 Vesikari 2007a-EU 18/2572 89/1302 32.0 % 0.10 [ 0.06, 0.17 ]
Subtotal (95% CI) 13471 10864 100.0 % 0.14 [ 0.08, 0.26 ]
Total events: 51 (RV1), 174 (Placebo)
Heterogeneity: Tau2 = 0.24; Chi2 = 8.72, df = 3 (P = 0.03); I2 =66%
Test for overall effect: Z = 6.23 (P < 0.00001)
2 G2
RV1 Ruiz-Palac 06-LA/EU 6/9009 10/8858 30.6 % 0.59 [ 0.21, 1.62 ]
RV1 Salinas 2005-LA 1/1392 3/454 6.1 % 0.11 [ 0.01, 1.04 ]
RV1 Vesikari 2007a-EU 14/2572 17/1302 63.2 % 0.42 [ 0.21, 0.84 ]
Subtotal (95% CI) 12973 10614 100.0 % 0.43 [ 0.24, 0.75 ]
Total events: 21 (RV1), 30 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.80, df = 2 (P = 0.41); I2 =0.0%
Test for overall effect: Z = 2.98 (P = 0.0029)
3 G3
RV1 Salinas 2005-LA 1/1392 2/454 22.4 % 0.16 [ 0.01, 1.79 ]
RV1 Vesikari 2007a-EU 3/2572 10/1302 77.6 % 0.15 [ 0.04, 0.55 ]
Subtotal (95% CI) 3964 1756 100.0 % 0.15 [ 0.05, 0.48 ]
Total events: 4 (RV1), 12 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.00, df = 1 (P = 0.96); I2 =0.0%
Test for overall effect: Z = 3.23 (P = 0.0013)
4 G4
RV1 Salinas 2005-LA 1/1392 0/454 10.5 % 0.98 [ 0.04, 24.01 ]
RV1 Vesikari 2007a-EU 6/2572 18/1302 89.5 % 0.17 [ 0.07, 0.42 ]
Subtotal (95% CI) 3964 1756 100.0 % 0.20 [ 0.07, 0.59 ]
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(. . . Continued)
Study or subgroup RV1 Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Total events: 7 (RV1), 18 (Placebo)
Heterogeneity: Tau2 = 0.10; Chi2 = 1.07, df = 1 (P = 0.30); I2 =7%
Test for overall effect: Z = 2.95 (P = 0.0032)
5 G9
RV1 Salinas 2005-LA 29/1392 15/454 45.9 % 0.63 [ 0.34, 1.17 ]
RV1 Vesikari 2007a-EU 38/2572 71/1302 54.1 % 0.27 [ 0.18, 0.40 ]
Subtotal (95% CI) 3964 1756 100.0 % 0.40 [ 0.17, 0.91 ]
Total events: 67 (RV1), 86 (Placebo)
Heterogeneity: Tau2 = 0.29; Chi2 = 5.20, df = 1 (P = 0.02); I2 =81%
Test for overall effect: Z = 2.18 (P = 0.029)
Test for subgroup differences: Chi2 = 8.84, df = 4 (P = 0.07), I2 =55%
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Analysis 1.33. Comparison 1 RV1 versus placebo, Outcome 33 Subgroup analysis: severe cases of rotavirus
diarrhoea (by G type).
Review: Vaccines for preventing rotavirus diarrhoea: vaccines in use
Comparison: 1 RV1 versus placebo
Outcome: 33 Subgroup analysis: severe cases of rotavirus diarrhoea (by G type)
Study or subgroup RV1 Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 G1
RV1 GSK[024] 2008-LA 6/4211 16/2099 23.4 % 0.19 [ 0.07, 0.48 ]
RV1 Kawamura 2010-JPN 1/498 6/250 7.5 % 0.08 [ 0.01, 0.69 ]
RV1 Madhi 2010-AF 17/2794 23/1443 33.1 % 0.38 [ 0.20, 0.71 ]
RV1 Phua 2009-AS 0/5263 21/5256 4.5 % 0.02 [ 0.00, 0.38 ]
RV1 Ruiz-Palac 06-LA/EU 10/7205 55/7081 31.4 % 0.18 [ 0.09, 0.35 ]
Subtotal (95% CI) 19971 16129 100.0 % 0.20 [ 0.11, 0.37 ]
Total events: 34 (RV1), 121 (Placebo)
Heterogeneity: Tau2 = 0.21; Chi2 = 7.36, df = 4 (P = 0.12); I2 =46%
Test for overall effect: Z = 5.04 (P < 0.00001)
2 G2
RV1 GSK[024] 2008-LA 1/4211 2/2099 14.3 % 0.25 [ 0.02, 2.75 ]
RV1 Phua 2005-SGP 0/1779 1/642 8.0 % 0.12 [ 0.00, 2.95 ]
RV1 Phua 2009-AS 0/5263 2/5256 8.9 % 0.20 [ 0.01, 4.16 ]
RV1 Ruiz-Palac 06-LA/EU 5/9009 9/8858 68.8 % 0.55 [ 0.18, 1.63 ]
Subtotal (95% CI) 20262 16855 100.0 % 0.40 [ 0.16, 0.98 ]
Total events: 6 (RV1), 14 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.20, df = 3 (P = 0.75); I2 =0.0%
Test for overall effect: Z = 2.01 (P = 0.045)
3 G3
RV1 Phua 2005-SGP 2/1779 0/642 44.6 % 1.81 [ 0.09, 37.57 ]
RV1 Phua 2009-AS 1/5263 18/5256 55.4 % 0.06 [ 0.01, 0.42 ]
Subtotal (95% CI) 7042 5898 100.0 % 0.26 [ 0.01, 8.16 ]
Total events: 3 (RV1), 18 (Placebo)
Heterogeneity: Tau2 = 4.50; Chi2 = 3.60, df = 1 (P = 0.06); I2 =72%
Test for overall effect: Z = 0.76 (P = 0.45)
4 G4
RV1 Phua 2005-SGP 0/1779 1/642 100.0 % 0.12 [ 0.00, 2.95 ]
Subtotal (95% CI) 1779 642 100.0 % 0.12 [ 0.00, 2.95 ]
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(. . . Continued)
Study or subgroup RV1 Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Total events: 0 (RV1), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.30 (P = 0.19)
5 G9
RV1 GSK[024] 2008-LA 7/4211 19/2099 79.3 % 0.18 [ 0.08, 0.44 ]
RV1 Phua 2005-SGP 0/1779 2/642 6.4 % 0.07 [ 0.00, 1.50 ]
RV1 Phua 2009-AS 1/5263 12/5256 14.3 % 0.08 [ 0.01, 0.64 ]
Subtotal (95% CI) 11253 7997 100.0 % 0.15 [ 0.07, 0.33 ]
Total events: 8 (RV1), 33 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.78, df = 2 (P = 0.68); I2 =0.0%
Test for overall effect: Z = 4.75 (P < 0.00001)
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Analysis 1.34. Comparison 1 RV1 versus placebo, Outcome 34 Subgroup analysis: rotavirus diarrhoea in
malnourished children.
Review: Vaccines for preventing rotavirus diarrhoea: vaccines in use
Comparison: 1 RV1 versus placebo
Outcome: 34 Subgroup analysis: rotavirus diarrhoea in malnourished children
Study or subgroup RV1 Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Up to 1 year of follow-up (at least 1 rotavirus season)
RV1 Salinas 2005-LA 14/211 13/76 100.0 % 0.39 [ 0.19, 0.79 ]
Total (95% CI) 211 76 100.0 % 0.39 [ 0.19, 0.79 ]
Total events: 14 (RV1), 13 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 2.62 (P = 0.0087)
Test for subgroup differences: Not applicable
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Analysis 1.35. Comparison 1 RV1 versus placebo, Outcome 35 Subgroup analysis: rotavirus diarrhoea in
HIV-infected children.
Review: Vaccines for preventing rotavirus diarrhoea: vaccines in use
Comparison: 1 RV1 versus placebo
Outcome: 35 Subgroup analysis: rotavirus diarrhoea in HIV-infected children
Study or subgroup RV1 Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
RV1 Steele 2010a-ZAF 4/50 4/50 100.0 % 1.00 [ 0.26, 3.78 ]
Total (95% CI) 50 50 100.0 % 1.00 [ 0.26, 3.78 ]
Total events: 4 (RV1), 4 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
Test for subgroup differences: Not applicable
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Analysis 1.36. Comparison 1 RV1 versus placebo, Outcome 36 Subgroup analysis: serious adverse events in
premature babies.
Review: Vaccines for preventing rotavirus diarrhoea: vaccines in use
Comparison: 1 RV1 versus placebo
Outcome: 36 Subgroup analysis: serious adverse events in premature babies
Study or subgroup RV1 Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
RV1 Omenaca 2012-EU 34/670 23/339 100.0 % 0.75 [ 0.45, 1.25 ]
Total (95% CI) 670 339 100.0 % 0.75 [ 0.45, 1.25 ]
Total events: 34 (RV1), 23 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.11 (P = 0.27)
Test for subgroup differences: Not applicable
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Analysis 1.37. Comparison 1 RV1 versus placebo, Outcome 37 Subgroup analysis: severe rotavirus
diarrhoea in breast fed and formula fed infants.
Review: Vaccines for preventing rotavirus diarrhoea: vaccines in use
Comparison: 1 RV1 versus placebo
Outcome: 37 Subgroup analysis: severe rotavirus diarrhoea in breast fed and formula fed infants
Study or subgroup RV1 Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Severe rotavirus diarrhoea (2 year follow-up) breast fed infants
RV1 Vesikari 2007a-EU 23/2005 130/1041 100.0 % 0.09 [ 0.06, 0.14 ]
Subtotal (95% CI) 2005 1041 100.0 % 0.09 [ 0.06, 0.14 ]
Total events: 23 (RV1), 130 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 10.71 (P < 0.00001)
2 Severe rotavirus diarrhoea (2 year follow-up): formula fed infants
RV1 Vesikari 2007a-EU 1/567 24/261 100.0 % 0.02 [ 0.00, 0.14 ]
Subtotal (95% CI) 567 261 100.0 % 0.02 [ 0.00, 0.14 ]
Total events: 1 (RV1), 24 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 3.88 (P = 0.00010)
Test for subgroup differences: Chi2 = 2.26, df = 1 (P = 0.13), I2 =56%
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Analysis 1.38. Comparison 1 RV1 versus placebo, Outcome 38 Sensitivity analysis: allocation concealment.
Review: Vaccines for preventing rotavirus diarrhoea: vaccines in use
Comparison: 1 RV1 versus placebo
Outcome: 38 Sensitivity analysis: allocation concealment
Study or subgroup RV1 Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Rotavirus diarrhoea: severe, up to 1 year follow-up (low-mortality countries)
RV1 Bernstein 1999-USA 2/108 9/107 20.3 % 0.22 [ 0.05, 1.00 ]
RV1 Phua 2009-AS 0/5263 15/5256 8.3 % 0.03 [ 0.00, 0.54 ]
RV1 Ruiz-Palac 06-LA/EU (1) 12/9009 77/8858 39.3 % 0.15 [ 0.08, 0.28 ]
RV1 Vesikari 2007a-EU 5/2572 60/1302 32.1 % 0.04 [ 0.02, 0.10 ]
Subtotal (95% CI) 16952 15523 100.0 % 0.10 [ 0.04, 0.23 ]
Total events: 19 (RV1), 161 (Placebo)
Heterogeneity: Tau2 = 0.43; Chi2 = 7.09, df = 3 (P = 0.07); I2 =58%
Test for overall effect: Z = 5.15 (P < 0.00001)
2 Rotavirus diarrhoea: severe, up to 1 year follow-up (high-mortality countries)
RV1 Madhi 2010-MWI 52/1182 47/591 53.0 % 0.55 [ 0.38, 0.81 ]
RV1 Madhi 2010-ZAF 16/2116 36/1050 47.0 % 0.22 [ 0.12, 0.40 ]
Subtotal (95% CI) 3298 1641 100.0 % 0.36 [ 0.15, 0.88 ]
Total events: 68 (RV1), 83 (Placebo)
Heterogeneity: Tau2 = 0.36; Chi2 = 6.70, df = 1 (P = 0.01); I2 =85%
Test for overall effect: Z = 2.23 (P = 0.026)
3 All-cause diarrhoea: severe, up to 1 year follow-up (high-mortality countries)
RV1 Madhi 2010-MWI 221/1182 139/591 53.6 % 0.79 [ 0.66, 0.96 ]
RV1 Madhi 2010-ZAF 92/2116 86/1050 46.4 % 0.53 [ 0.40, 0.71 ]
Subtotal (95% CI) 3298 1641 100.0 % 0.66 [ 0.44, 0.98 ]
Total events: 313 (RV1), 225 (Placebo)
Heterogeneity: Tau2 = 0.07; Chi2 = 5.42, df = 1 (P = 0.02); I2 =82%
Test for overall effect: Z = 2.06 (P = 0.039)
Test for subgroup differences: Chi2 = 15.34, df = 2 (P = 0.00), I2 =87%
0.01 0.1 1 10 100
Favours RV1 Favours placebo
(1) This multinational study includes 12 Latin America countries, two of them with high mortality (Nicaragua and Peru)
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Analysis 2.1. Comparison 2 RV5 versus placebo, Outcome 1 Rotavirus diarrhoea: severe (up to 1 year
follow-up).
Review: Vaccines for preventing rotavirus diarrhoea: vaccines in use
Comparison: 2 RV5 versus placebo
Outcome: 1 Rotavirus diarrhoea: severe (up to 1 year follow-up)
Study or subgroup RV5 Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Low-mortality countries (WHO strata A % B)
RV5 Block 2007-EU/USA 0/551 6/564 5.8 % 0.08 [ 0.00, 1.39 ]
RV5 Clark 2004-USA 0/187 8/183 7.7 % 0.06 [ 0.00, 0.99 ]
RV5 Zaman 2010-VNM (1) 2/435 7/424 6.4 % 0.28 [ 0.06, 1.33 ]
Subtotal (95% CI) 1173 1171 19.9 % 0.13 [ 0.04, 0.45 ]
Total events: 2 (RV5), 21 (Placebo)
Heterogeneity: Chi2 = 1.30, df = 2 (P = 0.52); I2 =0.0%
Test for overall effect: Z = 3.26 (P = 0.0011)
2 High-mortality countries (WHO strata D % E)
RV5 Armah 2010-GHA (2) 15/981 42/989 37.7 % 0.36 [ 0.20, 0.64 ]
RV5 Armah 2010-KEN (3) 2/575 12/573 10.8 % 0.17 [ 0.04, 0.74 ]
RV5 Armah 2010-MLI (4) 4/845 4/843 3.6 % 1.00 [ 0.25, 3.98 ]
RV5 Zaman 2010-BGD (5) 17/556 31/554 28.0 % 0.55 [ 0.31, 0.98 ]
Subtotal (95% CI) 2957 2959 80.1 % 0.43 [ 0.29, 0.62 ]
Total events: 38 (RV5), 89 (Placebo)
Heterogeneity: Chi2 = 4.01, df = 3 (P = 0.26); I2 =25%
Test for overall effect: Z = 4.44 (P < 0.00001)
Total (95% CI) 4130 4130 100.0 % 0.37 [ 0.26, 0.53 ]
Total events: 40 (RV5), 110 (Placebo)
Heterogeneity: Chi2 = 7.72, df = 6 (P = 0.26); I2 =22%
Test for overall effect: Z = 5.51 (P < 0.00001)
Test for subgroup differences: Chi2 = 3.22, df = 1 (P = 0.07), I2 =69%
0.001 0.01 0.1 1 10 100 1000
Favours RV5 Favours placebo
(1) Data from RV5 Zaman 2010-AS for Vietnam only
(2) Total number of participants taken from Tapia et al. 2012, Table 4, data for Ghana only.
(3) Total number of participants taken from Tapia et al. 2012, Table 4, data for Kenya only.
(4) Total number of participants taken from Tapia et al. 2012, Table 4, data for Mali only.
(5) Data from RV5 Zaman 2010-AS for Bangladesh only
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Analysis 2.2. Comparison 2 RV5 versus placebo, Outcome 2 Rotavirus diarrhoea: severe (up to 2 years
follow-up).
Review: Vaccines for preventing rotavirus diarrhoea: vaccines in use
Comparison: 2 RV5 versus placebo
Outcome: 2 Rotavirus diarrhoea: severe (up to 2 years follow-up)
Study or subgroup RV5 Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Low-mortality countries (WHO strata A % B)
RV5 NCT00718237 2010-JPN 0/381 10/381 2.1 % 0.05 [ 0.00, 0.81 ]
RV5 Vesikari 2006b-INT (1) 2/813 17/756 6.6 % 0.11 [ 0.03, 0.47 ]
RV5 Zaman 2010-VNM (2) 5/435 15/424 11.1 % 0.32 [ 0.12, 0.89 ]
Subtotal (95% CI) 1629 1561 19.8 % 0.18 [ 0.07, 0.50 ]
Total events: 7 (RV5), 42 (Placebo)
Heterogeneity: Tau2 = 0.23; Chi2 = 2.73, df = 2 (P = 0.26); I2 =27%
Test for overall effect: Z = 3.31 (P = 0.00092)
2 High-mortality countries (WHO strata D % E)
RV5 Armah 2010-GHA (3) 26/982 57/989 22.0 % 0.46 [ 0.29, 0.72 ]
RV5 Armah 2010-KEN (4) 5/569 14/568 11.0 % 0.36 [ 0.13, 0.98 ]
RV5 Armah 2010-MLI (5) 48/832 58/835 24.1 % 0.83 [ 0.57, 1.20 ]
RV5 Zaman 2010-BGD (6) 33/556 56/554 23.1 % 0.59 [ 0.39, 0.89 ]
Subtotal (95% CI) 2939 2946 80.2 % 0.59 [ 0.43, 0.82 ]
Total events: 112 (RV5), 185 (Placebo)
Heterogeneity: Tau2 = 0.05; Chi2 = 5.28, df = 3 (P = 0.15); I2 =43%
Test for overall effect: Z = 3.19 (P = 0.0014)
Total (95% CI) 4568 4507 100.0 % 0.46 [ 0.30, 0.70 ]
Total events: 119 (RV5), 227 (Placebo)
Heterogeneity: Tau2 = 0.16; Chi2 = 15.15, df = 6 (P = 0.02); I2 =60%
Test for overall effect: Z = 3.63 (P = 0.00028)
Test for subgroup differences: Chi2 = 4.79, df = 1 (P = 0.03), I2 =79%
0.001 0.01 0.1 1 10 100 1000
Favours RV5 Favours placebo
(1) This study was conducted mainly in European and Latin American low mortality countries, but also in high mortality Guatemala
(2) Data from RV5 Zaman 2010-AS for Vietnam only
(3) Total number of participants taken from Tapia et al. 2012, Table 4, data for Ghana only.
(4) Total number of participants taken from Tapia et al. 2012, Table 4, data for Kenya only.
(5) Total number of participants taken from Tapia et al. 2012, Table 4, data for Mali only.
(6) Data from RV5 Zaman 2010-AS for Bangladesh only
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Analysis 2.3. Comparison 2 RV5 versus placebo, Outcome 3 All-cause diarrhoea: severe cases (up to 1 year
follow-up).
Review: Vaccines for preventing rotavirus diarrhoea: vaccines in use
Comparison: 2 RV5 versus placebo
Outcome: 3 All-cause diarrhoea: severe cases (up to 1 year follow-up)
Study or subgroup RV5 Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Low-mortality countries (WHO stratum A)
RV5 Vesikari 2006a-FIN 23/767 28/262 23.3 % 0.28 [ 0.16, 0.48 ]
Subtotal (95% CI) 767 262 23.3 % 0.28 [ 0.16, 0.48 ]
Total events: 23 (RV5), 28 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 4.67 (P < 0.00001)
2 High-mortality countries (WHO strata D % E)
RV5 Armah 2010-GHA (1) 49/753 78/737 27.5 % 0.61 [ 0.44, 0.87 ]
RV5 Armah 2010-KEN (2) 21/481 22/477 22.1 % 0.95 [ 0.53, 1.70 ]
RV5 Armah 2010-MLI (3) 55/823 56/814 27.1 % 0.97 [ 0.68, 1.39 ]
Subtotal (95% CI) 2057 2028 76.7 % 0.80 [ 0.58, 1.11 ]
Total events: 125 (RV5), 156 (Placebo)
Heterogeneity: Tau2 = 0.04; Chi2 = 3.70, df = 2 (P = 0.16); I2 =46%
Test for overall effect: Z = 1.32 (P = 0.19)
Total (95% CI) 2824 2290 100.0 % 0.64 [ 0.39, 1.06 ]
Total events: 148 (RV5), 184 (Placebo)
Heterogeneity: Tau2 = 0.21; Chi2 = 15.94, df = 3 (P = 0.001); I2 =81%
Test for overall effect: Z = 1.74 (P = 0.081)
Test for subgroup differences: Chi2 = 10.95, df = 1 (P = 0.00), I2 =91%
0.001 0.01 0.1 1 10 100 1000
Favours RV5 Favours placebo
(1) Data collected from Tapia et al. 2012, Table 3, data for Ghana only.
(2) Data collected from Tapia et al. 2012, Table 3, data for Kenya only.
(3) Data collected from Tapia et al. 2012, Table 3, data for Mali only.
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Analysis 2.4. Comparison 2 RV5 versus placebo, Outcome 4 All-cause diarrhoea: severe cases (up to 2 years
follow-up).
Review: Vaccines for preventing rotavirus diarrhoea: vaccines in use
Comparison: 2 RV5 versus placebo
Outcome: 4 All-cause diarrhoea: severe cases (up to 2 years follow-up)
Study or subgroup RV5 Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Low-mortality countries (WHO strata A % B)
RV5 Vesikari 2006a-FIN 0/767 4/262 1.7 % 0.04 [ 0.00, 0.70 ]
Subtotal (95% CI) 767 262 1.7 % 0.04 [ 0.00, 0.70 ]
Total events: 0 (RV5), 4 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 2.20 (P = 0.028)
2 High-mortality countries (WHO strata D % E)
RV5 Armah 2010-GHA (1) 80/747 101/725 26.0 % 0.77 [ 0.58, 1.01 ]
RV5 Armah 2010-KEN (2) 25/472 29/472 7.4 % 0.86 [ 0.51, 1.45 ]
RV5 Armah 2010-MLI (3) 147/797 148/795 37.6 % 0.99 [ 0.81, 1.22 ]
RV5 Zaman 2010-AS (4) 81/991 107/978 27.3 % 0.75 [ 0.57, 0.98 ]
Subtotal (95% CI) 3007 2970 98.3 % 0.85 [ 0.75, 0.98 ]
Total events: 333 (RV5), 385 (Placebo)
Heterogeneity: Chi2 = 3.47, df = 3 (P = 0.32); I2 =14%
Test for overall effect: Z = 2.26 (P = 0.024)
Total (95% CI) 3774 3232 100.0 % 0.84 [ 0.73, 0.96 ]
Total events: 333 (RV5), 389 (Placebo)
Heterogeneity: Chi2 = 7.89, df = 4 (P = 0.10); I2 =49%
Test for overall effect: Z = 2.51 (P = 0.012)
Test for subgroup differences: Chi2 = 4.36, df = 1 (P = 0.04), I2 =77%
0.001 0.01 0.1 1 10 100 1000
Favours RV5 Favours placebo
(1) Data collected from Tapia et al. 2012, Table 3, data for Ghana only.
(2) Data collected from Tapia et al. 2012, Table 3, data for Kenya only.
(3) Data collected from Tapia et al. 2012, Table 3, data for Mali only.
(4) This study was mainly conducted in high mortality Bangladesh, but also in low mortality Vietnam.
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Analysis 2.5. Comparison 2 RV5 versus placebo, Outcome 5 All-cause death.
Review: Vaccines for preventing rotavirus diarrhoea: vaccines in use
Comparison: 2 RV5 versus placebo
Outcome: 5 All-cause death
Study or subgroup RV5 Placebo Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Low-mortality countries (WHO strata A % B)
RV5 Block 2007-EU/USA 1/650 0/660 3.05 [ 0.12, 74.64 ]
RV5 Ciarlet 2009-EU 0/201 0/202 0.0 [ 0.0, 0.0 ]
RV5 Merck[009] 2005-USA 0/680 0/113 0.0 [ 0.0, 0.0 ]
RV5 NCT00718237 2010-JPN 0/381 0/381 0.0 [ 0.0, 0.0 ]
RV5 NCT00953056 2010-CHI 0/24 0/24 0.0 [ 0.0, 0.0 ]
RV5 Vesikari 2006a-FIN 0/1027 0/322 0.0 [ 0.0, 0.0 ]
RV5 Vesikari 2006b-INT (1) 24/34035 20/34003 1.20 [ 0.66, 2.17 ]
RV5 Zaman 2010-VNM (2) 0/450 1/450 0.33 [ 0.01, 8.16 ]
Subtotal (95% CI) 37448 36155 1.18 [ 0.67, 2.08 ]
Total events: 25 (RV5), 21 (Placebo)
Heterogeneity: Chi2 = 0.94, df = 2 (P = 0.62); I2 =0.0%
Test for overall effect: Z = 0.58 (P = 0.56)
2 High-mortality countries (WHO strata D % E)
RV5 Armah 2010-GHA (3) 35/1098 43/1102 0.82 [ 0.53, 1.27 ]
RV5 Armah 2010-KEN (4) 38/656 34/652 1.11 [ 0.71, 1.74 ]
RV5 Armah 2010-MLI (5) 3/979 5/981 0.60 [ 0.14, 2.51 ]
RV5 Zaman 2010-BGD (6) 3/568 3/568 1.00 [ 0.20, 4.93 ]
Subtotal (95% CI) 3301 3303 0.93 [ 0.69, 1.25 ]
Total events: 79 (RV5), 85 (Placebo)
Heterogeneity: Chi2 = 1.30, df = 3 (P = 0.73); I2 =0.0%
Test for overall effect: Z = 0.48 (P = 0.63)
Total (95% CI) 40749 39458 0.98 [ 0.75, 1.28 ]
Total events: 104 (RV5), 106 (Placebo)
Heterogeneity: Chi2 = 2.77, df = 6 (P = 0.84); I2 =0.0%
Test for overall effect: Z = 0.14 (P = 0.88)
Test for subgroup differences: Chi2 = 0.54, df = 1 (P = 0.46), I2 =0.0%
0.01 0.1 1 10 100
Favours RV5 Favours placebo
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(1) This study was conducted mainly in European and Latin American low mortality countries, but also in high mortality Guatemala
(2) Data from RV5 Zaman 2010-AS for Vietnam only
(3) Data from RV5 Armah 2010-AF for Ghana only
(4) Data from RV5 Armah 2010-AF for Kenya only
(5) Data from RV5 Armah 2010-AF for Mali only
(6) Data from RV5 Zaman 2010-AS for Bangladesh only
Analysis 2.6. Comparison 2 RV5 versus placebo, Outcome 6 All serious adverse events.
Review: Vaccines for preventing rotavirus diarrhoea: vaccines in use
Comparison: 2 RV5 versus placebo
Outcome: 6 All serious adverse events
Study or subgroup RV5 Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Low-mortality countries (WHO strata A % B)
RV5 Block 2007-EU/USA 21/650 27/660 2.7 % 0.79 [ 0.45, 1.38 ]
RV5 Ciarlet 2009-EU 3/201 6/202 0.6 % 0.50 [ 0.13, 1.98 ]
RV5 Kim 2008-KOR 6/115 7/63 0.9 % 0.47 [ 0.16, 1.34 ]
RV5 NCT00718237 2010-JPN 7/380 9/381 0.9 % 0.78 [ 0.29, 2.07 ]
RV5 NCT00953056 2010-CHI 0/24 4/24 0.5 % 0.11 [ 0.01, 1.96 ]
RV5 Vesikari 2006b-INT (1) 803/34035 859/34003 87.7 % 0.93 [ 0.85, 1.03 ]
RV5 Zaman 2010-VNM (2) 9/450 3/450 0.3 % 3.00 [ 0.82, 11.01 ]
Subtotal (95% CI) 35855 35783 93.7 % 0.92 [ 0.84, 1.01 ]
Total events: 849 (RV5), 915 (Placebo)
Heterogeneity: Chi2 = 8.08, df = 6 (P = 0.23); I2 =26%
Test for overall effect: Z = 1.69 (P = 0.091)
2 High-mortality countries (WHO strata D % E)
RV5 Armah 2010-GHA (3) 17/1098 18/1102 1.8 % 0.95 [ 0.49, 1.83 ]
RV5 Armah 2010-KEN (4) 20/649 21/643 2.2 % 0.94 [ 0.52, 1.72 ]
RV5 Armah 2010-MLI (5) 5/979 6/981 0.6 % 0.84 [ 0.26, 2.73 ]
RV5 Zaman 2010-BGD (6) 16/568 17/568 1.7 % 0.94 [ 0.48, 1.84 ]
0.001 0.01 0.1 1 10 100 1000
Favours RV5 Favours placebo
(Continued . . . )
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(. . . Continued)
Study or subgroup RV5 Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Subtotal (95% CI) 3294 3294 6.3 % 0.93 [ 0.66, 1.33 ]
Total events: 58 (RV5), 62 (Placebo)
Heterogeneity: Chi2 = 0.04, df = 3 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 0.38 (P = 0.70)
Total (95% CI) 39149 39077 100.0 % 0.92 [ 0.85, 1.01 ]
Total events: 907 (RV5), 977 (Placebo)
Heterogeneity: Chi2 = 8.12, df = 10 (P = 0.62); I2 =0.0%
Test for overall effect: Z = 1.73 (P = 0.083)
Test for subgroup differences: Chi2 = 0.00, df = 1 (P = 0.95), I2 =0.0%
0.001 0.01 0.1 1 10 100 1000
Favours RV5 Favours placebo
(1) This study was conducted mainly in European and Latin American low mortality countries, but also in high mortality Guatemala
(2) Data from RV5 Zaman 2010-AS for Vietnam only
(3) Data from RV5 Armah 2010-AF for Ghana only
(4) Data from RV5 Armah 2010-AF for Kenya only
(5) Data from RV5 Armah 2010-AF for Mali only
(6) Data from RV5 Zaman 2010-AS for Bangladesh only
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Analysis 2.7. Comparison 2 RV5 versus placebo, Outcome 7 Serious adverse events: intussusception.
Review: Vaccines for preventing rotavirus diarrhoea: vaccines in use
Comparison: 2 RV5 versus placebo
Outcome: 7 Serious adverse events: intussusception
Study or subgroup RV5 Placebo Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Low-mortality countries (WHO strata A % B)
RV5 Block 2007-EU/USA 0/650 0/660 0.0 [ 0.0, 0.0 ]
RV5 Ciarlet 2009-EU 0/201 0/202 0.0 [ 0.0, 0.0 ]
RV5 Clark 2003-USA 0/573 0/148 0.0 [ 0.0, 0.0 ]
RV5 Clark 2004-USA 0/218 0/221 0.0 [ 0.0, 0.0 ]
RV5 Kim 2008-KOR 0/115 0/63 0.0 [ 0.0, 0.0 ]
RV5 Merck[009] 2005-USA 0/680 0/113 0.0 [ 0.0, 0.0 ]
RV5 NCT00718237 2010-JPN 0/381 0/381 0.0 [ 0.0, 0.0 ]
RV5 NCT00953056 2010-CHI 0/24 0/24 0.0 [ 0.0, 0.0 ]
RV5 Vesikari 2006a-FIN 1/1027 0/322 0.94 [ 0.04, 23.08 ]
RV5 Vesikari 2006b-INT (1) 13/34002 19/33969 0.68 [ 0.34, 1.38 ]
RV5 Zaman 2010-VNM (2) 0/450 1/450 0.33 [ 0.01, 8.16 ]
Subtotal (95% CI) 38321 36553 0.67 [ 0.34, 1.31 ]
Total events: 14 (RV5), 20 (Placebo)
Heterogeneity: Chi2 = 0.23, df = 2 (P = 0.89); I2 =0.0%
Test for overall effect: Z = 1.18 (P = 0.24)
2 High-mortality countries (WHO strata D % E)
RV5 Armah 2010-GHA (3) 0/1098 0/1102 0.0 [ 0.0, 0.0 ]
RV5 Armah 2010-KEN (4) 0/649 0/643 0.0 [ 0.0, 0.0 ]
RV5 Armah 2010-MLI (5) 0/979 0/981 0.0 [ 0.0, 0.0 ]
RV5 Zaman 2010-BGD (6) 0/568 0/568 0.0 [ 0.0, 0.0 ]
Subtotal (95% CI) 3294 3294 0.0 [ 0.0, 0.0 ]
Total events: 0 (RV5), 0 (Placebo)
Heterogeneity: Chi2 = 0.0, df = 0 (P<0.00001); I2 =0.0%
Test for overall effect: Z = 0.0 (P < 0.00001)
Total (95% CI) 41615 39847 0.67 [ 0.34, 1.31 ]
Total events: 14 (RV5), 20 (Placebo)
Heterogeneity: Chi2 = 0.23, df = 2 (P = 0.89); I2 =0.0%
Test for overall effect: Z = 1.18 (P = 0.24)
Test for subgroup differences: Not applicable
0.001 0.01 0.1 1 10 100 1000
Favours RV5 Favours placebo
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(1) This study was conducted mainly in European and Latin American low mortality countries, but also in high mortality Guatemala
(2) Data from RV5 Zaman 2010-AS for Vietnam only
(3) Data from RV5 Armah 2010-AF for Ghana only
(4) Data from RV5 Armah 2010-AF for Kenya only
(5) Data from RV5 Armah 2010-AF for Mali only
(6) Data from RV5 Zaman 2010-AS for Bangladesh only
Analysis 2.8. Comparison 2 RV5 versus placebo, Outcome 8 Rotavirus diarrhoea: of any severity (up to 1
year follow-up).
Review: Vaccines for preventing rotavirus diarrhoea: vaccines in use
Comparison: 2 RV5 versus placebo
Outcome: 8 Rotavirus diarrhoea: of any severity (up to 1 year follow-up)
Study or subgroup RV5 Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Low-mortality countries (WHO strata A % B)
RV5 Block 2007-EU/USA 21/551 63/564 16.5 % 0.34 [ 0.21, 0.55 ]
RV5 Clark 2003-USA 5/342 7/114 6.9 % 0.24 [ 0.08, 0.74 ]
RV5 Clark 2004-USA 11/187 39/183 13.4 % 0.28 [ 0.15, 0.52 ]
RV5 Vesikari 2006b-INT (1) 82/2834 315/2839 21.4 % 0.26 [ 0.21, 0.33 ]
Subtotal (95% CI) 3914 3700 58.2 % 0.27 [ 0.22, 0.33 ]
Total events: 119 (RV5), 424 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.03, df = 3 (P = 0.79); I2 =0.0%
Test for overall effect: Z = 12.78 (P < 0.00001)
2 High-mortality countries (WHO strata D % E)
RV5 Armah 2010-GHA (2) 31/981 70/989 17.9 % 0.45 [ 0.30, 0.68 ]
RV5 Armah 2010-KEN (3) 6/575 21/573 9.3 % 0.28 [ 0.12, 0.70 ]
RV5 Armah 2010-MLI (4) 22/845 24/843 14.6 % 0.91 [ 0.52, 1.62 ]
Subtotal (95% CI) 2401 2405 41.8 % 0.52 [ 0.28, 0.94 ]
Total events: 59 (RV5), 115 (Placebo)
Heterogeneity: Tau2 = 0.18; Chi2 = 6.02, df = 2 (P = 0.05); I2 =67%
Test for overall effect: Z = 2.16 (P = 0.031)
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Favours RV5 Favours placebo
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(. . . Continued)
Study or subgroup RV5 Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Total (95% CI) 6315 6105 100.0 % 0.36 [ 0.26, 0.52 ]
Total events: 178 (RV5), 539 (Placebo)
Heterogeneity: Tau2 = 0.14; Chi2 = 18.87, df = 6 (P = 0.004); I2 =68%
Test for overall effect: Z = 5.62 (P < 0.00001)
Test for subgroup differences: Chi2 = 3.85, df = 1 (P = 0.05), I2 =74%
0.001 0.01 0.1 1 10 100 1000
Favours RV5 Favours placebo
(1) This study was conducted mainly in European and Latin American low mortality countries, but also in high mortality Guatemala
(2) Data collected from Tapia et al. 2012, Table 4 for Ghana only.
(3) Data collected from Tapia et al. 2012, Table 4 for Kenya only.
(4) Data collected from Tapia et al. 2012, Table 4 for Mali only.
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Analysis 2.9. Comparison 2 RV5 versus placebo, Outcome 9 Rotavirus diarrhoea: of any severity (up to 2
years follow-up).
Review: Vaccines for preventing rotavirus diarrhoea: vaccines in use
Comparison: 2 RV5 versus placebo
Outcome: 9 Rotavirus diarrhoea: of any severity (up to 2 years follow-up)
Study or subgroup RV5 Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Low-mortality countries (WHO strata A % B)
RV5 NCT00718237 2010-JPN 7/355 27/356 9.6 % 0.26 [ 0.11, 0.59 ]
RV5 Vesikari 2006b-INT (1) 36/813 88/756 18.3 % 0.38 [ 0.26, 0.55 ]
Subtotal (95% CI) 1168 1112 28.0 % 0.36 [ 0.25, 0.50 ]
Total events: 43 (RV5), 115 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.69, df = 1 (P = 0.41); I2 =0.0%
Test for overall effect: Z = 5.94 (P < 0.00001)
2 High-mortality countries (WHO strata D % E)
RV5 Armah 2010-GHA (2) 46/982 88/989 19.0 % 0.53 [ 0.37, 0.74 ]
RV5 Armah 2010-KEN (3) 9/569 24/568 10.5 % 0.37 [ 0.18, 0.80 ]
RV5 Armah 2010-MLI (4) 151/832 182/835 22.3 % 0.83 [ 0.69, 1.01 ]
RV5 Zaman 2010-AS (5) 65/991 109/978 20.2 % 0.59 [ 0.44, 0.79 ]
Subtotal (95% CI) 3374 3370 72.0 % 0.61 [ 0.45, 0.83 ]
Total events: 271 (RV5), 403 (Placebo)
Heterogeneity: Tau2 = 0.06; Chi2 = 9.72, df = 3 (P = 0.02); I2 =69%
Test for overall effect: Z = 3.21 (P = 0.0013)
Total (95% CI) 4542 4482 100.0 % 0.51 [ 0.36, 0.70 ]
Total events: 314 (RV5), 518 (Placebo)
Heterogeneity: Tau2 = 0.12; Chi2 = 22.80, df = 5 (P = 0.00037); I2 =78%
Test for overall effect: Z = 4.07 (P = 0.000047)
Test for subgroup differences: Chi2 = 5.43, df = 1 (P = 0.02), I2 =82%
0.001 0.01 0.1 1 10 100 1000
Favours RV5 Favours placebo
(1) This study was conducted mainly in European and Latin American low mortality countries, but also in high mortality Guatemala
(2) Data collected from Tapia et al. 2012, Table 4 for Ghana only.
(3) Data collected from Tapia et al. 2012, Table 4 for Kenya only.
(4) Data collected from Tapia et al. 2012, Table 4 for Mali only.
(5) This study was mainly conducted in high mortality Bangladesh, but also in low mortality Vietnam.
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Analysis 2.10. Comparison 2 RV5 versus placebo, Outcome 10 All-cause diarrhoea: of any severity (up to 1
year follow-up).
Review: Vaccines for preventing rotavirus diarrhoea: vaccines in use
Comparison: 2 RV5 versus placebo
Outcome: 10 All-cause diarrhoea: of any severity (up to 1 year follow-up)
Study or subgroup RV5 Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Low-mortality countries (WHO strata A % B)
RV5 Vesikari 2006a-FIN 51/766 43/264 44.0 % 0.41 [ 0.28, 0.60 ]
Subtotal (95% CI) 766 264 44.0 % 0.41 [ 0.28, 0.60 ]
Total events: 51 (RV5), 43 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 4.60 (P < 0.00001)
2 High-mortality countries (WHO stratum E)
RV5 Armah 2010-KEN (1) 66/525 82/534 56.0 % 0.82 [ 0.61, 1.11 ]
Subtotal (95% CI) 525 534 56.0 % 0.82 [ 0.61, 1.11 ]
Total events: 66 (RV5), 82 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.30 (P = 0.19)
Total (95% CI) 1291 798 100.0 % 0.64 [ 0.51, 0.81 ]
Total events: 117 (RV5), 125 (Placebo)
Heterogeneity: Chi2 = 7.89, df = 1 (P = 0.005); I2 =87%
Test for overall effect: Z = 3.77 (P = 0.00016)
Test for subgroup differences: Chi2 = 7.86, df = 1 (P = 0.01), I2 =87%
0.001 0.01 0.1 1 10 100 1000
Favours RV5 Favours placebo
(1) Data from RV5 Armah 2010-AF for Kenya only
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Analysis 2.11. Comparison 2 RV5 versus placebo, Outcome 11 All-cause diarrhoea: of any severity (up to 2
years follow-up).
Review: Vaccines for preventing rotavirus diarrhoea: vaccines in use
Comparison: 2 RV5 versus placebo
Outcome: 11 All-cause diarrhoea: of any severity (up to 2 years follow-up)
Study or subgroup RV5 Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 High-mortality countries (WHO stratum E)
RV5 Armah 2010-KEN (1) 82/525 94/534 100.0 % 0.89 [ 0.68, 1.16 ]
Subtotal (95% CI) 525 534 100.0 % 0.89 [ 0.68, 1.16 ]
Total events: 82 (RV5), 94 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.87 (P = 0.39)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours RV5 Favours placebo
(1) Data from RV5 Armah 2010-AF for Kenya only
Analysis 2.12. Comparison 2 RV5 versus placebo, Outcome 12 Rotavirus diarrhoea: requiring
hospitalization.
Review: Vaccines for preventing rotavirus diarrhoea: vaccines in use
Comparison: 2 RV5 versus placebo
Outcome: 12 Rotavirus diarrhoea: requiring hospitalization
Study or subgroup RV5 Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Up to 1 year of follow-up
RV5 Vesikari 2006b-INT 6/28646 138/28488 100.0 % 0.04 [ 0.02, 0.10 ]
Subtotal (95% CI) 28646 28488 100.0 % 0.04 [ 0.02, 0.10 ]
Total events: 6 (RV5), 138 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 7.53 (P < 0.00001)
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Analysis 2.13. Comparison 2 RV5 versus placebo, Outcome 13 Rotavirus diarrhoea: requiring medical
attention.
Review: Vaccines for preventing rotavirus diarrhoea: vaccines in use
Comparison: 2 RV5 versus placebo
Outcome: 13 Rotavirus diarrhoea: requiring medical attention
Study or subgroup RV5 Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Up to 1 year of follow-up
RV5 Vesikari 2006b-INT 13/28646 191/28488 100.0 % 0.07 [ 0.04, 0.12 ]
Subtotal (95% CI) 28646 28488 100.0 % 0.07 [ 0.04, 0.12 ]
Total events: 13 (RV5), 191 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 9.40 (P < 0.00001)
0.01 0.1 1 10 100
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232Vaccines for preventing rotavirus diarrhoea: vaccines in use (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 2.14. Comparison 2 RV5 versus placebo, Outcome 14 Reactogenicity: fever.
Review: Vaccines for preventing rotavirus diarrhoea: vaccines in use
Comparison: 2 RV5 versus placebo
Outcome: 14 Reactogenicity: fever
Study or subgroup RV5 Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 After dose 1
RV5 Clark 2004-USA 25/213 27/218 15.4 % 0.95 [ 0.57, 1.58 ]
RV5 Block 2007-EU/USA 87/650 58/660 34.7 % 1.52 [ 1.11, 2.09 ]
RV5 Vesikari 2006a-FIN 255/1027 64/322 49.9 % 1.25 [ 0.98, 1.59 ]
Subtotal (95% CI) 1890 1200 100.0 % 1.28 [ 1.04, 1.58 ]
Total events: 367 (RV5), 149 (Placebo)
Heterogeneity: Tau2 = 0.01; Chi2 = 2.55, df = 2 (P = 0.28); I2 =21%
Test for overall effect: Z = 2.30 (P = 0.021)
2 After dose 2
RV5 Clark 2004-USA 26/208 35/209 100.0 % 0.75 [ 0.47, 1.19 ]
Subtotal (95% CI) 208 209 100.0 % 0.75 [ 0.47, 1.19 ]
Total events: 26 (RV5), 35 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.22 (P = 0.22)
3 After dose 3
RV5 Clark 2004-USA 47/207 43/209 100.0 % 1.10 [ 0.77, 1.59 ]
Subtotal (95% CI) 207 209 100.0 % 1.10 [ 0.77, 1.59 ]
Total events: 47 (RV5), 43 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.53 (P = 0.60)
4 End of follow-up
RV5 NCT00718237 2010-JPN 29/380 31/381 4.0 % 0.94 [ 0.58, 1.52 ]
RV5 Clark 2003-USA 157/568 36/147 8.1 % 1.13 [ 0.82, 1.54 ]
RV5 Clark 2004-USA 70/218 73/220 10.1 % 0.97 [ 0.74, 1.27 ]
RV5 Merck[009] 2005-USA 370/680 53/113 14.0 % 1.16 [ 0.94, 1.43 ]
RV5 Block 2007-EU/USA 195/650 158/660 16.4 % 1.25 [ 1.05, 1.50 ]
RV5 Ciarlet 2009-EU 106/201 115/202 16.6 % 0.93 [ 0.78, 1.11 ]
RV5 Vesikari 2006b-INT 1974/4826 2073/4821 30.7 % 0.95 [ 0.91, 1.00 ]
Subtotal (95% CI) 7523 6544 100.0 % 1.03 [ 0.93, 1.15 ]
Total events: 2901 (RV5), 2539 (Placebo)
Heterogeneity: Tau2 = 0.01; Chi2 = 12.47, df = 6 (P = 0.05); I2 =52%
Test for overall effect: Z = 0.64 (P = 0.52)
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Analysis 2.15. Comparison 2 RV5 versus placebo, Outcome 15 Reactogenicity: diarrhoea.
Review: Vaccines for preventing rotavirus diarrhoea: vaccines in use
Comparison: 2 RV5 versus placebo
Outcome: 15 Reactogenicity: diarrhoea
Study or subgroup RV5 Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 After dose 1
RV5 Clark 2003-USA 127/565 33/146 100.0 % 0.99 [ 0.71, 1.39 ]
Subtotal (95% CI) 565 146 100.0 % 0.99 [ 0.71, 1.39 ]
Total events: 127 (RV5), 33 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.03 (P = 0.97)
2 End of follow-up
RV5 Ciarlet 2009-EU 57/201 65/202 5.1 % 0.88 [ 0.65, 1.19 ]
RV5 Clark 2003-USA 205/573 52/148 6.4 % 1.02 [ 0.80, 1.30 ]
RV5 Clark 2004-USA 97/218 80/220 6.2 % 1.22 [ 0.97, 1.54 ]
RV5 Merck[009] 2005-USA 367/680 51/113 6.8 % 1.20 [ 0.96, 1.48 ]
RV5 NCT00718237 2010-JPN 46/380 47/381 3.7 % 0.98 [ 0.67, 1.44 ]
RV5 Vesikari 2006b-INT 951/4826 921/4821 71.8 % 1.03 [ 0.95, 1.12 ]
Subtotal (95% CI) 6878 5885 100.0 % 1.04 [ 0.98, 1.12 ]
Total events: 1723 (RV5), 1216 (Placebo)
Heterogeneity: Chi2 = 4.85, df = 5 (P = 0.43); I2 =0.0%
Test for overall effect: Z = 1.27 (P = 0.20)
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Analysis 2.16. Comparison 2 RV5 versus placebo, Outcome 16 Reactogenicity: vomiting.
Review: Vaccines for preventing rotavirus diarrhoea: vaccines in use
Comparison: 2 RV5 versus placebo
Outcome: 16 Reactogenicity: vomiting
Study or subgroup RV5 Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 After dose 1
RV5 Clark 2003-USA 91/565 27/146 100.0 % 0.87 [ 0.59, 1.29 ]
Subtotal (95% CI) 565 146 100.0 % 0.87 [ 0.59, 1.29 ]
Total events: 91 (RV5), 27 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.70 (P = 0.49)
2 End of follow-up
RV5 Ciarlet 2009-EU 62/201 49/202 5.8 % 1.27 [ 0.92, 1.75 ]
RV5 Clark 2003-USA 171/573 41/148 7.7 % 1.08 [ 0.81, 1.44 ]
RV5 Clark 2004-USA 58/218 52/220 6.2 % 1.13 [ 0.81, 1.56 ]
RV5 NCT00718237 2010-JPN 31/380 29/381 3.4 % 1.07 [ 0.66, 1.74 ]
RV5 Vesikari 2006b-INT 618/4826 646/4821 76.8 % 0.96 [ 0.86, 1.06 ]
Subtotal (95% CI) 6198 5772 100.0 % 1.00 [ 0.91, 1.09 ]
Total events: 940 (RV5), 817 (Placebo)
Heterogeneity: Chi2 = 3.77, df = 4 (P = 0.44); I2 =0.0%
Test for overall effect: Z = 0.05 (P = 0.96)
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Analysis 2.17. Comparison 2 RV5 versus placebo, Outcome 17 Adverse events requiring discontinuation
(end of follow-up).
Review: Vaccines for preventing rotavirus diarrhoea: vaccines in use
Comparison: 2 RV5 versus placebo
Outcome: 17 Adverse events requiring discontinuation (end of follow-up)
Study or subgroup RV5 Placebo Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
RV5 Armah 2010-AF 9/2733 15/2735 0.60 [ 0.26, 1.37 ]
RV5 Block 2007-EU/USA 1/650 5/660 0.20 [ 0.02, 1.73 ]
RV5 Ciarlet 2009-EU 1/201 0/202 3.01 [ 0.12, 73.57 ]
RV5 Clark 2004-USA 4/218 1/221 4.06 [ 0.46, 35.99 ]
RV5 Kim 2008-KOR 0/115 0/63 0.0 [ 0.0, 0.0 ]
RV5 Merck[009] 2005-USA 1/680 1/113 0.17 [ 0.01, 2.64 ]
RV5 NCT00718237 2010-JPN 1/381 3/381 0.33 [ 0.03, 3.19 ]
RV5 NCT00953056 2010-CHI 0/24 1/24 0.33 [ 0.01, 7.80 ]
RV5 Zaman 2010-AS 1/1018 0/1018 3.00 [ 0.12, 73.56 ]
Total (95% CI) 6020 5417 0.67 [ 0.38, 1.19 ]
Total events: 18 (RV5), 26 (Placebo)
Heterogeneity: Chi2 = 7.10, df = 7 (P = 0.42); I2 =1%
Test for overall effect: Z = 1.37 (P = 0.17)
Test for subgroup differences: Not applicable
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Analysis 2.18. Comparison 2 RV5 versus placebo, Outcome 18 Immunogenicity: rotavirus vaccine shedding
(after dose 3).
Review: Vaccines for preventing rotavirus diarrhoea: vaccines in use
Comparison: 2 RV5 versus placebo
Outcome: 18 Immunogenicity: rotavirus vaccine shedding (after dose 3)
Study or subgroup RV5 Placebo Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
RV5 Clark 2003-USA 277/355 13/93 5.58 [ 3.36, 9.27 ]
RV5 Clark 2004-USA 104/159 2/155 50.69 [ 12.73, 201.81 ]
RV5 NCT00953056 2010-CHI 6/23 0/24 13.54 [ 0.81, 227.50 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Total events: 387 (RV5), 15 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.0, df = 0 (P<0.00001); I2 =0.0%
Test for overall effect: Z = 0.0 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 2.19. Comparison 2 RV5 versus placebo, Outcome 19 Immunogenicity: seroconversion (after dose
3).
Review: Vaccines for preventing rotavirus diarrhoea: vaccines in use
Comparison: 2 RV5 versus placebo
Outcome: 19 Immunogenicity: seroconversion (after dose 3)
Study or subgroup RV5 Placebo Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
RV5 Armah 2010-AF 148/189 34/169 3.89 [ 2.86, 5.31 ]
RV5 Block 2007-EU/USA 64/67 9/73 7.75 [ 4.19, 14.32 ]
RV5 Ciarlet 2009-EU 184/201 12/202 15.41 [ 8.89, 26.72 ]
RV5 Clark 2003-USA 404/455 3/113 33.44 [ 10.95, 102.19 ]
RV5 Clark 2004-USA 162/185 3/185 54.00 [ 17.55, 166.11 ]
RV5 Vesikari 2006a-FIN 959/1027 43/322 6.99 [ 5.29, 9.24 ]
RV5 Vesikari 2006b-INT 180/189 23/161 6.67 [ 4.56, 9.75 ]
RV5 Zaman 2010-AS 115/131 24/132 4.83 [ 3.34, 6.97 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Total events: 2216 (RV5), 151 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.0, df = 0 (P<0.00001); I2 =0.0%
Test for overall effect: Z = 0.0 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 2.20. Comparison 2 RV5 versus placebo, Outcome 20 Drop outs before the end of the trial.
Review: Vaccines for preventing rotavirus diarrhoea: vaccines in use
Comparison: 2 RV5 versus placebo
Outcome: 20 Drop outs before the end of the trial
Study or subgroup RV5 Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
RV5 Armah 2010-AF 376/2733 387/2735 22.9 % 0.97 [ 0.85, 1.11 ]
RV5 Block 2007-EU/USA 99/651 96/661 10.2 % 1.05 [ 0.81, 1.36 ]
RV5 Clark 2003-USA 97/581 36/150 6.7 % 0.70 [ 0.50, 0.98 ]
RV5 Clark 2004-USA 11/218 12/221 1.4 % 0.93 [ 0.42, 2.06 ]
RV5 Merck[009] 2005-USA 71/680 16/113 3.3 % 0.74 [ 0.45, 1.22 ]
RV5 NCT00718237 2010-JPN 13/381 15/381 1.6 % 0.87 [ 0.42, 1.80 ]
RV5 NCT00953056 2010-CHI 2/24 4/24 0.4 % 0.50 [ 0.10, 2.48 ]
RV5 Vesikari 2006a-FIN 390/1624 60/322 11.1 % 1.29 [ 1.01, 1.65 ]
RV5 Vesikari 2006b-INT 5846/34035 5882/34003 38.9 % 0.99 [ 0.96, 1.03 ]
RV5 Zaman 2010-AS 27/1018 40/1018 3.6 % 0.68 [ 0.42, 1.09 ]
Total (95% CI) 41945 39628 100.0 % 0.97 [ 0.88, 1.07 ]
Total events: 6932 (RV5), 6548 (Placebo)
Heterogeneity: Tau2 = 0.01; Chi2 = 13.56, df = 9 (P = 0.14); I2 =34%
Test for overall effect: Z = 0.63 (P = 0.53)
Test for subgroup differences: Not applicable
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Analysis 2.21. Comparison 2 RV5 versus placebo, Outcome 21 Subgroup analysis: rotavirus diarrhoea of any
severity (by G type).
Review: Vaccines for preventing rotavirus diarrhoea: vaccines in use
Comparison: 2 RV5 versus placebo
Outcome: 21 Subgroup analysis: rotavirus diarrhoea of any severity (by G type)
Study or subgroup RV5 Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 G1
RV5 Block 2007-EU/USA 13/551 53/564 13.8 % 0.25 [ 0.14, 0.46 ]
RV5 Clark 2004-USA 10/187 26/183 10.0 % 0.38 [ 0.19, 0.76 ]
RV5 Vesikari 2006b-INT 72/2834 286/2839 76.2 % 0.25 [ 0.20, 0.32 ]
Subtotal (95% CI) 3572 3586 100.0 % 0.26 [ 0.21, 0.33 ]
Total events: 95 (RV5), 365 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.14, df = 2 (P = 0.57); I2 =0.0%
Test for overall effect: Z = 11.87 (P < 0.00001)
2 G2
RV5 Clark 2004-USA 1/187 2/183 13.1 % 0.49 [ 0.04, 5.35 ]
RV5 Vesikari 2006b-INT 6/2834 17/2839 86.9 % 0.35 [ 0.14, 0.90 ]
Subtotal (95% CI) 3021 3022 100.0 % 0.37 [ 0.16, 0.88 ]
Total events: 7 (RV5), 19 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.06, df = 1 (P = 0.80); I2 =0.0%
Test for overall effect: Z = 2.26 (P = 0.024)
3 G3
RV5 Block 2007-EU/USA 2/551 1/564 33.8 % 2.05 [ 0.19, 22.51 ]
RV5 Clark 2004-USA 0/187 10/183 29.0 % 0.05 [ 0.00, 0.79 ]
RV5 Vesikari 2006b-INT 1/2834 6/2839 37.3 % 0.17 [ 0.02, 1.39 ]
Subtotal (95% CI) 3572 3586 100.0 % 0.27 [ 0.03, 2.29 ]
Total events: 3 (RV5), 17 (Placebo)
Heterogeneity: Tau2 = 2.04; Chi2 = 4.66, df = 2 (P = 0.10); I2 =57%
Test for overall effect: Z = 1.20 (P = 0.23)
4 G4
RV5 Clark 2004-USA 0/187 1/183 15.8 % 0.33 [ 0.01, 7.96 ]
RV5 Vesikari 2006b-INT 3/2834 6/2839 84.2 % 0.50 [ 0.13, 2.00 ]
Subtotal (95% CI) 3021 3022 100.0 % 0.47 [ 0.13, 1.67 ]
Total events: 3 (RV5), 7 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.06, df = 1 (P = 0.81); I2 =0.0%
Test for overall effect: Z = 1.17 (P = 0.24)
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(. . . Continued)
Study or subgroup RV5 Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
5 G9
RV5 Vesikari 2006b-INT 1/2834 3/2839 100.0 % 0.33 [ 0.03, 3.21 ]
Subtotal (95% CI) 2834 2839 100.0 % 0.33 [ 0.03, 3.21 ]
Total events: 1 (RV5), 3 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.95 (P = 0.34)
Test for subgroup differences: Chi2 = 1.31, df = 4 (P = 0.86), I2 =0.0%
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Analysis 2.22. Comparison 2 RV5 versus placebo, Outcome 22 Subgroup analysis: severe cases of rotavirus
diarrhoea (by G type).
Review: Vaccines for preventing rotavirus diarrhoea: vaccines in use
Comparison: 2 RV5 versus placebo
Outcome: 22 Subgroup analysis: severe cases of rotavirus diarrhoea (by G type)
Study or subgroup Favours RV5 Placebo Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 G1
RV5 Armah 2010-AF 42/2357 62/2348 0.67 [ 0.46, 0.99 ]
RV5 Vesikari 2006b-INT 16/34035 328/34003 0.05 [ 0.03, 0.08 ]
Subtotal (95% CI) 36392 36351 0.18 [ 0.01, 2.97 ]
Total events: 58 (Favours RV5), 390 (Placebo)
Heterogeneity: Tau2 = 4.01; Chi2 = 77.62, df = 1 (P<0.00001); I2 =99%
Test for overall effect: Z = 1.20 (P = 0.23)
2 G2
RV5 Armah 2010-AF 32/2357 44/2348 0.72 [ 0.46, 1.14 ]
RV5 Vesikari 2006b-INT 1/34035 8/34003 0.12 [ 0.02, 1.00 ]
Subtotal (95% CI) 36392 36351 0.41 [ 0.08, 2.09 ]
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(. . . Continued)
Study or subgroup Favours RV5 Placebo Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Total events: 33 (Favours RV5), 52 (Placebo)
Heterogeneity: Tau2 = 0.99; Chi2 = 2.69, df = 1 (P = 0.10); I2 =63%
Test for overall effect: Z = 1.08 (P = 0.28)
3 G3
RV5 Armah 2010-AF 3/2357 8/2348 0.37 [ 0.10, 1.41 ]
RV5 Vesikari 2006b-INT 1/34035 15/34003 0.07 [ 0.01, 0.50 ]
Subtotal (95% CI) 36392 36351 0.19 [ 0.03, 1.06 ]
Total events: 4 (Favours RV5), 23 (Placebo)
Heterogeneity: Tau2 = 0.87; Chi2 = 2.15, df = 1 (P = 0.14); I2 =53%
Test for overall effect: Z = 1.90 (P = 0.058)
4 G4
RV5 Armah 2010-AF 0/2357 0/2348 0.0 [ 0.0, 0.0 ]
RV5 Vesikari 2006b-INT 2/34035 18/34003 0.11 [ 0.03, 0.48 ]
Subtotal (95% CI) 36392 36351 0.11 [ 0.03, 0.48 ]
Total events: 2 (Favours RV5), 18 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.0, df = 0 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 2.95 (P = 0.0032)
5 G9
RV5 Armah 2010-AF 1/2357 2/2348 0.50 [ 0.05, 5.49 ]
RV5 Vesikari 2006b-INT 0/34035 13/34003 0.04 [ 0.00, 0.62 ]
Subtotal (95% CI) 36392 36351 0.15 [ 0.01, 2.37 ]
Total events: 1 (Favours RV5), 15 (Placebo)
Heterogeneity: Tau2 = 2.21; Chi2 = 2.24, df = 1 (P = 0.13); I2 =55%
Test for overall effect: Z = 1.35 (P = 0.18)
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Analysis 2.23. Comparison 2 RV5 versus placebo, Outcome 23 Subgroup analysis: HIV-infected children.
Review: Vaccines for preventing rotavirus diarrhoea: vaccines in use
Comparison: 2 RV5 versus placebo
Outcome: 23 Subgroup analysis: HIV-infected children
Study or subgroup RV5 Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Rotavirus diarrhoea: severe (up to two years follow-up)
RV5 Armah 2010-KEN 1/21 0/17 100.0 % 2.45 [ 0.11, 56.68 ]
Subtotal (95% CI) 21 17 100.0 % 2.45 [ 0.11, 56.68 ]
Total events: 1 (RV5), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.56 (P = 0.58)
2 All-cause diarrhoea: severe (up to two years follow-up)
RV5 Armah 2010-KEN 5/21 1/17 100.0 % 4.05 [ 0.52, 31.43 ]
Subtotal (95% CI) 21 17 100.0 % 4.05 [ 0.52, 31.43 ]
Total events: 5 (RV5), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.34 (P = 0.18)
3 All-cause death
RV5 Armah 2010-KEN 8/21 4/17 100.0 % 1.62 [ 0.59, 4.47 ]
Subtotal (95% CI) 21 17 100.0 % 1.62 [ 0.59, 4.47 ]
Total events: 8 (RV5), 4 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.93 (P = 0.35)
4 Serious adverse events (up to 14 days after each dose)
RV5 Armah 2010-KEN 5/21 2/16 100.0 % 1.90 [ 0.42, 8.58 ]
Subtotal (95% CI) 21 16 100.0 % 1.90 [ 0.42, 8.58 ]
Total events: 5 (RV5), 2 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.84 (P = 0.40)
Test for subgroup differences: Chi2 = 0.64, df = 3 (P = 0.89), I2 =0.0%
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Analysis 2.24. Comparison 2 RV5 versus placebo, Outcome 24 Subgroup analysis: rotavirus diarrhoea of any
severity in premature babies (1 year follow-up).
Review: Vaccines for preventing rotavirus diarrhoea: vaccines in use
Comparison: 2 RV5 versus placebo
Outcome: 24 Subgroup analysis: rotavirus diarrhoea of any severity in premature babies (1 year follow-up)
Study or subgroup RV5 Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
RV5 Vesikari 2006b-INT 5/84 13/86 100.0 % 0.39 [ 0.15, 1.06 ]
Total (95% CI) 84 86 100.0 % 0.39 [ 0.15, 1.06 ]
Total events: 5 (RV5), 13 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.85 (P = 0.064)
Test for subgroup differences: Not applicable
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Analysis 2.25. Comparison 2 RV5 versus placebo, Outcome 25 Sensitivity analysis: allocation concealment.
Review: Vaccines for preventing rotavirus diarrhoea: vaccines in use
Comparison: 2 RV5 versus placebo
Outcome: 25 Sensitivity analysis: allocation concealment
Study or subgroup RV5 Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Rotavirus diarrhoea: severe, up to 2 years follow-up (high-mortality countries)
RV5 Armah 2010-GHA (1) 26/982 57/989 30.1 % 0.46 [ 0.29, 0.72 ]
RV5 Armah 2010-MLI (2) 48/832 58/835 36.8 % 0.83 [ 0.57, 1.20 ]
RV5 Zaman 2010-BGD 33/556 56/554 33.2 % 0.59 [ 0.39, 0.89 ]
Subtotal (95% CI) 2370 2378 100.0 % 0.62 [ 0.44, 0.87 ]
Total events: 107 (RV5), 171 (Placebo)
Heterogeneity: Tau2 = 0.05; Chi2 = 4.10, df = 2 (P = 0.13); I2 =51%
Test for overall effect: Z = 2.76 (P = 0.0059)
2 All-cause diarrhoea: severe, up to 1 year follow-up (high-mortality countries)
RV5 Armah 2010-GHA (3) 49/753 78/737 50.7 % 0.61 [ 0.44, 0.87 ]
RV5 Armah 2010-MLI (4) 55/823 56/814 49.3 % 0.97 [ 0.68, 1.39 ]
Subtotal (95% CI) 1576 1551 100.0 % 0.77 [ 0.49, 1.21 ]
Total events: 104 (RV5), 134 (Placebo)
Heterogeneity: Tau2 = 0.07; Chi2 = 3.26, df = 1 (P = 0.07); I2 =69%
Test for overall effect: Z = 1.14 (P = 0.25)
Test for subgroup differences: Chi2 = 0.57, df = 1 (P = 0.45), I2 =0.0%
0.01 0.1 1 10 100
Favours RV5 Favours placebo
(1) Total number of participants taken from Tapia et al. 2012, Table 4.
(2) Total number of participants taken from Tapia et al. 2012, Table 4.
(3) Data collected from Tapia et al. 2012, Table 3.
(4) Data collected from Tapia et al. 2012, Table 3.
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A P P E N D I C E S
Appendix 1. Search methods: detailed search strategies
Search set CIDG SRa CENTRAL MEDLINEb EMBASEb LILACSb BIOSIS
1 rotavirus rotavirus rotavirus rotavirus rotavirus rotavirus
2 diarrhoea diarrhoea ROTAVIRUS IN-
FECTIONS
ROTAVIRUS diarrhoea diarrhoea
3 diarrhea diarrhea 1 or 2 1 or 2 diarrhea diarrhea
4 gastroenteritis gastroenteritis diarrhea diarrhea gastroenteritis gastroenteritis
5 2 or 3 or 4 2 or 3 or 4 gastroenteritis gastroenteritis 2 or 3 or 4 2 or 3 or 4
6 1 and 5 1 and 5 4 or 5 4 or 5 1 and 5 1 and 5
aCochrane Infectious Diseases Group Specialized Register.
bSearch terms used in combination with the search strategy for retrieving trials developed by The Cochrane Collaboration (Lefebvre
2008); upper case: MeSH or EMTREE heading; lower case: free text term.
Appendix 2. Trial type (efficacy or safety) and length of follow-up
Trial Type: efficacy or safety Follow-up time
RV1 Anh 2011-PHL Safety 1 month after last dose
RV1 Anh 2011-VNM Safety 1 month after last dose
RV1 Bernstein 1998-USA Safety 1 month
RV1 Bernstein 1999-USA Efficacy/Safety 2 years
RV1 Dennehy 2005-NA Safety 10 to 12 months
RV1 GSK[021] 2007-PAN Safety 1 month after dose 3
RV1 GSK[024] 2008-LA Efficacy/Safety Up to age 1 year
RV1 GSK[033] 2007-LA Safety 1 month
RV1 GSK[041] 2007-KOR Safety 2 months
RV1 GSK[101555] 2008-PHL Safety 1 month
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RV1 Kawamura 2010-JPN Efficacy/Safety Up to the age of 2 years
RV1 Kerdpanich 2010-THA Safety 2 months after last dose
RV1 Madhi 2010-AF Efficacy/Safety 2 years
RV1 Narang 2009-IND Safety 1 month
RV1 Omenaca 2012-EU Safety At least 1 month after dose 2
RV1 Phua 2005-SGP Efficacy/Safety Until infant aged 18 months (ie 13 to 15 months)
RV1 Phua 2009-AS Efficacy/Safety 3 years
RV1 Rivera 2011-DOM Safety 17 weeks after each dose
RV1 Ruiz-Palac 06-LA/EU Efficacy/Safety 9 to 10 months
RV1 Salinas 2005-LA Efficacy/Safety Up to 2 years
RV1 Steele 2008-ZAF Safety Up to 6 months
RV1 Steele 2010a-ZAF Safety 31 days after each dose, 42 days after the last dose
RV1 Steele 2010b-ZAF Safety Up to 6 months
RV1 Vesikari 2004a-FIN Safety 8 to 30 days after each dose
RV1 Vesikari 2004b-FIN Efficacy/Safety 1 and 2 years (both reported)
RV1 Vesikari 2007a-EU Efficacy/Safety 1 and 2 years (plus 3 years in Finland)
RV1 Vesikari 2011-FIN Safety 2 months
RV1 Ward 2006-USA Safety 7 days after each vaccination; 3 to 5 weeks after dose 2
RV1 Zaman 2009-BGD Safety 31 days
RV5 Armah 2010-AF Efficacy/Safety Up to 43 days for safety outcomes, up to 21 months for efficacy out-
comes
RV5 Block 2007-EU/USA Efficacy/Safety 42 days for safety/immunogenicity; 1 year for efficacy
RV5 Ciarlet 2009-EU Safety 42 days
RV5 Clark 2003-USA Efficacy/Safety 1 year
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RV5 Clark 2004-USA Efficacy/Safety 1 year
RV5 Kim 2008-KOR Safety 42 days
RV5 Merck[009] 2005-USA Safety 42 days
RV5 NCT00718237 2010-JPN Efficacy/Safety 25 months
RV5 NCT00953056 2010-CHI Safety 2 weeks after last dose
RV5 Vesikari 2006a-FIN Efficacy/Safety 1 to 3 years
RV5 Vesikari 2006b-INT Efficacy/Safety 43 days for safety; 2 years for efficacy
RV5 Zaman 2010-AS Efficacy/Safety Up to 43 days for safety outcomes, up to 2 years for efficacy outcomes
Appendix 3. Efficacy outcome measures by trial
Trial Rotavirus diarrhoea (any sever-
ity)
All-cause diarrhoea ED visit Hospitaliza-
tion (all-
cause)
All-cause
death
Drop outs
All Severe Hospital All Severe
RV1 Anh
2011-PHL
X X X X
RV1
Anh 2011-
VNM
X X X X
RV1
Bernstein
1998-
USA
RV1
Bernstein
1999-
USA
X X X Xa Xa X
RV1
Dennehy
2005-NA
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RV1
GSK[021]
2007-PAN
X X
RV1
GSK[024]
2008-LA
X Xa X X
RV1
GSK[033]
2007-LA
X X
RV1
GSK[041]
2007-
KOR
X X X
RV1
GSK[101555]
2008-
PHL
X X X
RV1
Kawamura
2010-JPN
X X X X X
RV1
Kerd-
panich
2010-
THA
X X X X
RV1
Madhi
2010-AF
X X X X X X
RV1
Narang
2009-IND
X X X
RV1
Omenaca
2012-EU
X X X
RV1 Phua
2009-AS
Xa X X Xa X Xa X
RV1 Phua
2005-SGP
X X X X X X X X X
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RV1
Rivera
2011-
DOM
X X X
RV1 Ruiz-
Palac 06-
LA/EU
Xa X X Xa X Xa X Xa
RV1
Salinas
2005-LA
X X X X Xa Xa X
RV1 Steele
2008-ZAF
X X
RV1 Steele
2010a-
ZAF
X X X X
RV1 Steele
2010b-
ZAF
X X X X
RV1
Vesikari
2004a-
FIN
Xa X
RV1
Vesikari
2004b-
FIN
X X X X X X
RV1
Vesikari
2007a-EU
X X X Xa X Xa Xa
RV1
Vesikari
2011-FIN
X X X X
RV1Ward
2006-USA
RV1
Zaman
2009-
BGD
X X
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RV5
Armah
2010-AF
X X X X X X
RV5 Block
2007-EU/
USA
X X X X
RV5
Ciarlet
2009-EU
X
RV5 Clark
2003-
USA
X Xa X
RV5 Clark
2004-USA
X X X
RV5
Kim 2008-
KOR
RV5
Merck[009]
2005-USA
X X
RV5
NCT00718237
2010-JPN
X X X X
RV5
NCT00953056
2010-CHI
X X
RV5
Vesikari
2006a-
FIN
Xa Xa X X X X
RV5
Vesikari
2006b-
INT
X X X Xa Xa X X
RV5
Zaman
2010-AS
X X X X X
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aReported as an outcome measure in trial, but no data available for analysis.
Appendix 4. Safety and immunogenicity outcomes measures by trial
Trial Safety Immunogenicity
Serious AE Reactogenicity AE to discontinuation Vaccine virus shedding Seroconversion
RV1 Anh
2011-PHL
X X X X
RV1 Anh
2011-VNM
X X X X
RV1 Bernstein
1998-USA
X X X X X
RV1 Bernstein
1999-USA
X X X
RV1 Dennehy
2005-NA
X X X X X
RV1 GSK[021]
2007-PAN
X X X X X
RV1 GSK[024]
2008-LA
X X X
RV1 GSK[033]
2007-LA
X X X X X
RV1 GSK[041]
2007-KOR
X X X X
RV1 GSK[101555]
2008-PHL
X X X X X
RV1 Kawamura
2010-JPN
X X X X
RV1 Kerdpanich
2010-THA
X X X X X
RV1 Madhi 2010-
AF
X
RV1 Narang 2009-
IND
X X X X
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RV1 Omenaca
2012-EU
X X X
RV1 Phua 2005-
SGP
X X Xa Xa X
RV1 Phua 2009-AS X X
RV1 Rivera 2011-
DOM
X X X
RV1 Ruiz-Palac 06-
LA/EU
X X X Xa
RV1 Salinas 2005-
LA
X X X X
RV1 Steele 2008-
ZAF
X X X X X
RV1 Steele 2010a-
ZAF
X Xa X X
RV1 Steele 2010b-
ZAF
X X X X X
RV1 Vesikari
2004a-FIN
X X X X X
RV1 Vesikari
2004b-FIN
X X X X
RV1 Vesikari
2007a-EU
X X X
RV1 Vesikari 2011-
FIN
X X X X X
RV1 Ward 2006-
USA
Xa X Xa
RV1 Zaman 2009-
BGD
X X X X
RV5 Armah 2010-
AF
X Xa X
RV5 Block 2007-
EU/USA
X X X X
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RV5 Ciarlet 2009-
EU
X X X X
RV5 Clark 2003-
USA
X X X X
RV5 Clark 2004-
USA
Xa X X X X
RV5 Kim
2008-KOR
X Xa X Xa
RV5 Merck[009]
2005-USA
X X X
RV5
NCT00718237
2010-JPN
Xa X X
RV5
NCT00953056
2010-CHI
X Xa X X
RV5 Vesikari
2006a-FIN
X X X
RV5 Vesikari
2006b-INT
X X Xa X
RV5 Zaman 2010-
AS
X Xa Xa
AE: adverse events.
aReported as an outcome measure in trial, but no data available for analysis.
Appendix 5. Trial location
Trial Year Location Sites Country mortal-
ity rate
WHO mortality
strata
Region
RV1 Anh 2011-
PHL
2007 Philippines 1 Low-mortality B Asia
RV1 Anh 2011-
VNM
2007 Vietnam 11 Low-mortality B Asia
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RV1 Bernstein
1998-USA
1998 USA 1 Low-mortality A North America
RV1 Bernstein
1999-USA
1999 USA 2 Low-mortality A North America
RV1 Dennehy
2005-NA
2005 USA and Canada 41 Low-mortality A North America
RV1 GSK[021]
2007-PAN
2007 Panama 1 Low-mortality B Latin America
RV1 GSK[024]
2008-LA
2008 Argentina,
Brazil, Colombia,
Dominican Re-
public, Honduras,
and Panama
Multiple sites in
each country
Low-mortality B Latin America
RV1 GSK[033]
2007-LA
2007 Colombia,
Mexico, and Peru
(2 in Colombia, 1
inMexico, and 4 in
Peru)
High-mortalitya B, D Latin America
RV1 GSK[041]
2007-KOR
2007 South Korea 6 Low-mortality B Asia
RV1 Narang
2009-IND
2007 India 4 High-mortality D Asia
RV1
GSK[101555]
2008-PHL
2008 Philippines 1 Low-mortality B Asia
RV1 Kawamura
2010-JPN
2009 Japan 18 Low-mortality A Asia
RV1 Kerdpanich
2010-THA
2005 Thailand 2 Low-mortality B Asia
RV1 Madhi
2010-AF
2010 South Africa and
Malawi
2 High-mortality E Africa
RV1 Narang
2009-IND
2009 India 4 High-mortality D Asia
RV1 Omenaca
2012-EU
2008 France,
Poland, Portugal,
and Spain
Multiple sites in
each country
Low-mortality A, B Europe
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RV1 Phua 2005-
SGP
2005 Singapore 8 Low-mortality A Asia
RV1 Phua 2009-
AS
2009 HongKong, Singa-
pore, and Taiwan
3 Low-mortality A Asia
RV1 Rivera
2011-DOM
2008 Dominican
Republic
1 Low-mortality B Latin America
RV1 Ruiz-Palac
06-LA/EU
2006 Argentina, Brazil,
Chile, Colombia,
Dominican
Republic, Finland,
Honduras, Mex-
ico, Nicaragua,
Panama, Peru, and
Venezuela
Multiple Low-mortalityb A, B, D Latin America/Eu-
rope
RV1 Salinas
2005-LA
2005 Brazil,Mexico, and
Venezuela
3 Low-mortality B Latin America
RV1 Steele
2008-ZAF
2007 South Africa 1 High-mortality E Africa
RV1 Steele
2010a-ZAF
2008 South Africa 5 High-mortality E Africa
RV1 Steele
2010b-ZAF
2007 South Africa 7 High-mortality E Africa
RV1 Vesikari
2004a-FIN
2004 Finland 2 Low-mortality A Europe
RV1 Vesikari
2004b-FIN
2004 Finland 6 Low-mortality A Europe
RV1 Vesikari
2007a-EU
2007 Czech
Republic, Finland,
France, Germany,
Italy, and Spain
98 Low-mortality A Europe
RV1 Vesikari
2011-FIN
2005 Finland 5 Low-mortality A Europe
RV1Ward 2006-
USA
2006 USA 2 Low mortality A North America
RV1 Zaman
2009-BGD
2005 Bangladesh 1 High mortality D Asia
256Vaccines for preventing rotavirus diarrhoea: vaccines in use (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(Continued)
RV5 Armah
2010-AF
2009 Ghana, Kenya, and
Mali
3 High-mortality D, E Africa
RV5 Block
2007-EU/USA
2007 Finland and USA 30 Low-mortality A Europe and North
America
RV5 Ciarlet
2009-EU
2008 Austria, Belgium,
and Germany
26 Low-mortality A Europe
RV5 Clark
2003-USA
2003 USA 19 Low-mortality A North America
RV5 Clark
2004-USA
2004 USA 10 Low-mortality A North America
RV5 Kim 2008-
KOR
2008 South Korea 8 Low-mortality B Asia
RV5
Merck[009]
2005-USA
2005 USA 10 Low-mortality A North America
RV5
NCT00718237
2010-JPN
2009 Japan 32 Low-mortality A Asia
RV5
NCT00953056
2010-CHI
2010 China Not reported Low-mortality B Asia
RV5 Vesikari
2006a-FIN
2006 Finland 4 Low-mortality A Europe
RV5 Vesikari
2006b-INT
2006 Belgium, Costa
Rica, Finland, Ger-
many, Guatemala,
Italy, Jamaica,
Mexico, Puerto
Rico, Sweden, Tai-
wan, and USA
356 Low-mortalityb A, B, D Asia, Caribbean,
Eu-
rope, Latin Amer-
ica, North America
RV5 Zaman
2010-AS
2009 Bangladesh and
Vietnam
Multiple High-mortalitya B, D Asia
aThis study was conducted mainly in high-mortality countries, but also in low-mortality countries.
bThis study was conducted mainly in low-mortality countries, but also in high-mortality countries.
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Appendix 6. Vaccine schedules
Trial No. doses Time between doses
(weeks)
No. arms: vaccine/
placebo
Infant vaccination
status
Note
RV1 Anh
2011-PHL
2 4 or 8 2/1 Commer-
cially available diph-
theria, tetanus, whole-
cell pertussis (DTPw),
hepatitis B (HBV) and
oral poliovirus (OPV)
vaccines were admin-
istered concomitantly
with the study vac-
cine/placebo as part of
the routine Expanded
Programme of Immu-
nization (EPI) in the
Philippines
Compares different
schedules: (1) vaccine
dose at month 1 and
2, and placebo at day
0; and (2) vaccine dose
at day 0 and month 2,
and placebo at month
1
RV1 Anh
2011-VNM
2 4 or 8 2/1 Commer-
cially available diph-
theria, tetanus, whole-
cell pertussis (DTPw),
hepatitis B (HBV) and
oral poliovirus (OPV)
vaccines were admin-
istered concomitantly
with the study vac-
cine/placebo as part of
the routine Expanded
Programme of Immu-
nization (EPI) in Viet-
nam
Com-
pares different sched-
ules: (1) vaccine dose
at day 0 and month 1,
and placebo at month
2; and (2) vaccine dose
at day 0 and month 2,
and placebo at month
1
RV1 Bernstein
1998-USA
2 6 to 10 1/1 Rotavirus vaccine was
sepa-
rated from all other in-
fant vaccines by at least
2 weeks
-
RV1 Bernstein
1999-USA
2 6 to 10 1/1 Other vaccines sepa-
rated from the trial
vaccines by at least 2
weeks
-
RV1 Dennehy
2005-NA
2 7 2/1 Vaccine or placebo
given concomi-
tantlywith diphtheria-
tetanus-acellular per-
2 different PFUs com-
pared
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tussis, inactivated po-
liovirus, H. influen-
zae type b, and S.
pneumoniae conjugate
vaccines for partici-
pants in USA or with
a diphtheria-tetanus-
acellular pertussis/in-
ac-
tivated poliovirus/H.
influenza type b com-
bination vaccine for
participants inCanada
“Routine hepatitis B
vaccinations were ad-
ministered according
to local practice.”
RV1 GSK[021]
2007-PAN
3 8 2/2 Use of other vaccines
not mentioned
Licensed formulation
versus modified for-
mulation
RV1 GSK[024]
2008-LA
2 4 or 8 1/1 All participants
received routine infant
vaccinations (Hepati-
tis B vaccine), diph-
theria-tetanus-
acellular pertussis, po-
liovirus, and H. in-
fluenzae type b) ac-
cording to Expanded
Program of Immu-
nization (EPI) recom-
mendations in each
country
First 2 doses of rou-
tine EPI vaccinations
were co-administered
with the RV1 vaccine
or placebo doses; the
third routine EPI vac-
cination was adminis-
tered 1 to 2 months
later according to the
national plan of im-
munization in each
country
-
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RV1 GSK[033]
2007-LA
2 8 3/1 Use of other vaccines
not mentioned
3 ‘Lots’ of RV1 vaccine
compared
RV1 GSK[041]
2007-KOR
2 8 1/1 H. influenzae type b
vaccine administered
concomitantly along
with the 2 doses of
vaccine/placebo and at
2 months after dose
2; other routine child-
hood vaccines were to
be given at least 14
days before trial vac-
cine/placebo
-
RV1 GSK[101555]
2008-PHL
2 8 2/2 No mention
of whether infants re-
ceived other vaccines
Data from
the lyophilized formu-
lation, which is not yet
approved or marketed,
are not reported
RV1 Kawamura
2010-JPN
2 4 1/1 Combined diphtheria
and tetanus toxoids
and acellular pertussis
(DTPa) and Hepatitis
B (HBV)
vaccines were allowed
to be co-administered
along with RV1 vac-
cine/placebo
-
RV1 Kerdpanich
2010-THA
2 8 3/2 Diph-
theria toxoid, tetanus
toxoid, acellular per-
tussis, inactivated po-
lio and H. influen-
zae type b combina-
tion vaccine (Infanrix
T M -IPV/Hib) at two
and fourmonths of age
and diphtheria toxoid,
tetanus toxoid, acel-
lular pertussis, hepati-
tis B, inactivated polio
and H. influenzae type
b combination vaccine
(Infanrix hexaT M ) at
six months of age
Compares:
regular vaccine recon-
stituted in buffer; vac-
cine reconstituted in
water; vaccine stored
above recommended
temperature; placebo
reconstituted in water;
placebo reconstituted
in buffer
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RV1 Madhi 2010-
AF
2 or 3 5 to 10 2/1 All partici-
pants received routine
infant vaccinations ac-
cording to Expanded
Program on Immu-
nization (EPI) recom-
mendations
-
RV1 Narang 2009-
IND
2 8 1/1 Routine vaccinations
(diphtheria-tetanus-
whole cell pertussis-
hepatitis b,H. influen-
zae type b, and oral po-
liovirus vaccine) were
administered at 6, 10,
and 14 weeks of age
(given with a 2-week
separation from the
first and subsequent
dose of the RV1 vac-
cine or placebo)
-
RV1 Omenaca
2012-EU
2 4 or 8 1/1 All partici-
pants received routine
infant vaccinations in
accordance with the
local National Plan of
Immunisation sched-
ule in each of the re-
spective participating
countries
-
RV1 Phua 2005-
SGP
2 4 3/1 Hepatitis B vaccine,
diphtheria-tetanus-
acellular pertussis, po-
liovirus, and H. in-
fluenzae type b co-ad-
ministered with inter-
ventions
3 different PFUs com-
pared
RV1 Phua 2009-AS 2 6 to 10 1/1 Infants received other
routine pae-
diatric immunizations
(combined diphtheria
toxoid-tetanus toxoid-
acellu-
lar pertussis [DTPa] -
inactivated poliovirus
[IPV] and H. influen-
-
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zae type B [Hib] vac-
cine and hepatitis B
vaccine [HBV]) dur-
ing the study period
ac-
cording to local sched-
ules. Almost all infants
received Bacille Cal-
mette-Guérin (BCG)
dose at birth. If oral
polio vaccine (OPV)
was given as part of
the routine schedule
in the participating
countries, a time inter-
val of 2 weeks was ob-
served be-
tween the OPV doses
and RIX4414 vaccine/
placebo doses
RV1 Rivera 2011-
DOM
2 7 1/1 All infants
received three doses
of combined diphthe-
ria, tetanus, acellular
pertussis, hepatitis B,
inactivated poliovirus
and H. influenzae vac-
cine.
One compli-
mentary dose of RV1
was administered to
all infants enrolled in
this study (both study
groups) whowere aged
less than 6 months at
Visit 3 (Week 13) as a
benefit to the placebo
group for participa-
tion in the study
RV1 Ruiz-Palac 06-
LA/EU
2 4 or 8 1/1 Routine immu-
nizations according to
local regulations; oral
poliovirus vaccination
at least 2 weeks before
or after rotavirus vac-
cine
-
RV1 Salinas 2005-
LA
2 8 3/1 Oral po-
lio vaccine given after
2 weeks, not together
with RV1
3 different PFUs com-
pared
Main publication did
not report that the trial
included 2 subsets:
2 doses of human ro-
tavirus or placebo sub-
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set: these participants
received 2 oral doses
of RV1 vaccine or
placebo according to a
0, 2 months schedule,
and routine vaccina-
tions (DTPw- Hepati-
tis B vaccine (HBV) +
Hib vaccine) at a 0, 2,
and 4 months sched-
ule
3 doses of RV1 or
placebo subset: these
participants received 3
oral doses of RV1 vac-
cine or placebo, and
routine vacci-
nations (DTPw-HBV
+ Hib vaccine) con-
comitantly with each
dose of human ro-
tavirus vaccine and
placebo at a 0, 2, and
4 months schedule
RV1 Steele 2008-
ZAF
2 4 3/1 RV1 plus (1) oral
polio vaccine (OPV)
+ diphtheria-tetanus-
acellular pertus-
sis/H. influenzae type
b (DTPA/HIB) vac-
cine; (2) OPV placebo
+ diphtheria-tetanus-
acellular pertussis in-
activated polio-H. in-
fluen-
zae type b (DTPA-
IPV/HIB) vaccine; or
(3) OPV + DTPA/
HIB vaccine
Compares differ-
ent co-administration
combinations (see pre-
vious column)
RV1 Steele 2010a-
ZAF
3 4 1/1 RV1 vaccine was
concomitantly admin-
istered with 3 doses of
combined diphtheria,
tetanus and whole-cell
pertussis, hepatitis B,
and H. influenzae type
b vaccine (Tritanrix-
For infants who de-
veloped clinical symp-
toms of HIV (WHO
stages III or IV dis-
ease) anytime after en-
rolment, access to an-
tiretrovi-
ral therapy (cotrimox-
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HepBHib) and OPV
(PolioSabin)
azole) according to the
SouthAfricannational
guidelines was facil-
itated. Infants who
needed treatmentwere
referred to antiretrovi-
ral therapy centres by
the investigators
RV1 Steele 2010b-
ZAF
2 or 3 4 2/1 Infants received rou-
tine vaccinations ac-
cording to the lo-
cal EPI schedule in
South Africa. Bacille
Calmette-
Guerin and OPV vac-
cinations were given at
birth; all other routine
vaccinations (includ-
ing diphtheria-tetanus
toxoids-whole cell per-
tussis, hepatitis B, H.
influenzae type b, and
OPV) were admin-
istered concomitantly
with the study vaccine
Compares number of
doses (2 or 3)
RV1 Vesikari
2004a-FIN
2 8 3/1 Infant routine vacci-
nations were separated
from the study vac-
cines by 2 weeks
3 different PFUs com-
pared
RV1 Vesikari
2004b-FIN
2 8 1/1 Infant routine vacci-
nations (diph-
theria tetanus toxoids-
pertussis, H. influen-
zae type b, and inac-
tivated poliovirus vac-
cines) were separated
from the study vac-
cines by at least 2
weeks
-
RV1 Vesikari
2007a-EU
2 4 or 8 1/1 Concomitant vaccines
included 7
valent pneumococcal
polysaccharide conju-
gate vaccine (Preve-
nar) and meningococ-
-
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cal group c conjugate
vaccine (Meningitec);
Hepatitis B vaccine,
diphtheria-tetanus-
acellular pertussis, po-
lio virus, and H. in-
fluenzae type b vac-
cines were co-adminis-
tered
RV1 Vesikari 2011-
FIN
2 4 2/2 Routine childhood
vaccinations were al-
lowed according to lo-
cal practice, but at least
14 days apart from
each dose of study vac-
cine
Compares
liquid and lyophilized
vaccine formulations
RV1 Ward 2006-
USA
2 4 2/1 Not specified 2 different PFUs com-
pared
RV1 Zaman 2009-
BGD
2 - 2/2 All children
in the study received
the standard EPI vac-
cines starting at 6
weeks of age. Oral po-
lio vaccine (OPV) co-
administered in trial:
either concomitantly
with RV1 or 15 days
before RV1
Compared RV1 plus
oral polio vaccine with
RV1 alone
RV5 Armah 2010-
AF
3 4 1/1 All
children in the study
received the standard
EPI vaccines (includ-
ing oral poliovirus vac-
cine) starting at 6
weeks of age
-
RV5 Block 2007-
EU/USA
3 4 to 10 1/1 Use of oral poliovirus
vaccine during the
course of the study or
within 42 days before
first dose of vaccine/
placebo was an exclu-
sion criterion; admin-
istration of other vac-
cines permitted
-
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RV5 Ciarlet 2009-
EU
3 4 to 6 1/1 Hepatitis B vaccine,
diphtheria-tetanus-
acellular pertussis, po-
lio virus, and H. in-
fluenzae type b co-ad-
ministered
-
RV5 Clark 2003-
USA
3 6 to 8 1/1 Children that had re-
cently received oral
polio vaccine were ex-
cluded from the study
Breastfed; infants in
the vaccine control
group (Group 1) re-
ceived the reassortants
as administered in pre-
vious studies within
30 min of feeding
Enfamil formula (30
ml) or Mylanta Dou-
ble Strength (0.5 ml/
kg). Infants in a corre-
sponding placebo
group (Group 2) were
pre-fed as in Group 1
RV5 Clark 2004-
USA
3 6 to 8 1/1 Receipt
of any other vaccines
within 14 days was not
allowed
-
RV5 Kim
2008-KOR
3 4 to 10 1/1 In-
fants excluded if they
had or were to receive
oral poliovirus vaccine
at any time during the
study or in the 42
days before the first
dose; concomitant ad-
ministration of other
licensed vaccines and
breastfeeding was not
restricted
-
RV5 Merck[009]
2005-USA
3 4 to 10 1/1 Infants were excluded
if they had or were to
receive oral poliovirus
vaccine at any time
during the study or in
the 42 days before the
first dose; concomi-
tant administration of
other licensed vaccines
-
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(Continued)
and breastfeeding was
not reported
RV5
NCT00718237
2010-JPN
3 4 to 10 1/1 No information about
use of other vaccines
-
RV5
NCT00953056
2010-CHI
3 4 to 10 1/1 Other live vaccines 14
days before or after
study vaccine were not
allowed
-
RV5 Vesikari
2006a-FIN
3 4 to 8 3/1 Licensed vac-
cines could be admin-
istered throughout the
study, but were not
given on the same day
as study vaccine; inac-
tivated poliovirus vac-
cine was exclusively
used in Finland at the
time of the study
Compares differ-
ent RV5 components:
G1-4, P1A; G1-4; and
P1A
RV5 Vesikari
2006b-INT
3 4 to 10 1/1 Admin-
istration of other li-
censed childhood vac-
cines and breastfeed-
ingwere not restricted;
for a subset of subjects
in the USA (U.A. con-
comitant use cohort)
, Merck also provided
the licensed paediatric
vaccines that were ad-
ministered concomi-
tantly (same day) with
RV5or placebo, which
included Comvax, In-
fanrix, Ipol, and Pre-
vnar
-
RV5 Zaman 2010-
AS
3 4 1/1 All
children in the study
received the standard
EPI vaccines (includ-
ing oral poliovirus vac-
cine) starting at 6
weeks of age
-
H. influenzae: Haemophilus influenzae; PFU: plaque-forming unit.
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Appendix 7. Methods to collect adverse event data
Trial Passive or active
RV1 Anh 2011-PHL Not reported
RV1 Anh 2011-VNM Not reported
RV1 Bernstein 1998-USA Passive
RV1 Bernstein 1999-USA Passive and active
RV1 Dennehy 2005-NA Passive and active
RV1 GSK[021] 2007-PAN Not reported
RV1 GSK[024] 2008-LA Not reported
RV1 GSK[033] 2007-LA Not reported
RV1 GSK[041] 2007-KOR Not reported
RV1 GSK[101555] 2008-PHL Not reported
RV1 Kawamura 2010-JPN Not reported
RV1 Kerdpanich 2010-THA Passive
RV1 Madhi 2010-AF Active
RV1 Narang 2009-IND Passive
RV1 Omenaca 2012-EU Not reported
RV1 Phua 2005-SGP Passive
RV1 Phua 2009-AS Passive
RV1 Rivera 2011-DOM Passive
RV1 Ruiz-Palac 06-LA/EU Active
RV1 Salinas 2005-LA Passive
RV1 Steele 2008-ZAF Not reported
RV1 Steele 2010a-ZAF Active and passive
RV1 Steele 2010b-ZAF Not reported
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(Continued)
RV1 Vesikari 2004a-FIN Passive
RV1 Vesikari 2004b-FIN Passive
RV1 Vesikari 2007a-EU Passive and active
RV1 Vesikari 2011-FIN Passive
RV1 Ward 2006-USA Not reported
RV1 Zaman 2009-BGD Passive and active
RV5 Armah 2010-AF Active
RV5 Block 2007-EU/USA Passive and active
RV5 Ciarlet 2009-EU Passive and active
RV5 Clark 2003-USA Passive and active
RV5 Clark 2004-USA Passive and active
RV5 Kim 2008-KOR Passive
RV5 Merck[009] 2005-USA Not reported
RV5 NCT00718237 2010-JPN Passive
RV5 NCT00953056 2010-CHI Not reported
RV5 Vesikari 2006a-FIN Passive and active
RV5 Vesikari 2006b-INT Active
RV5 Zaman 2010-AS Active and passive
Appendix 8. Ongoing studies: vaccine and location
Trial Rotavirus vaccine Location
Region Country
Other
ACTRN12610000525088
RV3-BB Oceania Australia
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(Continued)
Other
ACTRN12611001212943
RV3-BB Oceania New Zealand
Other CTRI-091-000102 ORV 116E Asia India
Other CTRI-091-003064 RotaVac Asia India
OtherCTRI2009-091-000821 RotaVac Asia India
Other NCT00981669 Brazilian Rotavirus vaccine South America Brazil
Other NCT01061658 BRV-TV Asia India
Other NCT01266850 RV1 and RV5 North America US
Other NCT01305109 ORV 116E Asia India
Other NCT01571505 Unspecified rotavirus vaccine Asia India
RV1 ISRCTN37373664 RV1 Africa South Africa
RV1 ISRCTN86632774 RV1 Africa South Africa
RV1 NCT00134732 RV1 Asia Republic of Korea
RV1 NCT00158756 RV1 Europe Moscow, Russian Federation
RV1 NCT00289172 RV1 Asia India
RV1 NCT00383903 RV1 Africa South Africa
RV1 NCT00420316 RV1 Europe Finland
RV1 NCT00425737 RV1 Europe Finland
RV1 NCT00429481 RV1 Asia Singapore
RV1 NCT01171963 RV1 Asia China
RV1 NCT01199874 RV1 Asia Pakistan
RV1 NCT01375647 RV1 Asia Bangladesh
RV1 NCT01575197 RV1 Africa Ghana
RV1 Tatochenko 2008 RV1 Not reported Not reported
RV5 NCT00880698 RV5 Africa Botswana
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Appendix 9. Deathsa: from published trials and from communication with trial authors
Vaccine Trial No. of deaths Cause of death
Vaccine Placebo Unclear Total
RV1 RV1 Anh 2011-
PHL
1 0 0 1 Salmonella gastroenteritis
RV1 Anh 2011-
VNM
0 0 0 0 -
RV1 Bernstein
1998-USA
0 0 0 0 -
RV1 Bernstein
1999-USA
0 0 1 (1) 1 Pneumococcal sepsis
RV1 GSK[021]
2007-PAN
0 0 0 0 -
RV1 GSK[024]
2008-LA
10 2 0 12 Meningitis bacterial (1 vaccine, 1 placebo), pneu-
monia (3 vaccine), aortic valve stenosis (1 vaccine)
, bronchiolitis (1 vaccine), dengue fever (1 vaccine),
endocarditis bacterial (1 vaccine), intussusception (1
vaccine), multi-organ failure (1 placebo), respiratory
failure (1 vaccine), sepsis (2 vaccine)
RV1 GSK[033]
2007-LA
3 0 0 3 Gastroenteritis (1 vaccine), bronchopneumonia (1
vaccine), aspiration (1 vaccine)
RV1 GSK[041]
2007-KOR
0 0 0 2 Not reported
RV1
GSK[101555]
2008-PHL
0 0 0 0 -
RV1 Kawamura
2010-JPN
0 0 0 0 -
RV1 Kerdpanich
2010-THA
0 0 0 0 -
RV1Madhi 2010-
AF
83 43 0 126 Reasons not stated
RV1 Narang
2009-IND
0 0 0 0 -
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(Continued)
RV1 Phua 2005-
SGP
3 0 0 3 Leukaemia (1 vaccine); accident induced subarach-
noid haemorrhage (1 vaccine); cardiorespiratory fail-
ure after acute viral pneumonitis (1 vaccine)
RV1 Phua 2009-
AS
1 3 0 4 Aspiration and metabolic disorder, adenoviral pneu-
monia, interstitial pneumonia, and sudden infant
death syndrome (not stated which group)
RV1 Rivera 2011-
DOM
0 0 0 0 -
RV1 Ruiz-Palac
06-LA/EU
56 43 0 99 Diarrhoea (4 vaccine, 2 placebo); pneumonia (16 vac-
cine, 6 placebo); other causes not mentioned
RV1Salinas 2005-
LA
2 1 0 3 Generalised visceral congestion (1 placebo); sepsis (1
vaccine); automobile accident (1 vaccine)
RV1 Steele 2008-
ZAF
3 5 0 8 Bronchopneumonia (1 placebo), pneumonia (2 vac-
cine, 2 placebo), hepatic steatosis (1 placebo), brain
oedema (1 vaccine, 1 placebo)
RV1Steele 2010a-
ZAF
6 9 0 15 Bronchopneumonia, sepsis, and gastroenteritis were
the most common causes
RV1 Steele
2010b-ZAF
3 0 0 3 Bronchopneumonia and gastroenteritis (3 vaccine)
RV1 Vesikari
2004b-FIN
0 0 0 0 -
RV1 Vesikari
2007a-EU
0 0 0 0 -
RV1 Vesikari
2011-FIN
0 0 0 0 -
RV1 Zaman
2009-BGD
1 0 0 1
RV5 RV5 Armah
2010-AF
76 82 0 158 Gastroenteritis (20 vaccine, 16 placebo); 11 deaths
occurred in identified HIV infected participants in
Kenya; sudden infant death syndrome (1 placebo);
other causes not mentioned
RV5 Block 2007-
EU/USA
1 0 0 1 Sudden infant death syndrome (1 vaccine)
RV5Ciarlet 2009-
EU
0 0 0 0 -
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(Continued)
RV5 Merck[009]
2005-USA
0 0 0 0 -
RV5
NCT00718237
2010-JPN
0 0 0 0 -
RV5
NCT00953056
2010-CHI
0 0 0 0 -
RV5 Vesikari
2006a-FIN
0 0 0 0 -
RV5 Vesikari
2006b-INT
24 20 0 44 Sudden infant death syndrome (7 vaccine and 7
placebo), other causes not mentioned
RV5 Zaman
2010-AS
3 4 0 7 Not all causes reported, most common causes were
drowning and sepsis
aNumbers in brackets are the number of deaths reported by the trial authors following personal communication with them, ie they are
not in the published trial reports.
WH A T ’ S N E W
Last assessed as up-to-date: 10 May 2012.
Date Event Description
10 May 2012 New search has been performed No new trials were identified from the updatedMay 2012
search
10 May 2012 New citation required but conclusions have not changed Review updated to incorporate different country mortal-
ity strata and outcomes changed to reflect the different
rotavirus vaccines’ efficacy and safety in countries with
different mortality rates
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HannaBergman and SukkrtiNagpal joined the author
team.
10 May 2010 Amended Minor typographical errors corrected.
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trials into the review
21 July 2009 New search has been performed The original rotavirus vaccines review (Soares-Weiser
2004) was split into two reviews: rotavirus vaccines in
use (this review); and other rotavirus vaccines, includ-
ing those no longer in use or in development (Soares-
Weiser 2004).
This involved a new search, revised inclusion criteria,
updated reviewmethods. All data from those trials also
included in the original review were re-extracted. New
authors joined the review team for this review
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